

Protein Sequence Searches - February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension **.rup**) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:39:13 ; Search time 169 Seconds
(without alignments)
1375.402 Million cell updates/sec

Title: US-10-712-479-2

Perfect score: 3167

Sequence: 1 MASMSMTWTGALITPCAA.....LLSVGVGIYLLPNRRHHHH 601

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3167	100.0	601	8	ADO19021
2	3034.5	95.8	580	8	ADO19023
3	3027	95.6	3010	2	AAR30616
4	3016	95.2	591	2	AAR01679
5	3016	95.2	2201	2	AAR01680
6	3016	95.2	3010	2	AAR20111
7	3016	95.2	3010	2	AAR20091
8	3016	95.2	3010	7	ADF88597
9	3015	95.2	3010	2	AAR98022
10	3015	95.2	3010	4	AAB311170
11	3015	95.2	3010	8	ADO36227
12	3015	95.2	3010	8	ADO79401
13	3014	95.2	592	8	ADO36215
14	3014	95.2	592	8	ADO79389
15	3014	95.2	3010	2	AAY06423
16	3013	95.1	3010	2	AAR68864
17	3012	95.1	591	4	AAB60130
18	3012	95.1	591	6	AAO26416
19	3012	95.1	1985	6	ABU09575
20	3012	95.1	3010	2	ABU09575
21	3011	95.1	591	5	AAG79560
22	3011	95.1	621	5	AAG79556
23	3011	95.1	621	5	AAE18903
24	3011	95.1	621	6	ABP71699
25	3011	95.1	621	6	ABR41892

26	3011	95.1	621	6	ABP97967	Abp97967 Amino aci
27	3011	95.1	627	5	AAG79561	Aag79561 HCV decre
28	3011	95.1	627	5	ADG19078	Adg19078 HCV NS5B
29	3011	95.1	3010	2	AAR82694	Aar82694 Partial H
30	3005	94.9	1985	5	AAO18001	Aao18001 Hepatitis
31	3005	94.9	1985	5	AAE15729	Aae15729 Hepatitis
32	3005	94.9	1985	5	AAE15731	Aae15731 Hepatitis
33	3005	94.9	1985	5	AAE15720	Aae15720 Hepatitis
34	3005	94.9	1985	5	AAE15717	Aae15717 Hepatitis
35	3005	94.9	1985	5	AAE15727	Aae15727 Hepatitis
36	3005	94.9	1985	5	AAE15728	Aae15728 Hepatitis
37	3005	94.9	1985	5	AAE15722	Aae15722 Hepatitis
38	3005	94.9	1985	5	AAE15730	Aae15730 Hepatitis
39	3005	94.9	1985	8	ADJ57846	Adj57846 HCV repli
40	3005	94.9	2201	5	ABG30591	Abg30591 Hepatitis
41	3005	94.9	2201	5	ABG30600	Abg30600 Hepatitis
42	3005	94.9	2201	5	ABG30581	Abg30581 Hepatitis
43	3005	94.9	2201	5	ABG30586	Abg30586 Hepatitis
44	3005	94.9	2201	5	ABG30593	Abg30593 Hepatitis
45	3005	94.9	2201	5	ABG30582	Abg30582 Hepatitis

ALIGNMENTS

RESULT 1
ADO19021
ID ADO19021 standard; protein; 601 AA.
XX AC ADO19021;
XX DT 12-AUG-2004 (first entry)
XX DE Full-length HCV NS5B polymerase, FL NS5B.
XX RNA polymerase activity; continuous-read assay;

Hepatitis C virus infection; HCV infection; polymerase; NS5B;
bone mineral disease; osteoporosis; carcinoma; cardiovascular disease;
diabetes; ocular disorder; renal dysfunction; lymphoma;
lymphoproliferative disorder; metabolic disorder; arthritis;
sleep disorder; thyroid disorder; antiinflammatory; hepatotropic;
viral; osteopathic; cytostatic; antidiabetic; ophthalmological;
nephrotropic; antiarthritic; enzyme.

OS Hepatitis C virus.

PN WO200404228-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036465.

XX 13-NOV-2002; 2002US-0425981P.

XX (PFIZ) PFIZER INC.

XX Yagi Y, Sheets MP, Wells PA, Shelly JA, Poorman RA, Epps DB;
Morgan AG;

DR WPI; 2004-420337/39.

XX N-PSDB; ADO19020.

PT Detecting RNA polymerase activity in a continuous-read manner, useful in
treating osteoporosis, carcinomas, cardiovascular diseases, ocular
disorders or arthritis, by contacting an RNA polymerase with an
oligonucleotide template.

XX Claim 5; SEQ ID NO 2; 46pp; English.

CC The present invention relates to a method for detecting RNA polymerase
activity in a continuous-read manner. The method comprises contacting an
RNA polymerase with an oligonucleotide template in a reaction mixture
comprising an assay buffer, under conditions in which the RNA polymerase

CC is active, adding a fluorescent dye capable of binding double-stranded
 CC nucleic acid molecules to the reaction mixture. The RNA polymerase is the Hepatitis
 CC fluorescence of the reaction mixture. The RNA polymerase is the Hepatitis
 CC C virus (HCV) polymerase, NS5B. The method is useful for treating HCV
 CC infection, bone mineral diseases like osteoporosis, carcinomas,
 CC cardiovascular diseases, diabetes, ocular disorders, renal dysfunction,
 CC lymphomas, lymphoproliferative disorders, metabolic disorders, arthritis,
 CC sleep disorders and thyroid disorders. The present sequence represents
 CC full-length HCV NS5B polymerase (designated FL NS5B).
 XX
 SQ Sequence 601 AA;

Query Match 100.0%; Score 3167; DB 8; Length 601;
 Best Local Similarity 100.0%; Pred. No. 4e-294;
 Matches 601; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MASMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNLVYSTTSASLRQKVTDFR 60
 Db 1 MASMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNLVYSTTSASLRQKVTDFR 60
 Qy 61 LOVLDDHYRDLKEMKAKASTVKALLSVEAECKLTPPHSAKSKFGYGAQDVRLSSRAV 120
 Db 61 LOVLDDHYRDLKEMKAKASTVKALLSVEAECKLTPPHSAKSKFGYGAQDVRLSSRAV 120
 Qy 121 NHIRSVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDGLGVRCCKMAY 180
 Db 121 NHIRSVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDGLGVRCCKMAY 180
 Qy 181 DVVSTLPOAVMGSSYGFQYSPKQRFVLTNTWAKKCPMGFSYDTRCFDSTVTENDIRVE 240
 Db 181 DVVSTLPOAVMGSSYGFQYSPKQRFVLTNTWAKKCPMGFSYDTRCFDSTVTENDIRVE 240
 Qy 241 ESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASCGLVLTSCGNTLTCY 300
 Db 241 ESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASCGLVLTSCGNTLTCY 300
 Qy 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQP 360
 Db 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQP 360
 Qy 361 EYDLELTSCSSNVSAHDASGKRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
 Db 361 EYDLELTSCSSNVSAHDASGKRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
 Qy 421 PTLWARMILMTHFFSILLAQBLEKALDCQYAGCYSIEPLDLQITLERLHGLSAFSLHS 480
 Db 421 PTLWARMILMTHFFSILLAQBLEKALDCQYAGCYSIEPLDLQITLERLHGLSAFSLHS 480
 Qy 481 YSPGEINRVASCLRLKGLVPPRLVRHRRARSVRKLLSOGGAAICGKYLFWAVRTKLL 540
 Db 481 YSPGEINRVASCLRLKGLVPPRLVRHRRARSVRKLLSOGGAAICGKYLFWAVRTKLL 540
 Qy 541 TPIPAASRLDLSGMFVAGYSGGDIYHLSRARPRFMLCLLLSVGVGIYLLPNRHHHH 600
 Db 541 TPIPAASRLDLSGMFVAGYSGGDIYHLSRARPRFMLCLLLSVGVGIYLLPNRHHHH 600
 Qy 601 H 601
 Db 601 H 601

RESULT 2

AD019023
 ID AD019023 standard; protein; 580 AA.

XX AC AD019023;

XX DT 12-AUG-2004 (first entry)

XX DE C-terminally truncated HCV NS5B polymerase, Cdelta21 NS5B.

XX KW RNA polymerase activity; continuous-read assay;

XX KW Hepatitis C virus infection; HCV infection; polymerase; NS5B;

KW bone mineral disease; osteoporosis; carcinoma; cardiovascular disease;
 KW diabetes; ocular disorder; renal dysfunction; lymphoma;
 KW lymphoproliferative disorder; metabolic disorder; arthritis;
 KW sleep disorder; thyroid disorder; antiinflammatory; hepatotropic;
 KW virucide; osteopathic; cytostatic; antidiabetic; ophthalmological;
 KW nephrotropic; antiarthritic; enzyme.
 XX Hepatitis C virus.
 XX WO2004044228-A2.
 FN 27-MAY-2004.
 XX 13-NOV-2003; 2003WO-US036465.
 PF 13-NOV-2002; 2002US-0425981P.
 PR (PFIZ) PFIZER INC.
 XX Yagi Y, Sheets MP, Wells PA, Shelly JA, Poorman RA, Epps DE;
 FI Morgan AG;
 XX WPI; 2004-420337/39.
 DR N-PSDB; ADO19022.
 XX Detecting RNA polymerase activity in a continuous-read manner, useful in
 XX treating osteoporosis, carcinomas, cardiovascular diseases, ocular
 PT disorders or arthritis, by contacting an RNA polymerase with an
 PT oligonucleotide template.
 XX Claim 7; SEQ ID NO 4; 46pp; English.

CC The present invention relates to a method for detecting RNA polymerase
 CC activity in a continuous-read manner. The method comprises contacting an
 CC RNA polymerase with an oligonucleotide template in a reaction mixture
 CC comprising an assay buffer, under conditions in which the RNA polymerase
 CC is active, adding a fluorescent dye capable of binding double-stranded
 CC nucleic acid molecules to the reaction mixture, and measuring the
 CC fluorescence of the reaction mixture. The RNA polymerase is the Hepatitis
 CC C virus (HCV) polymerase, NS5B. The method is useful for treating HCV
 CC infection, bone mineral diseases like osteoporosis, carcinomas,
 CC cardiovascular diseases, diabetes, ocular disorders, renal dysfunction,
 CC lymphomas, lymphoproliferative disorders, metabolic disorders, arthritis,
 CC sleep disorders and thyroid disorders. The present sequence represents C-
 CC terminally truncated HCV NS5B polymerase (designated Cdelta21 NS5B).
 XX

SQ Sequence 580 AA;

Query Match 95.8%; Score 3034.5; DB 8; Length 580;
 Best Local Similarity 96.5%; Pred. No. 1.9e-281;
 Matches 580; Conservative 0; Mismatches 0; Indels 21; Gaps 1;

Qy 1 MASMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNLVYSTTSASLRQKVTDFR 60
 Db 1 MASMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNLVYSTTSASLRQKVTDFR 60
 Qy 61 LOVLDDHYRDLKEMKAKASTVKALLSVEAECKLTPPHSAKSKFGYGAQDVRLSSRAV 120
 Db 61 LOVLDDHYRDLKEMKAKASTVKALLSVEAECKLTPPHSAKSKFGYGAQDVRLSSRAV 120
 Qy 121 NHIRSVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDGLGVRCCKMAY 180
 Db 121 NHIRSVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDGLGVRCCKMAY 180
 Qy 181 DVVSTLPOAVMGSSYGFQYSPKQRFVLTNTWAKKCPMGFSYDTRCFDSTVTENDIRVE 240
 Db 181 DVVSTLPOAVMGSSYGFQYSPKQRFVLTNTWAKKCPMGFSYDTRCFDSTVTENDIRVE 240
 Qy 241 ESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASCGLVLTSCGNTLTCY 300
 Db 241 ESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASCGLVLTSCGNTLTCY 300
 Qy 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQP 360

```
Db 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTAMTRYSAAPPDPPQ 360
QY 361 EYDLELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
Db 361 EYDLELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
QY 421 PTLWARMILMTHFFSILLAQEQLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHS 480
Db 421 PTLWARMILMTHFFSILLAQEQLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHS 480
QY 481 YSPGGINRVASCLRLKGVPPPLRVWHRARSVRAKLLSQGGRRAICGKYLFWAVRTKLL 540
Db 481 YSPGGINRVASCLRLKGVPPPLRVWHRARSVRAKLLSQGGRRAICGKYLFWAVRTKLL 540
QY 541 TPIPAASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGVIYLLPNRHHHH 600
Db 541 TPIPAASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGVIYLLPNRHHHH 600
QY 601 H 601
Db 580 H 580

RESULT 3
ID AAR30616 standard; protein; 3010 AA.
AC AAR30616;
XX
DT 27-AUG-2003 (revised)
DT 25-MAR-2003 (revised)
DT 19-MAY-1993 (first entry)
XX
DE Polypeptide coded by Korean HCV full cDNA sequence LBC1.
XX
KW KHCY-LBC1; diagnosis; vaccine.
XX
OS Hepatitis C virus.
XX
PN EP521318-A2.
XX
PD 07-JAN-1993.
XX
PF 10-JUN-1992; 92EP-00109753.
XX
PR 10-JUN-1991; 91KR-00009510.
PR 06-AUG-1991; 91KR-00013601.
XX
PA (LUCK-) LUCKY LTD.
XX
PI Cho JM, Lee YB, Park YW, Lim KJ, Choi DY, So HS, Kim CH;
PI Kim ST, Yang JY;
XX
DR WPI; 1993-001883/01.
DR N-PSDB; AAQ33282.
XX
PT DNA and polypeptide(s) from a new type of hepatitis C virus (KHCY) - for
PT diagnosing and vaccinating against KHCY infections.
XX
PS Disclosure; Fig 2; 119pp; English.
XX
CC The polypeptide is that encoded by the full cDNA sequence of Korean
CC hepatitis C virus (KHCY) cDNA, KHCY-LBC1. It or its fragments may be used
CC in a specific and accurate method for detecting KHCY antibodies in the
CC serum of hepatitis C patients. Antibodies directed against these
CC polypeptides are useful for the purification of KHCY antigens and for the
CC development of an improved diagnostic to detect KHCY antigens in a
CC sample. The polypeptides may also be used in a vaccine for treatment and
CC prevention of KHCY infection at a dosage of 5-200 ug/peptide. (Updated on
CC 25-MAR-2003 to correct PN field.) (Updated on 27-AUG-2003 to correct OS
XX field.)
XX
```

```
SQ Sequence 3010 AA;
Query Match 95.6%; Score 3027; DB 2; Length 3010;
Beat Local Similarity 96.8%; Pred. No. 1.3e-279;
Matches 572; Conservative 9; Mismatches 10; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAAEESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFORLQVL 64
Db 2420 SMSYTWTCALITPCAAEESKLPINPLSNLSLRHNLVYSTTSRSASLRQKKVTFORLQVL 2479
QY 65 DDHYRDVLKEMKAKASTYKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSRAVNHR 124
Db 2480 DDHYRDVLKEMKAKASTYKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSRAVNHR 2539
QY 125 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 2540 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 2599
QY 185 TLPOAVMGSSYGFQYSPKQVFEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPOAVMGSSYGFQYSPKQVFEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPEARQAIRSLTERLYVGGPMWNSKQNCQYRCRASGVLTTSCGNTLTCYLKAA 304
Db 2660 QCCDLAPEARQAIRSLTERLYVGGPMWNSKQNCQYRCRASGVLTTSCGNTLTCYLKAT 2719
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 2779
QY 365 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
Db 2780 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2839
QY 425 ARMLMTHFFSILLAQEQLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 2840 ARMLMTHFFSILLAQEQLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 2899
QY 485 EINRVASCLRLKGVPPPLRVWHRARSVRAKLLSQGGRRAICGKYLFWAVRTKLLTPIP 544
Db 2900 EINRVASCLRLKGVPPPLRVWHRARSVRAKLLSQGGRRAICGKYLFWAVRTKLLTPIP 2959
QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGVIYLLPNR 595
Db 2960 AASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGVIYLLPNR 3010

RESULT 4
ID AAW01679 standard; protein; 591 AA.
XX
AC AAW01679;
XX
DT 17-OCT-2003 (revised)
DT 25-MAR-2003 (revised)
DT 19-AUG-1997 (first entry)
XX
DE NS5B protein (residues 2420-3010 of the HCV polyprotein).
XX
KW Hepatitis C virus; HCV; non-structural protein; NS5B; polyprotein;
KW RNA-dependent RNA polymerase; RdRp; terminal nucleotidyl transferase;
KW TNase; method; assay; in vitro activity; therapy; inhibitor.
XX
OS Hepatitis C virus; strain BK.
XX
PN WO9637619-A1.
XX
PD 28-NOV-1996.
XX
PF 24-MAY-1996; 96WO-IT000106.
XX
PR 25-MAY-1995; 95IT-RM000343.
XX
```

PA (RICE-) 1ST RICERCHE BIOL MOLECOLARE ANGELETTI.
 XX De Francesco R, Tomei L, Behrens S;
 XX WPI; 1997-021225/02.
 PT Reproducing enzymatic activities of HCV in vitro - using sequences contg.
 PT NS5B for RNA-dependent RNA polymerase and terminal nucleotidyl
 PT transferase activities.
 XX Claim 1; Page 24-26; 49pp; English.
 XX A novel method for reproducing in vitro the RNA-dependent RNA polymerase
 CC (RdRp) activity or the terminal nucleotidyl transferase (TNTase) activity
 CC encoded by hepatitis C virus (HCV), is characterised in that sequences
 CC contg. NS5B are used in the mixture. The method is used for assaying in
 CC vitro the activities of RdRp and TNTase encoded by HCV in order to
 CC identify, for therapeutic purposes, compounds that inhibit these
 CC enzymatic activities and therefore might interfere with the replication
 CC of the HCV. The present sequence comprises amino acids 2420-3010 of the
 CC HCV polyprotein and corresponds to the NS5B protein. cDNA encoding this
 CC protein was cloned between the BamHI and HindIII sites of pBlueBacII to
 CC form pBac58. Another expression plasmid, pBac25 (containing cDNA encoding
 CC amino acids 810-3010 of HCV; see AAW01680) was also constructed. Extracts
 CC of Bac25- or Bac58-infected Sf9 cells contain a novel magnesium-dependent
 CC enzymatic activity that catalyses de novo RNA synthesis. This activity
 CC was shown to be dependent on the presence of RNA, but independent of an
 CC added primer or of the origin of the input RNA molecule. As the products
 CC generated by extracts of Sf9 cells infected with either Bac25 or Bac58
 CC appeared to be identical, the experiments indicated that the observed
 CC RdRp activity is encoded by the HCV NS5B protein. (Updated on 25-MAR-2003
 CC to correct PR field.) (Updated on 17-OCT-2003 to standardise OS field)
 XX Sequence 591 AA;
 SQ Query Match 95.2%; Score 3016; DB 2; Length 591;
 Best Local Similarity 96.6%; Pred. No. 1.2e-279;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
 QY 5 SMSYTTGALITPCAAERSKLPINALNSLRHNHNVYTSRSASLRQKVKVTFDRQLVL 64
 DB 1 SMSYTTGALITPCAAERSKLPINALNSLRHNHNVYATTSRSAGLRQKVKVTFDRQLVL 60
 QY 65 DDHVRDLVKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRNLSRAVNHIR 124
 DB 61 DDHVRDLVKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRNLSRAVNHIIH 120
 QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCCKMALYDVVS 184
 DB 121 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCCKMALYDVVS 180
 QY 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWAKKCPMGFSYDTRCFDSTVTENDIRVBSIY 244
 DB 181 TLPOAVMGSSYGFQYSPQKRVFELVNTWAKKCPMGFSYDTRCFDSTVTENDIRVBSIY 240
 QY 245 QCCDLAPARQAIKSLTERLVGGPMVTKSKGNCYRCRAGSVLTTSCGNLTFCYLKAA 304
 DB 241 QCCDLAPARQAIKSLTERLVGGPMVTKSKGNCYRCRAGSVLTTSCGNLTFCYLKAS 300
 QY 305 AACRAAKLQDCTMLVNGDDLVVIESAGTQDAASLRVFTAMTRYSPAPGDPQPEYDL 364
 DB 301 AACRAAKLQDCTMLVNGDDLVVIESAGTQDAASLRVFTAMTRYSPAPGDPQPEYDL 360
 QY 365 ELITSCSNVSAHDASGRVYVTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 DB 361 ELITSCSNVSAHDASGRVYVTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 420
 QY 425 ARMIILMTHFFSILLAQEQLKALCOIYGACVSTIEPLDLPOIIRLHGLSAPLSHSYSPG 484
 DB 421 ARMIILMTHFFSILLAQEQLKALCOIYGACVSTIEPLDLPOIIRLHGLSAPLSHSYSPG 480
 QY 485 EINRVASCLRLKLGVPPLRVWHRARSVRALLSQGGRAATCGKYLEFNWAVTKLKLTPIP 544

DB 481 EINRVASCLRLKLGVPPLRVWHRARSVRALLSQGGRAATCGKYLEFNWAVTKLKLTPIP 540
 QY 545 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 595
 DB 541 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 591
 RESULT 5
 AAW01680
 ID AAW01680 standard; protein; 2201 AA.
 XX
 AC AAW01680;
 XX 17-OCT-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 19-AUG-1997 (first entry)
 XX
 DE HCV NS2-NS5B non-structural protein.
 XX
 KW Hepatitis C virus; HCV; non-structural protein; NS5B; polyprotein;
 KW RNA-dependent RNA polymerase; RdRp; terminal nucleotidyl transferase;
 KW TNTase; method; assay; in vitro activity; therapy; inhibitor.
 XX
 OS Hepatitis C virus; strain BK.
 XX
 PN W09637619-A1.
 XX
 PD 28-NOV-1996.
 XX
 PF 24-MAY-1996; 96WO-IT000106.
 XX
 PR 25-MAY-1995; 95IT-RM000343.
 XX
 PA (RICE-) 1ST RICERCHE BIOL MOLECOLARE ANGELETTI.
 XX De Francesco R, Tomei L, Behrens S;
 XX WPI; 1997-021225/02.
 PT Reproducing enzymatic activities of HCV in vitro - using sequences contg.
 PT NS5B for RNA-dependent RNA polymerase and terminal nucleotidyl
 PT transferase activities.
 XX Example 1; Page 26-34; 49pp; English.
 XX A novel method for reproducing in vitro the RNA-dependent RNA polymerase
 CC (RdRp) activity or the terminal nucleotidyl transferase (TNTase) activity
 CC encoded by hepatitis C virus (HCV), is characterised in that sequences
 CC contg. NS5B are used in the mixture. The method is used for assaying in
 CC vitro the activities of RdRp and TNTase encoded by HCV in order to
 CC identify, for therapeutic purposes, compounds that inhibit these
 CC enzymatic activities and therefore might interfere with the replication
 CC of the HCV. The present sequence comprises amino acids 810-3010 of the
 CC HCV polyprotein and corresponds to NS2-NS5B proteins. cDNA encoding this
 CC protein was cloned between the NcoI and HindIII sites of pBlueBacII to
 CC form pBac25. Another expression plasmid, pBac58 (containing cDNA encoding
 CC amino acids 2420-3010 of HCV; see AAW01679) was also constructed.
 CC Extracts of Bac25- or Bac58-infected Sf9 cells contain a novel magnesium-
 CC dependent enzymatic activity that catalyses de novo RNA synthesis. This
 CC activity was shown to be dependent on the presence of RNA, but
 CC independent of an added primer or of the origin of the input RNA
 CC molecule. As the products generated by extracts of Sf9 cells infected
 CC with either Bac25 or Bac58 appeared to be identical, the experiments
 CC indicated that the observed RdRp activity is encoded by the HCV NS5B
 CC protein. (Updated on 25-MAR-2003 to correct PR field.) (Updated on 17-OCT
 CC -2003 to standardise OS field)
 XX Sequence 2201 AA;
 SQ Query Match 95.2%; Score 3016; DB 2; Length 2201;
 Best Local Similarity 96.6%; Pred. No. 9.1e-279;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAESKLPINALNSLRLHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
 Db 1611 SMSYTWTCALITPCAAESKLPINALNSLRLHHNLVYSTTSRSASLRQKKVTFDRLOVL 1670
 QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
 Db 1671 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 1730
 QY 125 SVWKDLLEDTPTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVYDVVS 184
 Db 1731 SVWKDLLEDTPTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVYDVVS 1790
 QY 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 Db 1791 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 1850
 QY 245 QCCDLAPEARQAIKSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
 Db 1851 QCCDLAPEARQAIKSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 1910
 QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSPAPGDPPOPEYDL 364
 Db 1911 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSPAPGDPPOPEYDL 1970
 QY 365 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
 Db 1971 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2030
 QY 425 ARMILMTHFFSILLAOEQLKALDCQIYACVYSIEPLDLPQIIERLHGLSAPLSHSYSPG 484
 Db 2031 ARMILMTHFFSILLAOEQLKALDCQIYACVYSIEPLDLPQIIERLHGLSAPLSHSYSPG 2090
 QY 485 EINRVASCLRLKGLVPLRWHRARSVRKALLSQCGRAAICGKYLFWNAVTKLKLTPIP 544
 Db 2091 EINRVASCLRLKGLVPLRWHRARSVRKALLSQCGRAAICGKYLFWNAVTKLKLTPIP 2150
 QY 545 AASRLDLGWFVAGYSGGDIYHLSLRARPRWFMCLCLLLSVGVGYLLPNR 595
 Db 2151 AASRLDLGWFVAGYSGGDIYHLSLRARPRWFMCLCLLLSVGVGYLLPNR 2201
 RESULT 6
 AAR20111 standard; protein; 3010 AA.
 XX AC AAR20111;
 XX AC AAR20111;
 DT 25-MAR-2003 (revised)
 DT 01-MAY-1992 (first entry)
 XX DE Non-A, non-B viral genome product.
 XX KW NANBV; vaccine; immunodiagnosis; antigen; antibody.
 XX OS Non-A.
 XX OS Non-B hepatitis virus.
 FH Key Location/Qualifiers
 FT Protein 1..115
 FT /label= C
 FT /note= "core protein"
 FT Protein 116..191
 FT /label= M
 FT /note= "matrix protein"
 FT Protein 192..389
 FT /label= E
 FT /note= "envelope protein"
 FT Protein 390..729
 FT /label= NS1
 FT Protein 730..1006
 FT /label= NS2
 FT Protein 1007..1614
 FT /label= NS3

FT Protein 1615..1862
 FT /label= NS4a
 FT Protein 1863..2012
 FT /label= NS4b
 FT Protein 2013..3010
 FT /label= NS5
 XX EP463848-A.
 PN 02-JAN-1992.
 XX 25-JUN-1991; 91EP-00305717.
 XX 25-JUN-1990; 90JP-00167466.
 PR 31-AUG-1990; 90JP-00230921.
 PR 09-NOV-1990; 90JP-00305605.
 PR 28-DEC-1990; 90US-00635451.
 PR 08-MAY-1991; 91JP-00132090.
 PR 14-MAY-1991; 91JP-00138493.
 XX (OSAU) UNIV OSAKA.
 PA (REMI-) RES FOUND MICROBIAL.
 XX WPI; 1992-009412/02.
 DR N-PSDB; AAQ20268.
 XX Non-A, non-B hepatitis virus (NANBV) particles - as vaccines, immuno-
 PT diagnostics and screening agents for NANBV, and to remove NANBV from
 PT blood.
 XX Disclosure; Fig 2; 89pp; English.
 XX The sequence (SEQ ID NO 1) was deduced from several overlapping from a
 CC library prep'd. from NANBV RNA. Antigenic polypeptides from the sequence
 CC can be used as immunoassay reagents, for screening donated blood, and as
 CC immunogens for vaccine prodn. Antibodies raised to the peptides can be
 CC used in immunoassays to detect or quantify NANBV antigens in liver tissue
 CC and blood. Preferred poly- peptides include residues 1-30, -115, or 2012;
 CC 47-77; 116-191; 192-207 or -298; 230-238 or -263; 287-300; 293-330; 390-
 CC 729; 730-1005; 1006-1614; 1384-1414; 1615-1862; 1737-1767; 1863-2012;
 CC and 2013-3010. The sequence is also disclosed in EP-464287 (SEQ ID NO 1).
 CC See AAR20091 for details of this specification. (Updated on 25-MAR-2003
 CC to correct PD field.) (Updated on 25-MAR-2003 to correct PA field.)
 XX Sequence 3010 AA;
 SQ
 Query Match 95.2%; Score 3016; DB 2; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 1.5e-278;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
 QY 5 SMSYTWTCALITPCAAESKLPINALNSLRLHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
 Db 2420 SMSYTWTCALITPCAAESKLPINALNSLRLHHNLVYSTTSRSASLRQKKVTFDRLOVL 2479
 QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
 Db 2480 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 2539
 QY 125 SVWKDLLEDTPTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVYDVVS 184
 Db 2540 SVWKDLLEDTPTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVYDVVS 2599
 QY 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 Db 2600 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
 QY 245 QCCDLAPEARQAIKSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
 Db 2660 QCCDLAPEARQAIKSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 2719
 QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSPAPGDPPOPEYDL 364
 Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSPAPGDPPOPEYDL 2779

QY 365 ELITSCSNVSAHDASGRVYVYLTDRDTPVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 DB 2780 ELITSCSNVSAHDASGRVYVYLTDRDTPVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2839

QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 484
 DB 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 2899

QY 485 EINRVASCLRLKLGVPPLRVWRHRAVSRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 544
 DB 2900 EINRVASCLRLKLGVPPLRVWRHRAVSRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 2959

QY 545 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 595
 DB 2960 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 3010

RESULT 7
 AAR20091
 ID AAR20091 standard; protein; 3010 AA.
 XX AC AAR20091;
 XX DT 25-MAR-2003 (revised)
 XX DT 01-MAY-1992 (first entry)
 XX DE Non-A, non-B viral genome product.
 XX KW NANBV; vaccine; immunodiagnosis; antigen; antibody.
 XX OS Non-A.
 XX OS non-B hepatitis virus.

XX FH Key Location/Qualifiers
 FT Protein 1..115
 FT /label= C
 FT /note= "core protein"
 FT 116..191
 FT /label= M
 FT /note= "matrix protein"
 FT 192..389
 FT /label= E
 FT /note= "envelope protein"
 FT 390..729
 FT /label= NS1
 FT 730..1006
 FT /label= NS2
 FT 1007..1614
 FT /label= NS3
 FT 1615..1862
 FT /label= NS4a
 FT 1863..2012
 FT /label= NS4b
 FT 2013..3010
 FT /label= NS5

XX EP464287-A.
 XX 08-JAN-1992.
 XX 28-DEC-1990; 90EP-00314371.
 XX 25-JUN-1990; 90JP-00167466.
 XX 31-AUG-1990; 90JP-00230921.
 XX 09-NOV-1990; 90JP-00305605.
 XX 17-JUN-1991; 91EP-00401604.
 XX (OSAU) UNIV OSAKA.
 XX WPI; 1992-009617/02.
 XX N-PSDB; AAQ21829.

PT New DNA from non-A, non-B hepatitis virus - and derived antigenic
 XX polypeptide(s) useful for diagnostics, blood screening and in vaccines.
 PS Claim 3; Fig 2; 89pp; English.
 XX

CC The sequence was deduced from several overlapping "BK" cDNA clones obd.
 CC by "gene walking" using a cDNA clone isolated from a library prepd. from
 CC NANBV RNA. Antigenic polypeptides from the sequence can be used as
 CC immunoassay reagents, for screening donated blood, and as immunogens for
 CC vaccine prodn. Antibodies raised to the peptides can be used in
 CC immunoassays to detect or quantify NANBV antigens in liver tissue and
 CC blood. Preferred polypeptides are include residues 1-30, -115, or 2012;
 CC 47-77; 116-191; 192-207 or -298; 230-238 or -263; 287-300; 293-330; 390-
 CC 729; 730-1005; 1006-1614; 1384-1414; 1615-1862; 1737-1767; 1863-2012;
 CC and 2013-3010. The sequence is also disclosed in EP-463848 (SEQ ID NO 1)
 CC in which a virus particle contg. antigens encoded by the sequence is
 CC claimed. See AAR20111 for details of this specification. (Updated on 25-
 CC MAR-2003 to correct PA field.)
 XX SQ Sequence 3010 AA;

Query Match 95.2%; Score 3016; DB 2; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 1.5e-278;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAAEESKLPINALSNLLRHNLVYVSTTSRASLRQKVKVTFDRLOVL 64
 DB 2420 SMSYTWGALITPCAAEESKLPINALSNLLRHNLVYVSTTSRASLRQKVKVTFDRLOVL 2479

QY 65 DDHYRDVLEKEMKAKASTVKAKLLSVEACKLTPPHSAKSPGYGAKDVRSLSSRAVNHR 124
 DB 2480 DDHYRDVLEKEMKAKASTVKAKLLSVEACKLTPPHSAKSPGYGAKDVRSLSSRAVNHR 2539

QY 125 SVWKDLEDDTPIQTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRCCKMALYDVVS 184
 DB 2540 SVWKDLEDDTPIQTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRCCKMALYDVVS 2599

QY 185 TLPOAVMGSSYGVFOYSPKQVFEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 DB 2600 TLPOAVMGSSYGVFOYSPKQVFEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 2659

QY 245 QCCLDAPEARQAINSLTERLYGVGPMTNKSGQNGCYRRCRASGLVLTSCGNLTLCYLKAA 304
 DB 2660 QCCLDAPEARQAINSLTERLYGVGPMTNKSGQNGCYRRCRASGLVLTSCGNLTLCYLKAS 2719

QY 305 AACRAAKLQDCTMLVNGDDLWVICESAGTOEDAASIRVFTTEAMTRYSAAPPDPPQPEYDL 364
 DB 2720 AACRAAKLQDCTMLVNGDDLWVICESAGTOEDAASIRVFTTEAMTRYSAAPPDPPQPEYDL 2779

QY 365 ELITSCSNVSAHDASGRVYVYLTDRDTPVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 DB 2780 ELITSCSNVSAHDASGRVYVYLTDRDTPVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2839

QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 484
 DB 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 2899

QY 485 EINRVASCLRLKLGVPPLRVWRHRAVSRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 544
 DB 2900 EINRVASCLRLKLGVPPLRVWRHRAVSRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 2959

QY 545 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 595
 DB 2960 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 3010

RESULT 8
 ADF88597
 ID ADF88597 standard; protein; 3010 AA.
 XX AC ADF88597;
 XX DT 26-FEB-2004 (first entry)

XX Hepatitis C virus NS3 gene protein, SEQ ID No 6.
XX liver cancer; hepatitis-C virus; NS3 gene; carcinogenicity.
XX Hepatitis C virus.
XX JP2003210181-A.
XX 29-JUL-2003.
XX 30-MAY-2002; 2002JP-00158335.
XX 16-NOV-2001; 2001JP-00352443.
XX (SHIN-) ZH SHINSANGYO SOZO KENKYU KIKO.
XX WPI; 2003-819836/77.
XX N-PSDB; ADF88596.

XX Diagnosing liver cancer, involves amplifying amino terminal region of
XX hepatitis-C virus gene using predetermined primer and determining
XX hepatitis-C virus in base sequence of obtained DNA fragment.
XX Disclosure; SEQ ID NO 6; 36pp; Japanese.
XX The invention relates to the novel testing method for diagnosing liver
XX cancer. The novel method comprises amplifying the amino terminal region
XX of a hepatitis-C virus NS3 gene using a predetermined primer and
XX determining the hepatitis-C virus in a base sequence of the obtained DNA
XX fragment. The novel testing method is useful for diagnosing liver cancer
XX and also used in a gene amplification technique, a clinical laboratory
XX test reagent, a polymerase chain reaction, a base sequence analysis and
XX genetic engineering. The method enables the detection of a hepatitis-C
XX virus having high carcinogenicity with high specificity. This sequence
XX represents the protein of the hepatitis-C virus NS3 gene of the
XX invention.
XX Sequence 3010 AA;

Query Match 95.2%; Score 3016; DB 7; Length 3010;
Best Local Similarity 96.3%; Pred. No. 1.5e-278;
Matches 569; Conservative 12; Mismatches 10; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAERSKLPINALSNLRLHNLVYSTRSASLRQKKVTPDRQLV 64
DB 2420 SMSYTWTCALITPCAAERSKLPINLNLHSHSVYSTRSASLRQKKVTPDRQLV 2479
QY 65 DDHYRDVLKMKAKASTVKAALLSVERACKLTPPHSAKSKFGYGAQVRSLSRAVNH 124
DB 2480 DDHYRDVLKMKAKASTVKAALLSVERACKLTPPHSAKSKFGYGAQVRSLSRAVNH 2539
QY 125 SVWKDLLEDTPPIOTTIMAKNEVFCVQPEKGGKRPABLI VPPDLGVRVCEKMALYDVVS 184
DB 2540 SVWKDLLEDTPPIOTTIMAKNEVFCVQPEKGGKRPABLI VPPDLGVRVCEKMALYDVVS 2599
QY 185 TLPOAVMGSSYGFQSPKQRFVFLVNTWKAKCPMGFSYDRCFDSTVTENDIRVEESIY 244
DB 2600 TLPOAVMGSSYGFQSPKQRFVFLVNTWKAKCPMGFSYDRCFDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKGCYRCRAGSVLTTSCGNTLTCLYKAA 304
DB 2660 QCCDLAPARQAIRSLTERLYVGGPMTNSKGCYRCRAGSVLTTSCGNTLTCLYKAT 2719
QY 305 AACRAKLDCTMLVNGDDLWICISAGTOEDAAALRAFTAMTRYSPAPGDPPEYDL 364
DB 2720 AACRAKLDCTMLVNGDDLWICISAGTOEDAAALRAFTAMTRYSPAPGDPPEYDL 2779
QY 365 ELITSCSNVSAHDASGRVYVLTFRDPTVPLARAWEETARTHTPVNSWLGNIIMVAPTLW 424
DB 2780 ELITSCSNVSAHDASGRVYVLTFRDPTVPLARAWEETARTHTPVNSWLGNIIMVAPTLW 2839
QY 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIEHLGLSAFSLHSYSPG 484

DB 2840 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIEHLGLSAFSLHSYSPG 2899
QY 485 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSQCGRAAICGKYLFPNNAVTKLKTPTIP 544
DB 2900 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSQCGRAATCGKYLFPNNAVTKLKTPTIP 2959
QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGYLLPNR 595
DB 2960 AASQLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGYLLPNR 3010

RESULT 9

AAW98022
ID AAW98022 standard; protein; 3010 AA.

XX AC AAW98022;

XX DT 21-JUN-1999 (first entry)

XX DE Infectious hepatitis C virus genotype 1b strain HC-J4 protein.

XX KW HCV; infectious clone; infection; diagnosis; therapy; vaccine; screening;

XX OS assay; antiviral; virucide.

XX PN Hepatitis C virus.

XX PD WO9904008-A2.

XX PF 28-JAN-1999.

XX PR 16-JUL-1998; 98WO-US014688.

XX PR 18-JUL-1997; 97US-0053062P.

XX PR 27-JAN-1998; 98US-00014416.

XX PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX PI Yanagi M, Bukh J, Emerson SU, Purcell RH;

XX DR WPI; 1999-132252/11.

XX DR N-PSDB; AAX24843.

XX PT New isolated hepatitis C virus nucleic acids - used to develop products
XX for the diagnosis, prevention and treatment of HCV infections and for
XX developing screening assays.

XX PS Claim 2; Fig 14G-H; 126pp; English.

XX This protein is encoded by the infectious hepatitis C virus (HCV)
XX genotype 1b strain HC-J4 genome (see AAX24833). HC-J4 was obtained from
XX acute phase plasma of a chimpanzee infected with serum containing HC-
XX J4/91. The infectious nucleic acid sequence can be used to produce
XX chimeric genomes (see AAX24833) consisting of the open reading frames of
XX infectious nucleic acid sequences of other genotypes (including genotypes
XX 1-6) and subtypes (such as 1b, 2a, 2b, 2c, 3a, 4a-f, 5a and 6a) of HCV.
XX The invention also relates to the introduction of mutations or deletions
XX into infectious nucleic acid sequences in order to produce an attenuated
XX HCV virus suitable for vaccine development. Infectious nucleic acid
XX sequences can also be used to produce attenuated virus via passage in
XX vitro or in vivo of the viruses produced by transfection of a host cell
XX with the infectious nucleic acid sequence. Vaccines comprising one or
XX more polypeptides made from the infectious nucleic acid sequence are used
XX to immunise mammals, especially humans, against hepatitis C. The nucleic
XX acid sequences can also be used to induce protective immunity against the
XX virus. The nucleic acid sequences or their encoded proteases (e.g. NS3
XX protease) can additionally be used to develop screening assays to
XX identify antiviral agents for HCV

XX SQ Sequence 3010 AA;

Query Match 95.2%; Score 3015; DB 2; Length 3010;
Best Local Similarity 95.9%; Pred. No. 1.9e-278;

Matches	567	Conservative	16	Mismatches	8	Indels	0	Gaps	0																															
QY	5	SMSTYWTGALITPCA	AEE	SKLPINAL	SNLSLRH	HNLVYSTTS	RSASLRQK	VTFDRLQVL	64																															
Db	2420	SMSTYWTGALITPCA	AEE	SKLPINPL	SNLSLRH	NMVYATTS	RSASLRQK	VTFDRLQVL	2479																															
QY	65	DDHYRDVLKEMKAKA	STVKA	KLISVE	BEACKLTP	PHSAKS	KFGYGA	KDVRSL	SRANVH	124																														
Db	2480	DDHYRDVLKEMKAKA	STVKA	KLISVE	BEACKLTP	PHSAKS	KFGYGA	KDVRSL	SRANVH	2539																														
QY	125	SVMKOLLEDDTDTPI	OTTIMAK	NVFCVQ	PEKG	GRKPAR	LIVFPDLG	VRVCE	KMALYDV	184																														
Db	2540	SVWEDDLEDDTETD	ITIMAK	SEVFCVQ	PEKG	GRKPAR	LIVFPDLG	VRVCE	KMALYDV	2599																														
QY	185	TLPOAVMGSSYGFQY	SPKQ	RVEFLV	NWTWAK	KCPMG	FSDY	TRCFD	STVTENDIR	244																														
Db	2600	TLPOAVMGSSYGFQY	SPKQ	RVEFLV	NWTWAK	KCPMG	FSDY	TRCFD	STVTESDIR	2659																														
QY	245	QCDDLAPEARQAI	RS	LTERLY	YVGGP	MWNSKG	QNGCYR	RCBAS	GVLT	TSCGNTLTCYL	304																													
Db	2660	QCDDLAPEARQAI	RS	LTERLY	YIGGLP	NSKGQ	NGCYR	RCBAS	GVLT	TSCGNTLTCYL	2719																													
QY	305	AACRAAKLQDCT	MLVNGD	DLVW	ICES	AGTQED	AA	SLRV	FT	TEAM	TRYSAP	PGDP	PPQ	PEYDL	364																									
Db	2720	AACRAAKLQDCT	MLVNGD	DLVW	ICES	AGTQED	AA	SLRA	FT	TEAM	TRYSAP	PGDP	PPQ	PEYDL	2779																									
QY	365	ELITSCSSNVS	VAHD	ASG	KRVY	YLTRD	PTVPLA	RAA	WETAR	HT	TPVNS	WLGNII	MYA	PTLW	424																									
Db	2780	ELITSCSSNVS	VAHD	ASG	KRVY	YLTRD	PTVPLA	RAA	WETAR	HT	TPVNS	WLGNII	MYA	PTLW	2839																									
QY	425	ARMILMTH	FP	SIIL	AQ	BLEK	ALDCQ	IYG	ACYSIE	PLDL	POI	TER	LHGL	SAP	LSH	SPG	484																							
Db	2840	ARMILMTH	FP	SIIL	AQ	BLEK	ALDCQ	IYG	ACYSIE	PLDL	POI	TER	LHGL	SAP	LSH	SPG	2899																							
QY	485	EINRVAS	CL	RKL	GV	PP	LR	VW	HR	ARS	VR	AK	LS	QGG	R	AAIC	GK	YLF	NW	AV	R	TK	L	T	P	P	544													
Db	2900	EINRVAS	CL	RKL	GV	PP	LR	VW	HR	ARS	VR	AK	LS	QGG	R	AAIC	GK	YLF	NW	AV	R	TK	L	T	P	P	2959													
QY	545	AASRLD	LSG	W	FV	AGY	G	G	D	I	YH	S	L	S	R	A	R	P	W	F	M	L	C	L	L	L	S	S	V	G	V	G	I	Y	L	L	P	N	R	595
Db	2960	AASOLD	LSG	W	FV	AGY	G	G	D	I	YH	S	L	S	R	A	R	P	W	F	M	L	C	L	L	L	S	S	V	G	V	G	I	Y	L	L	P	N	R	3010

RESULT 10	
AAB31170	
ID	AAB31170 standard; protein; 3010 AA.
XX	
AC	AAB31170;
XX	
DT	02-APR-2001 (first entry)
XX	
DE	Amino acid sequence of a hepatitis C virus (HCV) clone genotype 1b.

New nucleic acid comprising a chimeric bovine viral diarrhoea virus genome
 in which the (non-)structural region has been replaced by hepatitis C
 virus (HCV) genome useful for treating or preventing HCV signs and
 symptoms.
 Disclosure; Fig 4G-H; 97pp; English.

[illegible]

XX AC ADO36227;
 XX DT 26-AUG-2004 (first entry)
 XX DE Hepatitis C virus (HCV) J4L6 wild-type polyprotein.
 XX KW hepatotropic; virucide; vaccine; gene therapy; vaccine;
 XX KW Hepatitis C virus; HCV; core protein; HCV infection; vaccination;
 XX KW polyprotein.
 XX OS Hepatitis C virus.
 XX PN WO2004046175-A1.
 XX PD 03-JUN-2004.
 XX PF 13-NOV-2003; 2003WO-EP012793.
 XX PR 15-NOV-2002; 2002GB-00026722.
 XX PA (GLAX) GLAXO GROUP LTD.
 XX PI Brett S, Hamblin PA, Ogilvie L;
 XX WI WI; 2004-420613/39.
 XX DR N-ESDB; ADO36222.
 XX PT New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes
 XX PT the polypeptide sequences of the HCV core and at least one other HCV
 XX PT protein, for use in medicine, particularly for manufacturing a medicament
 XX PT for treating HCV.
 XX PS Disclosure; Fig 6; 78pp; English.
 XX CC The invention describes a polynucleotide vaccine comprising a
 XX CC polynucleotide sequence (S1) encoding the Hepatitis C virus (HCV) Core
 XX CC protein and at least 1 other HCV protein, and causes expression of the
 XX CC proteins in cells (in which (S1) has been mutated or positioned relative
 XX CC to the polynucleotide sequence encoding the other HCV protein, so that
 XX CC the negative effect of the Core protein on expression of the other HCV
 XX CC protein is reduced). Also described are: a method of preventing or
 XX CC treating an HCV infection in a mammal, comprising administering the
 XX CC vaccine cited above to a mammal; and a method of vaccination of an
 XX CC individual, comprising taking a polynucleotide vaccine as cited above,
 XX CC coating the polynucleotide onto gold beads and delivering the gold beads
 XX CC into the skin. HCV nucleic acids, polypeptides, host cells, vectors and
 XX CC antibodies used in the methods, are also disclosed. The polynucleotide
 XX CC vaccine is useful in the manufacture of a medicament for the treatment of
 XX CC HCV. This is the amino acid sequence of the wild type HCV polyprotein.
 XX SQ Sequence 3010 AA;

Query Match 95.2%; Score 3015; DB 8; Length 3010;
 Best Local Similarity 95.9%; Pred. NO. 1.9e-278;
 Matches 567; Conservative 16; Mismatches 8; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAEESEKLPINALNSLRHNLVYSTTSRSASIRQKVTDFRQVL 64
 Db 2420 SMSYTWGALITPCAEESEKLPINPLNSLRHNLVYATTSRSASIRQKVTDFRQVL 2479
 Qy 65 DDHYRDVLKEMKAKSTVKALLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
 Db 2480 DDHYRDVLKEMKAKSTVKALLSIEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 2539
 Qy 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPKGRKPARLIIVPDLGVRVCCKMALYDVVS 184
 Db 2540 SVWEDLLEDTPITOTTIMAKSEVFCVQPKGRKPARLIIVPDLGVRVCCKMALYDVVS 2599
 Qy 185 TLPOAVNGSSYGFQYSPKQRFELVNTWKAKCPMGFSYDFRCFDSVTENDIRVESIY 244
 Db 2600 TLPOAVNGSSYGFQYSPKQRFELVNTWKSKCPMGFSYDFRCFDSVTENDIRVESIY 2659

Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 304
 Db 2660 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAT 2719
 Qy 305 AACRAAKLODCTMLVNGDDLWVVCESAGTQEDAAASLRVFTTEAMTRYSAAPPQPEYDL 364
 Db 2720 AACRAAKLODCTMLVNGDDLWVVCESAGTQEDAAALRAFTTEAMTRYSAAPPQPEYDL 2779
 Qy 365 ELITSCSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 424
 Db 2780 ELITSCSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 2839
 Qy 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
 Db 2840 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 2899
 Qy 485 EINRVASCLRLKGVPPPLRVWRHRSVRAKLLSOGGAAICGKYLFWNAVTKLTLTIP 544
 Db 2900 EINRVASCLRLKGVPPPLRVWRHRSVRAKLLSOGGAAICGKYLFWNAVTKLTLTIP 2959
 Qy 545 AASRLDLGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 595
 Db 2960 AASRLDLGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNR 3010

RESULT 12
 ADO79401
 ID ADO79401 standard; protein; 3010 AA.
 AC ADO79401;
 XX DT 26-AUG-2004 (first entry)
 XX DE Hepatitis C virus J4L6 genome wild-type polyprotein.
 XX KW HCV; polyprotein; vaccine; DNA immunisation; hepatotropic; virucide.
 XX OS Hepatitis C virus.
 XX OS Synthetic.
 XX PN WO2004046176-A1.
 XX PD 03-JUN-2004.
 XX PF 13-NOV-2003; 2003WO-EP012830.
 XX PR 15-NOV-2002; 2002GB-00026722.
 XX PA (GLAX) GLAXO GROUP LTD.
 XX PI Brett S, Hamblin PA, Ogilvie L;
 XX WI WI; 2004-420614/39.
 XX DR N-ESDB; ADO79396.
 XX PT New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes
 XX PT the polypeptide sequences of the HCV core, NS3, NS4B and NS5B proteins,
 XX PT for use in medicine, in particular for manufacturing a medicament for the
 XX PT treatment of HCV.
 XX PS Disclosure; Fig 6; 79pp; English.
 XX CC The present sequence is the hepatitis C virus (HCV) J4L6 genome wild-type
 XX CC polyprotein sequence. HCV DNA vaccines of the invention comprise a
 XX CC polynucleotide that encodes the HCV proteins Core, NS3, NS4B and NS5B,
 XX CC and does not encode the NS4A and/or NS5A proteins. Preferably, the codon
 XX CC usage of the polynucleotide sequence resembles that of highly expressed
 XX CC human genes. The polynucleotides may encode individual proteins or fusion
 XX CC proteins. Preferred fusions include double fusions between NS4B and NS5B
 XX CC and between Core and NS3. The vaccines are useful for the treatment or
 XX CC prevention of an HCV infection.
 XX SQ Sequence 3010 AA;

Query Match 95.2%; Score 3015; DB 8; Length 3010;
Best Local Similarity 95.9%; Pred. No. 1.9e-278;
Matches 567; Conservative 16; Mismatches 8; Indels 0; Gaps 0;
Qy 5 SMSYTWGALITPCAAEESKLPINALNSLLRHNLVYSTTSRSASLRQKQKVTDFRLQVL 64
Db 2420 SMSYTWGALITPCAAEESKLPINPLNSLLRHNMVYATTSSASLRQKQKVTDFRLQVL 2479
Qy 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHR 124
Db 2480 DDHYRDVLKEMKAKASTVAKLLSIEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHR 2539
Qy 125 SVWKDLLEDTPTIOTTIMAKNEVFCVQPEKGRKPARLIIVFDLGVRCCKMALYDVS 184
Db 2540 SVWKDLLEDTPTIOTTIMAKNEVFCVQPEKGRKPARLIIVFDLGVRCCKMALYDVS 2599
Qy 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 2600 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKSKKCPMGFSYDTRCFDSTVTESDIRVESIY 2659
Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMNSKGQNGCYRRCRASGLVLTSCGNLTTCYLKAA 304
Db 2660 QCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNGCYRRCRASGLVLTSCGNLTTCYLKAT 2719
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTORDAASLRVFTTEAMTRYAPGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTORDAALRAFTTEAMTRYAPGDPPOPEYDL 2779
Qy 365 ELITSCSSNVSAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWGLNIIIMYAPTLW 424
Db 2780 ELITSCSSNVSAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWGLNIIIMYAPTLW 2839
Qy 425 ARMTLMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Db 2840 ARMTLMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPOIIRLHGLSAFTLHSYSPG 2899
Qy 485 EINKVASCRLKGLVPPPLRVWRHRSVRKALLSOGGAAICGKYLEFNWAVRTKLTPI 544
Db 2900 EINKVASCRLKGLVPPPLRVWRHRSVRKALLSOGGAAATCGRYLFNWAVRTKLTPI 2959
Qy 545 AASRLDLSGFWFVAGYSGGDIYHSLSRARPRWFMCLILLSVGVGIYLLPNR 595
Db 2960 AASQLDLSGFWFVAGYSGGDIYHSLSRARPRWFPCLILLSVGVGIYLLPNR 3010

RESULT 13
ID ADO36215
XX ADO36215 standard; protein; 592 AA.
AC ADO36215;
XX
DT 26-AUG-2004 (first entry)
XX
DE Hepatitis C virus (HCV) NS5B protein.
XX
KW hepatotropic; virucide; vaccine; gene therapy; vaccination; NS5B.
KW Hepatitis C virus; HCV; core protein; HCV infection; vaccination; NS5B.
XX
OS Hepatitis C virus.
XX
PN WO2004046175-A1.
XX
PD 03-JUN-2004.
XX
PF 13-NOV-2003; 2003WO-EP012793.
XX
PR 15-NOV-2002; 2002GB-00026722.
XX
PA (GLAX) GLAXO GROUP LTD.
XX
FI Brett S, Hamblin PA, Ogilvie L;
XX

DR WPI; 2004-420613/39.
DR N-PSDB; ADO36226.
XX
PT New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes
PT the polypeptide sequences of the HCV core and at least one other HCV
PT protein, for use in medicine, particularly for manufacturing a medicament
PT for treating HCV.
XX
PS Example 2; Page 27; 78pp; English.
XX
CC The invention describes a polynucleotide vaccine comprising a
CC polynucleotide sequence (S1) encoding the Hepatitis C virus (HCV) Core
CC protein and at least 1 other HCV protein, and causes expression of the
CC proteins in cells (in which (S1) has been mutated or positioned relative
CC to the polynucleotide sequence encoding the other HCV protein, so that
CC the negative effect of the Core protein on expression of the other HCV
CC protein is reduced). Also described are: a method of preventing or
CC treating an HCV infection in a mammal, comprising administering the
CC vaccine cited above to a mammal; and a method of vaccination of an
CC individual, comprising taking a polynucleotide vaccine as cited above,
CC coating the polynucleotide onto gold beads and delivering the gold beads
CC into the skin. HCV nucleic acids, polypeptides, host cells, vectors and
CC antibodies used in the methods, are also disclosed. The polynucleotide
CC vaccine is useful in the manufacture of a medicament for the treatment of
CC HCV. This is the amino acid sequence of the HCV NS5B protein.
XX
SQ Sequence 592 AA;

Query Match 95.2%; Score 3014; DB 8; Length 592;
Best Local Similarity 96.1%; Pred. No. 1.8e-279;
Matches 569; Conservative 14; Mismatches 9; Indels 0; Gaps 0;
Qy 4 MSMSYTWGALITPCAAEESKLPINALNSLLRHNLVYSTTSASLRQKQKVTDFRLQV 63
Db 1 MSMSYTWGALITPCAAEESKLPINPLNSLLRHNMVYATTSSASLRQKQKVTDFRLQV 60
Qy 64 LDDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHI 123
Db 61 LDDHYRDVLKEMKAKASTVAKLLSIEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHI 120
Qy 124 RSVWKDLLEDTPTIOTTIMAKNEVFCVQPEKGRKPARLIIVFDLGVRCCKMALYDVV 183
Db 121 RSVWKDLLEDTPTIOTTIMAKNEVFCVQPEKGRKPARLIIVFDLGVRCCKMALYDVV 180
Qy 184 STLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESI 243
Db 181 STLPQAVMGSSYGFQYSPKQRFVFLVNTWKSKKCPMGFSYDTRCFDSTVTESDIRVESI 240
Qy 244 YQCCDLAPEARQAIRSLTERLYVGGPMNSKGQNGCYRRCRASGLVLTSCGNLTTCYLKA 303
Db 241 YQCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNGCYRRCRASGLVLTSCGNLTTCYLKA 300
Qy 304 AACRAAKLQDCTMLVNGDDLVIICESAGTORDAASLRVFTTEAMTRYAPGDPPOPEYD 363
Db 301 TAACRAAKLQDCTMLVNGDDLVIICESAGTORDAALRAFTTEAMTRYAPGDPPOPEYD 360
Qy 364 LELITSCSSNVSAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWGLNIIIMYAPTL 423
Db 361 LELITSCSSNVSAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWGLNIIIMYAPTL 420
Qy 424 WARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSP 483
Db 421 WARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSP 480
Qy 484 GEINRVASCLRLKGLVPPPLRVWRHRSVRKALLSOGGAAICGKYLEFNWAVRTKLTPI 543
Db 481 GEINRVASCLRLKGLVPPPLRVWRHRSVRKALLSOGGAAATCGRYLFNWAVRTKLTPI 540
Qy 544 PAASRLDLSGFWFVAGYSGGDIYHSLSRARPRWFMCLILLSVGVGIYLLPNR 595
Db 541 PAASQLDLSGFWFVAGYSGGDIYHSLSRARPRWFPCLILLSVGVGIYLLPNR 592

RESULT 14

ADO79389
ID ADO79389 standard; protein; 592 AA.

XX
AC ADO79389;

XX
DT 26-AUG-2004 (first entry)

XX
DE Hepatitis C virus NS5B protein.

XX
KW HCV; NS5B; vaccine; DNA immunisation; hepatotropic; virucide; mutant;
KW mutein.

XX
OS Hepatitis C virus.

XX
OS Synthetic.

XX
PN WO2004046176-A1.

XX
XX 03-JUN-2004.

XX
XX 13-NOV-2003; 2003WO-EP012830.

XX
XX 15-NOV-2002; 2002GB-00026722.

XX
XX (GLAXO) GLAXO GROUP LTD.

XX
XX Brett S, Hamblin PA, Ogilvie L;

XX
XX WPI; 2004-420614/39.

XX
XX N-PSDB; ADO79400.

XX
XX New Hepatitis C virus (HCV) vaccine having a polynucleotide that encodes
PT the polypeptide sequences of the HCV core, NS3, NS4B and NS5B proteins,
PT for use in medicine, in particular for manufacturing a medicament for the
PT treatment of HCV.

XX
XX Example 2; Page 27; 79pp; English.

XX
XX The present sequence is that of the NS5B protein of hepatitis C virus
CC (HCV). The sequence is the translation sequence of a polynucleotide in
CC which codon usage was altered to resemble that of highly expressed human
CC genes. HCV vaccines of the invention comprise a polynucleotide that
CC encodes the HCV proteins Core, NS3, NS4B and NS5B, and does not encode
CC the NS4A and/or NS5A proteins. The proteins may be expressed as
CC individual proteins or as fusion proteins. Preferred fusions include
CC double fusions between NS4B and NS5B and between Core and NS3. The
CC vaccines are useful for the treatment or prevention of an HCV infection.

XX
XX SQ Sequence 592 AA;

Query Match 95.2%; Score 3014; DB 8; Length 592;

Best Local Similarity 96.1%; Pred. No. 1.8e-279;

Matches 569; Conservative 14; Mismatches 9; Indels 0; Gaps 0;

Qy 4 MSMSYTWGALITPCAAEESKLPINALNSLRHNLVYTTSSASLRQKKVTFDRLOV 63

Db 1 MSMSYTWGALITPCAAEESKLPINPLNSLRHNLVYTTSSASLRQKKVTFDRLOV 60

Qy 64 LDDHYRDVLEKMKAKASTVTKALISVEACKLTPPHSAKSKFGYCAKDVRSLSRVNH 123

Db 61 LDDHYRDVLEKMKAKASTVTKALISVEACKLTPPHSAKSKFGYCAKDVRSLSRVNH 120

Qy 124 RSVNKKDLEDDTPTQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVDV 183

Db 121 RSVNKKDLEDDTPTQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAVDV 180

Qy 184 STLPAQVMGSSYGFQYSPKQKVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESI 243

Db 181 STLPAQVMGSSYGFQYSPKQKVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESI 240

Qy 244 YQCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTTCYLKA 303

Db 241 YQCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTTCYLKA 300

Qy 304 AACRAAKLQDCTMLVNGDDLWVVCESAGTQEDAAASLRVFTTEAMTRYAPPDGPQPEYD 363
Db 301 TAACRAAKLQDCTMLVNGDDLWVVCESAGTQEDAAALRAFTTEAMTRYAPPDGPQPEYD 360
Qy 364 LELITSCSSNVSAHDASGKRVYVLTDRPTVPLARAAMETARHTTVNSWLGNIIMYAPTL 423
Db 361 LELITSCSSNVSAHDASGKRVYVLTDRPTVPLARAAMETARHTTVNSWLGNIIMYAPTL 420
Qy 424 WARMLMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSP 483
Db 421 WARMLMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSP 480
Qy 484 GEINRVASCLRLKLGVPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLTP 543
Db 481 GEINRVASCLRLKLGVPPLRVWRHARSVRAKLLSQGGRAATCGRYLFWNAVTKLKLTP 540
Qy 544 PAASRLDLGSHFVAGYSGGDIYHSLSRARPMFLCLLLLSVGVGIIYLLPNR 595
Db 541 PAASQLDLSGWFVAGYSGGDIYHSLSRARPMFLCLLLLSVGVGIIYLLPNR 592

RESULT 15

AA06423

ID AA06423 standard; protein; 3010 AA.

XX
AC AA06423;

XX
XX 20-MAR-2003 (revised)

XX
XX 27-SEP-1999 (first entry)

XX
XX Non-A, non-B hepatitis virus polypeptide.

XX
XX Non-A, non-B hepatitis B virus; NANBV; antigen; infection; diagnosis;

XX
XX vaccine.

XX
XX Non-A.

XX
XX non-B hepatitis virus.

XX
XX Key Location/Qualifiers

XX
XX Protein

XX
XX /note= "core protein"

XX
XX Protein

XX
XX /note= "matrix protein"

XX
XX Protein

XX
XX /note= "envelope protein"

XX
XX Protein

XX
XX /note= "NS1 protein"

XX
XX Protein

XX
XX /note= "NS2 protein"

XX
XX Protein

XX
XX /note= "NS3 protein"

XX
XX Protein

XX
XX /note= "NS4a protein"

XX
XX Protein

XX
XX /note= "NS4b protein"

XX
XX Protein

XX
XX /note= "NS5 protein"

XX
XX EP933426-A1.

XX
XX 04-AUG-1999.

XX
XX 28-DEC-1990; 99EP-00106005.

XX
XX 25-JUN-1990; 90JP-00167466.

XX
XX 31-AUG-1990; 90JP-00230921.

XX
XX 09-NOV-1990; 90JP-00305605.

XX
XX 28-DEC-1990; 90EP-00314371.

XX
XX (OSAU) UNIV OSAKA.

XX
XX Okayama H, Fuke I, Mori C, Takamizawa A, Yoshida I;

Search completed: September 22, 2005, 14:47:11
Job time : 172 secs

```

XX WPI: 1999-407152/35.
DR N-PSDB; AAX59394.
XX
PT New hepatitis virus polypeptides, useful for diagnosing and treating
PT hepatitis infections.
XX
PS Claim 2; Fig 2(1)-(16); 56pp; English.
XX
CC This sequence represents the non-A, non-B hepatitis virus (NANBV)
CC polypeptide, as predicted from cDNA (see AAX59394) containing the entire
CC open reading frame of the NANBV genome. To obtain this cDNA, NANBV RNAs
CC were extracted directly from NANBV particles contained in whole blood of
CC a patient having NANB hepatitis, or from a resected liver of a patient
CC having NANB hepatitis and liver cancer. The RNA was then converted to
CC double-stranded cDNA. A cDNA library was produced and screened using
CC serum from a convalescent patient having acute NANB hepatitis and serum
CC from a patient having chronic NANB hepatitis. The isolated cDNA allows
CC recombinant production of NANBV antigen polypeptides in microbial or
CC eukaryotic cell culture. The method provides the safe production of NANBV
CC antigens with high purity on a large scale at low cost without the
CC biohazard associated with multiplying virus in animals. Claimed NANBV
CC nucleotide sequences are useful for the recombinant production of
CC polypeptides useful as antigens for vaccines, and as diagnostic reagents.
CC (Updated on 20-MAR-2003 to correct PF field.) (Updated on 20-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 3010 AA;
    Query Match          95.2%; Score 3014; DB 2; Length 3010;
    Best Local Similarity 96.6%; Pred. No. 2,3e-278;
    Matches 571; Conservative 10; Mismatches 10; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAAESKLPINALSNSLLRHNLVYSTTSRSASLRFQKKVTFDRLOVL 64
DB 2420 SMSYTWTCALITPCAAESKLPINALSNSLLRHNLVYSTTSRSASLRFQKKVTFDRLOVL 2479
QY 65 DDHYRDVLKEMKASTYKALLSVEEACKLTPHSAKSKFGYGNKDVSRSLSSRAVNHIR 124
DB 2480 DDHYRDVLKEMKASTYKALLSVEEACKLTPHSAKSKFGYGNKDVSRSLSSRAVNHIR 2539
QY 125 SVWKDLLEDTDTPITIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
DB 2540 SVWKDLLEDTDTPITIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 2599
QY 185 TLPQAVMGSSYGFQYSPQGVFEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESYI 244
DB 2600 TLPQAVMGSSYGFQYSPQGVFEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESYI 2659
QY 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKGNGCYRCRASGVLTTSCGNTLTCYLKAA 304
DB 2660 QCCDLAPARQAIRSLTERLYVGGPMTNSKGNGCYRCRASGVLTTSCGNTLTCYLKAA 2719
QY 305 AACRAKLQDCTMLVNGDDLVCESAGTQBDASLRVFTAMTRYSAAPPDPOPEYDL 364
DB 2720 AACRAKLQDCTMLVNGDDLVCESAGTQBDASLRVFTAMTRYSAAPPDPOPEYDL 2779
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
DB 2780 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 2839
QY 425 ARMLIMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSPG 484
DB 2840 ARMLIMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSPG 2899
QY 485 EINRVASCLRLKLGVPPLRVWRHARSVRKALLSQGRAAICGKYLFWNAVTKLKTPIIP 544
DB 2900 EINRVASCLRLKLGVPPLRVWRHARSVRKALLSQGRAAICGKYLFWNAVTKLKTPIIP 2959
QY 545 AASRLDLSGWVFVAGYSGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 595
DB 2960 AASRLDLSGWVFVAGYSGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 3010
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:40:28 ; Search time 19 Seconds
(without alignments)
3043.488 Million cell updates/sec

Title: US-10-712-479-2

Perfect score: 3167

Sequence: 1 MASMSMTWTGALITPCAA.....LLSVGVGIYLLPNRHHHHH 601

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_79:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3016	95.2	3010	1 GNMVJC	genome polyprotein
2	3016	95.2	3010	1 GNMVJC	genome polyprotein
3	3003	94.8	3010	1 A45573	genome polyprotein
4	2968	93.7	3010	1 GNMVTC	genome polyprotein
5	2944	93.0	3010	1 S18030	genome polyprotein
6	2798	88.3	3011	1 S40770	genome polyprotein
7	2764	87.3	3011	1 GNMVJC	genome polyprotein
8	2725	86.0	3011	1 GNMVCH	genome polyprotein
9	2511	79.3	3014	1 JC5620	genome polyprotein
10	2392	75.5	3033	1 GNMVJ8	genome polyprotein
11	2380	75.1	3033	1 JQ1303	genome polyprotein
12	1886	59.6	365	2 JQ0879	NS5 protein - hepa
13	1750	55.3	365	2 JQ0880	NS5 protein - hepa
14	1471.5	46.5	874	2 JQ0883	genome polyprotein
15	1442	45.5	874	2 JQ0881	genome polyprotein
16	951	30.0	189	2 S60587	non-structural pro
17	774	24.4	284	2 P80104	genome polyprotein
18	744	23.5	259	2 P30102	genome polyprotein
19	719	22.7	156	2 D39109	genome polyprotein
20	667	21.1	135	2 S44214	genome polyprotein
21	654	20.7	3005	2 T08841	polyprotein - dour
22	636	20.1	1435	2 T01075	polyprotein - hepa
23	629	19.9	2970	2 T08839	polyprotein - marm
24	569	18.0	113	2 PC1278	NS5 protein - hepa
25	563	17.8	113	2 PC1277	NS5 protein - hepa
26	562	17.7	113	2 PC1274	NS5 protein - hepa
27	562	17.7	113	2 PC1275	NS5 protein - hepa
28	560	17.7	113	2 PC1276	NS5 protein - hepa
29	513	16.2	113	2 PC1279	NS5 protein - hepa

ALIGNMENTS

RESULT 1

GNMVJC

genome polyprotein - hepatitis C virus (strain J)

N:contains: capsid protein C; envelope protein M; major envelope protein E; nonstructural protein NS4a; nonstructural protein NS4b; nonstructural protein NS5

C:Species: hepatitis C virus

C:Date: 30-Jun-1992 #sequence_revision 30-Jun-1992 #text_change 09-Jul-2004

C:Accession: A39253; PS0086

R:Kato, N.; Hijikata, M.; Ootsuyama, Y.; Nakagawa, M.; Ohkoshi, S.; Sugimura, T.; Shimoto

Proc. Natl. Acad. Sci. U.S.A. 87, 9524-9528, 1990

A:Title: Molecular cloning of the human hepatitis C virus genome from Japanese patients v

A:Reference number: A39253; MUID:91088550; PMID:2175903

A:Accession: A39253

A:Molecule type: genomic RNA

A:Residues: 1-3010 <KA>

A:Cross-references: UNIPROT:P26662; GB:D90208; NID:G221610; PID:BAAL4233.1; PID:G221611

R:Kato, N.; Ohkoshi, S.; Shimotohno, K.

Proc. Jpn. Acad. 65B, 219-223, 1989

A:Title: Japanese isolates of the non-A, non-B hepatitis viral genome show sequence varie

A:Reference number: PS0085

A:Accession: PS0086

A:Molecule type: Genomic RNA

A:Residues: 2650-2707 <KA2>

A:Experimental source: Japanese isolate

C:Comment: The cleavage sites of this polyprotein have not been determined.

C:Superfamily: hepatitis C virus genome polyprotein

C:Keywords: ATP; glycoprotein; hydrolase; nucleotide binding; P-loop; polyprotein; serine

F:2-115/Product: capsid protein C #status predicted <CPC>

F:116-191/Product: envelope protein M #status predicted <BPM>

F:192-389/Product: major envelope protein E #status predicted <MBE>

F:390-729/Product: nonstructural protein NS1 #status predicted <NS1>

F:730-1006/Product: nonstructural protein NS2 #status predicted <NS2>

F:1007-1615/Product: hepatitis C virus #status predicted <NS3>

F:1230-1237/Region: nucleotide-binding motif A (P-loop)

F:1312-1317/Region: DEXH motif

F:1316-1862/Product: nonstructural protein NS4a #status predicted <NS4>

F:1863-2013/Product: nonstructural protein NS4b #status predicted <NS4b>

F:2014-2019/Product: nonstructural protein NS5 #status predicted <NS5>

F:196,209,234,250,305,325,417,423,430,448,532,556,576,623,645,1213,1255,2041,2077,2240,2;

Query Match 95.2%; Score 3016; DB 1; Length 3010;

Best Local Similarity 96.3%; Pred. No. 3.8e-223;

Matches 569; Conservative 12; Mismatches 10; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAAEESKLPINALSNLRHNLVYSTTSRSASLRQKKVTFDLQVL 64

Db 2420 SMSYTWGALITPCAAEESKLPINPLSNLRHNSMVYSTTSRSASLRQKKVTFDLQVL 2479

Qy 65 DDHYRDVLKEMKAKASTVKALLSVBEACKLTPPHSAKSKFGYKGVKQVRSLSRAVNHIR 124

Db 2480 DDHYRDVLKEMKAKASTVKARLLSIEACKLTPPHSAKSKFGYKGVKQVRSLSRAVNHIR 2539

```
QY 125 SVMKDLLEDTTPIOTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS 184
Db 2540 SVWEDLLEDTTPIOTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS 2599

QY 185 TLPQAVMGSSYGFQYSPQKRVFELVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPQAVMGSPYGFQYSPQKRVFELVNTWKSKKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659

QY 245 QCCDLAPPEARQAIISRLTERLYVGGPMWNSKQNGCYRRCRASGVLTTCGNTLTCYLKAA 304
Db 2660 QCCDLAPPEARQAIISRLTERLYVGGPLTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAT 2719

QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAALRAFTTEAMTRYSPAGDPPOPEYDL 2779

QY 365 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Db 2780 ELITSCSSNVSAHDASGKRVYILTRDPTTTPPLARAAMETARHTPVNSWLGNIIMVAPTLW 2839

QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 2899

QY 485 EINRVASCLRKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLEFNWAVTKLKLTPIP 544
Db 2900 EINRVASCLRKLGVPPLRVWHRARSVRAKLLSOGGAAATCGKYLEFNWAVTKLKLTPIP 2959

QY 545 AASRLDLSGWVFVAGYSGGDIYHLSLRAPRPFMLCLLLLSVGVGIYLLPNR 595
Db 2960 AASRLDLSGWVFVAGYSGGDIYHLSLRAPRPFMLCLLLLSVGVGIYLLPNR 3010

RESULT 2
GNVWTC
genome polyprotein - hepatitis C virus
N;Contains: capsid protein C; envelope protein M; hepatitis C virus genome polyprotein NS5
C;Species: hepatitis C virus
C;Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 09-Jul-2004
C;Accession: A38465
R;Takamizawa, A.; Mori, C.; Fuke, I.; Manabe, S.; Murakami, S.; Fujita, J.; Onishi, E.;
J. Virol. 65, 1105-1113, 1991
A;Title: Structure and organization of the hepatitis C virus genome isolated from human
A;Reference number: A38465; MUID:91140698; PMID:1847440
A;Accession: A38465
A;Molecule type: genomic RNA
A;Residues: 1-3010 <TAK>
A;Cross-references: UNIPROT:P26663; EMBL:M58335; NID:g329770; PIDN:AAAT2945.1; PID:g3297
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: ATP; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructural
F;2-115/Product: capsid protein C #status predicted <CPC>
F;116-191/Product: envelope protein M #status predicted <EPM>
F;192-389/Product: major envelope protein E #status predicted <MEE>
F;330-729/Product: nonstructural protein NS1 #status predicted <NS1>
F;730-1006/Product: nonstructural protein NS2 #status predicted <NS2>
F;1007-1615/Product: hepatitis C virus genome polyprotein
F;1230-1237/Region: nucleotide-binding motif A (P-loop)
F;1312-1317/Region: nucleotide-binding motif B
F;1316-1319/Region: DEXH motif
F;1616-1862/Product: nonstructural protein NS4a #status predicted <N4a>
F;1863-2013/Product: nonstructural protein NS4b #status predicted <N4b>
F;2014-3010/Product: nonstructural protein NS5 #status predicted <NS5>
F;196,209,234,250,305,325,417,423,430,448,534,540,556,576,623,645,1213,1255,2041,2077,22
Query Match 95.2%; Score 3016; DB 1; Length 3010;
Best Local Similarity 96.6%; Pred. No. 3.8e-253; Indels 0; Gaps 0;
Matches 571; Conservative 11; Mismatches 9;

QY 5 SMSYTWTCALITPCAEESEKLPINALNSLRHNLVYTTTSRGSASLRQKVKVTFDRQLQVL 64
Db 2420 SMSYTWTCALITPCAEESEKLPINALNSLRHNLVYTTTSRGSASLRQKVKVTFDRQLQVL 2479
```

```
QY 65 DDHYRDVLEKMAKASTVYKAKLLSVBEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 2480 DDHYRDVLEKMAKASTVYKAKLLSVBEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 2539

QY 125 SVMKDLLEDTTPIOTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS 184
Db 2540 SVMKDLLEDTTPIOTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS 2599

QY 185 TLPQAVMGSSYGFQYSPQKRVFELVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPQAVMGSSYGFQYSPQKRVFELVNTWKSKKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659

QY 245 QCCDLAPPEARQAIISRLTERLYVGGPMWNSKQNGCYRRCRASGVLTTCGNTLTCYLKAA 304
Db 2660 QCCDLAPPEARQAIISRLTERLYVGGPLTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAS 2719

QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAGDPPOPEYDL 2779

QY 365 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Db 2780 ELITSCSSNVSAHDASGKRVYILTRDPTTTPPLARAAMETARHTPVNSWLGNIIMVAPTLW 2839

QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 2899

QY 485 EINRVASCLRKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLEFNWAVTKLKLTPIP 544
Db 2900 EINRVASCLRKLGVPPLRVWHRARSVRAKLLSOGGAAATCGKYLEFNWAVTKLKLTPIP 2959

QY 545 AASRLDLSGWVFVAGYSGGDIYHLSLRAPRPFMLCLLLLSVGVGIYLLPNR 595
Db 2960 AASRLDLSGWVFVAGYSGGDIYHLSLRAPRPFMLCLLLLSVGVGIYLLPNR 3010

RESULT 3
A45573
genome polyprotein - hepatitis C virus (strain JT)
N;Contains: capsid protein C; envelope protein M; hepatitis C virus genome polyprotein NS5
C;Species: hepatitis C virus
C;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004
C;Accession: A45573
R;Tanaka, T.; Kato, N.; Nakagawa, M.; Ootsuyama, Y.; Cho, M.J.; Nakazawa, T.; Hijikata, N.
Virus Res. 23, 39-53, 1992
A;Title: Molecular cloning of hepatitis C virus genome from a single Japanese carrier: se
A;Reference number: A45573; MUID:92295714; PMID:1318627
A;Accession: A45573
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-3010 <TAN>
A;Cross-references: UNIPROT:Q00269; GB:D11168; GB:D11168; NID:g221612; PIDN:BAA01943.1; I
A;Experimental source: HCV-JT
A;Note: sequence extracted from NCBI backbone (NCBI:106206, NCBI:106207)
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: ATP; glycoprotein; hydrolase; nucleotide binding; P-loop; polyprotein; serine
F;2-115/Product: capsid protein C #status predicted <CPC>
F;116-191/Product: envelope protein M #status predicted <EPM>
F;192-389/Product: major envelope protein E #status predicted <MEE>
F;330-729/Product: nonstructural protein NS1 #status predicted <NS1>
F;730-1006/Product: nonstructural protein NS2 #status predicted <NS2>
F;1007-1615/Product: hepatitis C virus genome polyprotein
F;1230-1237/Region: nucleotide-binding motif A (P-loop)
F;1312-1317/Region: nucleotide-binding motif B
F;1316-1319/Region: DEXH motif
F;1616-1862/Product: nonstructural protein NS4a #status predicted <N4a>
F;1863-2013/Product: nonstructural protein NS4b #status predicted <N4b>
F;2014-3010/Product: nonstructural protein NS5 #status predicted <NS5>
Query Match 94.8%; Score 3003; DB 1; Length 3010;
```


F:1863-2013/Product: nonstructural protein NS4b #status predicted <N4>		
F:2014-3010/Product: nonstructural protein NS5 #status predicted <NS5>		
F:196,209,233,234,250,325,417,423,430,448,556,576,623,645,1213,1255,2041,207:		
Query Match	93.7%: Score 2968; DB 1; Length 3010;	
Best Local Similarity	94.9%: Pred. No. 1.9e-219;	
Matches 561; Conservative 15; Mismatches 15; Indels 0; Gaps 0;		
Qy	5 SMSYTTWTGALITPCAAEESKLPINALNSLLRHNLVYSTTSRSASLRKKVTFDRQLVL 64	
Db	2420 SMSYTTWTGALITPCAAEESKLPINALNSLLRHNLVYSTTSRSASLRKKVTFDRQLVL 2479	
Qy	65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVSLSSRAVNHIR 124	
Db	2480 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVSLSSRAVNHIR 2539	
Qy	125 SVKXDLLEDTPDTIOTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMAALYDVVS 184	
Db	2540 SVKXDLLEDTPDTIOTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMAALYDVVS 2599	
Qy	185 TLPQAVMGSSYGFQSPQQRVEFLVNTWAKKACPMGFSDYTRCFDSTVTENDIRVEESIY 244	
Db	2600 TLPQAVMGSSYGFQSPQQRVEFLVNTWAKKACPMGFSDYTRCFDSTVTENDIRVEESIY 2659	
Qy	245 QCCDLAPEARQAIRSLTERLYXVGPMNTSKGQNCYRCRASGVLTTSCGNTLTCYLKAA 304	
Db	2660 QCCDLAPEARQAIRSLTERLYXVGPMNTSKGQNCYRCRASGVLTTSCGNTLTCYLKAS 2719	
Qy	305 AACBAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRFVTEAMTRYSAAPGPPQPEYDL 364	
Db	2720 AACBAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRFVTEAMTRYSAAPGPPQPEYDQ 2779	
Qy	365 ELITSCSNVSAVHADSGKRVYLYLTRDPTVPLARAAMETARHTPVNSWLTGNIIMYAPTLM 424	
Db	2780 ELITSCSNVSAVHADSGKRVYLYLTRDPTVPLARAAMETARHTPVNSWLTGNIIMYAPTLM 2839	
Qy	425 ARMTLMTWTFPSILLAOBLEKALDCQIYGACYSIEPLDLPQIIERLHGLSASFSLHSYSPG 484	
Db	2840 ARMTLMTWTFPSILLAOBLEKALDCQIYGACYSIEPLDLPQIIERLHGLSASFSLHSYSPG 2899	
Qy	485 E1NRVASCLRLKGLVPPFLRVMRHARSVRAKLLSQGGRAAICGKYLFNMAVRKTLKLTPIP 544	

QY 545 AASRLDLSGWMFVAGSGGDIIYHSLSRAPRWFMLCLLLSVGVGIYLLPNR 595
|||||
Db 2960 AASQLDLSKFMFVAGSGGDIIYHSLSRAPRWFMLCLLLSVGVGIYLLPNR 3010
|||||

RESULT 5
S18030

genome polyprotein - hepatitis C virus (isolate JK1)
N;Contains: capsid protein C; envelope protein M; hepacivirin (EC 3.4.21.98) (nonstructural protein NS4a; nonstructural protein NS4b; nonstructural protein NS5
C;Species: hepatitis C virus
A;Variety: isolate JK1
A;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004
C;Accession: S18030; S33570; A48332; S18029
R/Honda, M.; Kaneko, S.; Masashi, U.; Kobayashi, K.; Murakami, S.
submitted to the EMBL Data Library, September 1991
A;Description: A whole genome of hepatitis C virus cDNA was isolated from a single patient
A;Reference number: S18028
A;Accession: S18030
A;Molecule type: genomic RNA
A;Residues: 1-3010 <HON>
A;Cross-references: UNIPROT:Q68949; EMBL:X61596; NID:g59478; PID:CAA43793.1; PID:g59479
A;Experimental source: isolate JK1 from an individual
R/Honda, M.; Kaneko, S.; Uncoura, R.; Kobayashi, K.; Murakami, S.
Arch. Virol. 128, 163-169, 1993
A;Title: Sequence analysis of putative structural regions of hepatitis C virus isolated f
A;Reference number: A48332; MUID:93119270; PMID:8380322
A;Accession: S33570
A;Molecule type: genomic RNA

A;Residues: 1-547,'T',549-621,'V',623-624,'S',626-652,'DL',655-761,'T',763-782 <HOW>									
A;Cross-references: EMBL:X61591									
A;Note: this sequence is inconsistent with the nucleotide translation									
A;Note: the authors translated the codon AGG for residue 43 as Pro, TGG for residue 320 as Trp, and TTC for residue 771 as Ser									
A;Note: sequence extracted from NCBI backbone (NCBIN:121747, NCBIPI:121748)									
C;Superfamily: hepatitis C virus genome polyprotein									
F;2-115/Product: capsid protein C #status predicted <CPC>									
F;116-191/Product: envelope protein M #status predicted <EPM>									
F;192-389/Product: major envelope protein E #status predicted <MEE>									
F;730-729/Product: nonstructural protein NS1 #status predicted <NS1>									
F;730-1006/Product: nonstructural protein NS2 #status predicted <NS2>									
F;1007-1615/Product: hepatitis C virus genome polyprotein									
F;1230-1237/Product: hepatitis C virus genome polyprotein									
F;1312-1317/Product: hepatitis C virus genome polyprotein									
F;1316-1862/Product: nonstructural protein NS4a #status predicted <N4A>									
F;1863-2013/Product: nonstructural protein NS4b #status predicted <N4B>									
F;2014-3011/Product: nonstructural protein NS5 #status predicted <NS>									
F;196,209,234,250,305,417,423,448,532,540,556,576,623,645/Binding site: carbohydrate (As									
Query Match 93.0%; Score 2944; DB 1; Length 3010;									
Best Local Similarity 93.9%; Pred. No. 1.3e-217;									
Matches 559; Conservative 17; Mismatches 19; Indels 0; Gaps 0;									
Qy	1	MASMSYTWGALITPCAAESKLPINALNSLLRHNLVYVSTTSRASLRQKKVTFDR	60						
Db	2416	VACCSMSYTWGALITPCAAESKLPINPLNSLLRHNLVYVSTTSRASLRQKKVTFDR	2475						
Qy	61	LQVLDHRYDVLKEMKAASTVKAKLLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAV	120						
Db	2476	LQVDDHRYDVLKEMKAASTVKAKLLSVEACKLTPPHSAKSKFGYCAKDVRLSSRAV	2535						
Qy	121	NHRSVWKDLLEDTPITQTTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMA	180						
Db	2536	NHHSVWKDLLEDTPITDTTMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMA	2595						
Qy	181	DVSTLPOAVMGSSYGFQYSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVE	240						
Db	2596	DVSTLPOAVMGSSYGFQYSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVE	2655						
Qy	241	ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGLVLTSCGNLTLCY	300						
Db	2656	ESIYQCCDLAPEARQVIRSLTERLYVGGPMTNSKQNGCYRRCRASGLVLTSCGNLTLCY	2715						
Qy	301	LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQ	360						
Db	2716	LKASAAACRAAKLQDCTMLVCGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQ	2775						
Qy	361	EYDLELITSCSSNSVVAHDASGKRVYVLTTRDPTVPLAAAWETARHTPVNSWLGNIIMYA	420						
Db	2776	EYDLELITSCSSNSVVAHDASGKRVYVLTTRDPTVPLAAAWETARHTPVNSWLGNIIMYA	2835						
Qy	421	PTLWARMILMTFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS	480						
Db	2836	PTLWARMILMTFFSILLAQOLEKALDCQIYGATYFIEPLDLPOIIRLHGLSAFSLHS	2895						
Qy	481	YSPGEINRVASCLRLKGLVPPPLRVWHRARSVRKLLSQGGRAATCGKYLFWAVRTKLKL	540						
Db	2896	YSPGEINRVASCLRLKGLVPPPLRVWHRARSVRKLLSQGGRAATCGKYLFWAVRTKLKL	2955						
Qy	541	TPIPAASRLDLSGWVAGYSGDDIYHLSRARPRWFMCLLLLSVGVGIIYLLPNR	595						
Db	2956	TPIPAASQLDLSGWVAGYSGDDIYHLSRARPRWFMCLLLLSVGVGIIYLLPNR	3010						
RESULT 6									
S40770									
Genome polyprotein - hepatitis C virus									
N;Contains: capsid protein C; envelope protein M; hepatitis C virus									
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5									
C;Species: hepatitis C virus									

C;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004									
C;Accession: S40770; PC1285									
R;Okamoto, H.									
submitted to the EMBL Data Library, March 1992									
A;Reference number: S40770									
A;Accession: S40770									
A;Molecule type: genomic RNA									
A;Residues: 1-3011 <OKA>									
A;Cross-references: UNIPROT:Q03463; EMBL:D10749; NID:g221586; PIDN:BAA01582.1; PID:g22158									
R;Okamoto, H.; Okada, S.; Sugiyama, Y.; Yotsumoto, S.; Tanaka, T.; Yoshizawa, H.; Tsuda,									
Jpn. J. Exp. Med. 60, 167-177, 1990									
A;Title: The 5'-terminal sequence of the hepatitis C virus genome.									
A;Reference number: PC1284; MUID:91013116; PMID:2170712									
A;Accession: PC1285									
A;Molecule type: genomic RNA									
A;Residues: 1-513 <OK2>									
A;Cross-references: GB:D00831; NID:g221511; PIDN:BAA00705.1; PID:g221512									
A;Experimental source: Isolate HC-J1									
C;Superfamily: hepatitis C virus genome polyprotein									
C;Keywords: ATP; glycoprotein; hydrolase; nucleotide binding; P-loop; polyprotein; serine									
F;2-115/Product: capsid protein C #status predicted <CPC>									
F;116-191/Product: envelope protein M #status predicted <EPM>									
F;192-389/Product: major envelope protein E #status predicted <MEE>									
F;730-729/Product: nonstructural protein NS1 #status predicted <NS1>									
F;730-1006/Product: nonstructural protein NS2 #status predicted <NS2>									
F;1007-1615/Product: hepatitis C virus genome polyprotein									
F;1230-1237/Product: hepatitis C virus genome polyprotein									
F;1312-1317/Product: hepatitis C virus genome polyprotein									
F;1316-1862/Product: nonstructural protein NS4a #status predicted <N4A>									
F;1863-2013/Product: nonstructural protein NS4b #status predicted <N4B>									
F;2014-3011/Product: nonstructural protein NS5 #status predicted <NS>									
Query Match 88.3%; Score 2798; DB 1; Length 3011;									
Best Local Similarity 88.8%; Pred. No. 2.3e-206;									
Matches 525; Conservative 28; Mismatches 38; Indels 0; Gaps 0;									
Qy	5	SMSYTWGALITPCAAESKLPINALNSLLRHNLVYVSTTSRASLRQKKVTFDR	64						
Db	2421	SMSYTWGALITPCAAEQKLPINALNSLLRHNLVYVSTTSRASLRQKKVTFDR	2480						
Qy	65	DDHYRDVLKEMKAASTVKAKLLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR	124						
Db	2481	DSHYQDVLKEMKAASTVKAKLLSVEACKLTPPHSAKSKFGYCAKDVRCARKAVNHIN	2540						
Qy	125	SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMA	184						
Db	2541	SVWKDLLEDSTPTITQTTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMA	2600						
Qy	185	TLPOAVMGSSYGFQYSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVE	244						
Db	2601	KLPPAVMGSSYGFQYSPQORVEFLVQAKSKRTPMGFSYDTRCFDSTVTESDIRTE	2660						
Qy	245	QCCLDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGLVLTSCGNLTLCY	304						
Db	2661	QCCLDLAPQARVIRSLTERLYVGGPMTNSKQNGCYRRCRASGLVLTSCGNLTLCY	2720						
Qy	305	AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYAPPDPPQ	364						
Db	2721	AACRAAGLQDCTMLVCGDDLVIICESAGVQEDAAASLRVFTTEAMTRYAPPDPPQ	2780						
Qy	365	ELITSCSSNSVVAHDASGKRVYVLTTRDPTVPLAAAWETARHTPVNSWLGNIIMYA	424						
Db	2781	ELITSCSSNSVVAHDGTGKRVYVLTTRDPTVPLAAAWETARHTPVNSWLGNIIMYA	2840						
Qy	425	ARMILMTFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS	484						
Db	2841	ARMILMTFFSVLJARQLEALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS	2900						
Qy	485	EINRVASCLRLKGLVPPPLRVWHRARSVRKLLSQGGRAAICGKYLFWAVRTKL	544						
Db	2901	EINRVAACLRLKGLVPPPLRVWHRARSVRKLLSGGAAICGKYLFWAVRTKL	2960						

[illegible]

```
QY 125 SVWKDLLEDDTPTPIOTTIMAKNEVFCVQPEKGGKRPKARLIIVFPDLGVRVCEKMALYDVVS 184
DB 2541 SVWKDLLEDDSTPTPIOTTIMAKNEVFCVQPEKGGKRPKARLIIVFPDLGVRVCEKMALYDVVS 2600
QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
DB 2601 KLPLAVMGSSYGFQYSPQORVEFLVQAKSKKTPMGLSYDTRCFDSTVTESDIRTEAIY 2660
QY 245 QCCDLAPPEARQAIRSLTERLYVGGPMTNKSGQNGCYRRCRASGLVTTTSCGNLTLCYLKAA 304
DB 2661 QCCDLDPQARVAIKSLTERLYVGGPLTNSRGNGCYRRCRASRLVTTSCGNLTTRYIKAR 2720
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 2721 AACRAAGLQDCTMLVCGDDLVIICESAGVQDDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 2780
QY 365 ELITSCSSNVSAHDGAKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2781 ELITSCSSNVSAHDGAKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2840
QY 425 ARMLTMTFFSILLAOBQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSPG 484
DB 2841 ARMLTMTFFSVLIARDQLEQALNCEIYGACYSIEPLDLPPIIQRLHGLSAFSLHSPG 2900
QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRAKLSOGGAAICGKYLFWAVRTKLTPIIP 544
DB 2901 EINRVAACLRLKGLVPPPLRAWRHRSVRARLLARGGKAAICGKYLFWAVRTKLTPIIT 2960
QY 545 AASRLDLSGFWFVAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGIYLLPNR 595
DB 2961 AAGRLDLSGFWTAGYSGGDIYHSHVSHARPRWFMFCLLLLAAGVGIYLLPNR 3011

RESULT 9
JC5620
genome polyprotein - hepatitis C virus (isolate EUH1480)
N;Contains: capsid protein C; envelope protein M; hepatitis C virus genome polyprotein
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5
C;Species: hepatitis C virus
C;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004
C;Accession: JC5620
R;Chamberlain, R.W.; Adams, N.J.; Taylor, L.A.; Simmonds, P.; Elliott, R.M.
Biochem. Biophys. Res. Commun. 236, 44-49, 1997
A;Title: The complete coding sequence of hepatitis C virus genotype 5a, the predominant
A;Reference number: JC5620; MUID:97366593; PMID:9223423
A;Accession: JC5620
A;Molecule type: mRNA
A;Residues: 1-3014 <CHA>
A;Cross-references: UNIPROT:O39928; GB:Y13184
A;Experimental source: genotype 5a, which predominates in South Africa
A;Note: the translation of the nucleotide sequence is not complete in this paper
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: ATP; glycoprotein; hydrolase; nucleotide binding; P-loop; polyprotein; serin
F;2-115/Product: capsid protein C #status predicted <CPC>
F;116-191/Product: envelope protein M #status predicted <EPM>
F;192-389/Product: major envelope protein E #status predicted <MEE>
F;384-408/Region: hypervariable #status predicted
F;390-730/Product: nonstructural protein NS1 #status predicted <NS1>
F;731-1007/Product: nonstructural protein NS2 #status predicted <NS2>
F;1008-1616/Product: hepatitis C virus genome polyprotein #status predicted <NS3>
F;1231-1238/Region: nucleotide-binding motif A (P-loop)
F;1313-1318/Region: nucleotide-binding motif B
F;1317-1320/Region: DEXH motif
F;1617-1863/Product: nonstructural protein NS4a #status predicted <NS4a>
F;1864-2014/Product: nonstructural protein NS4b #status predicted <NS4b>
F;2015-3014/Product: nonstructural protein NS5 #status predicted <NS5>
F;2210-2249/Region: interferon sensitivity determining #status predicted

Query Match 79.3%; Score 2511; DB 1; Length 3014;
Best Local Similarity 78.8%; Pred. No. 2.9e-184;
Matches 466; Conservative 53; Mismatches 72; Indels 0; Gaps 0;
```

```
QY 5 SMSYTWGTGALITPCAAEESKLPINALSNSLLRHNLVYSTTSRSASLRQKVKVTFDRLOVL 64
DB 2424 SMSYTWGTGALITPCSAEEKLPINPLSNLTLRHNLVYSTTSRSAGLRQKVKVTFDRLOVL 2483
QY 65 DDHYRDVLEKEMKAKASTVYKAKLSLVEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 2484 DDHYREVVDKMRKASKVKARLLPLEEACGLTPPHSARSKYGYGAKEVRSLLDKKALHIE 2543
QY 125 SVWKDLLEDDTPTPIOTTIMAKNEVFCVQPEKGGKRPKARLIIVFPDLGVRVCEKMALYDVVS 184
DB 2544 GVWODLLDSDSTPTPIOTTIMAKNEVFAVEPSKGGKRPKARLIIVFPDLGVRVCEKRALYDVAQ 2603
QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
DB 2604 KLPLAVMGSSYGFQYSPAQRVDFLLKAWSKKIIPMAFSYDTRCFDSTITEHDIITEESIY 2663
QY 245 QCCDLAPPEARQAIRSLTERLYVGGPMTNKSGQNGCYRRCRASGLVTTTSCGNLTLCYLKAA 304
DB 2664 QCCDLQPEARVAIRSLTORLYCGGPMYNSKQCGYRRCRASGVTTTSMGNTWTCYIKAL 2723
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 2724 ASCRAAKLRDCTLLVCGDDLVAICESQGTHEDEASLRVFTTEAMTRYSAAPPDPPVAYDL 2783
QY 365 ELITSCSSNVSAHDGAKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2784 ELVTSCSSNVSAHDGAKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2843
QY 425 ARMLTMTFFSILLAOBQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSPG 484
DB 2844 ARIVLMTFFSVLQSQBQLEKTLAFEMVGSYVSTPLDLPALIIQRLHGLSAFSLHSPG 2903
QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRAKLSOGGAAICGKYLFWAVRTKLTPIIP 544
DB 2904 EINRVASCLRLKGLVPPPLRAWRHRSVRARAKLJAQGGAAICGKYLFWAVRTKLTPLA 2963
QY 545 AASRLDLSGFWFVAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGIYLLPNR 595
DB 2964 DADRLDLSSTFTVGAGGDIYHNSRARPRNLLLCLLLSVGVGIFILLPAR 3014

RESULT 10
GNWJ78
genome polyprotein - hepatitis C virus (strain HC-J8)
N;Contains: capsid protein C; envelope protein M; hepatitis C virus genome polyprotein
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5
C;Species: hepatitis C virus
C;Date: 31-Dec-1992 #sequence_revision 31-Dec-1992 #text_change 09-Jul-2004
C;Accession: A40250; PQ0397; PQ0559
R;Okamoto, H.; Kurai, K.; Okada, S.I.; Yamamoto, K.; Lizuka, H.; Tanaka, T.; Fukuda, S.;
Virology 188, 331-341, 1992
A;Title: Full-length sequence of a hepatitis C virus genome having poor homology to repo:
A;Reference number: A40250; MUID:92230232; PMID:1314459
A;Accession: A40250
A;Molecule type: genomic RNA
A;Residues: 1-3033 <OKA>
A;Cross-references: UNIPROT:P26661; GB:D10988; GB:D01221; NID:g221608; PIDN:BAA01761.1; I
J.Chan, S.W.; McOmish, F.; Holmes, E.C.; Dow, B.; Feutheer, J.F.; Follett, E.; Yap, P.L.
J. Gen. Virol. 73, 1131-1141, 1992
A;Title: Analysis of a new hepatitis C virus type and its phylogenetic relationship to e
A;Reference number: PQ0393; MUID:92268871; PMID:1316939
A;Accession: PQ0397
A;Molecule type: genomic RNA
A;Residues: 2678-2754 <CHA>
A;Cross-references: DDBJ:D10134
A;Experimental source: isolate E-b12
R;Kato, N.; Ootsuyama, Y.; Ohkoshi, S.; Nakazawa, T.; Mori, S.; Hijikata, M.; Shimotohno,
Biochem. Biophys. Res. Commun. 181, 279-285, 1991
A;Title: Distribution of plural HCV types in Japan.
A;Reference number: PQ0554; MUID:92068204; PMID:1720309
A;Accession: PQ0559
A;Molecule type: mRNA
A;Residues: 2678-2729 <KAT>
```

A;Cross-references: GB:D10562; GB:P90518; NID:g221523; PIDN:BAA01418.1; PID:g221524
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: ATP; capsid protein; envelope protein; glycoprotein; hydrolase; nonstructural
P;1-115/Product: capsid protein C #status predicted <CPC>
P;116-191/Product: envelope protein M #status predicted <BPM>
P;192-389/Product: major envelope protein E #status predicted <MBE>
P;390-733/Product: nonstructural protein NS1 #status predicted <NS1>
P;734-1010/Product: nonstructural protein NS2 #status predicted <NS2>
P;1011-1619/Product: hepatitis C virus genome polyprotein
P;1234-1241/Product: capsid protein C #status predicted <CPC>
P;1234-1241/Product: envelope protein M #status predicted <BPM>
P;1316-1321/Region: nucleotide-binding motif A (P-loop)
P;1316-1321/Region: nucleotide-binding motif B
P;1320-1323/Region: DEXH motif
P;1620-1866/Product: nonstructural protein NS4a #status predicted <N4A>
P;1867-2017/Product: nonstructural protein NS4b #status predicted <N4B>
P;2018-3033/Product: nonstructural protein NS5 #status predicted <NS>
P;196,209,233,299,305,417,423,430,448,477,534,542,558,578,627,649,1091,1217,1259,2038,23

Query Match 75.5%; Score 2392; DB 1; Length 3033;
Best Local Similarity 75.5%; Pred. No. 4.2e-175;
Matches 446; Conservative 59; Mismatches 86; Indels 0; Gaps 0;

```
QY 5 SMSTWTGALITPCAABESKLPINALSNLSLRHNLVYTTSSASLRQKVTDFRLOVL 64
DB 2443 SMSTWTGALITPCAABESKLPINALSNLSLRHNLVYTTSSASLRQKVTDFRLOVL 2502

QY 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAOVRSLSRAVNHIR 124
DB 2503 DAHYDSVLQDVKRAKSVARLLTVEEACALTTPPHSAKSKFGYGAOVRSLSRAVNHIR 2562

QY 125 SVWKDLLEDDTPTIOTTIMAKNEVFCVOPKGRKPARLIVPDLGVRCRMALYDVVS 184
DB 2563 SVWKDLLEDDTPTIOTTIMAKNEVFCVOPKGRKPARLIVPDLGVRCRMALYDVVS 2622

QY 185 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 2623 KLPAKIMGPSYGFQYSPAERVDFLKAWGSKKDPMGFSYDTRCFDSTVTENDIRVEESIY 2682

QY 245 QCCDLAPARQAIRSLTERLVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 304
DB 2683 QACSLPQEARVTVIHLTERLVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 2742

QY 305 AACRAAKLQDCTMLVNGDDLVVICSAGTQDAASLRVFTAMTRYSPAPGDPPEYDL 364
DB 2743 AACRAAGITVDPMVLVCGDDLVVISESQNEEDERNLRAFTAMTRYSPAPGDPPEYDL 2802

QY 365 ELITSCSSNVSDANDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 424
DB 2803 ELITSCSSNVSDANDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 2862

QY 425 ARMTLMTFFSILLAQBOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPSLHSYSPG 484
DB 2863 VRWVIMTHFFSILLAQDTLNQNLAPFMYGAVYSVNPDLPLAIIRLHGLSAPSLHSYSPG 2922

QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSOGGRAAICGKYLFWNAVTKLKLTPIP 544
DB 2923 ELSRVAATLRLKGLGAPPLRAWKSRAVARASLIAQARAACGKYLFWNAVTKLKLTPIP 2982

QY 545 AASRLDLSCGFVAGYSGGDIYHLSRARPRFWMCLILLSVGVGIYLLPNR 595
DB 2983 EASRLDLSCGFVAGYSGGDIYHLSRARPRFWMCLILLSVGVGIYLLPNR 3033
```

RESULT 11
QJ01303
Genome polyprotein - hepatitis C virus (isolate HC-J6)
N;Contains: capsid protein C; envelope protein M; hepatitis C virus genome polyprotein
protein NS4a; nonstructural protein NS4b; nonstructural protein NS5
C;Species: hepatitis C virus
C;Date: 19-May-2000 #sequence_revision 19-May-2000 #text_change 09-Jul-2004
C;Accession: JQ01303
R;Okamoto, H.; Sugiyama, Y.; Kura, K.; Iizuka, H.; Machida, A.; Miyakawa, Y.
J. Gen. Virol. 72, 2697-2704, 1991
A;Title: Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human

A;Reference number: JQ1303; MUID:92044440; PMID:1658196

A;Accession: JQ1303
A;Molecule type: genomic RNA
A;Residues: 1-3033 <OKA>
A;Cross-references: UNIPROT:P26660; GB:D00944; NID:g221650; PIDN:BAA00792.1; PID:g221651
A;Experimental source: isolate HC-J6 from a Japanese individual
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: ATP; glycoprotein; hydrolase; P-loop; polyprotein; serine proteinase; transmembrane
P;2-115/Product: capsid protein C #status predicted <CPC>
P;116-191/Product: capsid protein C #status predicted <CPC>
P;192-389/Product: major envelope protein E #status predicted <MBE>
P;390-733/Product: nonstructural protein NS1 #status predicted <NS1>
P;734-1010/Product: nonstructural protein NS2 #status predicted <NS2>
P;1011-1619/Product: hepatitis C virus genome polyprotein
P;1316-1321/Region: nucleotide-binding motif B
P;1320-1323/Region: DEXH motif
P;1620-1866/Product: nonstructural protein NS4a #status predicted <N4A>
P;1867-2017/Product: nonstructural protein NS4b #status predicted <N4B>
P;2018-3033/Product: nonstructural protein NS5 #status predicted <NS>
P;196,209,234,305,325,417,423,430,448,477,534,542,558,578,627,649,1091,1217,1259,2038,281

Query Match 75.1%; Score 2380; DB 1; Length 3033;
Best Local Similarity 75.6%; Pred. No. 3.5e-174;
Matches 447; Conservative 57; Mismatches 87; Indels 0; Gaps 0;

```
QY 5 SMSTWTGALITPCAABESKLPINALSNLSLRHNLVYTTSSASLRQKVTDFRLOVL 64
DB 2443 SMSTWTGALITPCAABESKLPINALSNLSLRHNLVYTTSSASLRQKVTDFRLOVL 2502

QY 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAOVRSLSRAVNHIR 124
DB 2503 DAHYDSVLQDKLAASKVARTLLTLEACQLTTPPHSAKSKFGYGAOVRSLSRAVNHIR 2562

QY 125 SVWKDLLEDDTPTIOTTIMAKNEVFCVOPKGRKPARLIVPDLGVRCRMALYDVVS 184
DB 2563 SVWKDLLEDDTPTIOTTIMAKNEVFCVOPKGRKPARLIVPDLGVRCRMALYDVVS 2622

QY 185 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 2623 KLPAKIMGPSYGFQYSPAERVDFLKAWGSKKDPMGFSYDTRCFDSTVTENDIRVEESIY 2682

QY 245 QCCDLAPARQAIRSLTERLVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 304
DB 2683 RACSLPQEARVTVIHLTERLVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 2742

QY 305 AACRAAKLQDCTMLVNGDDLVVICSAGTQDAASLRVFTAMTRYSPAPGDPPEYDL 364
DB 2743 AACRAAGITVDPMVLVCGDDLVVISESQNEEDERNLRAFTAMTRYSPAPGDPPEYDL 2802

QY 365 ELITSCSSNVSDANDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 424
DB 2803 ELITSCSSNVSDANDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 2862

QY 425 ARMTLMTFFSILLAQBOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPSLHSYSPG 484
DB 2863 ARWVIMTHFFSILLAQDTLNQNLAPFMYGAVYSVNPDLPLAIIRLHGLSAPSLHSYSPG 2922

QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSOGGRAAICGKYLFWNAVTKLKLTPIP 544
DB 2923 ELTVASALRLKGLGAPPLRAWKSRAVARASLIAQARAACGKYLFWNAVTKLKLTPIP 2982

QY 545 AASRLDLSCGFVAGYSGGDIYHLSRARPRFWMCLILLSVGVGIYLLPNR 595
DB 2983 EARLLDLSCGFVAGYSGGDIYHLSRARPRFWMCLILLSVGVGIYLLPNR 3033
```

RESULT 12
JQ0879
NS5 protein - hepatitis C virus (strain J4) (fragment)
C;Species: hepatitis C virus
C;Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004
C;Accession: JQ0879
R;Okamoto, H.

submitted to JIPID, January 1991
A:Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis
A:Reference number: JQ0879
A:Accession: JQ0879
A:Molecule type: genomic RNA
A:Residues: 1-365 <OKA>
A:Cross-references: UNIPROT:Q81717
A:Experimental source: strain J4
C:Superfamily: hepatitis C virus genome polyprotein

Query Match 59.6%; Score 1886; DB 2; Length 365;
Best Local Similarity 96.7%; Pred. No. 2.1e-137;
Matches 353; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

Qy 231 TVTENDIRVESIIYQCCDLAPARQAIRSLTERLYVGGPMTNSKGNGCYRRCASGVLT 290
Db 1 TVTESDIRVESIIYQCCDLAPARQAIRSLTERLYVGGPMTNSKGNGCYRRCASGVLT 60

Qy 291 TSCGNLTCTYLKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDDAASLRVFTTEAMTRY 350
Db 61 TSCGNLTCTYLKATPACRAAKLQDCTMLVNGDDLVIICESAGTQEDDAASLRVFTTEAMTRY 120

Qy 351 SAPGDPDPQPEYDLELITSCSNVSAHDASGKRVYLLTRDPTVPLARAAWETARHTPVN 410
Db 121 SAPGDPDPQPEYDLELITSCSNVSAHDASGKRVYLLTRDPTVPLARAAWETARHTPVN 180

Qy 411 SWLGNIMYAPTLWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLQIIRL 470
Db 181 SWLGNIMYAPALWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLQIIRL 240

Qy 471 HGLSAFSLHSYSGEINRVASCLRKLGVPPLRVWRHARSVRAKLLSOGGAAACGKYL 530
Db 241 HGLSAFSLHSYSGEINRVASCLRKLGVPPLRVWRHARSVRAKLLSOGGAAACGKYL 300

Qy 531 NWAVRTKLTPIPAASRLDLSGMFVAGYSGGDIYHLSLRAPRWFMLCLLLLSVGVGIY 590
Db 301 NWAVRTKLTPIPAASQLDLSGMFVAGYSGGDIYHLSLRAPRWFMLCLLLLSVGVGIY 360

Qy 591 LLPNR 595
Db 361 LLPNR 365

RESULT 13
JQ0880
NS5 protein - hepatitis C virus (strain J1) (fragment)
C:Species: hepatitis C virus
C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004
C:Accession: JQ0880
R:Okamoto, H.
submitted to JIPID, January 1991
A:Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis
A:Reference number: JQ0879
A:Accession: JQ0880
A:Molecule type: genomic RNA
A:Residues: 1-365 <OKA>
A:Cross-references: UNIPROT:Q81716
A:Experimental source: strain J1
C:Superfamily: hepatitis C virus genome polyprotein

Query Match 55.3%; Score 1750; DB 2; Length 365;
Best Local Similarity 88.2%; Pred. No. 6.1e-127;
Matches 322; Conservative 23; Mismatches 20; Indels 0; Gaps 0;

Qy 231 TVTENDIRVESIIYQCCDLAPARQAIRSLTERLYVGGPMTNSKGNGCYRRCASGVLT 290
Db 1 TVTESDIRTEAIIYQCCDLDPQARVAIKSLTERLYVGGPMTNSRGNGCYRRCASGVLT 60

Qy 291 TSCGNLTCTYLKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDDAASLRVFTTEAMTRY 350
Db 61 TSCGNLTCTYLKAAACRAAGLRDCTMLVNGDDLVIICESAGTQEDDAASLRVFTTEAMTRY 120

Qy 351 SAPGDPDPQPEYDLELITSCSNVSAHDASGKRVYLLTRDPTVPLARAAWETARHTPVN 410

Db 121 SAPGDPDPQPEYDLELITSCSNVSAHDGKRVYLLTRDPTVPLARAAWETARHTPVN 180
Qy 411 SWLGNIMYAPTLWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLQIIRL 470
Db 181 SWLGNIMYAPTLWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLQIIRL 240

Qy 471 HGLSAFSLHSYSGEINRVASCLRKLGVPPLRVWRHARSVRAKLLSOGGAAACGKYL 530
Db 241 HGLSAFSLHSYSGEINRVAACTRLKLGVPPLRVWRHARSVRARLLSRGGAAACGKYL 300

Qy 531 NWAVRTKLTPIPAASRLDLSGMFVAGYSGGDIYHLSLRAPRWFMLCLLLLSVGVGIY 590
Db 301 NWAVRTKLTPIPAAGRLDLSGMFTAGYSGGDIYHVSHPARPRWFMLCLLLLAAGVGIY 360

Qy 591 LLPNR 595
Db 361 LLPNR 365

RESULT 14
JQ0883
Genome polyprotein - hepatitis C virus (strain J7) (fragments)
N:Contains: NS5 protein
C:Species: hepatitis C virus
C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004
C:Accession: JQ0883
R:Okamoto, H.
submitted to JIPID, January 1991
A:Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis
A:Reference number: JQ0879
A:Accession: JQ0883
A:Molecule type: genomic RNA
A:Residues: 1-874 <OKA>
A:Cross-references: UNIPROT:Q7LZY6
A:Experimental source: strain J7
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: polyprotein
C:Product: NS5 protein (fragment) #status predicted <NS5>
F:510-874/

Query Match 46.5%; Score 1471.5; DB 2; Length 874;
Best Local Similarity 70.0%; Pred. No. 5.6e-105;
Matches 282; Conservative 40; Mismatches 64; Indels 17; Gaps 3;

Qy 195 YGFOYSPKQVFEFLVNTWAKKCPMGF-SYDTRCFD-STVTENDIRVEESYQCCDLAPE 252
Db 487 YCWHYPPK-----PCGIVSAKTVCGPVYTVTERDIRTEESYQACSLPQE 531

Qy 253 AROAIRSLTERLYVGGPMTNSKGNGCYRRCASGVLTTCGNTLTCTYLKAAACRAAKL 312
Db 532 ARTAHSALTERLYVGGPMTNSKGNGCYRRCASGVLTTSIGNTWTCYIKALAAKANGI 591

Qy 313 QDCTMLVNGDDLVIICESAGTQEDDAASLRVFTTEAMTRYAPPDPQPEYDLEITSCSS 372
Db 592 KDPIMLVCGDDLVIISQNGNEEDERNLRAPEATMTRYAPPDGLPRPEYDLEITSCSS 651

Qy 373 NVSAHDASGKRVYLLTRDPTVPLARAAWETARHTPVNSWLGNIIMYAPTWARMLMTH 432
Db 652 NVSVALDPGRGRYLLTRDPTTISRAAWETVRHSPVNSWLGNIITQAPTIVWRVINTH 711

Qy 433 FFSILLAQBLEKALDCQIYGACYSIEPLDLQIIRLHLSAFSLHSYSGEINRVASC 492
Db 712 FFNILLAQDTLNQNLNEMYGAVYVSNPLDLPALLERLHGLDAFSLHTYSHEISRVNAT 771

Qy 493 LRKLGVPLRVWRHARSVRAKLLSOGGAAACGKYLFPNNAVRTKLTPIPAASRLDLS 552
Db 772 LRKLGAFLRAWSRAVARASLIAQGGAAACGKYLFPNNAVRTKLTPIPAASRLDLS 831

Qy 553 GWFVAGYSGGDIYHLSLRAPRWFMLCLLLLSVGVGIYLLPNR 595
Db 832 GWFTVAGGGDIFHVSHPARPRLLLLCLLLLSVGVGIFLLPAR 874

Search completed: September 22, 2005, 14:48:09
Job time : 22 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:36:26 ; Search time 78 Seconds
(without alignments)
3945.636 Million cell updates/sec

Title: US-10-712-479-2

Perfect score: 3167

Sequence: 1 MASMSYTWGALITPCAA.....LLSVGVGYLLPNRHHHH 601

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3040	96.0	3010	2 Q9DTE6	Q9dte6 hepatitis c
2	3040	96.0	3010	2 Q9J310	Q9j310 hepatitis c
3	3038	96.0	3010	2 Q93077	Q93077 hepatitis c
4	3039	95.9	3010	2 Q9DTE9	Q9dte9 hepatitis c
5	3034	95.8	3010	2 Q81760	Q81760 hepatitis c
6	3030	95.7	3010	2 Q02829	Q02829 hepatitis c
7	3027	95.6	3010	2 Q68285	Q68285 hepatitis c
8	3027	95.6	3010	2 Q81825	Q81825 hepatitis c
9	3026	95.5	3010	2 Q9J3H0	Q9j3h0 hepatitis c
10	3025	95.5	3010	2 Q9QIX5	Q9qix5 hepatitis c
11	3024	95.5	3010	2 Q9QIX5	Q9qix5 hepatitis c
12	3022	95.4	3010	2 P89966	P89966 hepatitis c
13	3022	95.4	3014	2 Q09796	Q09796 hepatitis c
14	3021	95.4	3010	2 Q09796	Q09796 hepatitis c
15	3020	95.4	591	2 Q39930	Q39930 hepatitis c
16	3020	95.4	591	2 Q80M22	Q80m22 hepatitis c
17	3019	95.3	591	2 Q80M22	Q80m22 hepatitis c
18	3018	95.3	591	2 Q9JGN9	Q9jgn9 hepatitis c
19	3018	95.3	3010	2 Q68826	Q68826 hepatitis c
20	3018	95.3	3010	2 Q097P3	Q097p3 hepatitis c
21	3017	95.3	591	2 Q80M70	Q80m70 hepatitis c
22	3016	95.2	2284	2 Q81817	Q81817 hepatitis c
23	3016	95.2	3010	1 POLG_HCVBK	P26663 h genome po
24	3016	95.2	3010	1 POLG_HCVJA	P26662 h genome po
25	3016	95.2	3010	2 Q9DTE4	Q9dte4 hepatitis c
26	3015	95.2	591	2 Q80MH3	Q80mh3 hepatitis c
27	3015	95.2	591	2 Q80MI0	Q80mi0 hepatitis c
28	3015	95.2	3010	2 Q92969	Q92969 hepatitis c
29	3015	95.2	3010	2 Q92971	Q92971 hepatitis c
30	3015	95.2	3010	2 Q92972	Q92972 hepatitis c
31	3015	95.2	3010	2 Q9J3H9	Q9j3h9 hepatitis c

RESULT 1

ID	Q9DTE6	PRELIMINARY;	PRT;	3010 AA.
AC	Q9DTE6;			
DT	01-MAR-2001 (TrEMBLrel. 16, Created)			
DT	01-MAR-2001 (TrEMBLrel. 16, Last sequence update)			
DT	01-MAR-2004 (TrEMBLrel. 26, Last annotation update)			
DE	Polyprotein.			
OS	Hepatitis C virus.			
OC	Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;			
OC	Hepacivirus.			
OX	NCBI_TaxID=11103;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Serum;			
RA	Takahashi K., Iwata K., Matsumoto M., Matsumoto H., Nakao K.,			
RA	Hatahara T., Ohka Y., Kanai K., Maruo H., Baba K., Hijikata M.,			
RA	Mishiro S.;			
RT	"Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients			
RT	with hepatocellular carcinoma: the 'progression score' revisited.";			
RL	Hepatol. Res. 20:161-171(2001).			
DR	EMBL; AB049091; BAB18804.1; -.			
DR	PIR; A61196; A61196.			
DR	PIR; PS0329; PS0329.			
DR	HSSP; Q81755; 1DXP.			
DR	GO; GO:0016021; C:integral to membrane; IEA.			
DR	GO; GO:0019028; C:viral capsid; IEA.			
DR	GO; GO:0019031; C:viral envelope; IEA.			
DR	GO; GO:0005534; F:ATP binding; IEA.			
DR	GO; GO:0008026; F:ATP-dependent helicase activity; IEA.			
DR	GO; GO:0016787; F:hydrolyase activity; IEA.			
DR	GO; GO:0003723; F:RNA binding; IEA.			
DR	GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.			
DR	GO; GO:0008236; F:serine-type peptidase activity; IEA.			
DR	GO; GO:0005198; F:structural molecule activity; IEA.			
DR	GO; GO:0006508; P:proteolysis and peptidolysis; IEA.			
DR	GO; GO:0006350; P:transcription; IEA.			
DR	GO; GO:0019079; P:viral genome replication; IEA.			
DR	GO; GO:0019087; P:viral transformation; IEA.			
DR	InterPro; IPR000345; CytC_heme_BS.			
DR	InterPro; IPR001410; DEAD.			
DR	InterPro; IPR011545; DEAD/DEAH N.			
DR	InterPro; IPR002522; HCV capsid.			
DR	InterPro; IPR000745; HCV NS4a.			
DR	InterPro; IPR001490; HCV NS4b.			
DR	InterPro; IPR002868; HCV NS5a.			
DR	InterPro; IPR002166; HCV RdRp.			
DR	InterPro; IPR001650; Helicase_C.			
DR	InterPro; IPR004109; Peptidase_S29.			
DR	InterPro; IPR009003; Pept_Ser_Cys.			
DR	InterPro; IPR002518; Pept_U39_HCV_NS2.			

ALIGNMENTS


```
QY 125 SVWKDLLEDTPTPTOTTIMAKNEVFCVQPEKGGKRPALIVFPDGLGVRVCEKMALYDVVS 184
Db 2540 SVWKDLLEDTPTPTINTTMAKNEVFCVQPEKGGKRPALIVFPDGLGVRVCEKMALYDVVS 2599
QY 185 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPQAVMGSSYGFQYSPQRVEFLVNTWKSKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPPEARQAIIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 304
Db 2660 QCCDLAPPEARQVIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAS 2719
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPOPEYDL 2779
QY 365 ELITSCSSNVSAHDAKGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
Db 2780 ELITSCSSNVSAHDAKGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2839
QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 484
Db 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 2899
QY 485 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 544
Db 2900 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFWNAVTKLKLTPIP 2959
QY 545 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLSVGVGYLLPNR 595
Db 2960 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLSVGVGYLLPNR 3010

RESULT 3
O93077 PRELIMINARY; PRT: 3010 AA.
AC O93077;
DT 01-NOV-1998 (TREMBlrel. 08, Created)
DT 01-NOV-1998 (TREMBlrel. 08, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Polypeptide.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=111103;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=9812249; PubMed=9462666; DOI=10.1002/hep.510270242;
RA Aizaki H., Aoki Y., Harada T., Iehii K., Suzuki T., Nagamori S.,
RA Toda G., Matsuura Y., Miyamura T.;
RT "Full-length complementary DNA of hepatitis C virus genome from an
RT infectious blood sample.";
RL Hepatology 27:621-627(1998).
DR EMBL; D89815; BAA25076.1; -.
DR PIR; A61196; A61196.
DR PIR; PQ0246; PQ0246.
DR PIR; PQ0804; PQ0804.
DR PIR; PS0329; PS0329.
DR HSSP; Q8JYS1; 1CW.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR GO; GO:0019087; P:viral transformation; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
```

```
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR011545; DEAD/DEAH N.
DR InterPro; IPR002522; HCV capsid.
DR InterPro; IPR002521; HCV core.
DR InterPro; IPR002519; HCV env.
DR InterPro; IPR002531; HCV NS1.
DR InterPro; IPR000745; HCV NS4a.
DR InterPro; IPR001490; HCV NS4b.
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV RdRp.
DR InterPro; IPR001650; Helicase C.
DR InterPro; IPR004109; Peptidase S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39_HCV_NS2.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF01543; HCV capsid; 1.
DR Pfam; PF01542; HCV core; 1.
DR Pfam; PF01539; HCV env; 1.
DR Pfam; PF01560; HCV NS1; 1.
DR Pfam; PF01538; HCV NS2; 1.
DR Pfam; PF02907; HCV NS3; 1.
DR Pfam; PF01006; HCV NS4a; 1.
DR Pfam; PF01001; HCV NS4b; 1.
DR Pfam; PF01506; HCV NS5a; 1.
DR Pfam; PF00271; Helicase C; 1.
DR Pfam; PF00998; Viral RdRp; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; Transmembrane.
SQ SEQUENCE 3010 AA; 327352 MW; 888BBA102A733390 CRC64;

Query Match 96.0%; Score 3039; DB 2; Length 3010;
Best Local Similarity 97.6%; Pred. No. 7.5e-228;
Matches 577; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAABESKLIPINALSNLSLRHNLVYSTTSRSASLRQKQKVTFRLOVL 64
Db 2420 SMSYTWGALITPCAABESKLIPINALSNPLLRHNMVYSTTSRSASLRQKQKVTFRMQVL 2479
QY 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 2480 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 2539
QY 125 SVWKDLLEDTPTPTOTTIMAKNEVFCVQPEKGGKRPALIVFPDGLGVRVCEKMALYDVVS 184
Db 2540 SVWKDLLEDTPTPTOTTIMAKNEVFCVQPEKGGKRPALIVFPDGLGVRVCEKMALYDVVS 2599
QY 185 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPPEARQAIIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 304
Db 2660 QCCDLAPPEARQAIIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 2719
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPOPEYDL 2779
QY 365 ELITSCSSNVSAHDAKGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
Db 2780 ELITSCSSNVSAHDAKGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2839
QY 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 484
Db 2840 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 2899
QY 485 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLTPIP 544
Db 2900 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAATCGKYLFWNAVTKLKLTPIP 2959
```

[illegible]

DR PIR; PQ0254; PQ0254.
 DR PIR; PQ0804; PQ0804.
 DR PIR; PS0329; PS0329.
 DR HSSP; Q8JYS1; 1CWK.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0019028; C:viral capsid; IEA.
 DR GO; GO:0019031; C:viral envelope; IEA.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
 DR GO; GO:0003723; F:RNA binding; IEA.
 DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
 DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
 DR GO; GO:0005198; F:structural molecule activity; IEA.
 DR GO; GO:0006350; P:transcription; IEA.
 DR GO; GO:0019079; P:viral genome replication; IEA.
 DR GO; GO:0019087; P:viral transformation; IEA.
 DR InterPro; IPR000345; CytC_heme_BS.
 DR InterPro; IPR001410; DEAD.
 DR InterPro; IPR011545; DEAD/DEAH_N.
 DR InterPro; IPR002522; HCV capsid.
 DR InterPro; IPR002521; HCV core.
 DR InterPro; IPR002519; HCV env.
 DR InterPro; IPR002531; HCV NS1.
 DR InterPro; IPR000745; HCV NS4a.
 DR InterPro; IPR001490; HCV NS4b.
 DR InterPro; IPR002166; HCV RdRp.
 DR InterPro; IPR001650; Helicase_C.
 DR InterPro; IPR004109; Peptidase_S29.
 DR InterPro; IPR009003; Pept_Ser_Cys.
 DR InterPro; IPR002518; Pept_U39_HCV NS2.
 DR InterPro; IPR007095; RNA pol DS PS.
 DR InterPro; IPR007094; RNA pol_PSVir.
 DR Pfam; PF01543; HCV capsid; 1.
 DR Pfam; PF01542; HCV core; 1.
 DR Pfam; PF01539; HCV env; 1.
 DR Pfam; PF01560; HCV NS1; 1.
 DR Pfam; PF01538; HCV NS2; 1.
 DR Pfam; PF02907; HCV NS3; 1.
 DR Pfam; PF01006; HCV NS4; 1.
 DR Pfam; PF01001; HCV NS4b; 1.
 DR Pfam; PF01506; HCV NS5a; 1.
 DR Pfam; PF00271; Helicase_C; 1.
 DR Pfam; PF00998; Viral RdRp; 1.
 DR SMART; SM00487; DEXDC; 1.
 DR PROSITE; PS00190; CRYPTOCHROME_C; UNKNOWN_1.
 DR KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
 DR Polyprotein; Transmembrane.
 DR SQ SEQUENCE 3010 AA; 326857 MW; EA7D306A4BA2E224 CRC64;

Query Match 95.8%; Score 3034; DB 2; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 1.8e-227;
 Matches 571; Conservative 14; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAABESKLPINALNSLLRHNLVSTTSRSASLRQKVTDFRLQVL 64
 Db 2420 SMSYTWTCALITPCAABESKLPINPLNSLLRHNLVSTTSRSASLRQKVTDFRLQVL 2479

Qy 65 DDHYRDVLKEMKAKASTVKALLSVEERACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 124
 Db 2480 DDHYRDVLKEMKAKASTVKALLSVEERACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 2539

Qy 125 SVWKDLLEDTTPIOTTIMANNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVS 184
 Db 2540 SVWKDLLEDTTPIOTTIMANNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVS 2599

Qy 185 TLPOAVMGSSYGFQYSPQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESYI 244
 Db 2600 TLPOAVMGSSYGFQYSPQRFVFLVNTWKSKCPMGFSYDTRCFDSTVTENDIRVEESYI 2659

Qy 245 QCCDLAPEAKQAISLTERLYIGGPLTNSKGQNCYRCRASGVLTTSCGNTLTLYLKAS 304

Db 2660 QCCDLAPEAKQAISLTERLYIGGPLTNSKGQNCYRCRASGVLTTSCGNTLTLYLKAS 2719

Qy 305 AACRAAKLQDCTMLVNGDDLVI CESAGTQDDAASLRVFTETAMTRYSA PPGDPPPEYDL 364
 Db 2720 AACRAAKLQDCTMLVNGDDLVI CESAGTQDDAASLRVFTETAMTRYSA PPGDPPPEYDL 2779

Qy 365 ELITSCSNVSVAHDASGKRVYVYTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
 Db 2780 ELITSCSNVSVAHDASGKRVYVYTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2839

Qy 425 ARMLTMTHFFSILLAEQLEKALCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSYG 484
 Db 2840 ARMLTMTHFFSILLAEQLEKALCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSYG 2899

Qy 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
 Db 2900 EINRVASCLRLKGLVPPPLRVWRHRSVRKLLSQGGRAATCGKYLFWNAVRTKLTPTIP 2959

Qy 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLLSVGVGIYLLPNR 595
 Db 2960 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLLSVGVGIYLLPNR 3010

RESULT 6
 Q02829
 ID Q02829 PRELIMINARY; PRT; 3010 AA.
 AC Q02829;
 DT 01-NOV-1996 (Tremblrel. 01, Created)
 DT 01-NOV-1996 (Tremblrel. 01, Last sequence update)
 DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
 DE Polyprotein.
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
 OC Hepacivirus.
 OX NCBI_TaxID=11103;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=HC-J4;
 RX MEDLINE=92391112; PubMed=1325713;
 RA Okamoto H., Kojima M., Okada S., Yoshizawa H., Iizuka H., Tanaka T.,
 RT "Genetic drift of hepatitis C virus during an 8.2-year infection in a
 RL chimpanzee: variability and stability."
 RL Virology 190:894-899(1992).
 DR EMBL; D13558; BAA02756.1; -.
 DR PIR; A61196; A61196.
 DR PIR; PQ0246; PQ0246.
 DR PIR; PS0329; PS0329.
 DR HSSP; Q8JYS1; 1CWK.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0019028; C:viral capsid; IEA.
 DR GO; GO:0019031; C:viral envelope; IEA.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
 DR GO; GO:0003723; F:RNA binding; IEA.
 DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
 DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
 DR GO; GO:0005198; F:structural molecule activity; IEA.
 DR GO; GO:0006350; P:transcription; IEA.
 DR GO; GO:0019079; P:viral genome replication; IEA.
 DR GO; GO:0019087; P:viral transformation; IEA.
 DR InterPro; IPR000345; CytC_heme_BS.
 DR InterPro; IPR001410; DEAD.
 DR InterPro; IPR011545; DEAD/DEAH_N.
 DR InterPro; IPR002522; HCV capsid.
 DR InterPro; IPR002521; HCV core.
 DR InterPro; IPR002519; HCV env.
 DR InterPro; IPR002531; HCV NS1.
 DR InterPro; IPR000745; HCV NS4a.
 DR InterPro; IPR001490; HCV NS4b.
 DR InterPro; IPR002868; HCV NS5a.
 DR InterPro; IPR002166; HCV RdRp.


```
Db 2420 SMSYTWTCALITPCAAEESKLPINPLNSLLRHHNMVATTSSRAGLRQKKVTFDRLOVL 2479
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
Db 2480 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVTHIR 2539
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
Db 2540 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 2599
Qy 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKSKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
Qy 245 QCCDLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRAGSVLTTCGNTLTCLYKAA 304
Db 2660 QCCDLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRAGSVLTTCGNTLTCLYKAT 2719
Qy 305 AACRAAKLODCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPEYDL 364
Db 2720 AACRAAKLRDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPEYDL 2779
Qy 365 ELITSCSSNVSAVHADSGKRVYLTDRPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 424
Db 2780 ELITSCSSNVSAVHADSGKRVYLTDRPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 2839
Qy 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPLSHSYSPG 484
Db 2840 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPLSHSYSPG 2899
Qy 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 544
Db 2900 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAATCGKYLFWNAVRTKLTIP 2959
Qy 545 AASRLDLSGFWAGYSGGDIYHLSRARPFRWMLCLLLSVGVGIYLLPNR 595
Db 2960 AASRLDLSGFWAGYSGGDIYHLSRARPFRWMLCLLLSVGVGIYLLPNR 3010

RESULT 8:
Q81825
ID Q81825 PRELIMINARY; PRT; 3010 AA.
AC Q81825;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE MRNA, complete cds.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OX Hepacivirus.
RN [1] NCBI_TaxID=11103;
RP SEQUENCE FROM N.A.
RA Cho J.-M.;
RL Submitted (JUN-1993) to the EMBL/GenBank/DBJ databases.
DR EMBL; M96362; AAA45721.1; -.
DR PIR; A61196; A61196.
DR PIR; P80329; P80329.
DR HSP; Q81755; IDRP.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR GO; GO:0019087; P:viral transformation; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
```

```
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR011545; DEAD/DEAH N.
DR InterPro; IPR002522; HCV capsid.
DR InterPro; IPR002521; HCV core.
DR InterPro; IPR002519; HCV env.
DR InterPro; IPR002531; HCV NS1.
DR InterPro; IPR000745; HCV NS4a.
DR InterPro; IPR001490; HCV NS4b.
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV NS5b.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR004109; Peptidase_S29.
DR InterPro; IPR009003; Pept Ser Cys.
DR InterPro; IPR002518; Pept U39 HCV NS2.
DR InterPro; IPR007095; RNA pol Ds PS.
DR InterPro; IPR007094; RNA pol_PVir.
DR Pfam; PF01543; HCV capsid; 1.
DR Pfam; PF01542; HCV core; 1.
DR Pfam; PF01539; HCV env; 1.
DR Pfam; PF01560; HCV NS1; 1.
DR Pfam; PF01538; HCV NS2; 1.
DR Pfam; PF02907; HCV NS3; 1.
DR Pfam; PF01006; HCV NS4a; 1.
DR Pfam; PF01001; HCV NS4b; 1.
DR Pfam; PF01506; HCV NS5a; 1.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF00998; Viral RdRp; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN_1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
Polyprotein; Transmembrane.
SQ SEQUENCE 3010 AA; 326925 MW; PE997D54EE05142B CRC64;

Query Match 95.6%; Score 3027; DB 2; Length 3010;
Best Local Similarity 96.8%; Pred.No. 6.5e-227;
Matches 572; Conservative 9; Mismatches 10; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 2420 SMSYTWTCALITPCAAEESKLPINPLNSLLRHHNMVATTSSRAGLRQKKVTFDRLOVL 2479
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
Db 2480 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVTHIR 2539
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
Db 2540 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 2599
Qy 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 2600 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKSKCPMGFSYDTRCFDSTVTENDIRVEESIY 2659
Qy 245 QCCDLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRAGSVLTTCGNTLTCLYKAA 304
Db 2660 QCCDLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRAGSVLTTCGNTLTCLYKAT 2719
Qy 305 AACRAAKLODCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPEYDL 364
Db 2720 AACRAAKLRDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGDPPEYDL 2779
Qy 365 ELITSCSSNVSAVHADSGKRVYLTDRPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 424
Db 2780 ELITSCSSNVSAVHADSGKRVYLTDRPTVPLARAAMETARHTPVNSWLGNIMYAPTILW 2839
Qy 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPLSHSYSPG 484
Db 2840 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPLSHSYSPG 2899
Qy 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 544
Db 2900 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAATCGKYLFWNAVRTKLTIP 2959
```

```
Qy 545 AASRLDLSGFWVAGYSGGDIYHLSRPRWFMCLLLSVGVGIYLLPNR 595
|||
Db 2960 AASRLDLSGFWVAGYSGGDIYHLSRPRWFMCLLLSVGVGIYLLPNR 3010
|||
RESULT 9
Q9J3H0 PRELIMINARY; PRT; 3010 AA.
ID Q9J3H0;
AC Q9J3H0;
DT 01-OCT-2000 (TReMBLrel. 15, Created)
DT 01-OCT-2000 (TReMBLrel. 15, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Polyprotein.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MD22;
RA Nagayama K., Kurosaki M., Enomoto N., Miyasaka Y., Marumo F., Sato C.;
RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF207763; AAF65953.1; -.
DR PIR; A61196; A61196.
DR PIR; PQ0246; PQ0246.
DR PIR; PQ0254; PQ0254.
DR PIR; PQ0329; PQ0329.
DR HSP; Q8JYS1; ICWX.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR GO; GO:0019087; P:viral transformation; IEA.
DR InterPro; IPR00345; CytC heme_BS.
DR InterPro; IPR01410; DEAD.
DR InterPro; IPR011545; DEAD/DEAH_N.
DR InterPro; IPR002522; HCV_capsid.
DR InterPro; IPR002521; HCV core.
DR InterPro; IPR002519; HCV env.
DR InterPro; IPR002531; HCV NS1.
DR InterPro; IPR000745; HCV NS4a.
DR InterPro; IPR001490; HCV NS4b.
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV RdRp.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR004109; Peptidase_S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39_HCV_NS2.
DR InterPro; IPR007095; RNA_pol_DS_P5.
DR InterPro; IPR007094; RNA_pol_Psvir.
DR Pfam; PF01543; HCV_capsid; 1.
DR Pfam; PF01542; HCV_core; 1.
DR Pfam; PF01539; HCV_env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF00998; Viral_RdRp; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
Polyprotein; Transmembrane.
```

```
SQ SEQUENCE 3010 AA; 327098 MW; 737EEF31E3C2B28D CRC64;
Query Match 95.5%; Score 3026; DB 2; Length 3010;
Best Local Similarity 96.3%; Pred. No. 7.8e-227;
Matches 569; Conservative 14; Mismatches 8; Indels 0; Gaps 0;
Qy 5 SMSYTWGALITPCAABESKLPINALSNLRLHNLVYSTTSASLRQKVKVTFDRQLQVL 64
|||||
Db 2420 SMSYTWGALITPCAABESKLPINALSNLRLHNLVYSTTSASLRQKVKVTFDRQLQVL 2479
|||||
Qy 65 DDHYRDVLEKMKAKASTVAKLLSVEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
|||||
Db 2480 DDHYRDVLEKMKAKASTVAKLLSIEACKLTPPHSARSKFGYGAQDVRSLSRAVNHIR 2539
|||||
Qy 125 SVWKDLLEDTDTPITQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 184
|||||
Db 2540 SVWKDLLEDTDTPITQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 2599
|||||
Qy 185 TLPOAVNGSSYGVFOYSPKORVEFLVNTWKAACKPMGFSYDTRCFDSTVTENDIRVESIY 244
|||||
Db 2600 TLPOAVNGSSYGVFOYSPKORVEFLVNTWKAACKPMGFSYDTRCFDSTVTENDIRVESIY 2659
|||||
Qy 245 QCCLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGYLTTCGNLTLCYLKAA 304
|||||
Db 2660 QCCLAPPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGYLTTCGNLTLCYLKAS 2719
|||||
Qy 305 AACRAAKLQDCTMLVNGDDLWICESAGTOEDASIRVFTTEMTTRYSAAGDPPOPEYDL 364
|||||
Db 2720 AACRAAKLQDCTMLVNGDDLWICESAGTOEDASIRVFTTEMTTRYSAAGDPPOPEYDL 2779
|||||
Qy 365 ELITSCSNVSVAHDSAGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
|||||
Db 2780 ELITSCSNVSVAHDSAGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 2839
|||||
Qy 425 ARMLTMHTFSSILIAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
|||||
Db 2840 ARMLTMHTFSSILIAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 2899
|||||
Qy 485 EINRVASCLRLKGLVPLRVWRHRSRAKLLSOGGAAATCGKYLEFNWAVTKLKTPIP 544
|||||
Db 2900 EINRVASCLRLKGLVPLRVWRHRSRAKLLSOGGAAATCGKYLEFNWAVTKLKTPIP 2959
|||||
Qy 545 AASRLDLSGFWVAGYSGGDIYHLSRPRWFMCLLLSVGVGIYLLPNR 595
|||||
Db 2960 AASRLDLSGFWVAGYSGGDIYHLSRPRWFMCLLLSVGVGIYLLPNR 3010
|||||
RESULT 10
Q9QIX6 PRELIMINARY; PRT; 3010 AA.
ID Q9QIX6;
AC Q9QIX6;
DT 01-MAY-2000 (TReMBLrel. 13, Created)
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Polyprotein.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MD8-1;
RA MEDLINE=20013325; PubMed=10544098; DOI=10.1006/viro.1999.9924;
RA Nagayama K., Kurosaki M., Enomoto N., Maekawa S.Y., Miyasaka Y.,
RA Tazawa J.I., Izumi N., Marumo F., Sato C.;
RT "Time-related changes in full-length hepatitis C virus and hepatitis
RT activity.";
RT Virolgy 263:244-253 (1999).
DR EMBL; AF165059; AAD56194.1; -.
DR PIR; A61196; A61196.
DR PIR; PQ0246; PQ0246.
DR PIR; PQ0254; PQ0254.
DR PIR; PQ0804; PQ0804.
```


DR PIR; PS0329; PS0329.
 DR HSP; Q8JYS1; 1CW.
 DR MEROPS; S29.002; -.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0019028; C:viral capsid; IEA.
 DR GO; GO:0019031; C:viral envelope; IEA.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
 DR GO; GO:0003723; F:RNA binding; IEA.
 DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
 DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
 DR GO; GO:0005198; F:structural molecule activity; IEA.
 DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
 DR GO; GO:0006350; P:transcription; IEA.
 DR GO; GO:0019079; P:viral genome replication; IEA.
 DR GO; GO:0019087; P:viral transformation; IEA.
 DR InterPro; IPR000345; CytC_heme_BS.
 DR InterPro; IPR001410; DEAD.
 DR InterPro; IPR011545; DEAD/DEAH_N.
 DR InterPro; IPR002522; HCV capsid.
 DR InterPro; IPR002521; HCV core.
 DR InterPro; IPR002519; HCV env.
 DR InterPro; IPR002531; HCV NS1.
 DR InterPro; IPR000745; HCV NS4b.
 DR InterPro; IPR001490; HCV NS4b.
 DR InterPro; IPR002868; HCV NS5a.
 DR InterPro; IPR002166; HCV RdRp.
 DR InterPro; IPR001650; Helicase C.
 DR InterPro; IPR004109; Peptidase S29.
 DR InterPro; IPR009003; Pept_Ser_Cys.
 DR InterPro; IPR002518; Pept_U39_HCV_NS2.
 DR InterPro; IPR007095; RNA pol_DS_PS.
 DR InterPro; IPR007094; RNA pol_PSVir.
 DR Pfam; PF01543; HCV capsid; 1.
 DR Pfam; PF01542; HCV core; 1.
 DR Pfam; PF01539; HCV env; 1.
 DR Pfam; PF01560; HCV NS1; 1.
 DR Pfam; PF01538; HCV NS2; 1.
 DR Pfam; PF02907; HCV NS3; 1.
 DR Pfam; PF01006; HCV NS4a; 1.
 DR Pfam; PF01001; HCV NS4b; 1.
 DR Pfam; PF01506; HCV NS5a; 1.
 DR Pfam; PF00271; Helicase C; 1.
 DR Pfam; PF00998; Viral RdRp; 1.
 DR SMART; SM00487; DEXDC; 1.
 DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
 KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
 Polyprotein; Transmembrane.
 SQ SEQUENCE 3010 AA; 327468 MW; 4613744EC4D4A013 CRC64;

Query Match 95.5%; Score 3025; DB 2; Length 3010;
 Best Local Similarity 96.4%; Pred. No. 9.3e-227;
 Matches 570; Conservative 15; Mismatches 6; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVKTFDRQLVL 64
 DB 2420 SMSYTWTCALITPCAABESKLPINPLNSLRHNLVYATTSSASLRQKVKTFDRQLVL 2479

QY 65 DDHYRDVLKEMKAKASTYKAKLLSVEEACKLTPPHSAKSKFGYKADYRSLSRAVNHIR 124
 DB 2480 DDHYRDVLKEMKAKASTYKAKLLSVEEACKLTPPHSAKSKFGYKADYRSLSRAVNHIR 2539

QY 125 SVWKDLLEDTDPIOTTIMAKNEVFCVQPEKGRKPARKLIVFPDGLGVRVCEKALYDVVS 184
 DB 2540 SVWKDLLEDTDPIOTTIMAKNEVFCVQPEKGRKPARKLIVFPDGLGVRVCEKALYDVVS 2599

QY 185 TLPOAVMGSSYGFQYSPKQRFVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 DB 2600 TLPOAVMGSSYGFQYSPKQRFVNTWKAKKCPMGFSYDTRCFDSTVTESDIRVEESIY 2659

QY 245 QCCDLAPARQAIRLTERLYVGGPMTHNSKGQNCYRRCRASGLVTTSCGNLTLCYLKAA 304
 DB 2660 QCCDLAPARQAIRLTERLYVGGPMTHNSKGQNCYRRCRASGLVTTSCGNLTLCYLKAS 2719

QY 305 AACRAAKLQDCTMLVNGDDLVLVVCESAGCTQEDAAALRVFTTEAMTRYSAAPPDPPQPEYDL 364
 DB 2720 AACRAAKLQDCTMLVNGDDLVLVVCESAGCTQEDAAALRVFTTEAMTRYSAAPPDPPQPEYDL 2779

QY 365 ELITSCSSNVSAHDASGRVYLLTRDTPVPLARAAMETARTHTPVNSWLGNIIMYAPTLM 424
 DB 2780 ELITSCSSNVSAHDASGRVYLLTRDTPVPLARAAMETARTHTPVNSWLGNIIMYAPTLM 2839

QY 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
 DB 2840 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 2899

QY 485 EINRVASCLRLKGLVPPPLRVWRHRRARSVRKALLSQSGRAAI CGKYLFWNAVRTKLTPTLP 544
 DB 2900 EINRVASCLRLKGLVPPPLRVWRHRRARSVRKALLSQSGRAATCGKYLFWNAVRTKLTPTLP 2959

QY 545 AASRLDLSCGWFVAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 595
 DB 2960 AASRLDLSCGWFVAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 3010

RESULT 11
 QSQIX5 PRELIMINARY; PRT; 3010 AA.
 AC QSQIX5;
 DT 01-MAY-2000 (TremBLrel. 13, Created)
 DT 01-MAY-2000 (TremBLrel. 13, Last sequence update)
 DT 01-MAR-2004 (TremBLrel. 26, Last annotation update)
 DE Polyprotein.
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
 OC Hepacivirus.
 OX NCBI_TaxID=11103;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=MD8-2;
 RX MEDLINE=20013325; PubMed=10544098; DOI=10.1006/viro.1999.9924;
 RA Nagayama K., Kurosaki M., Enomoto N., Maekawa S.Y., Miyasaka Y.,
 RA Tazawa J.i., Izumi N., Marumo F., Sato C.;
 RT "Time-related changes in full-length hepatitis C virus and hepatitis
 RT activity.";
 RL Virology 263:244-253(1999).
 DR EMBL; AF165060; AAD56195.1; -.
 DR PIR; A61196; A61196.
 DR PIR; P02246; P02246.
 DR PIR; P02254; P02254.
 DR PIR; P08004; P08004.
 DR PIR; PS0329; PS0329.
 DR HSSP; Q8JYS1; 1CW.
 DR MEROPS; S29.002; -.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0019028; C:viral capsid; IEA.
 DR GO; GO:0019031; C:viral envelope; IEA.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
 DR GO; GO:0003723; F:RNA binding; IEA.
 DR GO; GO:0008236; F:serine-type RNA polymerase activity; IEA.
 DR GO; GO:0005198; F:structural molecule activity; IEA.
 DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
 DR GO; GO:0006350; P:transcription; IEA.
 DR GO; GO:0019079; P:viral genome replication; IEA.
 DR GO; GO:0019087; P:viral transformation; IEA.
 DR InterPro; IPR000345; CytC_heme_BS.
 DR InterPro; IPR001410; DEAD.
 DR InterPro; IPR011545; DEAD/DEAH_N.
 DR InterPro; IPR002522; HCV capsid.
 DR InterPro; IPR002521; HCV core.
 DR InterPro; IPR002519; HCV env.
 DR InterPro; IPR002531; HCV NS1.
 DR InterPro; IPR000745; HCV NS4b.
 DR InterPro; IPR001490; HCV NS4b.
 DR InterPro; IPR002868; HCV NS5a.
 DR InterPro; IPR002166; HCV RdRp.
 DR InterPro; IPR001650; Helicase C.
 DR InterPro; IPR004109; Peptidase S29.
 DR InterPro; IPR009003; Pept_Ser_Cys.
 DR InterPro; IPR002518; Pept_U39_HCV_NS2.
 DR InterPro; IPR007095; RNA pol_DS_PS.
 DR InterPro; IPR007094; RNA pol_PSVir.
 DR Pfam; PF01543; HCV capsid; 1.
 DR Pfam; PF01542; HCV core; 1.
 DR Pfam; PF01539; HCV env; 1.
 DR Pfam; PF01560; HCV NS1; 1.
 DR Pfam; PF01538; HCV NS2; 1.
 DR Pfam; PF02907; HCV NS3; 1.
 DR Pfam; PF01006; HCV NS4a; 1.
 DR Pfam; PF01001; HCV NS4b; 1.
 DR Pfam; PF01506; HCV NS5a; 1.
 DR Pfam; PF00271; Helicase C; 1.
 DR Pfam; PF00998; Viral RdRp; 1.
 DR SMART; SM00487; DEXDC; 1.
 DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
 KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
 Polyprotein; Transmembrane.
 SQ SEQUENCE 3010 AA; 327468 MW; 4613744EC4D4A013 CRC64;

```
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV RdRP.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR004109; Peptidase_S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39 HCV NS2.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF01543; HCV_capsid; 1.
DR Pfam; PF01542; HCV_core; 1.
DR Pfam; PF01539; HCV_env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF00998; Viral_RdRP; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; Transmembrane.
SQ SEQUENCE 3010 AA; 327295 MW; 8B99F1EBAGA50F56 CRC64;

Query Match 95.5%; Score 3024; DB 2; Length 3010;
Best Local Similarity 96.4%; Pred.No.1.le-226; Mismatches 7; Indels 0; Gaps 0;
Matches 570; Conservative 14;

QY 5 SMSYTWTCALITPCAABESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRQLVL 64
DB 2420 SMSYTWTCALITPCAABESKLPINPLSNLSLRHNLVYSTTSRSASLRQKKVTFDRQLVL 2479
QY 65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTTPHSAKSKFYGAKVRSLSRAVNHR 124
DB 2480 DDHYRDVLKEMKAKASTVAKLLSVEACKLTTPHSAKSKFYGAKVRSLSRAVNHR 2539
QY 125 SVWDLLEDTTPIOTTIMANNEVCPOPEKGGKPARLIIVFDLGVRCFKMALYDVVS 184
DB 2540 SVWDLLEDTTPIOTTIMANNEVCPOPEKGGKPARLIIVFDLGVRCFKMALYDVVS 2599
QY 185 TLPQAVMGSSYGFQYSPQRVFEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
DB 2600 TLPQAVMGSSYGFQYSPQRVFEFLVNTWKSKCPMGFSYDTRCFDSTVTESDIRTESIY 2659
QY 245 QCCLDAPARQAIRSLTERLVGGPMWNSKQNCYRRCRASGVLTTSCTGNTLTCYLKAA 304
DB 2660 QCCLDAPARQAIRSLTERLVGGPMWNSKQNCYRRCRASGVLTTSCTGNTLTCYLKAT 2719
QY 305 AACRAAKLODCTMLVNGDDLVIACESACTOEDASLRVFTTEAMTRYSAAPGDPQPEYDL 364
DB 2720 AACRAAKLODCTMLVNGDDLVIACESACTOEDASLRVFTTEAMTRYSAAPGDPQPEYDL 2779
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDTPVLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2780 ELITSCSSNVSAHDASGRVYVLTTRDTPVLARAAMETARHTPVNSWLGNIIMVAPTLW 2839
QY 425 ARMLTMTHTFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIERHLGSLAFSLHSYSPG 484
DB 2840 ARMLTMTHTFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIERHLGSLAFSLHSYSPG 2899
QY 485 EINRVASCLKLGVPPLRWHRARSVRKLLSQGGRAAIICGKLYFNWAVTKLKLTP 544
DB 2900 EINRVASCLKLGVPPLRWHRARSVRKLLSQGGRAATCGKLYFNWAVTKLKLTP 2959
QY 545 AASRLDLSGFWVAGYSGGDIYHLSRARPRFWMCLLLSSVGVGYLLPNR 595
DB 2960 AASRLDLSGFWVAGYSGGDIYHLSRARPRFWMCLLLSSVGVGYLLPNR 3010

RESULT 12
P89966
ID P89966 PRELIMINARY; PRT; 3010 AA.
Query Match 95.4%; Score 3022; DB 2; Length 3010;
```

```
AC P89966;
DT 01-MAY-1997 (TrEMBLrel. 03, Created)
DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)
DT 01-MAY-2004 (TrEMBLrel. 26, Last annotation update)
DE RNA for polyprotein, complete cds.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=type 1b;
RA TANAKA T.;
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=type 1b;
RA Tanaka T.;
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; D89872; BAA14035.1; -.
DR PIR; A61196; A61196.
DR PIR; PQ0246; PQ0246.
DR PIR; PQ0804; PQ0804.
DR PIR; PS0329; PS0329.
DR HSSP; O81755; 1DXP.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0008026; F:ATP-dependent helicase activity; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR GO; GO:0019087; P:viral transformation; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR011545; DEAD/DEAH_N.
DR InterPro; IPR002522; HCV_capsid.
DR InterPro; IPR002521; HCV_core.
DR InterPro; IPR002519; HCV_env.
DR InterPro; IPR002531; HCV_NS1.
DR InterPro; IPR000745; HCV_NS4a.
DR InterPro; IPR001490; HCV_NS4b.
DR InterPro; IPR002868; HCV_NS5a.
DR InterPro; IPR002166; HCV_RdRP.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR004109; Peptidase_S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39 HCV NS2.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF01543; HCV_capsid; 1.
DR Pfam; PF01542; HCV_core; 1.
DR Pfam; PF01539; HCV_env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF00998; Viral_RdRP; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; Transmembrane.
SQ SEQUENCE 3010 AA; 327024 MW; E075BD9CFD8D1261 CRC64;
```

```
Best Local Similarity 96.4%; Pred. No. 1.6e-226;
Matches 570; Conservative 12; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAAEESKLPINALSNLLRHNLVSTTSRSASLRQKKVTFDRLOVL 64
D 2420 SMSYTWGALITPCAAEESKLPINPLSNLLRHNSWVSTTSRSASLRQKKVTFDRLOVL 2479
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 124
D 2480 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 2539
QY 125 SVWKDLLEDTPDTPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKALYDVVS 184
D 2540 SVWKDLLEDTPDTPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKALYDVVS 2599
QY 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCPDSTVTENDIRVEESIY 244
D 2600 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCPDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPBARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
D 2660 QCCDLAPBARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAT 2719
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAAASLRVFTTEAMTRYSAAPPDPPPEYDL 364
D 2720 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAAASLRVFTTEAMTRYSAAPPDPPPEYDL 2779
QY 365 ELITSCSNVSAVHADSGKRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
D 2780 ELITSCSNVSAVHADSGKRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 2839
QY 425 ARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPG 484
D 2840 ARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPG 2899
QY 485 EINRVASCLRKLGVPPLRWRHARSVRKALLSQGGRAAICSKYLPNVAVRTKLTPI 544
D 2900 EINRVASCLRKLGVPPLRWRHARSVRKALLSQGGRAAICSKYLPNVAVRTKLTPI 2959
QY 545 AASRLDLSGFWFVAGYSGGDIYHLSRARPRWFMLCLLLSVGVGYLLPNR 595
D 2960 AASRLDLSGFWFVAGYSGGDIYHLSRARPRWFMLCLLLSVGVGYLLPNR 3010

RESULT 13
QSDTE0 PRELIMINARY; PRT; 3014 AA.
AC QSDTE0;
DT 01-MAR-2001 (TREMELrel. 16, Created)
DT 01-MAR-2001 (TREMELrel. 16, Last sequence update)
DT 01-MAR-2004 (TREMELrel. 26, Last annotation update)
DE Polyprotein.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=111103;
RN [1]_
RP SEQUENCE FROM N.A.
RC TISSUE=Serum;
RA Takahashi K., Iwata K., Matsumoto M., Matsumoto H., Nakao K.,
RA Hatahara T., Ohta Y., Kanai K., Maruo H., Baba K., Hijikata M.,
RA Mishiro S.;
RT "Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients
RT with hepatocellular carcinoma: the 'progression score' revisited.";
RL Hepatol. Res. 20:161-171(2001).
DR EMBL; AB049097; BAB18810.1; -.
DR PIR; A61196; A61196.
DR PIR; PS0329; PS0329.
DR HSSP; Q81755; 1DXP.
DR MEROPS; S29.002; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0019028; C:viral capsid; IEA.
DR GO; GO:0019031; C:viral envelope; IEA.
```

```
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0008026; F:RNA-dependent helicase activity; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F:serine-type peptidase activity; IEA.
DR GO; GO:0005198; F:structural molecule activity; IEA.
DR GO; GO:0006508; P:proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR GO; GO:0019087; P:viral transformation; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR011545; DEAD/DEAH N.
DR InterPro; IPR002522; HCV capsid.
DR InterPro; IPR002521; HCV core.
DR InterPro; IPR002519; HCV env.
DR InterPro; IPR002531; HCV NS1.
DR InterPro; IPR000745; HCV NS4a.
DR InterPro; IPR001490; HCV NS4b.
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV RdRP.
DR InterPro; IPR001650; Helicase C.
DR InterPro; IPR004109; Peptidase S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39_HCV_NS2.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF01543; HCV capsid; 1.
DR Pfam; PF01542; HCV_core; 1.
DR Pfam; PF01539; HCV_env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00271; Helicase C; 1.
DR Pfam; PF00998; Viral RdRP; 1.
DR SMART; SM00487; DEXDC; 1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; Transmembrane.
SQ SEQUENCE 3014 AA; 327498 MW; ED9BF4F94BDB6287 CRC64;

Query Match 95.4%; Score 3022; DB 2; Length 3014;
Best Local Similarity 96.1%; Pred. No. 1.6e-226;
Matches 568; Conservative 15; Mismatches 8; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAAEESKLPINALSNLLRHNLVSTTSRSASLRQKKVTFDRLOVL 64
D 2424 SMSYTWGALITPCAAEESKLPINPLSNLLRHNMIVATTSSAGLRQKKVTFDRLOVL 2483
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 124
D 2484 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 2543
QY 125 SVWKDLLEDTPDTPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKALYDVVS 184
D 2544 SVWKDLLEDTPDTPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKALYDVVS 2603
QY 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCPDSTVTENDIRVEESIY 244
D 2604 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCPDSTVTENDIRVEESIY 2663
QY 245 QCCDLAPBARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
D 2664 QCCDLAPBARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAS 2723
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAAASLRVFTTEAMTRYSAAPPDPPPEYDL 364
D 2724 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAAASLRVFTTEAMTRYSAAPPDPPPEYDL 2783
QY 365 ELITSCSNVSAVHADSGKRVYLLTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLM 424
```

```
Db 2784 ELITSCSSNVSAHDASGKRVYLTDRPTTPARAAMETARHTPVNSWLGNIIMVAPTLW 2843
Qy 425 ARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 484
Db 2844 ARMLTMTHFFSILLVQELKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 2903
Qy 485 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSGGAAICGKYLEFNWAVRTKLTPIP 544
Db 2904 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSGGAAICGKYLEFNWAVRTKLTPIP 2963
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 595
Db 2964 AASRLDLSGWFVAGYSGGDIYHLSVRARPRFWMCLLLLSVGVGIYLLPNR 3014

RESULT 14
CO09796 PRELIMINARY; PRT; 3010 AA.
AC O09796;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DE Genomic RNA, complete cds.
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=genotype II/1b;
RX MEDLINE=97170750; PubMed=9018054;
RA Sugiyama K., Kato N., Mizutani T., Ikeda M., Tanaka T., Shimotohno K.;
RT "Genetic analysis of the hepatitis C virus (HCV) genome from HCV-
    infected human T cells.";
RL J. Gen. Virol. 78:329-336(1997).
DR EMBL; D85516; BAA19625.1; -.
DR PIR; A61196; A61196.
DR PIR; FQ0804; FQ0804.
DR PIR; F50329; F50329.
DR HSSP; Q8JYS1; ICWX.
DR GO; GO:0016021; C: integral to membrane; IEA.
DR GO; GO:0019028; C: viral capsid; IEA.
DR GO; GO:0019031; C: viral envelope; IEA.
DR GO; GO:0005524; F: ATP binding; IEA.
DR GO; GO:0008026; F: ATP-dependent helicase activity; IEA.
DR GO; GO:0003723; F: RNA binding; IEA.
DR GO; GO:0003968; F: RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0008236; F: serine-type peptidase activity; IEA.
DR GO; GO:0005198; F: structural molecule activity; IEA.
DR GO; GO:0006508; F: proteolysis and peptidolysis; IEA.
DR GO; GO:0006350; P: transcription; IEA.
DR GO; GO:0019087; P: viral genome replication; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
DR InterPro; IPR001410; DEAD_heme_BS.
DR InterPro; IPR011545; DEAD/DEAH_N.
DR InterPro; IPR002522; HCV capsid.
DR InterPro; IPR002521; HCV core.
DR InterPro; IPR002519; HCV env.
DR InterPro; IPR002531; HCV NS1.
DR InterPro; IPR001490; HCV NS4a.
DR InterPro; IPR000745; HCV NS4b.
DR InterPro; IPR002868; HCV NS5a.
DR InterPro; IPR002166; HCV RDRP.
DR InterPro; IPR001650; Helicase_C.
DR InterPro; IPR004109; Peptidase_S29.
DR InterPro; IPR009003; Pept_Ser_Cys.
DR InterPro; IPR002518; Pept_U39_HCV_NS2.
DR InterPro; IPR007095; RNA_pol_DS_P5.
DR InterPro; IPR007094; RNA_pol_P5vir.
DR Pfam; PF01543; HCV capsid; 1.
DR Pfam; PF01542; HCV core; 1.
```

```
DR Pfam; PF01539; HCV env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00271; Helicase_C; 1.
DR Pfam; PF00998; Viral_RDRP; 1.
DR SMART; SM00487; DEAD_C; 1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
DR Coar protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; Transmembrane.
SQ SEQUENCE 3010 AA; 327266 MW; 4324643E6A1D5CE4 CRC64;

Query Match 95.4%; Score 3021; DB 2; Length 3010;
Best Local Similarity 96.3%; Pred. No. 1.9e-226;
Matches 569; Conservative 14; Mismatches 8; Indels 0; Gaps 0;

Qy 5 SMSYTWGTGALITPCAABESKLPINALSNLSLRHNLVYVTSRSASLRQKQKVTDFRLQVL 64
Db 2420 SMSYTWGTGALITPCAABESKLPINPLSNLSLRHNLVYVTSRSAGLRQKQKVTDFRLQVL 2479
Qy 65 DDHYRDVLEKMAKASTVKAKLLSVEBACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR 124
Db 2480 DDHYRDVLEKMAKASTVKAKLLSIEBACKLTPPHSAKSKYGYCAKDVRLSSRAVNHIR 2539
Qy 125 SVWKDLEDGDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 2540 SVWEDLLEDGDTPIQTTIMAKSEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 2599
Qy 185 TLPQAVNGSSVGFQYSPKQVPEPLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 2600 TLPQAVNGSSVGFQYSPKQVPEPLVNTWKSKCPMGFSYDTRCFDSTVTENDIRVESIY 2659
Qy 245 QCCLDAPEARQAIRSLTERLYVGGPMNTNSKQNGCYRRCRASGVLTTSCGNLTLCYLKAA 304
Db 2660 QCCLDAPEAKAIRSLTERLYVGGPLNTSKQNGCYRRCRASGVLTTSCGNLTLCYLKAS 2719
Qy 305 AACRAAKLQDCTMLVNGDDLVCESAGTQEDAAASLRVFTFAMTRYSAPODPPQPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLVCESAGTQEDAAASLRVFTFAMTRYSAPODPPQPEYDL 2779
Qy 365 ELITSCSSNVSAHDASGKRVYLTDRPTTPARAAMETARHTPVNSWLGNIIMVAPTLW 424
Db 2780 ELITSCSSNVSAHDASGKRVYLTDRPTTPARAAMETARHTPVNSWLGNIIMVAPTLW 2839
Qy 425 ARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 484
Db 2840 ARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 2899
Qy 485 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSGGAAICGKYLEFNWAVRTKLTPIP 544
Db 2900 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSGGAAICGKYLEFNWAVRTKLTPIP 2959
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 595
Db 2960 AASRLDLSGWFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 3010

RESULT 15
CO09930 PRELIMINARY; PRT; 591 AA.
AC O39930;
DT 01-JAN-1998 (TrEMBLrel. 05, Created)
DT 01-JAN-1998 (TrEMBLrel. 05, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE RNA-dependent RNA-polymerase (Fragment).
GN Name=NS5b;
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
```

```

[1]
RN SEQUENCE FROM N.A.
RX MEDLINE=98001363; PubMed=9343198;
RA Lohmann V., Korner F., Herian U., Bartenschlager R.;
RT "Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA
RT polymerase and identification of amino acid sequence motifs essential
RT for enzymatic activity.";
RL J. Virol. 71:8416-8428(1997).
DR EMBL; Z97730; CAB10747.1; -.
DR PDB; INHU; X-ray; A/B=1-570.
DR PDB; INHV; X-ray; A/B=1-570.
DR GO; GO:0005524; P:ATP binding; IEA.
DR GO; GO:0003723; F:RNA binding; IEA.
DR GO; GO:0003968; F:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:viral genome replication; IEA.
DR InterPro; IPR002166; HCV RdRp.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RdRp; 1.
FT NON_TER 1
SQ SEQUENCE 591 AA; 65753 MW; 6FA9C2F970260349 CRC64;

Query Match 95.4%; Score 3020; DB 2; Length 591;
Best Local Similarity 96.6%; Fred. No. 2.5e-227;
Matches 571; Conservative 12; Mismatches 8; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAERSKLPINALSNLSLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Qy 1 SMSYTWGALITPCAERSKLPINALSNLSLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAKOVRSLSSRAVNHR 124
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 61 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAKOVRNLSKAVNHR 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 125 SWKDLLEDTPITQTTIMAKNEVFCQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 184
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 121 SWKDLLEDTPITQTTIMAKNEVFCQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 180
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 185 TLPOAVMGSSYGFQVSPKORVEELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVERSIY 244
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 181 TLPOAVMGSSYGFQVSPQQRVEFLVNTWKSCKPMGFSYDTRCFDSTVTENDIRVERSIY 240
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCGYRRCRASGVLTTSCGNLTLCYLKAA 304
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 241 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCGYRRCRASGVLTTSCGNLTLCYLKAS 300
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 301 AACRAAKLQDCTMLVCGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 360
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 365 ELITSCSSNVSVADHASKRVYVLTROPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 361 ELITSCSSNVSVADHASKRVYVLTROPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 420
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 425 ARMILMTHFFSILLAQEALQDCIYGACYSIEPLDLPQIERLHGLSFAFSLSHSPG 484
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 421 ARMILMTHFFSILLAQEALQDCIYGACYSIEPLDLPQIERLHGLSFAFSLSHSPG 480
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 485 EINRVASCLRLKGVPPPLRVWRHRSVRRAKLLSQGGRAAICGKYLEFNWVTKLTPIP 544
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 481 EINRVASCLRLKGVPPPLRVWRHRSVRRAKLLSQGGRAAICGKYLEFNWVTKLTPIP 540
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 545 AASRLDLSGWFPVAGYSGGDIYVHSLSRARPRFMLECLLLLSVGVGIYLLPNR 595
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

Qy 541 AASQLDLSGWFPVAGYSGGDIYVHSLSRARPRFMLECLLLLSVGVGIYLLPNR 591
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:39:31 ; Search time 27 Seconds
(without alignments)
1661.633 Million cell updates/sec

Title: US-10-712-479-2

Perfect score: 3167

Sequence: 1 MASMSYTWGALITPCA.....LLSGVGIGYLLPNRHHHHH 601

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/PTCUS_COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3016	95.2	591	3	US-08-952-981A-1
2	3016	95.2	997	1	US-08-324-977-50
3	3016	95.2	997	2	US-08-384-616-50
4	3016	95.2	997	2	US-08-904-686A-50
5	3016	95.2	997	3	US-09-315-850-50
6	3016	95.2	2201	3	US-08-952-981A-2
7	3016	95.2	2621	1	US-08-324-977-36
8	3016	95.2	2621	2	US-08-384-616-36
9	3016	95.2	2621	3	US-08-904-686A-36
10	3016	95.2	2621	3	US-09-315-850-36
11	3016	95.2	3010	1	US-08-324-977-2
12	3016	95.2	3010	1	US-08-324-977-14
13	3016	95.2	3010	2	US-08-384-616-2
14	3016	95.2	3010	2	US-08-384-616-14
15	3016	95.2	3010	2	US-08-904-686A-2
16	3016	95.2	3010	3	US-08-904-686A-14
17	3016	95.2	3010	3	US-09-315-850-2
18	3016	95.2	3010	3	US-09-315-850-14
19	3016	95.2	3010	3	US-09-014-416-3
20	3014	95.2	593	4	US-09-597-877-23
21	3011	95.1	621	4	US-09-898-297-1
22	3011	95.1	621	4	US-09-995-099-1
23	3011	95.1	621	4	US-10-238-282-1
24	3011	95.1	2620	1	US-08-324-977-32
25	3011	95.1	2620	2	US-08-384-616-32
26	3011	95.1	2620	2	US-08-904-686A-32
27	3011	95.1	2620	3	US-09-315-850-32

28	3005	94.9	1985	4	US-09-539-601-9	Sequence 9, Appli
29	3005	94.9	1985	4	US-09-539-601-12	Sequence 12, Appl
30	3005	94.9	1985	4	US-09-539-601-24	Sequence 24, Appl
31	3005	94.9	2201	4	US-09-539-601-6	Sequence 6, Appli
32	3005	94.9	2201	4	US-09-539-601-15	Sequence 15, Appl
33	3005	94.9	2201	4	US-10-029-907-3	Sequence 3, Appli
34	3005	94.9	3010	4	US-09-539-601-3	Sequence 3, Appli
35	3005	94.9	3010	4	US-09-539-601-27	Sequence 27, Appl
36	3004	94.9	1985	4	US-09-539-601-18	Sequence 18, Appl
37	3004	94.9	3010	4	US-09-539-601-21	Sequence 21, Appl
38	3002	94.8	1985	4	US-09-539-601-30	Sequence 30, Appl
39	3002	94.8	3010	4	US-09-539-601-33	Sequence 33, Appl
40	2993	94.5	591	4	US-09-720-095A-2	Sequence 2, Appli
41	2987	94.3	593	4	US-09-597-877-12	Sequence 12, Appl
42	2927	92.4	590	4	US-09-194-949A-15	Sequence 15, Appl
43	2879	90.9	576	4	US-09-541-990A-1	Sequence 1, Appli
44	2786	88.0	591	3	US-09-208-140-2	Sequence 2, Appli
45	2774	87.6	3011	3	US-09-014-416-1	Sequence 1, Appli

ALIGNMENTS

RESULT 1

US-08-952-981A-1

; Sequence 1, Application US/08952981A

; Patent No. 6383768

; GENERAL INFORMATION:

; APPLICANT: DE FRANCESCO, Raffaele

; APPLICANT: TOMEI, Licia

; APPLICANT: BEHRENS, Sven-Erik

; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE

; TITLE OF INVENTION: ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)

; FILE REFERENCE: IT0002P

; CURRENT APPLICATION NUMBER: US/08/952,981A

; CURRENT FILING DATE: 1998-03-23

; NUMBER OF SEQ ID NOS: 14

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1

; LENGTH: 591

; TYPE: PRT

; ORGANISM: Hepatitis C virus

US-08-952-981A-1

Query Match 95.2%; Score 3016; DB 3; Length 591;

Best Local Similarity 96.6%; Pred. No. 2e-298;

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy	5	SMSYTWGALITPCAABESKLPINALNSLRHNLVYVSTTSRGSASLRQKVTFRLOVL	64
Db	1	SMSYTWGALITPCAABESKLPINALNSLRHNLVYVSTTSRGSASLRQKVTFRLOVL	60
Qy	65	DDHYRDLVKEMKAKASTVAKLLSVEEACKLTTPHSAKSKFGYGAOVRSLSRAVNHHR	124
Db	61	DDHYRDLVKEMKAKASTVAKLLSVEEACKLTTPHSAKSKFGYGAOVRLSSKAVNHHR	120
Qy	125	SVWKDLLEDTTPTQTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS	184
Db	121	SVWKDLLEDTTPTQTTIMAKNEVFCVQPEKGGKPARLIIVFPDLGVRVCEKMAIYDVVS	180
Qy	185	TLPOAVNGSSYGFQYSPKORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY	244
Db	181	TLPOAVNGSSYGFQYSPQORVEFLVNTWKSKNPMGFSYDTRCFDSTVTENDIRVEESIY	240
Qy	245	QCCDLAPEARQAIKSLTERLYVGGPMNTSKQNGCYRRCRASGLVTTSCGNTLTCLYKAA	304
Db	241	QCCDLAPEARQAIKSLTERLYVGGPLTNSKQNGCYRRCRASGLVTTSCGNTLTCLYKAS	300
Qy	305	AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGPPQPEYDL	364
Db	301	AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSPAPGPPQPEYDL	360

365	Qy	ELITSCSSNVSAHADSGKRVYVYLTRDTPVLARAAWETARHTPVNSWGLNIIIMYAPTLW	424
366			
367			
368			
369			
370			
371			
372			
373			
374			
375			
376			
377			
378			
379			
380			
381			
382			
383			
384			
385			
386			
387			
388			
389			
390			
391			
392			
393			
394			
395			
396			
397			
398			
399			
400			
401			
402			
403			
404			
405			
406			
407			
408			
409			
410			
411			
412			
413			
414			
415			
416			
417			
418			
419			
420			
421			
422			
423			
424			
425	Qy	ARWILMTHFFSILLAQEOLKALDCQIYGACVSTIEPDLQPIERLHGLSAFSLHSVSPG	484
426			
427			
428			
429			
430			
431			
432			
433			
434			
435			
436			
437			
438			
439			
440			
441			
442			
443			
444			
445			
446			
447			
448			
449			
450			
451			
452			
453			
454			
455			
456			
457			
458			
459			
460			
461			
462			
463			
464			
465			
466			
467			
468			
469			
470			
471			
472			
473			
474			
475			
476			
477			
478			
479			
480			
481	Qy	EINRVASCLRLKLGVPPLRWRHRAARSVRAKLISQGGRAAICGKYLFWNAVTKLKLTPIP	544
482			
483			
484			
485			
486			
487			
488			
489			
490			
491			
492			
493			
494			
495			
496			
497			
498			
499			
500			
501			

RESULT 2

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```



```
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/384,616
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/769,996
FILING DATE: 02-OCT-1991
APPLICATION NUMBER: JP 2-167466
FILING DATE: 25-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-230921
FILING DATE: 31-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-305605
FILING DATE: 09-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/635,451
FILING DATE: 28-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Stevens-Smith, Theresa M.
REGISTRATION NUMBER: 36,281
REFERENCE/DOCKET NUMBER: 900703B
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 659-2930
TELEFAX: (202) 887-0357
TELEX: 440142
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 997 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-384-616-50

Query Match 95.2%; Score 3016; DB 2; Length 997;
Best Local Similarity 96.6%; Pred.No. 4.8e-298;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAABESSKLPINALSNLSLRHNLVYTTSSASLRQKVKVTFDRQLVL 64
Db 407 SMSYTWTCALITPCAABESSKLPINALSNLSLRHNLVYTTSSASLRQKVKVTFDRQLVL 466
Qy 65 DDHYRDVLKEMKAKASTVKALLSVEBEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 467 DDHYRDVLKEMKAKASTVKALLSVEBEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 526
Qy 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCCKMALYDVVS 184
Db 527 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCCKMALYDVVS 586
Qy 185 TLPQVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 587 TLPQVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 646
Qy 245 QCCLDAPARQAIRSLRILYVGGPMTNSKQNCYRRCRAGSVLTTSCGNLTLCYLKAA 304
Db 647 QCCLDAPARQAIRSLRILYVGGPMTNSKQNCYRRCRAGSVLTTSCGNLTLCYLKAA 706
Qy 305 AACRAAKLQDCTMLVNGDDLVVIESAGTQEDAAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Db 707 AACRAAKLQDCTMLVNGDDLVVIESAGTQEDAAASLRVFTAMTRYSAAPPDPPQPEYDL 766
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLAARAWEATARTHPVNSWLGNIIMYAPTLW 424
Db 767 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLAARAWEATARTHPVNSWLGNIIMYAPTLW 826
Qy 425 ARMTLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG 484
Db 827 ARMTLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG 886
Qy 485 EINRVASCLRLKLGVPPLRVWRHRARSVRKLLSQGRRAAICGKYLFWNAVRTKLTPTIP 544
Db 887 EINRVASCLRLKLGVPPLRVWRHRARSVRARLLSQGRRAATCGKYLFWNAVRTKLTPTIP 946
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGYLLPNR 595
Db 947 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGYLLPNR 997

RESULT 4
US-08-904-686A-50
; Sequence 50, Application US/08904686A
; Patent No. 5998130
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
; ADDRESS: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/904,686A
; FILING DATE: 01-AUG-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/324,977
; FILING DATE: 18-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-230921
; FILING DATE: 31-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-305605
; FILING DATE: 09-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/099,706
; FILING DATE: 30-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/769,996
; FILING DATE: 02-OCT-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/635,451
; FILING DATE: 28-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: McLeland, Le-Nhung
; REGISTRATION NUMBER: 31,541
; REFERENCE/DOCKET NUMBER: 900703G
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; INFORMATION FOR SEQ ID NO: 50:
; LENGTH: 997 amino acids
; TYPE: amino acid
; SEQUENCE CHARACTERISTICS:
; TOPOLOGY: linear
```

```

; MOLECULE TYPE: protein
US-08-904-686A-50

Query Match 95.2%; Score 3016; DB 2; Length 997;
Best Local Similarity 96.6%; Pred. No. 4.8e-298;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 64
Db 407 SMSYTWGALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 466

Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Db 467 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 526

Qy 125 SVWKDLLEDVTPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 527 SVWKDLLEDVTPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 586

Qy 185 TLPQAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 587 TLPQAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 646

Qy 245 QCCLDLAPARQAISLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTLCYLKAA 304
Db 647 QCCLDLAPARQAISLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTLCYLKAS 706

Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAPOGDPPEYDL 364
Db 707 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAPOGDPPEYDL 766

Qy 365 ELITSCSSNSVSAHDASGKRYVYLTDRPTVPLAARAWEETARHTPVNSWLGNIIMYAPTLW 424
Db 767 ELITSCSSNSVSAHDASGKRYVYLTDRPTVPLAARAWEETARHTPVNSWLGNIIMYAPTLW 826

; ATTORNEY/AGENT INFORMATION:
; NAME: McLeeland, Le-Nhung
; REGISTRATION NUMBER: 31,541
; REFERENCE/DOCKET NUMBER: 900703G
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 997 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-315-850-50

Query Match 95.2%; Score 3016; DB 3; Length 997;
Best Local Similarity 96.6%; Pred. No. 4.8e-298;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWGALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 64
Db 407 SMSYTWGALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 466

Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Db 467 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 526

Qy 125 SVWKDLLEDVTPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 527 SVWKDLLEDVTPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 586

Qy 185 TLPQAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 587 TLPQAVMGSSYGFQYSPKQRFVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 646

Qy 245 QCCLDLAPARQAISLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTLCYLKAA 304
Db 647 QCCLDLAPARQAISLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNLTLCYLKAS 706

Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAPOGDPPEYDL 364
Db 707 AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTTEAMTRYSAPOGDPPEYDL 766

Qy 365 ELITSCSSNSVSAHDASGKRYVYLTDRPTVPLAARAWEETARHTPVNSWLGNIIMYAPTLW 424
Db 767 ELITSCSSNSVSAHDASGKRYVYLTDRPTVPLAARAWEETARHTPVNSWLGNIIMYAPTLW 826

; ARMITLTHFFSILLAEQLEKALDQIYACYSIEPLDLPQIERLHGLSAFSLHSYSPG 484
; ARMITLTHFFSILLAEQLEKALDQIYACYSIEPLDLPQIERLHGLSAFSLHSYSPG 886
; BINRVASCLRLGVPPLRWHRARSVRARLLSQGGRATCGKYLFWNAVTKLKLTPIP 544
; BINRVASCLRLGVPPLRWHRARSVRARLLSQGGRATCGKYLFWNAVTKLKLTPIP 946
; AASRLDLSGWFVAGYSGGDIYHLSRARPWFMLCLLLSVGVGIYLLPNR 595
; AASRLDLSGWFVAGYSGGDIYHLSRARPWFMLCLLLSVGVGIYLLPNR 997

RESULT 5
US-09-315-850-50
; Sequence 50, Application US/09315850
; Patent No. 6217872
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Ieao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLeeland &
; ADDRESS: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44MB
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0

```

QY 425 ARMILMTHFFSILLAOEOLKALDQOYGCYSIEPLDLPOIERLHGLSAPSLHSYSPG 484
DB 827 ARMILMTHFFSILLAOEOLKALDQOYGCYSIEPLDLPOIERLHGLSAPSLHSYSPG 886
QY 485 EINRVASCLRLKLGVPPLRVWRHRSVRARLLSQGAAICCKYLFWAVRTKLTIP 544
DB 887 EINRVASCLRLKLGVPPLRVWRHRSVRARLLSQGAAICCKYLFWAVRTKLTIP 946
QY 545 AASRLDLSGFWAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 595
DB 947 AASRLDLSGFWAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 997
RESULT 6
US-08-952-981A-2
; Sequence 2, Application US/08952981A
; Patent No. 6383768
; GENERAL INFORMATION:
; APPLICANT: DE FRANCESCO, Raffaele
; APPLICANT: TOMEI, Licia
; APPLICANT: BEHRENS, Sven-Erik
; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE RNA-DEPENDENT RNA
; TITLE OF INVENTION: POLYMERASE AND TERMINAL NUCLEOTIDYL TRANSFERASE
; TITLE OF INVENTION: ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)
; FILE REFERENCE: IT0002P
; CURRENT APPLICATION NUMBER: US/08/952,981A
; CURRENT FILING DATE: 1998-03-23
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 2
; LENGTH: 2201
; TYPE: PRT
; ORGANISM: CDNA clone pCD (38-9.4)
US-08-952-981A-2
Query Match 95.2%; Score 3016; DB 3; Length 2201;
Best Local Similarity 96.6%; Pred. No. 1.8e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAARESKLPINALNSLRHHNLVYSTSRASLRQKVTDFORLVL 64
DB 1611 SMSYTWTCALITPCAARESKLPINALNSLRHHNLVYSTSRASLRQKVTDFORLVL 1670
QY 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
DB 1671 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 1730
QY 125 SVWKDLEDLTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
DB 1731 SVWKDLEDLTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 1790
QY 185 TLPOAVMGSSYGFQSPQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESYI 244
DB 1791 TLPOAVMGSSYGFQSPQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESYI 1850
QY 245 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNCQYRRCRAGSVLTTSCGNLTCLYKAA 304
DB 1851 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNCQYRRCRAGSVLTTSCGNLTCLYKAA 1910
QY 305 AACRAKLQDCTMLVNGDDLWVVCESAGTQEDAAASLRVFTTEAMTRYSPAPGDPQPEYDL 364
DB 1911 AACRAKLQDCTMLVNGDDLWVVCESAGTQEDAAASLRVFTTEAMTRYSPAPGDPQPEYDL 1970
QY 365 ELITSCSSNVSAHDASGRVYLLTRDTVPLARAAMETARHTPVNSWGLNIIMYAPTLW 424
DB 1971 ELITSCSSNVSAHDASGRVYLLTRDTVPLARAAMETARHTPVNSWGLNIIMYAPTLW 2030
QY 425 ARMILMTHFFSILLAOEOLKALDQOYGCYSIEPLDLPOIERLHGLSAPSLHSYSPG 484
DB 2031 ARMILMTHFFSILLAOEOLKALDQOYGCYSIEPLDLPOIERLHGLSAPSLHSYSPG 2090
QY 485 EINRVASCLRLKLGVPPLRVWRHRSVRARLLSQGAAICCKYLFWAVRTKLTIP 544

DB 2091 EINRVASCLRLKLGVPPLRVWRHRSVRARLLSQGAAICCKYLFWAVRTKLTIP 2150
QY 545 AASRLDLSGFWAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 595
DB 2151 AASRLDLSGFWAGYSGGDIYHSLSRARPRWFMCLLLLSVGVGYLLPNR 2201
RESULT 7
US-08-324-977-36
; Sequence 36, Application US/08324977
; Patent No. 5747339
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, Mcleland &
; ADDRESSEE: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44MB
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/324,977
; FILING DATE: 18-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-230921
; FILING DATE: 31-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-305605
; FILING DATE: 09-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/099,706
; FILING DATE: 30-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/769,996
; FILING DATE: 02-OCT-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/635,451
; FILING DATE: 28-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Stevens-Smith, Theresa M.
; REGISTRATION NUMBER: 36,281
; REFERENCE/DOCKET NUMBER: 900703D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; TELEFAX: 440142
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2621 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-324-977-36
Query Match 95.2%; Score 3016; DB 1; Length 2621;
Best Local Similarity 96.6%; Pred. No. 2.4e-297;

Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 64
DB 2031 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 2090

QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 124
DB 2091 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 2150

QY 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
DB 2151 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 2210

QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 2211 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 2270

QY 245 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
DB 2271 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAS 2330

QY 305 AACRAAKLQDCTMLVNGDDLVCESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 364
DB 2331 AACRAAKLQDCTMLVNGDDLVCESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 2390

QY 365 ELITSCSNVSVAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2391 ELITSCSNVSVAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2450

QY 425 ARMITLMTHTFFSILLAOBLEKALDCQIYGACVSTIEPLDLPQIERLHGLSAFSLHSYSPG 484
DB 2451 ARMITLMTHTFFSILLAOBLEKALDCQIYGACVSTIEPLDLPQIERLHGLSAFSLHSYSPG 2510

QY 485 EIRNVASCLRLKGLVPPPLRVWRHARSVRALKLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
DB 2511 EIRNVASCLRLKGLVPPPLRVWRHARSVRALKLSQGGRAAICGKYLFWNAVRTKLTPIIP 2570

QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRFWMCLLLLSVGVGIYLLPNR 595
DB 2571 AASRLDLSGWFVAGYSGGDIYHLSRARPRFWMCLLLLSVGVGIYLLPNR 2621

RESULT 8

US-08-384-616-36
; Sequence 36, Application US/08384616
; Patent No. 5847101
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLealand &
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44MB
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,616
; FILING DATE:
; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/769,996
; FILING DATE: 02-OCT-1991
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-230921
; FILING DATE: 31-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-305605
; FILING DATE: 09-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/635,451
; FILING DATE: 28-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Stevens-Smith, Theresa M.
; REGISTRATION NUMBER: 36,281
; REFERENCE/DOCKET NUMBER: 900703B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; TELEX: 440142
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2621 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-384-616-36

Query Match 95.2%; Score 3016; DB 2; Length 2621;
Best Local Similarity 96.6%; Pred. No. 2.4e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 64
DB 2031 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 2090

QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 124
DB 2091 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAADVRSLSRAVNHIR 2150

QY 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
DB 2151 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 2210

QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 2211 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 2270

QY 245 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAA 304
DB 2271 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCLYKAS 2330

QY 305 AACRAAKLQDCTMLVNGDDLVCESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 364
DB 2331 AACRAAKLQDCTMLVNGDDLVCESAGTQBDAAASLRVFTAMTRYSAAPPDPPQPEYDL 2390

QY 365 ELITSCSNVSVAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2391 ELITSCSNVSVAHDASGRVYVLTDRPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2450

QY 425 ARMITLMTHTFFSILLAOBLEKALDCQIYGACVSTIEPLDLPQIERLHGLSAFSLHSYSPG 484
DB 2451 ARMITLMTHTFFSILLAOBLEKALDCQIYGACVSTIEPLDLPQIERLHGLSAFSLHSYSPG 2510

QY 485 EIRNVASCLRLKGLVPPPLRVWRHARSVRALKLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
DB 2511 EIRNVASCLRLKGLVPPPLRVWRHARSVRALKLSQGGRAAICGKYLFWNAVRTKLTPIIP 2570

QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRFWMCLLLLSVGVGIYLLPNR 595
DB 2571 AASRLDLSGWFVAGYSGGDIYHLSRARPRFWMCLLLLSVGVGIYLLPNR 2621

RESULT 9
 US-08-904-686A-36
 ; Sequence 36, Application US/08904686A
 ; Patent No. 5998130
 ; GENERAL INFORMATION:
 ; APPLICANT: OKAYAMA, Hiroto
 ; APPLICANT: FUKU, Isao
 ; APPLICANT: MORI, Chisato
 ; APPLICANT: TAKAMIZAWA, Akahisa
 ; APPLICANT: YOSHIDA, Iwao
 ; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ; NUMBER OF SEQUENCES: 50
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESS: Armstrong, Westerman, Hattori, McLeland &
 ; ADDRESS: Naughton
 ; STREET: 1725 K St. N.W. Suite 1000
 ; CITY: Washington
 ; STATE: D.C.
 ; COUNTRY: U.S.A.
 ; ZIP: 20006
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/904,686A
 ; FILING DATE: 01-AUG-1997
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/324,977
 ; FILING DATE: 18-OCT-1994
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-167466
 ; FILING DATE: 25-JUN-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-230921
 ; FILING DATE: 31-AUG-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-305605
 ; FILING DATE: 09-NOV-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/099,706
 ; FILING DATE: 30-JUL-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/769,996
 ; FILING DATE: 02-OCT-1991
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/635,451
 ; FILING DATE: 28-DEC-1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: McLeland, Le-Nhung
 ; REGISTRATION NUMBER: 31,541
 ; REFERENCE/DOCKET NUMBER: 900703G
 ; TELEPHONE: (202) 659-2930
 ; TELEFAX: (202) 887-0357
 ; INFORMATION FOR SEQ ID NO: 36:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2621 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-08-904-686A-36

Query Match 95.2%; Score 3016; DB 2; Length 2621;
 Best Local Similarity 96.6%; Pred. No. 2.4e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLLRHNNVYATTSRSASLRQKVTDFRLQVL 64
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db 2031 SMSYTWTCALITPCAABESKLPINALNSLLRHNNVYATTSRSASLRQKVTDFRLQVL 2090
 QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGVGAKDVSLSRSRVNHIR 124
 Db 2091 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGVGAKDVSLSRSRVNHIR 2150
 QY 125 SVWKDLLEDTPPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKMAVYVVS 184
 Db 2151 SVWKDLLEDTPPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKMAVYVVS 2210
 QY 185 TLPQAVMGSSYGFQSPKORVEFLVNTWKAKCPMGFSVDTCFDPSTVTENDIRVEESIY 244
 Db 2211 TLPQAVMGSSYGFQSPKORVEFLVNTWKAKCPMGFSVDTCFDPSTVTENDIRVEESIY 2270
 QY 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTVCYLKAA 304
 Db 2271 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTVCYLKAA 2330
 QY 305 AACRAAKLQDCTMLVNGDDLVIWVICSAGTQEDAAASLRVFTTEAMTRYSPAPPDPPQPEYDL 364
 Db 2331 AACRAAKLQDCTMLVNGDDLVIWVICSAGTQEDAAASLRVFTTEAMTRYSPAPPDPPQPEYDL 2390
 QY 365 ELITSCSSNSVVAHDASGRVYLYLTRDPTVPLARAWEETARHTPVNSWLGNIIMYAPILW 424
 Db 2391 ELITSCSSNSVVAHDASGRVYLYLTRDPTVPLARAWEETARHTPVNSWLGNIIMYAPILW 2450
 QY 425 ARMLMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIRLHGLSFAFLSHSYSPG 484
 Db 2451 ARMLMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIRLHGLSFAFLSHSYSPG 2510
 QY 485 EIRNVASCLRLKGLVPPPLRVWRHRSVRKLLSQGAAICQKYLFWNAVRTKLLTPIP 544
 Db 2511 EIRNVASCLRLKGLVPPPLRVWRHRSVRKLLSQGAAICQKYLFWNAVRTKLLTPIP 2570
 QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGYLLPNR 595
 Db 2571 AASRLDLSGWFVAGYSGGDIYHSLSRAPRPFMLCLLLSVGVGYLLPNR 2621

RESULT 10
 US-09-315-850-36
 ; Sequence 36, Application US/09315850
 ; Patent No. 6217872
 ; GENERAL INFORMATION:
 ; APPLICANT: OKAYAMA, Hiroto
 ; APPLICANT: FUKU, Isao
 ; APPLICANT: MORI, Chisato
 ; APPLICANT: TAKAMIZAWA, Akahisa
 ; APPLICANT: YOSHIDA, Iwao
 ; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ; NUMBER OF SEQUENCES: 50
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESS: Armstrong, Westerman, Hattori, McLeland &
 ; ADDRESS: Naughton
 ; STREET: 1725 K St. N.W. Suite 1000
 ; CITY: Washington
 ; STATE: D.C.
 ; COUNTRY: U.S.A.
 ; ZIP: 20006
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/315,850
 ; FILING DATE:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/904,686
 ; FILING DATE: 01-AUG-1997
 ; APPLICATION NUMBER: US 08/324,977
 ; FILING DATE: 18-OCT-1994

; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-167466
 ; FILING DATE: 25-JUN-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-230921
 ; FILING DATE: 31-AUG-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-305605
 ; FILING DATE: 09-NOV-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/099,706
 ; FILING DATE: 30-JUL-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/769,996
 ; FILING DATE: 02-OCT-1991
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/635,451
 ; FILING DATE: 28-DEC-1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: McLeland, Le-Nhung
 ; REGISTRATION NUMBER: 31,541
 ; REFERENCE/DOCKET NUMBER: 900703G
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202) 659-2930
 ; TELEFAX: (202) 887-0357
 ; INFORMATION FOR SEQ ID NO: 36:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2621 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-09-315-850-36

Query Match 95.2%; Score 3016; DB 3; Length 2621;
 Best Local Similarity 96.6%; Pred. No. 2.4e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy	5	SMSYTWTCALITPCAABESKLPINALSNLRRHNLVSTTSRSASLRQKKVTFDRLOVL	64
Db	2031	SMSYTWTCALITPCAABESKLPINALSNLRRHNLVSTTSRSASLRQKKVTFDRLOVL	2090
Qy	65	DDHYRDLVKEMKAKASTYKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR	124
Db	2091	DDHYRDLVKEMKAKASTYKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR	2150
Qy	125	SWKDLLEDDTPTOTTMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVS	184
Db	2151	SWKDLLEDDTPTOTTMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVS	2210
Qy	185	TLPOAVMGSSYGFQSPKORVEFLVNTWKAKCPMGFSYDTRCPDSTVTENDIRVEESIY	244
Db	2211	TLPOAVMGSSYGFQSPKORVEFLVNTWKAKCPMGFSYDTRCPDSTVTENDIRVEESIY	2270
Qy	245	QCDDLAPEARQAIRSLTERLYVGGPMTNKSGQCYRRCRASGVLTITSCGNTLTCLYKAA	304
Db	2271	QCDDLAPEARQAIRSLTERLYVGGPMTNKSGQCYRRCRASGVLTITSCGNTLTCLYKAS	2330
Qy	305	AACRAAKLQDCTMLVNGDDLVCESAGTQEDAAASLRVFTAMTRYSAAPPDGPQPEYDL	364
Db	2331	AACRAAKLQDCTMLVNGDDLVCESAGTQEDAAASLRVFTAMTRYSAAPPDGPQPEYDL	2390
Qy	365	ELITSCSNVSVAHDASGRVYVLTTRDTPVLARAWEATARTPNSWLNIIIVAPTLM	424
Db	2391	ELITSCSNVSVAHDASGRVYVLTTRDTPVLARAWEATARTPNSWLNIIIVAPTLM	2450
Qy	425	ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG	484
Db	2451	ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG	2510
Qy	485	EINRVASCLRLKGVPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLPIIP	544
Db	2511	EINRVASCLRLKGVPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLPIIP	2570

Qy 545 AASRLDLSGWFVAGYSGDIYHLSRARPWFMLCLLLLSVGVIYLLPNR 595
 |||||
 Db 2571 AASRLDLSGWFVAGYSGDIYHLSRARPWFMLCLLLLSVGVIYLLPNR 2621
 |||||
 RESULT 11
 US-08-324-977-2
 ; Sequence 2, Application US/08324977
 ; Patent No. 5747339
 ; GENERAL INFORMATION:
 ; APPLICANT: OKAYAMA, Hiroto
 ; APPLICANT: FUKU, Isao
 ; APPLICANT: MORI, Chisato
 ; APPLICANT: TAKAMIZAWA, Akahisa
 ; APPLICANT: YOSHIDA, Iwao
 ; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
 ; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
 ; NUMBER OF SEQUENCES: 50
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Armstrong, Westerman, Hattori, McLeland &
 ; ADDRESSEE: Naughton
 ; STREET: 1725 K St. N.W. Suite 1000
 ; CITY: Washington
 ; STATE: D.C.
 ; COUNTRY: U.S.A.
 ; ZIP: 20006
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
 ; SOFTWARE: ASCII
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/324,977
 ; FILING DATE: 18-OCT-1994
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-167466
 ; FILING DATE: 25-JUN-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-230921
 ; FILING DATE: 31-AUG-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: JP 2-305605
 ; FILING DATE: 09-NOV-1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/099,706
 ; FILING DATE: 30-JUL-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/769,996
 ; FILING DATE: 02-OCT-1991
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/635,451
 ; FILING DATE: 28-DEC-1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Stevens-Smith, Theresa M.
 ; REGISTRATION NUMBER: 36,281
 ; REFERENCE/DOCKET NUMBER: 900703D
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202) 659-2930
 ; TELEFAX: (202) 887-0357
 ; TELEX: 440142
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 3010 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; US-08-324-977-2

Query Match 95.2%; Score 3016; DB 1; Length 3010;
 Best Local Similarity 96.6%; Pred. No. 3e-297;
 Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAABESKLPINALSNLRRHNLVSTTSRSASLRQKKVTFDRLOVL 64

[illegible]

RESULT 12

```

US-08-324-977-14
; Sequence 14, Application US/08324977
; Patent No. 5747339
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUXE, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLealand &
; ADDRESSEE: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/324,977
; FILING DATE: 18-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:

```

```
RESULT 13
US-08-384-616-2
; Sequence 2, Application US/08384616
; Patent No. 5847101
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLeand &
; ADDRESSEE: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,616
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/769,996
; FILING DATE: 02-OCT-1991
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-230921
; FILING DATE: 31-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-305605
; FILING DATE: 09-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/635,451
; FILING DATE: 28-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Stevens-Smith, Theresa M.
; REGISTRATION NUMBER: 36,281
; REFERENCE/DOCKET NUMBER: 900703B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; TELEX: 440142
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3010 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-384-616-2

Query Match 95.2%; Score 3016; DB 2; Length 3010;
Best Local Similarity 96.6%; Pred. No. 3e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAARESKLPINALSNLLRHNLVYSTRSASLRQKKVTFDRLOVL 64
Db 2420 SMSYTWTCALITPCAARESKLPINALSNLLRHNLVYSTRSASLRQKKVTFDRLOVL 2479

Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 2480 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 2539

Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCYQPEKGGKRPARLIVFPDLGVRVCEKMALYDVVS 184
Db 2540 SVWKDLLEDVTPTIDTTIMAKNEVFCYQPEKGGKRPARLIVFPDLGVRVCEKMALYDVVS 2599

Qy 185 TLPQAVMGSSYGFQYSPKQRFVEFLVNTWKAKCKPMGFSDYTRCFDSTVTENDIRVESIY 244
Db 2600 TLPQAVMGSSYGFQYSPQRFVEFLVNTWKSKNPMGFSDYTRCFDSTVTENDIRVESIY 2659

Qy 245 QCCLDLAPARQAIRSLTERLYVGGPMTNSGQNGCYRRCRASGVLTTCGNTLTCYLKAA 304
Db 2660 QCCLDLAPARQAIRSLTERLYIGGLTNSGQNGCYRRCRASGVLTTCGNTLTCYLKAS 2719

Qy 305 AACRAAKLQDCTMLVNGDDLWVWICESAGTQDAASLVFTEAMTRYSGAPGDPPOPEYDL 364
Db 2720 AACRAAKLQDCTMLVNGDDLWVWICESAGTQDAASLVFTEAMTRYSGAPGDPPOPEYDL 2779

Qy 365 ELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 2780 ELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 2839

Qy 425 ARMLTMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 2840 ARMLTMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 2899

Qy 485 EINEVASCLRKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLEFNWAVETKLTLP 544
Db 2900 EINEVASCLRKLGVPPLRVWHRARSVRARLLSOGGAAICGKYLEFNWAVETKLTLP 2959

Qy 545 AASRLDLSGMFVAGYSGGDIYHLSRARPWFMLCLLLLSVGVGIYLLPNR 595
Db 2960 AASRLDLSGMFVAGYSGGDIYHLSRARPWFMLCLLLLSVGVGIYLLPNR 3010

RESULT 14
US-08-384-616-14
; Sequence 14, Application US/08384616
; Patent No. 5847101
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao
; APPLICANT: MORI, Chisato
; APPLICANT: TAKAMIZAWA, Akahisa
; APPLICANT: YOSHIDA, Iwao
; TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
; TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Armstrong, Westerman, Hattori, McLeand &
; ADDRESSEE: Naughton
; STREET: 1725 K St. N.W. Suite 1000
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 in, 1.44Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,616
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/769,996
; FILING DATE: 02-OCT-1991
; APPLICATION NUMBER: JP 2-167466
; FILING DATE: 25-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-230921
; FILING DATE: 31-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 2-305605
; FILING DATE: 09-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/635,451
; FILING DATE: 28-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Stevens-Smith, Theresa M.
; REGISTRATION NUMBER: 36,281
; REFERENCE/DOCKET NUMBER: 900703B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 659-2930
; TELEFAX: (202) 887-0357
; TELEX: 440142
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3010 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
```


APPLICATION NUMBER: JP 2-305605
FILING DATE: 09-NOV-1990
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/635,451
FILING DATE: 28-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Stevens-Smith, Theresa M.
REGISTRATION NUMBER: 36,281
REFERENCE/DOCKET NUMBER: 900703B
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 659-2930
TELEFAX: (202) 887-0357
TELEX: 440142
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 3010 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-384-616-14

Query Match 95.2%; Score 3016; DB 2; Length 3010;
Best Local Similarity 96.6%; Pred. No. 3e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHHNLVYTTSSASLRQKVKVTFDRLOVL 64
DB 2420 SMSYTWTCALITPCAAEESKLPINALNSLLRHHNMVYATTSRAGLRQKVKVTFDRLOVL 2479
QY 65 DDHYRDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 2480 DDHYRDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRLSSKAVNHIIH 2539
QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLI VFPDLGVRCVMALYDVVS 184
DB 2540 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLI VFPDLGVRCVMALYDVVS 2599
QY 185 TLPQVGMSSYGFQSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 2600 TLPQVGMSSYGFQSPQRVEFLVNTWKSKNPMGFSYDTRCFDSTVTENDIRVEESIY 2659
QY 245 QCCDLAPARQAIRSLTRLVYGGPMWNSKQNCYRCRAGSVLTJTS CGNTLTCYLKAA 304
DB 2660 QCCDLAPARQAIRSLTRLVYGGPMWNSKQNCYRCRAGSVLTJTS CGNTLTCYLKAS 2719
QY 305 AACRAAKLQDCTMLVNGDVLVVCESAGTQBDAAASLRVFTAMTRYSAAPGDPPEYDL 364
DB 2720 AACRAAKLQDCTMLVNGDVLVVCESAGTQBDAAASLRVFTAMTRYSAAPGDPPEYDL 2779
QY 365 ELITSCSNVSVAHDAKGRVYLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
DB 2780 ELITSCSNVSVAHDAKGRVYLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 2839
QY 425 ARMLTMTHFFSILLAEQLEKALDQIYGACYSIEPLDPIIERLHGLSAFSLHSYSPG 484
DB 2840 ARMLTMTHFFSILLAEQLEKALDQIYGACYSIEPLDPIIERLHGLSAFSLHSYSPG 2899
QY 485 EINRVASCLRLGVPPPLRVWRHRSVRKALLSOGGRAAICGKYLFWNAVTKLKTIP 544
DB 2900 EINRVASCLRLGVPPPLRVWRHRSVRKALLSOGGRAATCGKYLFWNAVTKLKTIP 2959
QY 545 AASRLDLSGFWVAGVSGGDIYHLSRARPFRWMLCLLLLSVGVGIYLLPNR 595
DB 2960 AASRLDLSGFWVAGVSGGDIYHLSRARPFRWMLCLLLLSVGVGIYLLPNR 3010

RESULT 15
US-08-904-686A-2
; Sequence 2, Application US/08904686A
; Patent No. 5998130
; GENERAL INFORMATION:
; APPLICANT: OKAYAMA, Hiroto
; APPLICANT: FUKU, Isao

APPLICANT: MORI, Chisato
APPLICANT: TAKAMIZAWA, Akahisa
APPLICANT: YOSHIDA, Iwao
TITLE OF INVENTION: NON-A, NON-B HEPATITIS VIRUS GENOMIC
TITLE OF INVENTION: CDNA AND ANTIGEN POLYPEPTIDE
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: Armstrong, Westerman, Hattori, McLeeland &
ADDRESSEE: Naughton
STREET: 1725 K St. N.W. Suite 1000
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20006
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 in, 1.44MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS, Version 5.0
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/904,686A
FILING DATE: 01-AUG-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/324,977
FILING DATE: 18-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-167466
FILING DATE: 25-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-230921
FILING DATE: 31-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 2-305605
FILING DATE: 09-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/099,706
FILING DATE: 30-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/769,996
FILING DATE: 02-OCT-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/635,451
FILING DATE: 28-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: McLeeland, Le-Nhung
REGISTRATION NUMBER: 31,541
REFERENCE/DOCKET NUMBER: 900703G
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 659-2930
TELEFAX: (202) 887-0357
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 3010 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-904-686A-2

Query Match 95.2%; Score 3016; DB 2; Length 3010;
Best Local Similarity 96.6%; Pred. No. 3e-297;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHHNLVYTTSSASLRQKVKVTFDRLOVL 64
DB 2420 SMSYTWTCALITPCAAEESKLPINALNSLLRHHNMVYATTSRAGLRQKVKVTFDRLOVL 2479
QY 65 DDHYRDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 2480 DDHYRDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRLSSKAVNHIIH 2539
QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLI VFPDLGVRCVMALYDVVS 184
DB 2540 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLI VFPDLGVRCVMALYDVVS 2599

Qy	185	TLPOAVMGSSYGFQYSPKQRYVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY	244
Db	2600	TLPOVVMGSSYGFQYSPQRYVEFLVNTWKSKNPMGFSYDTRCFDSTVTENDIRVEESIY	2659
Qy	245	QCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVLTTSCGNTLTCYLKAA	304
Db	2660	QCCDLAPEARQAIKSLTERLYIGGPLTNSKGQNGCYRRCRASGVLTTSCGNTLTCYLKAS	2719
Qy	305	AACRAAKLQDCTMLVNGDDLVI CESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL	364
Db	2720	AACRAAKLQDCTMLVNGDDLVI CESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL	2779
Qy	365	ELITSCSSNVSAHDASGRVYVYLTROPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW	424
Db	2780	ELITSCSSNVSAHDASGRVYVYLTROPTTPLARAAMETARHTPVNSWLGNIIMYAPTLW	2839
Qy	425	ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIERLHGLSAFSLHSYSPG	484
Db	2840	ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIERLHGLSAFSLHSYSPG	2899
Qy	485	EINRVASCLRKLGVPPLRVVWRHARSVRAKLLSQGGRAAICGKYLEFNNAVTKLKLTPIP	544
Db	2900	EINRVASCLRKLGVPPLRVVWRHARSVRARLLSQGGRAAICGKYLEFNNAVTKLKLTPIP	2959
Qy	545	AASRLDLSGWFVAGYGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR	595
Db	2960	AASRLDLSGWFVAGYGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR	3010

Search completed: September 22, 2005, 14:47:44
Job time : 30 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:43:14 ; Search time 76 Seconds
(without alignments)

3218.609 Million cell updates/sec

Title: US-10-712-479-2

Perfect score: 3167

Sequence: 1 MASMSMTWTGALITPCAA.....LLSVGVGYLLPNRRHHHH 601

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1826521 seqs, 407012169 residues

Total number of hits satisfying chosen parameters: 1826521

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
- 19: /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
- 21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
- 22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3167	100.0	601	16	US-10-712-479-2
2	3034.5	95.8	580	16	US-10-712-479-4
3	3016	95.2	591	13	US-10-085-476-1
4	3016	95.2	2201	13	US-10-085-476-2
5	3014	95.2	593	14	US-10-241-872-23
6	3012	95.1	1985	16	US-10-492-178-6
7	3011	95.1	591	16	US-10-471-164-5
8	3011	95.1	621	9	US-09-898-297-1
9	3011	95.1	621	14	US-10-198-680A-1
10	3011	95.1	621	15	US-10-238-282-1
11	3011	95.1	621	15	US-10-198-259A-1
					Sequence 2, Appli
					Sequence 4, Appli
					Sequence 1, Appli
					Sequence 2, Appli
					Sequence 23, Appli
					Sequence 6, Appli
					Sequence 5, Appli
					Sequence 1, Appli
					Sequence 1, Appli
					Sequence 1, Appli

12	3011	95.1	621	15	US-10-198-384A-1	Sequence 1, Appli
13	3011	95.1	621	16	US-10-471-164-1	Sequence 1, Appli
14	3011	95.1	621	16	US-10-851-710-1	Sequence 1, Appli
15	3011	95.1	627	9	US-09-838-386-12	Sequence 12, Appli
16	3011	95.1	627	16	US-10-471-164-6	Sequence 6, Appli
17	3006	94.9	2865	9	US-09-742-659-6	Sequence 6, Appli
18	3005	94.9	1985	14	US-10-259-275-42	Sequence 42, Appli
19	3005	94.9	1985	16	US-10-639-150-2	Sequence 2, Appli
20	3005	94.9	1985	20	US-11-006-313-42	Sequence 42, Appli
21	3005	94.9	2201	13	US-10-029-907-3	Sequence 3, Appli
22	3005	94.9	2201	14	US-10-309-561-3	Sequence 3, Appli
23	3005	94.9	2201	16	US-10-789-355-3	Sequence 3, Appli
24	3005	94.9	2201	16	US-10-686-835-3	Sequence 3, Appli
25	3005	94.9	3010	15	US-10-467-000-1	Sequence 1, Appli
26	2991	94.4	1985	16	US-10-492-178-1	Sequence 1, Appli
27	2987	94.3	593	14	US-10-241-872-12	Sequence 12, Appli
28	2978	94.0	2985	14	US-10-259-275-40	Sequence 40, Appli
29	2978	94.0	2985	20	US-11-006-313-40	Sequence 40, Appli
30	2972	93.8	3010	16	US-10-333-449A-34	Sequence 34, Appli
31	2937.5	92.8	576	17	US-10-842-046-1	Sequence 1, Appli
32	2927	92.4	590	10	US-09-194-949-15	Sequence 15, Appli
33	2927	92.4	590	17	US-10-664-391-15	Sequence 15, Appli
34	2925.5	92.4	578	14	US-10-211-455-1	Sequence 1, Appli
35	2925.5	92.4	578	16	US-10-471-164-3	Sequence 3, Appli
36	2904	91.7	591	14	US-10-211-455-2	Sequence 2, Appli
37	2904	91.7	591	14	US-10-211-455-4	Sequence 4, Appli
38	2904	91.7	591	16	US-10-471-164-2	Sequence 2, Appli
39	2879	90.9	576	14	US-10-170-131-1	Sequence 1, Appli
40	2876	88.0	591	9	US-09-733-183A-2	Sequence 2, Appli
41	2786	88.0	591	14	US-10-342-372-2	Sequence 2, Appli
42	2776	87.7	3011	15	US-10-296-734-406	Sequence 406, App
43	2774	87.6	3011	9	US-09-742-659-4	Sequence 4, Appli
44	2774	87.6	3011	9	US-09-952-572-9	Sequence 9, Appli
45	2774	87.6	3011	9	US-09-747-419-20	Sequence 20, Appli

ALIGNMENTS

RESULT 1

US-10-712-479-2
; Sequence 2, Application US/10712479
; Publication No. US20040209283A1
; GENERAL INFORMATION:
; APPLICANT: Yagi, Yoshihiko
; APPLICANT: Sheets, Michael P.
; APPLICANT: Wells, Peter A.
; APPLICANT: Shelly, John A.
; APPLICANT: Poorman, Roger A.
; APPLICANT: Epps, Dennis E.
; TITLE OF INVENTION: A Continuous-Read Assay for the Detection of De Novo HCV RNA Polym
; TITLE OF INVENTION: Activity
; FILE REFERENCE: 02-333-A
; CURRENT APPLICATION NUMBER: US/10/712.479
; CURRENT FILING DATE: 2003-11-13
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 601
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-10-712-479-2

Query Match	100.0%	Score	3167;	DB	16;	Length	601;
Best Local Similarity	100.0%	Pred. No.	4e-280;				
Matches	601;	Conservative	0;	Mismatches	0;	Indels	0;
Gaps	0;						
Qy	1	MASMSMTWTGALITPCAAEESKLIPINALSNSLLRHHNLVYSTTSRSGASLRQKVTFR	60				
Db	1	MASMSMTWTGALITPCAAEESKLIPINALSNSLLRHHNLVYSTTSRSGASLRQKVTFR	60				
Qy	61	LQVLDHYRDLKEMKAKASTVKAKLSVERACKLTPPHSAKSGFYGAKDVRSLSRAV	120				

Db 61 LOVLDDHYRDLVKEMKAKASTVKAALLSVEBEACKLTPPHSAKSKFGYGAKDVRSLSSRAV 120
Qy 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDLGVVRVCEKMAly 180
Db 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDLGVVRVCEKMAly 180
Qy 181 DWSTLPAQVMGSSYGFOYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
Db 181 DWSTLPAQVMGSSYGFOYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
Qy 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVLTTCGNTLTCY 300
Db 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVLTTCGNTLTCY 300
Qy 301 LKAAAACRAAKLODCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPGDPPOP 360
Db 301 LKAAAACRAAKLODCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPGDPPOP 360
Qy 361 EYDLELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
Db 361 EYDLELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
Qy 421 PTLWARMILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
Db 421 PTLWARMILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
Qy 481 YSPGEINRVASCLRLKGLVPPPLRVHRHARSVRKLLSQGGRAAICGKYLFWNAVTKLKL 540
Db 481 YSPGEINRVASCLRLKGLVPPPLRVHRHARSVRKLLSQGGRAAICGKYLFWNAVTKLKL 540
Qy 541 TPIPAASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNRHHHH 600
Db 541 TPIPAASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNRHHHH 600
Qy 601 H 601
Db 601 H 601

RESULT 2

US-10-712-479-4
; Sequence 4, Application US/10712479
; Publication No. US20040209283A1
; GENERAL INFORMATION:
; APPLICANT: Yagi, Yoshihiko
; APPLICANT: Sheets, Michael P.
; APPLICANT: Wells, Peter A.
; APPLICANT: Shelly, John A.
; APPLICANT: Poorman, Roger A.
; APPLICANT: Epps, Dennis E.
; TITLE OF INVENTION: A Continuous-Read Assay for the Detection of De Novo HCV RNA Poly
; FILE REFERENCE: 02-333-A
; CURRENT APPLICATION NUMBER: US/10/712,479
; CURRENT FILING DATE: 2003-11-13
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 580
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: C-terminally truncated HCV NS5B polymerase (C delta 21 NS5B)
US-10-712-479-4

Query Match 95.8%; Score 3034.5; DB 16; Length 580;
Best Local Similarity 96.5%; Pred. No. 4.9e-268;
Matches 580; Conservative 0; Mismatches 0; Indels 21; Gaps 1;

Qy 1 MASMSMTWTGALTTPCAABESKLPINALNSLLRHNLVYSTTSRASLRQKVTTPDR 60
Db 1 MASMSMTWTGALTTPCAABESKLPINALNSLLRHNLVYSTTSRASLRQKVTTPDR 60

Qy 61 LOVLDDHYRDLVKEMKAKASTVKAALLSVEBEACKLTPPHSAKSKFGYGAKDVRSLSSRAV 120
Db 61 LOVLDDHYRDLVKEMKAKASTVKAALLSVEBEACKLTPPHSAKSKFGYGAKDVRSLSSRAV 120
Qy 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDLGVVRVCEKMAly 180
Db 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALRVFPDLGVVRVCEKMAly 180
Qy 181 DWSTLPAQVMGSSYGFOYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
Db 181 DWSTLPAQVMGSSYGFOYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
Qy 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVLTTCGNTLTCY 300
Db 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVLTTCGNTLTCY 300
Qy 301 LKAAAACRAAKLODCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPGDPPOP 360
Db 301 LKAAAACRAAKLODCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPGDPPOP 360
Qy 361 EYDLELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
Db 361 EYDLELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYA 420
Qy 421 PTLWARMILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
Db 421 PTLWARMILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
Qy 481 YSPGEINRVASCLRLKGLVPPPLRVHRHARSVRKLLSQGGRAAICGKYLFWNAVTKLKL 540
Db 481 YSPGEINRVASCLRLKGLVPPPLRVHRHARSVRKLLSQGGRAAICGKYLFWNAVTKLKL 540
Qy 541 TPIPAASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNRHHHH 600
Db 541 TPIPAASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLLLLSVGVGIYLLPNRHHHH 600
Qy 601 H 601
Db 580 H 580

RESULT 3

US-10-085-476-1
; Sequence 1, Application US/10085476
; Publication No. US20020164722A1
; GENERAL INFORMATION:
; APPLICANT: Tomei, Licia
; APPLICANT: Behrens, Sven-Erik
; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE
; TITLE OF INVENTION: RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL
; FILE REFERENCE: IT0002PCA
; CURRENT APPLICATION NUMBER: US/10/085,476
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: 08/952,981
; PRIOR FILING DATE: 1998-03-23
; PRIOR APPLICATION NUMBER: PCT/IT96/00106
; PRIOR FILING DATE: 1996-05-24
; PRIOR APPLICATION NUMBER: RM95A000343
; PRIOR FILING DATE: 1995-05-25
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 591
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-10-085-476-1

Query Match 95.2%; Score 3016; DB 13; Length 591;
Best Local Similarity 96.6%; Pred. No. 2.5e-266;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALSNSLLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 1 SMSYTWTCALITPCAAEESKLPINALSNSLLRHNLVYSTTSRSASLRQKKVTFDRLOVL 60
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVERACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHR 124
Db 61 DDHYRDVLKEMKAKASTVKAKLLSVERACKLTPPHSAKSKFGYGAKDVRNLSKAVNIH 120
QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCEKMALYDVVS 184
Db 121 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCEKMALYDVVS 180
QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKCPMGFSYDTRCPDSTVTENDIRVEESIY 244
Db 181 TLPQAVMGSSYGFQYSPQORVEFLVNTWKSKKNPMGFSYDTRCPDSTVTENDIRVEESIY 240
QY 245 OCCDLAPEARQAIKSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 304
Db 241 OCCDLAPEARQAIKSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAS 300
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 301 AACRAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 360
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDTPVPLARAAMETARHTPNSWLGNIIMYAPTLW 424
Db 361 ELITSCSSNVSAHDASGRVYVLTTRDTPVPLARAAMETARHTPNSWLGNIIMYAPTLW 420
QY 425 ARMTLMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 484
Db 421 ARMTLMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 480
QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAAICGKYLFWNAVRTKLTIP 544
Db 481 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAATCGKYLFWNAVRTKLTIP 540
QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRARPRWFMCLLLLLSVGVGIYLLPNR 595
Db 541 AASRLDLSGWFVAGYSGGDIYHSLSRARPRWFMCLLLLLSVGVGIYLLPNR 591

RESULT 4

US-10-085-476-2
; Sequence 2, Application US/10085476
; Publication No. US20020164722A1
; GENERAL INFORMATION:
; APPLICANT: De Francesco, Raffaele
; APPLICANT: Tomei, Lucia
; APPLICANT: Behrens, Sven-Erik
; TITLE OF INVENTION: METHOD FOR REPRODUCING IN VITRO THE
; TITLE OF INVENTION: RNA-DEPENDENT RNA POLYMERASE AND TERMINAL NUCLEOTIDYL
; TITLE OF INVENTION: TRANSFERASE ACTIVITIES ENCODED BY HEPATITIS C VIRUS (HCV)
; FILE REFERENCE: IT0002PCA
; CURRENT APPLICATION NUMBER: US/10/085,476
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: 08/952,981
; PRIOR FILING DATE: 1998-03-23
; PRIOR APPLICATION NUMBER: PCT/IT96/00106
; PRIOR FILING DATE: 1996-05-24
; PRIOR APPLICATION NUMBER: RM95A000343
; PRIOR FILING DATE: 1995-05-25
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 2201
; TYPE: PRT
; ORGANISM: cDNA clone pCD (38-9.4)
US-10-085-476-2

Query Match 95.2%; Score 3016; DB 13; Length 2201;
Best Local Similarity 96.6%; Pred. No. 1.7e-265;
Matches 571; Conservative 11; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALSNSLLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 1611 SMSYTWTCALITPCAAEESKLPINALSNSLLRHNLVYATTSRSAGLRQKKVTFDRLOVL 1670
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVERACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHR 124
Db 1671 DDHYRDVLKEMKAKASTVKAKLLSVERACKLTPPHSAKSKFGYGAKDVRNLSKAVNIH 1730
QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCEKMALYDVVS 184
Db 1731 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCEKMALYDVVS 1790
QY 185 TLPQAVMGSSYGFQYSPQORVEFLVNTWKAKCPMGFSYDTRCPDSTVTENDIRVEESIY 244
Db 1791 TLPQAVMGSSYGFQYSPQORVEFLVNTWKSKKNPMGFSYDTRCPDSTVTENDIRVEESIY 1850
QY 245 OCCDLAPEARQAIKSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 304
Db 1951 OCCDLAPEARQAIKSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAS 1910
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 1911 AACRAAKLQDCTMLVNGDDLVIICESAGTOBDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 1970
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDTPVPLARAAMETARHTPNSWLGNIIMYAPTLW 424
Db 1971 ELITSCSSNVSAHDASGRVYVLTTRDTPVPLARAAMETARHTPNSWLGNIIMYAPTLW 2030
QY 425 ARMTLMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 484
Db 2031 ARMTLMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIEHLHGLSAFSLHSYSPG 2090
QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAAICGKYLFWNAVRTKLTIP 544
Db 2091 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAATCGKYLFWNAVRTKLTIP 2150
QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRARPRWFMCLLLLLSVGVGIYLLPNR 595
Db 2151 AASRLDLSGWFVAGYSGGDIYHSLSRARPRWFMCLLLLLSVGVGIYLLPNR 2201

RESULT 5

US-10-241-872-23
; Sequence 23, Application US/10241872
; Publication No. US20030152915A1
; GENERAL INFORMATION:
; APPLICANT: Hagedorn, Curt H.
; TITLE OF INVENTION: Recombinant Hepatitis C Virus RNA Replicase
; FILE REFERENCE: 76-95C
; CURRENT APPLICATION NUMBER: US/10/241,872
; CURRENT FILING DATE: 2002-09-12
; PRIOR APPLICATION NUMBER: 09/597,877
; PRIOR FILING DATE: 2000-06-20
; PRIOR APPLICATION NUMBER: 60/004,383
; PRIOR FILING DATE: 1995-09-27
; PRIOR APPLICATION NUMBER: 08/722,806
; PRIOR FILING DATE: 1996-09-27
; PRIOR APPLICATION NUMBER: 09/337,028
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 23
; LENGTH: 593
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-10-241-872-23

Query Match 95.2%; Score 3014; DB 14; Length 593;
Best Local Similarity 96.3%; Pred. No. 3.8e-266;
Matches 569; Conservative 12; Mismatches 10; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALSNSLLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
|||||

Db 3 SMSYTWGALITPCAAEESKLPINALNSLRRHNHNVYATTSRSASLRQKKVTFDRQLVL 62
 QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKAKDVRSLSRAVNHIR 124
 Db 63 DDHYQDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKAKDVRSLSRAVNHII 122
 QY 125 SVWKDLLEDTDTPITTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMAKYDVVS 184
 Db 123 SVWKDLLEDTEPTITTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMAKYDVVS 182
 QY 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 Db 183 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 242
 QY 245 QCCDLAPARQAISLTERLYVGGPMWNSKQNGCYRRCRASGVLTSSCGNTLTCYLKAA 304
 Db 243 QCCDLAPARQAISLTERLYVGGPMWNSKQNGCYRRCRASGVLTSSCGNTLTCYLKAS 302
 QY 305 AACRAAKLQDCTMLVNGDDLVIWICESAGTQDAASLRVFTTEAMTRYSGAPDPPQPEYDL 364
 Db 303 AACRAAKLQDCTMLVNGDDLVIWICESAGTQDAASLRVFTTEAMTRYSGAPDPPQPEYDL 362
 QY 365 ELITSCSSNVSAHDASGRVYVYLRDPTVPLARAAMETARHTTPVNSWLGNIIMYAPTLW 424
 Db 363 ELITSCSSNVSAHDASGRVYVYLRDPTVPLARAAMETARHTTPVNSWLGNIIMYAPTLW 422
 QY 425 ARMLMTHFFSILLAOEALDQCIYGCYSIEPLDLPOIIRLHGLSFAFSLSHSPG 484
 Db 423 ARMLMTHFFSILLAOEALDQCIYGCYSIEPLDLPOIIRLHGLSFAFSLSHSPG 482
 QY 485 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLPIIP 544
 Db 483 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAATCGKYLFWNAVTKLKLPIIP 542
 QY 545 AASRLDLSGMFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 595
 Db 543 AASQLDLSGMFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 593

RESULT 6
 US-10-492-178-6
 ; Sequence 6, Application US/10492178
 ; Publication No. US20040247615A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Emimi, Emilio A.
 ; APPLICANT: Kaslow, David C.
 ; APPLICANT: Bett, Andrew J.
 ; APPLICANT: Shiver, John W.
 ; APPLICANT: Nicosia, Alfredo
 ; APPLICANT: Lahm, Armin
 ; APPLICANT: Luzzago, Alessandra
 ; APPLICANT: Cortese, Riccardo
 ; APPLICANT: Colloca, Stefano
 ; TITLE OF INVENTION: HEPATITIS C VIRUS VACCINE
 ; FILE REFERENCE: ITR0015YP
 ; CURRENT APPLICATION NUMBER: US/10/492,178
 ; PRIOR FILING DATE: 2004-04-07
 ; PRIOR APPLICATION NUMBER: PCT/US02/32512
 ; PRIOR FILING DATE: 2002-10-10
 ; PRIOR APPLICATION NUMBER: 60/363,774
 ; PRIOR FILING DATE: 2002-03-13
 ; PRIOR APPLICATION NUMBER: 60/328,655
 ; PRIOR FILING DATE: 2001-10-11
 ; NUMBER OF SEQ ID NOS: 17
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 6
 ; LENGTH: 1985
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: NS sequence
 US-10-492-178-6

Query Match 95.1%; Score 3012; DB 16; Length 1985;
 Best Local Similarity 96.4%; Pred. No. 3.4e-265;
 Matches 570; Conservative 12; Mismatches 9; Indels 0; Gaps 0;
 QY 5 SMSYTWGALITPCAAEESKLPINALNSLRRHNHNVYATTSRSASLRQKKVTFDRQLVL 64
 Db 1395 SMSYTWGALITPCAAEESKLPINALNSLRRHNHNVYATTSRSASLRQKKVTFDRQLVL 1454
 QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKAKDVRSLSRAVNHIR 124
 Db 1455 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYKAKDVRSLSRAVNHII 1514
 QY 125 SVWKDLLEDTDTPITTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMAKYDVVS 184
 Db 1515 SVWKDLLEDTEPTITTIMAKNEVFCVQPEKGGKRPARLIVFPDLGVRVCEKMAKYDVVS 1574
 QY 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 Db 1575 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 1634
 QY 245 QCCDLAPARQAISLTERLYVGGPMWNSKQNGCYRRCRASGVLTSSCGNTLTCYLKAA 304
 Db 1635 QCCDLAPARQAISLTERLYVGGPMWNSKQNGCYRRCRASGVLTSSCGNTLTCYLKAS 1694
 QY 305 AACRAAKLQDCTMLVNGDDLVIWICESAGTQDAASLRVFTTEAMTRYSGAPDPPQPEYDL 364
 Db 1695 AACRAAKLQDCTMLVNGDDLVIWICESAGTQDAASLRVFTTEAMTRYSGAPDPPQPEYDL 1754
 QY 365 ELITSCSSNVSAHDASGRVYVYLRDPTVPLARAAMETARHTTPVNSWLGNIIMYAPTLW 424
 Db 1755 ELITSCSSNVSAHDASGRVYVYLRDPTVPLARAAMETARHTTPVNSWLGNIIMYAPTLW 1814
 QY 425 ARMLMTHFFSILLAOEALDQCIYGCYSIEPLDLPOIIRLHGLSFAFSLSHSPG 484
 Db 1815 ARMLMTHFFSILLAOEALDQCIYGCYSIEPLDLPOIIRLHGLSFAFSLSHSPG 1874
 QY 485 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVTKLKLPIIP 544
 Db 1875 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAATCGKYLFWNAVTKLKLPIIP 1934
 QY 545 AASRLDLSGMFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 595
 Db 1935 AASQLDLSGMFVAGYSGGDIYHLSLRARPRFWMCLLLLSVGVGIYLLPNR 1985

RESULT 7
 US-10-471-164-5
 ; Sequence 5, Application US/10471164
 ; Publication No. US20040110126A1
 ; GENERAL INFORMATION:
 ; APPLICANT: George KUKOLJ and Ginette MCKERCHER
 ; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
 ; FILE REFERENCE: 13/094
 ; CURRENT APPLICATION NUMBER: US/10/471,164
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIOR APPLICATION NUMBER: 60/274,374
 ; PRIOR FILING DATE: 2001-03-08
 ; NUMBER OF SEQ ID NOS: 6
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 5
 ; LENGTH: 591
 ; TYPE: PRT
 ; ORGANISM: HCV
 US-10-471-164-5

Query Match 95.1%; Score 3011; DB 16; Length 591;
 Best Local Similarity 95.9%; Pred. No. 7.1e-266;
 Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
 QY 5 SMSYTWGALITPCAAEESKLPINALNSLRRHNHNVYATTSRSASLRQKKVTFDRQLVL 64
 Db 1 SMSYTWGALITPCAAEESKLPINALNSLRRHNHNVYATTSRSASLRQKKVTFDRQLVL 60

```
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
Db 61 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSKAVDHIR 120
QY 125 SVWKDLLEDTDPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 184
Db 121 SVWKDLLEDTEPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 180
QY 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 181 TLPOAVMGSSYGFQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTESDIRVEESIY 240
QY 245 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCTYLKAA 304
Db 241 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCTYLKAS 300
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 360
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSMLGNIIMYAPTILW 424
Db 361 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSMLGNIIMYAPTILW 420
QY 425 ARMLMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 484
Db 421 ARMLMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 480
QY 485 EINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFPNVAVRTKLTPTIP 544
Db 481 EINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFPNVAVRTKLTPTIP 540
QY 545 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMLCLLLLSVGVGIYLLPNR 595
Db 541 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMLCLLLLSVGVGIYLLPNR 591
```

RESULT 8

```
US-09-898-297-1
; Sequence 1, Application US/09898297
; Publication No. US20020065418A1
; GENERAL INFORMATION:
; APPLICANT: BOEHRINGER INGELHEIM (CANADA) LTD.
; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS
; CURRENT APPLICATION NUMBER: US/09/898,297
; CURRENT FILING DATE: 2001-07-03
; PRIOR APPLICATION NUMBER: 60/216,084
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/281,434
; PRIOR FILING DATE: 2001-04-02
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PR1
; ORGANISM: Hepatitis C Virus
```

```
Query Match 95.1%; Score 3011; DB 9; Length 621;
Best Local Similarity 95.9%; Pred. No. 7,6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
```

```
QY 5 SMSYTWTCALITPCAABESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 31 SMSYTWTCALITPCAABESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 90
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSKAVDHIR 150
```

```
QY 125 SVWKDLLEDTDPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 184
Db 151 SVWKDLLEDTEPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 210
QY 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 211 TLPOAVMGSSYGFQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTESDIRVEESIY 270
QY 245 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCTYLKAA 304
Db 271 OCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCTYLKAS 330
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 331 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 390
QY 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSMLGNIIMYAPTILW 424
Db 391 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSMLGNIIMYAPTILW 450
QY 425 ARMLMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 484
Db 451 ARMLMTHFFSILLAOEQLKALDCQIYGACYSIEPLDLPQIIRLHGLSAPSLHSYSPG 510
QY 485 EINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFPNVAVRTKLTPTIP 544
Db 511 EINRVASCLRKLGVPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFPNVAVRTKLTPTIP 570
QY 545 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMLCLLLLSVGVGIYLLPNR 595
Db 571 AASRLDLSGFWVAGYSGGDIYHLSRARPRWFMLCLLLLSVGVGIYLLPNR 621
```

RESULT 9

```
US-10-198-680A-1
; Sequence 1, Application US/10198680A
; Publication No. US20030176433A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim (Canada) Ltd.
; TITLE OF INVENTION: Viral Polymerase Inhibitors
; FILE REFERENCE: 13/095
; CURRENT APPLICATION NUMBER: US/10/198,680A
; CURRENT FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: 60/338,061
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/307,674
; PRIOR FILING DATE: 2001-07-25
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PR1
; ORGANISM: HCV NS5B
```

```
Query Match 95.1%; Score 3011; DB 14; Length 621;
Best Local Similarity 95.9%; Pred. No. 7,6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
```

```
QY 5 SMSYTWTCALITPCAABESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 31 SMSYTWTCALITPCAABESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 90
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSKAVDHIR 150
QY 125 SVWKDLLEDTDPIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 184
Db 151 SVWKDLLEDTEPIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVVS 210
QY 185 TLPOAVMGSSYGFQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
```

Db 211 TLPOAVMGSSYGFQYSPKQVFEFLVNAWKKCPMGFSYDTRCFDSTVTESDIRVEESIY 270
Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAA 304
Db 271 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAS 330
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 331 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDLPQPEYDL 390
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 424
Db 391 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 450
Qy 424 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 484
Db 450 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 510
Qy 484 ARMLTMTHFFSILLAOEQLEKALDQIYGACYSIEPLDLPOIIEHLHGLSAFSLHSYSPG 544
Db 510 ARMLTMTHFFSILLAOEQLEKALDQIYGACYSIEPLDLPOIIEHLHGLSAFSLHSYSPG 570
Qy 544 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 595
Db 570 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 621
Qy 595 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 595
Db 621 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 621

RESULT 10

US-10-238-282-1
; Sequence 1, Application US/10238282
; Publication No. US20030232816A1
; GENERAL INFORMATION:
; APPLICANT: BOEHRINGER INGELHEIM (CANADA) LTD.
; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS
; FILE REFERENCE: 13/079
; CURRENT APPLICATION NUMBER: US/10/238,282
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: 60/216,084
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/281,434
; PRIOR FILING DATE: 2001-04-02
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PRF
; ORGANISM: Hepatitis C Virus

US-10-238-282-1

Query Match 95.1%; Score 3011; DB 15; Length 621;
Best Local Similarity 95.9%; Pred. No. 7.6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
Qy 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLOVL 64
Db 31 SMSYTWTCALITPCAABESQLPINALNSLRHNLVYSTTSRSAAURQKVTDFRLOVL 90
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 150
Qy 124 SVWKDLLEDTPPTQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 184
Db 150 SVWKDLLEDTPPTQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 210
Qy 184 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 210 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 270
Qy 244 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 304
Db 270 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 330
Qy 304 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAA 364
Db 330 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAS 390

Db 271 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAS 330
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 331 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDLPQPEYDL 390
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 424
Db 391 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMVAPTLW 450
Qy 424 ARMLTMTHFFSILLAOEQLEKALDQIYGACYSIEPLDLPOIIEHLHGLSAFSLHSYSPG 484
Db 451 ARMLTMTHFFSILLAOEQLEKALDQIYGACYSIEPLDLPOIIEHLHGLSAFSLHSYSPG 510
Qy 484 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
Db 511 EINRVASCLRLKGLVPPPLRVWHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 570
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 595
Db 621 AASRLDLSGWFVAGYSGGDIYHLSLRARPRWFMCLLLLLSVGVGIYLLPNR 621

RESULT 11

US-10-198-259A-1
; Sequence 1, Application US/10198259A
; Publication No. US2003023251A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim (Canada) Ltd.
; TITLE OF INVENTION: Viral Polymerase Inhibitors
; FILE REFERENCE: 13/089
; CURRENT APPLICATION NUMBER: US/10/198,259A
; CURRENT FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: 60/306,669
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: 60/338,324
; PRIOR FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PRF
; ORGANISM: HCV NS5B

US-10-198-259A-1

Query Match 95.1%; Score 3011; DB 15; Length 621;
Best Local Similarity 95.9%; Pred. No. 7.6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
Qy 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLOVL 64
Db 31 SMSYTWTCALITPCAABESQLPINALNSLRHNLVYSTTSRSAAURQKVTDFRLOVL 90
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTTPHSAKSKFGYGAQVRSLSRAVNHIR 150
Qy 124 SVWKDLLEDTPPTQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 184
Db 151 SVWKDLLEDTPPTQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVWS 210
Qy 184 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 211 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 270
Qy 244 TLPOAVMGSSYGFQYSPKQVFEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 304
Db 271 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVTTSCGNTLTCYLKAS 330
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 331 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAALRVFTTEAMTRYSAAPPDLPQPEYDL 390

QY 365 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 424
DB 391 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 450
QY 425 ARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 484
DB 451 ARMVLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 510
QY 485 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
DB 511 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 570
QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 595
DB 571 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 621
RESULT 12
US-10-198-384A-1
; Sequence 1, Application US/10198384A
; Publication No. US20040024190A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim (Canada) Ltd.
; TITLE OF INVENTION: Viral Polymerase inhibitors
; FILE REFERENCE: 13/090
; CURRENT APPLICATION NUMBER: US/10/198,384A
; CURRENT FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: 60/338,061
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/307,674
; PRIOR FILING DATE: 2001-07-25
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PRT
; ORGANISM: HCV NS5B
US-10-198-384A-1
Query Match 95.1%; Score 3011; DB 15; Length 621;
Best Local Similarity 95.9%; Pred. No. 7.6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAABESKLPINALSNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
DB 31 SMSYTWTCALITPCAABESKLPINALSNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 90
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
DB 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 150
QY 125 SVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVS 184
DB 151 SVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVS 210
QY 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 211 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 270
QY 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 304
DB 271 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 330
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTOEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 331 AACRAAKLQDCTMLVNGDDLVIICESAGTOEDAAANLRFTEAMTRYSAAPPDLPQPEYDL 390
QY 365 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 424
DB 391 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 450
QY 425 ARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 484
DB 511 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 595
DB 571 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 621

DB 451 ARMVLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 510
QY 485 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
DB 511 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 570
QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 595
DB 571 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 621
RESULT 13
US-10-471-164-1
; Sequence 1, Application US/10471164
; Publication No. US20040110126A1
; GENERAL INFORMATION:
; APPLICANT: George KUKOLJ and Ginette MCKERCHER
; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
; FILE REFERENCE: 13/094
; CURRENT APPLICATION NUMBER: US/10/471,164
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PRT
; ORGANISM: HCV
US-10-471-164-1
Query Match 95.1%; Score 3011; DB 16; Length 621;
Best Local Similarity 95.9%; Pred. No. 7.6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;
QY 5 SMSYTWTCALITPCAABESKLPINALSNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
DB 31 SMSYTWTCALITPCAABESKLPINALSNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 90
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
DB 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 150
QY 125 SVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVS 184
DB 151 SVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVS 210
QY 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 211 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 270
QY 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 304
DB 271 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGLVLTSCGNTLTCLYKAA 330
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTOEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 331 AACRAAKLQDCTMLVNGDDLVIICESAGTOEDAAANLRFTEAMTRYSAAPPDLPQPEYDL 390
QY 365 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 424
DB 391 ELITSCSSNVSAHDASGRVYLLTRDPTVPLARAAMETARHTPNSWMLGNIIMYAPTLM 450
QY 425 ARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 484
DB 451 ARMVLMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAPFSLHSYSPG 510
QY 485 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
DB 511 EINRVASCLRLKGLVPPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 570
QY 545 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 595
DB 571 AASRLDLSGWFVAGYSGGDIYHLSRARPRWFMCLCLLLSVGVGIYLLPNR 621

Db 571 AASRLDLSGWFVAGYNGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 621

RESULT 14

US-10-851-710-1
; Sequence 1, Application US/10851710
; Publication No. US20040224955A1
; GENERAL INFORMATION:
; APPLICANT: BOEHRINGER INGELHEIM (CANADA) LTD.
; TITLE OF INVENTION: VIRAL POLYMERASE INHIBITORS
; FILE REFERENCE: 13/079
; CURRENT APPLICATION NUMBER: US/10/851,710
; CURRENT FILING DATE: 2004-05-21
; PRIOR APPLICATION NUMBER: US/10/238,282
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: 60/216,084
; PRIOR FILING DATE: 2000-07-06
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: 60/281,434
; PRIOR FILING DATE: 2001-04-02
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 621
; TYPE: PRT
; ORGANISM: Hepatitis C Virus
US-10-851-710-1

Query Match 95.1%; Score 3011; DB 16; Length 621;
Best Local Similarity 95.9%; Pred. No. 7,6e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 64
Db 31 SMSYTWTCALITPCAAEESKLPINALNSLRHNLVYSTTSRSAAALRQKVTDFRLQVL 90
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVNHIR 124
Db 91 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVDHIR 150
Qy 125 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 151 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 210
Qy 185 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 211 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 270
Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 304
Db 271 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAS 330
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 331 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAANLRFVFTTEAMTRYSAAPPDLPQPEYDL 390
Qy 365 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAWETARHTPVNSWLGNIIMVAPTLW 424
Db 391 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAWETARHTPVNSWLGNIIMVAPTLW 450
Qy 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Db 451 ARMVLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 510
Qy 485 EIRNVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
Db 511 EIRNVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 570
Qy 545 AASRLDLSGWFVAGYNGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 595
Db 571 AASRLDLSGWFVAGYNGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 621

RESULT 15

US-09-838-386-12
; Sequence 12, Application US/09838386
; Patent No. US20010055756A1
; GENERAL INFORMATION:
; APPLICANT: Kukulj, George
; APPLICANT: Kukulj, George
; TITLE OF INVENTION: Internal De No. US20010055756A10 Initiation Sites of the HCV NS5B
; FILE REFERENCE: 1011.2180001
; CURRENT APPLICATION NUMBER: US/09/838,386
; CURRENT FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: US 60/198,793
; PRIOR FILING DATE: 2000-04-21
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 12
; LENGTH: 627
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: HTA5B polymerase
US-09-838-386-12

Query Match 95.1%; Score 3011; DB 9; Length 627;
Best Local Similarity 95.9%; Pred. No. 7.7e-266;
Matches 567; Conservative 18; Mismatches 6; Indels 0; Gaps 0;

Qy 5 SMSYTWTCALITPCAAEESKLPINALNSLRHNLVYSTTSRSASLRQKVTDFRLQVL 64
Db 37 SMSYTWTCALITPCAAEESKLPINALNSLRHNLVYSTTSRSAAALRQKVTDFRLQVL 96
Qy 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVNHIR 124
Db 97 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVDHIR 156
Qy 125 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 157 SVWKDLLEDTTPIQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 216
Qy 185 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
Db 217 TLPOAVMGSSYGFQYSPKQRFVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 276
Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAA 304
Db 277 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTSCGNTLTCLYKAS 336
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 337 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAANLRFVFTTEAMTRYSAAPPDLPQPEYDL 396
Qy 365 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAWETARHTPVNSWLGNIIMVAPTLW 424
Db 397 ELITSCSSNVSAHDASGKRVYILTRDPTVPLARAAWETARHTPVNSWLGNIIMVAPTLW 456
Qy 425 ARMILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Db 457 ARMVLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 516
Qy 485 EIRNVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
Db 517 EIRNVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTPIIP 576
Qy 545 AASRLDLSGWFVAGYNGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 595
Db 577 AASRLDLSGWFVAGYNGGDIYHLSLRARPRWFMCLCLLLSVGVGIYLLPNR 627

Search completed: September 22, 2005, 14:49:31
Job time : 79 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:44:29 ; Search time 78 Seconds
(without alignments)
2875.911 Million cell updates/sec

Title: US-10-712-479-4

Perfect score: 3055

Sequence: 1 MASMSMTWTGALITPCAA.....GGDIYHLSLRPRRHRRHHH 580

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 1964263

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A Geneseq_16Dec04:*

- 1: geneseqp1980s:*
- 2: geneseqp1990s:*
- 3: geneseqp2000s:*
- 4: geneseqp2001s:*
- 5: geneseqp2002s:*
- 6: geneseqp2003as:*
- 7: geneseqp2003bs:*
- 8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3055	100.0	580	8	ADO19023
2	2951	96.6	576	6	AAO26417
3	2948	96.5	576	6	AAO26419
4	2944	96.4	576	6	AAO26418
5	2942	96.3	579	4	AAO60131
6	2936	96.1	578	5	AAO60131
7	2936	96.1	578	6	ABP71662
8	2879	94.2	576	6	ABP72214
9	2879	94.2	576	6	ADH74494
10	2846	93.2	567	7	ADM69007
11	2734.5	89.5	545	5	AAO79559
12	2279	74.6	462	2	AAO58592
13	2279	74.6	462	8	ADL17783
14	2144	70.2	547	2	AAO67630
15	1812	59.3	389	2	AAO29906
16	1801	59.0	389	2	AAO29904
17	1798	58.9	389	2	AAO29905
18	1798	58.9	389	2	AAO29876
19	1755	57.4	365	2	AAO38284
20	1645	53.8	365	2	AAO38283
21	1634	53.5	365	2	AAO67592
22	1630	53.4	365	2	AAO67590
23	1430	46.8	352	2	AAO50081
24	1430	46.8	352	8	ADJ81686
25	1391	45.5	300	5	ABB77283

26	1391	45.5	365	2	AAO38287	Aar38287 NANB hepa
27	1384	45.3	365	2	AAO38286	Aar38286 NANB hepa
28	1375	45.0	365	2	AAO38285	Aar38285 NANB hepa
29	1363	44.6	285	2	AAO29879	Aar29879 HCV NS4-N
30	1232	40.3	260	5	ABB77285	Abb77285 HCV bait
31	1178	38.6	270	2	AAO25896	Aar25896 HK21. 9/2
32	1177	38.5	247	2	AAO25874	Aar25874 HCV poly
33	1177	38.5	247	2	AAO41752	Aar41752 Hepatitis
34	1175	38.5	239	2	AAO25869	Aar25869 HCV poly
35	1175	38.5	239	2	AAO41747	Aar41747 Hepatitis
36	1175	38.5	253	2	AAO25891	Aar25891 HK16. 9/2
37	1158.5	37.9	251	2	AAO25895	Aar25895 HK20. 9/2
38	1154	37.8	224	2	AAO25873	Aar25873 HCV poly
39	1154	37.8	224	2	AAO41751	Aar41751 Hepatitis
40	1129	37.0	496	2	AAO21568	Aar21568 HCV CKS-N
41	1124	36.8	496	2	AAO33635	Aar33635 HCV CKS-N
42	1124	36.8	496	2	AAO33597	Aar33597 HCV CKS-N
43	1124	36.8	496	2	AAO33577	Aar33577 HCV CKS-N
44	1124	36.8	496	4	AAO51375	Aar51375 HCV recom
45	1124	36.8	496	7	ABO1861	Abw01861 HCV-CKS-N

ALIGNMENTS

RESULT 1

ADO19023

ID ADO19023 standard; protein; 580 AA.

AC ADO19023;

DT 12-AUG-2004 (first entry)

DE C-terminally truncated HCV NS5B polymerase, Cdelta21 NS5B.

XX RNA polymerase activity; continuous-read assay;

KW Hepatitis C virus infection; HCV infection; polymerase; NS5B;

KW bone mineral disease; osteoporosis; carcinoma; cardiovascular disease;

KW diabetes; ocular disorder; renal dysfunction; lymphoma;

KW lymphoproliferative disorder; metabolic disorder; arthritis;

KW sleep disorder; thyroid disorder; antiinflammatory; hepatotropic;

KW virulence; osteopathic; cytostatic; antidiabetic; ophthalmological;

KW nephrotropic; antiarthritic; enzyme.

OS Hepatitis C virus.

PN WO200404228-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036465.

PR 13-NOV-2002; 2002US-0425981P.

XX (PFIZ) PFIZER INC.

PI Yagi Y, Sheets MP, Wells PA, Shelly JA, Poorman RA, Epps DB;

PI Morgan AG;

XX WPI; 2004-420337/39.

DR N-ESDB; ADO19022.

XX Detecting RNA polymerase activity in a continuous-read manner, useful in

PT treating osteoporosis, carcinomas, cardiovascular diseases, ocular

PT disorders or arthritis, by contacting an RNA polymerase with an

PT oligonucleotide template.

XX Claim 7; SEQ ID NO 4; 46pp; English.

XX The present invention relates to a method for detecting RNA polymerase

CC activity in a continuous-read manner. The method comprises contacting an

CC RNA polymerase with an oligonucleotide template in a reaction mixture

CC comprising an assay buffer, under conditions in which the RNA polymerase

CC is active, adding a fluorescent dye capable of binding double-stranded
 CC nucleic acid molecules to the reaction mixture, and measuring the
 CC fluorescence of the reaction mixture. The RNA polymerase is the Hepatitis
 CC C virus (HCV) polymerase, NS5B. The method is useful for treating HCV
 CC infection, bone mineral diseases like osteoporosis, carcinomas,
 CC cardiovascular diseases, diabetes, ocular disorders, renal dysfunction,
 CC lymphomas, lymphoproliferative disorders, metabolic disorders, arthritis,
 CC sleep disorders and thyroid disorders. The present sequence represents C-
 CC terminally truncated HCV NS5B polymerase (designated Cdelta21 NS5B).
 XX

SQ Sequence 580 AA;
 Query Match 100.0%; Score 3055; DB 8; Length 580;
 Best Local Similarity 100.0%; Pred. No. 7e-285;
 Matches 580; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MASMSYTTWTGALITPCAAESKLPINALSNSLRHNLVYVTSRSASLRQKVTDFDR 60
 DB 1 MASMSYTTWTGALITPCAAESKLPINALSNSLRHNLVYVTSRSASLRQKVTDFDR 60
 QY 61 LQVLDHRYDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYGAKDVRSLSSRAV 120
 DB 61 LQVLDHRYDLVKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYGAKDVRSLSSRAV 120
 QY 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALIVFPDLGVRVCEKMAV 180
 DB 121 NHIRSVKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALIVFPDLGVRVCEKMAV 180
 QY 181 DVVSTLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVE 240
 DB 181 DVVSTLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVE 240
 QY 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRCRASGLVTTSCGNLTTCY 300
 DB 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRCRASGLVTTSCGNLTTCY 300
 QY 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYAPGDPPOP 360
 DB 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYAPGDPPOP 360
 QY 361 EYDLELITSCSNVSAHDSAGKRVYLTTRDPTVPLAARAAETARHTPVNSWLGNIIMYA 420
 DB 361 EYDLELITSCSNVSAHDSAGKRVYLTTRDPTVPLAARAAETARHTPVNSWLGNIIMYA 420
 QY 421 PTLWARMILMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
 DB 421 PTLWARMILMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHS 480
 QY 481 YSPGEINRVASCLRLKGVPPPLRVWRHRRARSVRAKLLSOGGAAICGKYLFWNAVTKL 540
 DB 481 YSPGEINRVASCLRLKGVPPPLRVWRHRRARSVRAKLLSOGGAAICGKYLFWNAVTKL 540
 QY 541 TPIPAASRLDLSGWPFVAGYSGGDIYHSLSRARPRLHHHHH 580
 DB 541 TPIPAASRLDLSGWPFVAGYSGGDIYHSLSRARPRLHHHHH 580

RESULT 2
 AAO26417
 ID AAO26417 standard; protein; 576 AA.
 XX
 AC AAO26417;
 XX
 DT 30-JAN-2003 (first entry)
 XX
 DE Mutant RNA polymerase MUT-2 protein.
 XX
 KW Antiviral; hepatitis C virus; HCV; NS5B RNA polymerase.
 XX
 OS Unidentified.
 XX
 PN EP1256628-A2.
 XX

PD 13-NOV-2002.
 XX 07-MAY-2002; 2002EP-00009387.
 XX 10-MAY-2001; 2001US-0289829P.
 PR (AGOU-) AGOURON PHARM INC.
 PA Love RA, Yu X, Diehl W, Hickey MJ, Parge HE, Gao J, Fuhrman S;
 FI WPI; 2003-031968/03.
 DR
 XX Isolated nucleic acid encoding a mutant hepatitis C virus (HCV) NS5B RNA
 PT polymerase, useful for producing the mutant RNA polymerase which can be
 PT used for identifying inhibitors that can treat HCV infection.
 XX
 PS Claim 7; Page; 32pp; English.
 CC The invention relates to an isolated, purified nucleic acid molecule,
 CC which encodes a mutant hepatitis C virus (HCV) NS5B RNA polymerase, where
 CC a point mutation occurs at least at one or all of positions 47, 101, 106,
 CC and/or 114 of the native RNA polymerase sequence not defined in the
 CC specification. The method of the invention is utilised to identify
 CC inhibitors of the polymerase. The inhibitors serving as lead compounds
 CC for the design of potentially therapeutic compounds for the treatment of
 CC HCV. The mutant HCV NS5B RNA polymerase has improved crystallisation
 CC properties as compared to a native HCV NS5B RNA polymerase. This sequence
 CC represents a mutant RNA polymerase protein of the invention. NOTE: This
 CC sequence is not shown in the specification. It is, however, described in
 CC the specification and its sequence has been obtained from an electronic
 CC data file
 XX

SQ Sequence 576 AA;

Query Match 96.6%; Score 2951; DB 6; Length 576;
 Best Local Similarity 96.5%; Pred. No. 7.4e-275;
 Matches 556; Conservative 11; Mismatches 9; Indels 0; Gaps 0;
 QY 5 SMSYTTWTGALITPCAAESKLPINALSNSLRHNLVYVTSRSASLRQKVTDFDRLOVL 64
 DB 1 SMSYTTWTGALITPCAAESKLPINALSNSLRHNLVYVTSRSASLRQKVTDFDRLOVL 60
 QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYGAKDVRSLSSRAVNHIR 124
 DB 61 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYGAKDVRSLSSRAVNHIR 120
 QY 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALIVFPDLGVRVCEKMAVYVVS 184
 DB 121 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGGKRPALIVFPDLGVRVCEKMAVYVVS 180
 QY 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESII 244
 DB 181 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESII 240
 QY 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRCRASGLVTTSCGNLTTCYLKAA 304
 DB 241 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRCRASGLVTTSCGNLTTCYLKAA 300
 QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYAPPDPPOPEYDL 364
 DB 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYAPPDPPOPEYDL 360
 QY 365 ELITSCSNVSAHDSAGKRVYLTTRDPTVPLAARAAETARHTPVNSWLGNIIMYAPTILW 424
 DB 361 ELITSCSNVSAHDSAGKRVYLTTRDPTVPLAARAAETARHTPVNSWLGNIIMYAPTILW 420
 QY 425 ARMILMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
 DB 421 ARMILMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 480
 QY 485 EINRVASCLRLKGVPPPLRVWRHRRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 544
 DB 481 EINRVASCLRLKGVPPPLRVWRHRRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 540

QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRARPRHHHHH 580
 Db 541 AASQDLDSGWFVAGYSGGDIYHSLSRARPRHHHHH 576

RESULT 3

AAO26419
 ID AAO26419 standard; protein; 576 AA.
 AC AAO26419;
 XX 30-JAN-2003 (first entry)
 DT Mutant RNA polymerase MUT-5 protein.
 DE Antiviral; hepatitis C virus; HCV; NS5B RNA polymerase.
 XX Unidentified.
 OS
 XX
 PN EP1256628-A2.
 XX
 PD 13-NOV-2002.
 XX
 PF 07-MAY-2002; 2002EP-00009387.
 XX
 PR 10-MAY-2001; 2001US-0289829P.
 XX
 PA (AGOU-) AGOURON PHARM INC.

PI Love RA, Yu X, Diehl W, Hickey MJ, Parge HE, Gao J, Fuhrman S;
 XX WPI; 2003-031968/03.
 DR
 XX
 PT Isolated nucleic acid encoding a mutant hepatitis C virus (HCV) NS5B RNA
 PT polymerase, useful for producing the mutant RNA polymerase which can be
 PT used for identifying inhibitors that can treat HCV infection.

XX Claim 9; Page; 32pp; English.

XX The invention relates to an isolated, purified nucleic acid molecule,
 CC which encodes a mutant hepatitis C virus (HCV) NS5B RNA polymerase, where
 CC a point mutation occurs at one or all of positions 47, 101, 106,
 CC and/or 114 of the native RNA polymerase sequence not defined in the
 CC specification. The method of the invention is utilised to identify
 CC inhibitors of the polymerase. The inhibitors serving as lead compounds
 CC for the design of potentially therapeutic compounds for the treatment of
 CC HCV. The mutant HCV NS5B RNA polymerase has improved crystallisation
 CC properties as compared to a native HCV NS5B RNA polymerase. This sequence
 CC represents a mutant RNA polymerase protein of the invention. NOTE: This
 CC sequence is not shown in the specification. It is, however, described in
 CC the specification and its sequence has been obtained from an electronic
 CC data file

XX Sequence 576 AA;

Query Match 96.5%; Score 2948; DB 6; Length 576;
 Best Local Similarity 96.4%; Pred No. 1.4e-274;
 Matches 555; Conservative 12; Mismatches 9; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 64
 Db 1 SMSYTWTCALITPCAAEESKLPINALNSLLRHNLVYVSTTSRSASLRQKVTDFRLQVL 60
 QY 65 DDHYRDVLKEMKAKASTVAKLLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
 Db 61 DDHYRDVLKEMKAKASTVAKLLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 120
 QY 125 SVWKDLLEDTDPTIOTTIMAXNEVFCVQPEKGRKPARLIYFPDILGVRVCKMALYDVVS 184
 Db 121 SVWKDLLEDTDPTIOTTIMAXNEVFCVQPEKGRKPARLIYFPDILGVRVCKMALYDVVS 180
 QY 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKSKNPMGFSYDTRCFDSTVTENDIRVEESIY 244

Db 181 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKSKNPMGFSYDTRCFDSTVTENDIRVEESIY 240
 QY 245 OCCDLAPARQAIKSLTERLYVGGMTNSKQNCYRRCRAGVLTTCGNTLTCTYLKAA 304
 Db 241 OCCDLAPARQAIKSLTERLYVGGMTNSKQNCYRRCRAGVLTTCGNTLTCTYLKAA 300
 QY 305 AACRAAKLQDCTMLVNGDDLVIICISACTQBDAAASLRVFTTEAMTRYSPGPPQPEYDL 364
 Db 301 AACRAAKLQDCTMLVNGDDLVIICISACTQBDAAASLRVFTTEAMTRYSPGPPQPEYDL 360
 QY 365 ELITSCSNVSVAHNDASGRVYLTTRDPTVPLARAWEETARHTPVNSLGNLIYAPTILW 424
 Db 361 ELITSCSNVSVAHNDASGRVYLTTRDPTVPLARAWEETARHTPVNSLGNLIYAPTILW 420
 QY 425 ARMIIMTHFFSILLAEQLEKALDCQIYGACVSTIEPLDLPOIIRLHGLSAPLSHSYSPG 484
 Db 421 ARMIIMTHFFSILLAEQLEKALDCQIYGACVSTIEPLDLPOIIRLHGLSAPLSHSYSPG 480
 QY 485 EINRVASCLRLKGVPPPLRVWRHRSVRARLLSQGGRATCGKYLFWNAVTKLKTIP 544
 Db 481 EINRVASCLRLKGVPPPLRVWRHRSVRARLLSQGGRATCGKYLFWNAVTKLKTIP 540
 QY 545 AASRLDLSGWFVAGYSGGDIYHSLSRARPRHHHHH 580
 Db 541 AASQDLDSGWFVAGYSGGDIYHSLSRARPRHHHHH 576

RESULT 4

AAO26418
 ID AAO26418 standard; protein; 576 AA.
 XX
 AC AAO26418;
 XX
 DT 30-JAN-2003 (first entry)
 XX
 DE Mutant RNA polymerase MUT-1 protein.
 XX
 KW Antiviral; hepatitis C virus; HCV; NS5B RNA polymerase.
 XX
 OS Unidentified.
 XX
 PN EP1256628-A2.
 XX
 PD 13-NOV-2002.
 XX
 PF 07-MAY-2002; 2002EP-00009387.
 XX
 PR 10-MAY-2001; 2001US-0289829P.
 XX
 PA (AGOU-) AGOURON PHARM INC.

PI Love RA, Yu X, Diehl W, Hickey MJ, Parge HE, Gao J, Fuhrman S;
 XX WPI; 2003-031968/03.

Isolated nucleic acid encoding a mutant hepatitis C virus (HCV) NS5B RNA
 polymerase, useful for producing the mutant RNA polymerase which can be
 used for identifying inhibitors that can treat HCV infection.

Claim 8; Page; 32pp; English.

The invention relates to an isolated, purified nucleic acid molecule,
 CC which encodes a mutant hepatitis C virus (HCV) NS5B RNA polymerase, where
 CC a point mutation occurs at least at one or all of positions 47, 101, 106,
 CC and/or 114 of the native RNA polymerase sequence not defined in the
 CC specification. The method of the invention is utilised to identify
 CC inhibitors of the polymerase. The inhibitors serving as lead compounds
 CC for the design of potentially therapeutic compounds for the treatment of
 CC HCV. The mutant HCV NS5B RNA polymerase has improved crystallisation
 CC properties as compared to a native HCV NS5B RNA polymerase. This sequence
 CC represents a mutant RNA polymerase protein of the invention. NOTE: This
 CC sequence is not shown in the specification. It is, however, described in

CC the specification and its sequence has been obtained from an electronic
CC data file
XX
SQ Sequence 576 AA;

Query Match 96.4%; Score 2944; DB 6; Length 576;
Best Local Similarity 96.2%; Pred. No. 3.5e-274;
Matches 554; Conservative 13; Mismatches 9; Indels 0; Gaps 0;
QY 5 SMSYTWGALITPCAABESKLPINALSNSLRHHNLVYSTTSRSASLRQKVTFRDLQVL 64
DB 1 SMSYTWGALITPCAABESKLPINALSNSLRHHNLVYSTTSRSASLRQKVTFRDLQVL 60
QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYKAKOVRSLSRAVNHR 124
DB 61 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYKAOQVNRNLSKAVNH 120
QY 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
DB 121 SVWKDLLEDTVPTIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 180
QY 185 TLPOAVMGSSYGFQYSPQORVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESI 244
DB 181 TLPOAVMGSSYGFQYSPQORVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESI 240
QY 245 QCCDLAPEARQAIRSLTERLYVGGPMNTSKGQNCYRRCRASGLVTTSCGNTLTCYLKAA 304
DB 241 QCCDLAPEARQAIRSLTERLYVGGPMNTSKGQNCYRRCRASGLVTTSCGNTLTCYLKAS 300
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 360
QY 365 ELITSCSNVSVVAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
DB 361 ELITSCSNVSVVAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 420
QY 425 ARMLMTTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 484
DB 421 ARMLMTTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSPG 480
QY 485 EINRVASCLRKLGVPPLRVWRHRARSVRARLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
DB 481 EINRVASCLRKLGVPPLRVWRHRARSVRARLLSQGGRAAICGKYLFWNAVRTKLTPTIP 540
QY 545 AASRLDLSCGFVAGYSGGDIYHSLSRARPRHHHHH 580
DB 541 AASRLDLSCGFVAGYSGGDIYHSLSRARPRHHHHH 576

RESULT 5
ID AAB60131
XX AAB60131 standard; protein; 579 AA.
AC AAB60131;
XX
DT 03-APR-2001 (first entry)
XX
DE Hepatitis C virus NS5B polymerase related protein.
XX
KW Hepatitis C virus; HCV; NS5B polymerase; protein coordinate data;
KW cirrhosis; hepatoma; inhibitor.
OS
OS Hepatitis C virus.
PN
PN
XX
XX
PD
XX
PF 30-JUN-2000; 2000EP-00113955.
XX
PR 02-JUL-1999; 99JP-00188630.
PR 07-JUL-1999; 99JP-00192488.

XX (NISB) JAPAN TOBACCO INC.
PA
XX Ago H, Miyano M, Adachi T;
XX WPI; 2001-104834/12.
DR
XX
XX New polypeptide, derived from hepatitis C virus (HCV) polymerase NS5B,
PT having a HCV polymerase activity, useful for crystal structure analysis
XX and for rational identification of HCV polymerase inhibitors.
XX Disclosure; Page 279-282; 295pp; English.
PS
XX
XX The present invention provides the hepatitis C virus (HCV) NS5B
CC polymerase protein and its structure. It also provides methods for
CC identifying inhibitors of the protein which can be used in the treatment
CC of HCV infection. HCV can lead to cirrhosis and hepatoma in its chronic
CC form
XX
SQ Sequence 579 AA;

Query Match 96.3%; Score 2942; DB 4; Length 579;
Best Local Similarity 96.0%; Pred. No. 5.5e-274;
Matches 556; Conservative 12; Mismatches 9; Indels 2; Gaps 1;
QY 4 MSMSYTWGALITPCAABESKLPINALSNSLRHHNLVYSTTSRSASLRQKVTFRDLQV 63
DB 1 MSMSYTWGALITPCAABESKLPINALSNSLRHHNLVYSTTSRSASLRQKVTFRDLQV 60
QY 64 LDDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYKAKOVRSLSRAVNHI 123
DB 61 LDDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYKAKOVRSLSRAVNHI 120
QY 124 RSVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVV 183
DB 121 RSVWKDLLEDTVPTIDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVV 180
QY 184 STLPOAVMGSSYGFQYSPQORVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESI 243
DB 181 STLPOAVMGSSYGFQYSPQORVEFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESI 240
QY 244 YQCCDLAPEARQAIRSLTERLYVGGPMNTSKGQNCYRRCRASGLVTTSCGNTLTCYLKA 303
DB 241 YQCCDLAPEARQAIRSLTERLYVGGPMNTSKGQNCYRRCRASGLVTTSCGNTLTCYLKA 300
QY 304 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYD 363
DB 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYD 360
QY 364 LELITSCSNVSVVAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTL 423
DB 361 LELITSCSNVSVVAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTL 420
QY 424 WARMILMTTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSP 483
DB 421 WARMILMTTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSFAFSLHSYSP 480
QY 484 GEINRVASCLRKLGVPPLRVWRHRARSVRARLLSQGGRAAICGKYLFWNAVRTKLTPTIP 543
DB 481 GEINRVASCLRKLGVPPLRVWRHRARSVRARLLSQGGRAAICGKYLFWNAVRTKLTPTIP 540
QY 544 PAASRLDLSCGFVAGYSGGDIYHSLSRARPR--HHHHH 580
DB 541 PAASRLDLSCGFVAGYSGGDIYHSLSRARPRGSHHHHH 579

RESULT 6
ID AAG79558
XX AAG79558 standard; protein; 578 AA.
XX AC AAG79558;
XX
DT 09-DEC-2002 (first entry)

XX HCV decrease-affinity NS5B polymerase, NS5Bdelta21C-HT.
 XX Enzyme; hepatitis C virus; HCV; decreased affinity; NS5B; polymerase;
 KW inhibitor; RNA-dependent RNA polymerase.
 XX Hepatitis C virus.
 OS WO200270739-A2.
 XX 12-SEP-2002.
 XX 06-MAR-2002; 2002WO-CA000323.
 XX 08-MAR-2001; 2001US-0274374P.
 XX (BOEH) BOEHRINGER INGELHEIM CANADA LTD.
 XX Kukolj G, Mckercher G;
 XX WPI; 2002-698759/75.
 XX Identifying inhibitors HCV NS5B RNA-dependent RNA polymerase, comprises
 PT incubating an HCV NS5B polymerase having decreased affinity for the
 PT primer template relative to the native polymerase, with a potential
 PT inhibitor.
 XX Claim 9; Page 47-48; 52pp; English.
 XX The sequences given in AAG79556-61 are hepatitis C virus (HCV) decreased
 CC affinity NS5B polymerases. These enzymes are used in the method of the
 CC invention for identifying a potential inhibitor of the binding between a
 CC HCV NS5B RNA-dependent RNA polymerase and an appropriate primer-template.
 CC The method comprises incubating the HCV NS5B polymerase with the primer-
 CC template in the presence and absence of a potential inhibitor. The HCV
 CC NS5B polymerase has a decreased affinity for the primer-template relative
 CC to that of native HCV NS5B RNA-dependent RNA polymerase. The method is
 CC useful for identifying a potential inhibitor of the binding between a HCV
 CC NS5B RNA-dependent RNA polymerase and a primer-template. Use of
 CC polymerase constructs having a lower affinity towards the primer-template
 CC than that of native NS5B polymerase is particularly useful for
 CC identifying potential inhibitors in screening large libraries of
 CC compounds. The new method reduces the difficulties and disadvantages of
 CC prior art. The present method provides an assay that is easy to perform
 CC on large libraries of compounds, and has improved sensitivity for
 CC detecting inhibitors that would not be identified as such using native
 CC NS5B polymerase. This protein represents a soluble form of mature HCV
 CC NS5B which lacks the C-terminal 21 amino acids and has an C-terminal hexa
 CC -histidine tag
 XX Sequence 578 AA;
 XX
 Query Match 96.1%; Score 2936; DB 5; Length 578;
 Best Local Similarity 95.5%; Pred. No. 2.1e-273;
 Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;
 QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVSTTSRSASLRQKVKTFDRQLVL 64
 DB 1 SMSYTWTCALITPCAABESQIPINALNSLRHNLVSTTSRSASLRQKVKTFDRQLVL 60
 QY 65 DDHYRDVLKEMKAKASTYKAKLLSYEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
 DB 61 DDHYRDVLKEMKAKASTYKAKLLSYEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 120
 QY 125 SWKDLLEDTPITPTTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRCVKMALYDVWS 184
 DB 121 SWKDLLEDTPITPTTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRCVKMALYDVWS 180
 QY 185 TLPQAVMGSSYGFQSPKQRYEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 DB 181 TLPQAVMGSSYGFQSPKQRYEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 240
 QY 245 QCCDLAPARQAIRSLTERLYIGGFLTNSKGQNCYRRRCRAGSVLTTCGNTLTCLYKAA 304

DB 241 QCCDLAPARQAIRSLTERLYIGGFLTNSKGQNCYRRRCRAGSVLTTCGNTLTCLYKAS 300
 QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQSDAASLRVFTFAMTRYSAAPGDPPOPEYDL 364
 DB 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQSDAANLRFVFTFAMTRYSAAPGDLPOPEYDL 360
 QY 365 ELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 424
 DB 361 ELITSCSSNVSAHDASGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 420
 QY 425 ARMTLMTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLQIILRLHGLSAPLSHSYSPG 484
 DB 421 ARMTLMTHFFSILLAOEQLEKALDCQIYGACYSIEPLDLQIILRLHGLSAPLSHSYSPG 480
 QY 485 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSQGGRRAICGKLYFNWAVRTKLKLTPTP 544
 DB 481 EINRVASCLRLKLGVPPLRVWRHRSVRKALLSQGGRRAICGKLYFNWAVRTKLKLTPTP 540
 QY 545 AASRLDLSGWVAGYSGGDIYHSLSRAPR--HHHHHH 580
 DB 541 AASRLDLSGWVAGYSGGDIYHSLSRAPRLEHHHHH 578
 RESULT 7
 ID ABP71662 standard; protein; 578 AA.
 XX ABP71662;
 AC ABP71662;
 XX 29-MAY-2003 (first entry)
 DT HCV NS5Bdelta21-His protein sequence.
 DE HCV NS5Bdelta21-His protein sequence.
 KW HCV; polymerase; virucide; hepatotropic; antiviral; enzyme; NS5B.
 OS Hepatitis C virus.
 XX WO2003014377-A2.
 XX 20-FEB-2003.
 XX 05-AUG-2002; 2002WO-CA001214.
 XX 07-AUG-2001; 2001US-0310272P.
 XX (BOEH) BOEHRINGER INGELHEIM CANADA LTD.
 XX Kukolj G, Beaulieu PL, Mckercher G;
 XX WPI; 2003-300535/29.
 XX Identifying compounds that bind to hepatitis C virus polymerase, useful
 PT as antiviral agents, from ability to displace bound probe from the
 PT polymerase.
 XX Example 2; Page 117-119; 125pp; English.
 XX The invention relates to a method for identifying compounds that bind to
 CC hepatitis C virus (HCV) polymerase. The method involves (a) treating HCV
 CC polymerase, or its analogue, with a probe that binds to the polymerase to
 CC form a complex but is displaceable by an inhibitor; (b) measuring a
 CC signal emitted from the probe in the complex to establish a baseline
 CC value; (c) incubating the complex with test compound; and (d) measuring
 CC the signal from the complex and comparing it with the baseline. Any
 CC modulation indicates that the test compound binds to HCV polymerase. The
 CC method is used to identify (also to determine potency) of HCV polymerase
 CC inhibitors, potentially useful as antiviral agents. The present sequence
 CC represents a HCV NS5Bdelta21-His polymerase
 XX Sequence 578 AA;
 SQ Query Match 96.1%; Score 2936; DB 6; Length 578;

```
Best Local Similarity 95.5%; Pred. No. 2.1e-273;
Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;

QY 5 SMSYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
DB 1 SMSYTWGALITPCAABESQLPINALNSLRHNRNVYSTTSRSAAALRQKKVTFDRLOVL 60
QY 65 DDHYRDVLKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 61 DDHYRDVLKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 120
QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALDYVVS 184
DB 121 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALDYVVS 180
QY 185 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 244
DB 181 TLPQAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIY 240
QY 245 OCCDLAPARQAIRSLTERLYVGGPMNTSKGNCGYRCRASGVLTTSCGNLTLCYLKAA 304
DB 241 OCCDLAPARQAIRSLTERLYVGGPMNTSKGNCGYRCRASGVLTTSCGNLTLCYLKAS 300
QY 305 AACRAAKLQDCTMLVNGDDLVIKESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
DB 301 AACRAAKLQDCTMLVNGDDLVIKESAGTQBDAAANLRVFTTEAMTRYSAAPPDLPQPEYDL 360
QY 365 ELITSCSSNVSAVHADSKRVYVLTDRPTVPLARAWEATARTHTPVNSWLGNIIMVAPTLW 424
DB 361 ELITSCSSNVSAVHADSKRVYVLTDRPTVPLARAWEATARTHTPVNSWLGNIIMVAPTLW 420
QY 425 ARMLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPG 484
DB 421 ARMLMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPG 480
QY 485 EINRVASCLRLKGLVPLVWRHRSVRKALLSQGGRAAICGKYLEFNWAVRTKLKLTPIP 544
DB 481 EINRVASCLRLKGLVPLVWRHRSVRKALLSQGGRATCGKYLEFNWAVRTKLKLTPIP 540
QY 545 AASRLDLSGFWAGYSGGDIYHLSRARPR--HHHHH 580
DB 541 AASRLDLSGFWAGYSGGDIYHLSRARPRLEHHHHH 578

RESULT 8
ID ABG72214 standard; protein; 576 AA.
AC ABG72214;
XX
XX
XX 17-FEB-2003 (first entry)
XX HCV mutant NS5B polymerase polypeptide, His-NS5BdelCT21.
XX
XX Crystallisation; crystal structure; hepatitis C virus; HCV;
KW NS5B polymerase; NS5B RNA-dependent RNA polymerase; x-ray diffraction;
KW atomic coordinate determination; drug screening; mutant; mutcin;
XX protein co-ordinate data; enzyme; His-NS5BdelCT21.
XX
XX Hepatitis C virus; BK isolate.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Misc-difference 335 /label= Thr, Val
FT /note= "Preferred amino acid at this position is valine."
FT Wild type residue at this position is threonine"
FT Misc-difference 344 /label= Val, Ala
FT /note= "Preferred amino acid at this position is alanine."
FT Wild type residue at this position is valine"
FT Misc-difference 550 /label= Arg, Gln
FT
```

```
/note= "Preferred amino acid at this position is
glutamine. Wild type residue at this position is
arginine"
US6434489-B1.
13-AUG-2002.
03-APR-2000; 2000US-00541990.
03-APR-2000; 2000US-00541990.
(SCHE ) SCHERING CORP.
Lesburg CA, Cable M, Hong Z, Mannarino AF, Weber PC;
WPI; 2003-110131/10.
New crystalline Hepatitis C Virus NS5B polypeptide composition useful for
determining the atomic coordinates of the polypeptide and drug screening.
Claim 1; Col 75-80; 44pp; English.
The present invention relates to the purification, crystallisation, and
structure of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.
The composition containing the crystals of HCV NS5B polymerase
polypeptide diffracts x-rays for determination of the atomic coordinates
of the polypeptide to greater than 4.0 Angstroms resolution. The crystal
is useful for determination of the atomic coordinates of the HCV NS5B
polypeptide, and is useful in drug screening methods. The present
sequence represents a mutant of the published sequence (Genbank Accession
No. 130458) for the HCV NS5B polypeptide, His-NS5BdelCT21. This mutant
contains 3 amino acid substitutions and a polyhistidine tag at the N-
terminus. The C-terminal 21 amino acids present in the wild type are also
deleted in His-NS5BdelCT21
Sequence 576 AA;
Query Match 94.2%; Score 2879; DB 6; Length 576;
Best Local Similarity 96.0%; Pred. No. 6.5e-268;
Matches 545; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 7 SYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVLDD 66
DB 9 SYTWGALITPCAABESKLPINALNSLRHNRNVYSTTSRSAGLRQKKVTFDRLOVLDD 68
QY 67 HYRDVLKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIRSV 126
DB 69 HYRDVLKEMKAKASTVKALLSVEERACKLTPPHSAKSKFGYGAQVRSLSRAVNHIRSV 128
QY 127 WKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALDYVVS 186
DB 129 WKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALDYVVS 188
QY 187 POAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIYQC 246
DB 189 POAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVESIYQC 248
QY 247 CDLAPARQAIRSLTERLYVGGPMNTSKGNCGYRCRASGVLTTSCGNLTLCYLKAAA 306
DB 249 CDLAPARQAIRSLTERLYVGGPMNTSKGNCGYRCRASGVLTTSCGNLTLCYLKAAA 308
QY 307 CRAAKLQDCTMLVNGDDLVIKESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLEL 366
DB 309 CRAAKLQDCTMLVNGDDLVIKESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLEL 368
QY 367 ITSCSSNVSAVHADSKRVYVLTDRPTVPLARAWEATARTHTPVNSWLGNIIMVAPTLWAR 426
DB 369 ITSCSSNVSAVHADSKRVYVLTDRPTVPLARAWEATARTHTPVNSWLGNIIMVAPTLWAR 428
QY 427 MILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPGEI 486
DB 429 MILMTHFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIERLHGLSAFSLHSYSPGEI 488
```

QY 487 NRVASCLRLKGVPPPLRVWHRARSVRRAKLLSQGRRRAICGKYLFWNAVRTKLTPIPA 546
DB 489 NRVASCLRLKGVPPPLRVWHRARSVRRAKLLSQGRRRAICGKYLFWNAVRTKLTPIPA 548
QY 547 SRLDLSGFWFVAGYSGGDIYHLSLRARPR 574
DB 549 SXLDLSGFWFVAGYSGGDIYHLSLRARPR 576

RESULT 9
ID ADH74494 standard; protein; 576 AA.
XX ADH74494;
XX 25-MAR-2004 (first entry)
XX HCV RNA-dependent RNA polymerase NS5B polypeptide.
XX HCV; RNA-dependent RNA polymerase; NS5B; cation exchange chromatography;
KW polyethylene glycol; crystallisation; tNS5B; truncated NS5B;
KW anti-HCV agent.
XX Hepatitis C virus.

XX Key Location/Qualifiers
FH Misc-difference 335 /label= Thr, Val
FT Misc-difference 344 /label= Val, Ala
FT Misc-difference 550 /label= Arg, Gln
XX US2003171874-A1.
XX 11-SEP-2003.
XX 12-JUN-2002; 2002US-00170131.
XX 03-APR-2000; 2000US-00541990.
XX (LESB/) LESBURG C A.
XX (CABL/) CABLE M.
XX (HONG/) HONG Z.
XX (MANN/) MANNARINO A F.
XX (WEBE/) WEBER P C.

PI Lesburg CA, Cable M, Hong Z, Mannarino AF, Weber PC;
XX WPI; 2004-119171/12.
XX Crystalline composition comprising a hepatitis C virus (HCV) RNA
PT dependent RNA polymerase NS5B polypeptide, useful for providing a target
PT for discovery of anti-HCV agents.
XX Claim 3; SEQ ID NO 1; 44pp; English.

CC The invention relates to a crystalline composition comprising a hepatitis
CC C virus (HCV) RNA-dependent RNA polymerase NS5B polypeptide. The
CC invention also relates to a composition comprising an NS5B protein having
CC at least one amino acid substitution and a method of preparing purified
CC crystalline HCV NS5B comprising stabilising an NS5B protein preparation
CC in a solution containing a protein stabilising agent, subjecting the NS5B
CC protein preparation to cation exchange chromatography in a buffer
CC containing glycine, and allowing crystals to form in a precipitant
CC containing a protein stabilising agent, a salt and polyethylene glycol
CC under conditions in which crystallisation occurs. The NS5B polypeptide is
CC preferably tNS5B, a truncated NS5B polypeptide. The invention is used to
CC provide a target for discovery of anti-HCV agents. This sequence
XX represents the NS5B polypeptide of the invention.

XX Sequence 576 AA;

Query Match 94.2%; Score 2879; DB 8; Length 576;
Best Local Similarity 96.0%; Pred. No. 6.5e-268;
Matches 545; Conservative 11; Mismatches 12; Indels 0; Gaps 0;
QY 7 SYTTGALITPCAAEESKLPINALNSLLRHNLVYSTTSASISROKVTDFRLQVLDD 66
DB 9 SYTTGALITPCAAEESKLPINALNSLLRHNLVYSTTSASISROKVTDFRLQVLDD 68
QY 67 HYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYGAQDVRSLSRVNHRISV 126
DB 69 HYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYGAQDVRSLSRVNHRISV 128
QY 127 WKDLLEDTDPTIQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVSTL 186
DB 129 WKDLLEDTDPTIQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAIYDVVSTL 188
QY 187 PQAVMGSSYGFQYSPKQVRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQC 246
DB 189 PQVVMGSSYGFQYSPKQVRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQC 248
QY 247 CDLAPEARQAIRSLTERLYVGPMNTNSKGQNGYRRRCRASGVLTTSCGNTLTCTYLKAAA 306
DB 249 CDLAPEARQAIRSLTERLYVGPMNTNSKGQNGYRRRCRASGVLTTSCGNTLTCTYLKAAA 308
QY 307 CRAAKLQDCTMLVNGDDDLVVICESAGTOEDAAASLRVFTFTEAMTRYSAAPGDPPEYDLEL 366
DB 309 CRAAKLQDCTMLVNGDDDLVVICESAGTOEDAAASLRVFTFTEAMTRYSAAPGDPPEYDLEL 368
QY 367 ITSCSSNVSVADHAGSKRVYVLTDPVPLARAAWETARHTPVSNSWLNIIIMYAPTLMAR 426
DB 369 ITSCSSNVSVADHAGSKRVYVLTDPVPLARAAWETARHTPVSNSWLNIIIMYAPTLMAR 428
QY 427 MILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEI 486
DB 429 MILMTHFFSILLAOBLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEI 488
QY 487 NRVASCLRLKGVPPPLRVWHRARSVRRAKLLSQGRRRAICGKYLFWNAVRTKLTPIPA 546
DB 489 NRVASCLRLKGVPPPLRVWHRARSVRRAKLLSQGRRRAICGKYLFWNAVRTKLTPIPA 548
QY 547 SRLDLSGFWFVAGYSGGDIYHLSLRARPR 574
DB 549 SXLDLSGFWFVAGYSGGDIYHLSLRARPR 576
RESULT 10
ADM69007
ID ADM69007 standard; protein; 567 AA.
XX AC ADM69007;
XX DT 03-JUN-2004 (first entry)
XX DE HCV NS5B RNA-dependent RNA polymerase (RdRp) protein.
XX KW HCV; NS5B; RNA-dependent RNA polymerase; RdRp; growth inhibitor; enzyme.
XX OS Hepatitis C virus.
XX FH Key Location/Qualifiers
XX FT Misc-difference 464 /note= "Encoded by GAA"
XX XX KR2002070125-A.
XX PD 05-SEP-2002.
XX PF 26-FEB-2002; 2002KR-00010174.
XX PR 27-FEB-2001; 2001KR-00009873.
XX PA (LGLI-) LG LIFE SCI LTD.

XX Hyun US, Kim JM, Lee MG, Noh GY;
 XX WPI; 2003-253755/25.
 DR N-PSDB; ADM69006.
 XX Recombinant hepatitis C virus ns5b protein, and preparation process and
 PT use thereof.
 XX Claim 3; SEQ ID NO 8; 19pp; Korean.
 XX The invention relates to a novel recombinant Hepatitis C virus (HCV) NS5B
 CC protein which is derived from a HCV patient's serum and has excellent RNA
 CC -dependent RNA polymerase (RdRp) activity. The polypeptide of the
 CC invention may be useful as a HCV growth inhibitor. The current sequence
 CC is that of the HCV NS5B RNA-dependent RNA polymerase (RdRp) protein of
 CC the invention.
 XX Sequence 567 AA;

Query Match 93.2%; Score 2846; DB 7; Length 567;
 Best Local Similarity 94.7%; Pred. No. 9.6e-265;
 Matches 537; Conservative 17; Mismatches 13; Indels 0; Gaps 0;
 QY 5 SMSYTWTCALITPCAAEESKLPINALNSLRLHNLVSTTSRSASLRFQKQKVTDFRLQVL 64
 DB 1 SMSYSWTCALITPCAAEESKLPINPLNSLRLHNLVSTTSRSASLRFQKQKVTDFRLQVL 60
 QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAOKVRSLSRAVNHIR 124
 DB 61 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAOKVRSLSRAVNHIR 120
 QY 125 SVWKDLLEDTTPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 184
 DB 121 SVWKDLLEDTTPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 180
 QY 185 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 DB 181 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTESDIRVESIY 240
 QY 245 QCCDLAPPEARQAIRSLTERLYVGGPMWNSKQNCYRRCRASGLVTTSCGNTLTCYLKAA 304
 DB 241 QCCDLAPPEARQAIRSLTERLYVGGPMWNSKQNCYRRCRASGLVTTSCGNTLTCYLKAS 300
 QY 305 AACRAAKLODCTMLVNGDVLVVCESAGTOEDAAASLRVFTTEAMTRYSAAPPDGPQPEYDL 364
 DB 301 AACRAAKLODCTMLVNGDVLVVCESAGTOEDAAASLRVFTTEAMTRYSAAPPDGPQPEYDL 360
 QY 365 ELITSCSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
 DB 361 ELITSCSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 420
 QY 425 ARMLMTFFSILLAOEALDQCIYGCYSIBPLDLPQIIRLHGLSAFSLHSYSPG 484
 DB 421 ARMLMTFFSILLAOEALDQCIYGCYSIBPLDLPQIIRLHGLSAFSLHSYSPG 480
 QY 485 EINRVASCLRLGVPLRVRHRAVSRAKLLSQGGRAAICGKYLFWAVATKLTPIIP 544
 DB 481 EINRVASCLRLGVPLRVRHRAVSRAKLLSQGGRAAICGKYLFWAVATKLTPIIP 540
 QY 545 AASRLDLSGFWAGYSGGDIYVSLRSRA 571
 DB 541 AASRLDLSGFWAGYSGGDIYVSLRSRA 567

RESULT 11
 AAG79559
 ID AAG79559 standard; protein; 545 AA.
 XX
 CC AAG79559;
 XX
 DT 09-DEC-2002 (first entry)

DE HCV decrease-affinity NS5B polymerase, NS5Bdelta57-HT.
 XX Enzyme; hepatitis C virus; HCV; decreased affinity; NS5B; polymerase;
 KW inhibitor; RNA-dependent RNA polymerase.
 XX Hepatitis C virus.
 OS
 PN WO200270739-A2.
 XX
 XX 12-SEP-2002.
 XX
 XX 06-MAR-2002; 2002WO-CA000323.
 XX
 XX 08-MAR-2001; 2001US-0274374P.
 XX (BOEH) BOEHRINGER INGELHEIM CANADA LTD.
 PA
 XX
 PI
 XX
 XX
 DR
 XX
 XX WPI; 2002-698759/75.
 XX
 XX Identifying inhibitors HCV NS5B RNA-dependent RNA polymerase, comprises
 PT incubating an HCV NS5B polymerase having decreased affinity for the
 PT primer template relative to the native polymerase, with a potential
 PT inhibitor.
 XX
 PS
 XX Claim 10; Page 48-49; 52pp; English.
 XX
 CC The sequences given in AAG79556-61 are hepatitis C virus (HCV) decreased
 CC affinity NS5B polymerases. These enzymes are used in the method of the
 CC invention for identifying a potential inhibitor of the binding between a
 CC HCV NS5B RNA-dependent RNA polymerase and an appropriate primer-template.
 CC The method comprises incubating the HCV NS5B polymerase with the primer-
 CC template in the presence and absence of a potential inhibitor. The HCV
 CC NS5B polymerase has a decreased affinity for the primer-template relative
 CC to that of native HCV NS5B RNA-dependent RNA polymerase. The method is
 CC useful for identifying a potential inhibitor of the binding between a HCV
 CC NS5B RNA-dependent RNA polymerase and a primer-template. Use of
 CC polymerase constructs having a lower affinity towards the primer-template
 CC than that of native NS5B polymerase is particularly useful for
 CC identifying potential inhibitors in screening large libraries of
 CC compounds. The new method reduces the difficulties and disadvantages of
 CC prior art. The present method provides an assay that is easy to perform
 CC on large libraries of compounds, and has improved sensitivity for
 CC detecting inhibitors that would not be identified as such using native
 CC NS5B polymerase. This protein represents a soluble form of mature HCV
 CC NS5B which lacks the C-terminal 57 amino acids and has an C-terminal hexa
 CC -histidine tag
 XX
 SQ Sequence 545 AA;

Query Match 89.5%; Score 2734.5; DB 5; Length 545;
 Best Local Similarity 90.1%; Pred. No. 5.1e-254;
 Matches 519; Conservative 19; Mismatches 7; Indels 31; Gaps 2;
 QY 5 SMSYTWTCALITPCAAEESKLPINALNSLRLHNLVSTTSRSASLRFQKQKVTDFRLQVL 64
 DB 1 SMSYTWTCALITPCAAEESKLPINALNSLRLHNLVSTTSRSASLRFQKQKVTDFRLQVL 60
 QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAOKVRSLSRAVNHIR 124
 DB 61 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAOKVRSLSRAVNHIR 120
 QY 125 SVWKDLLEDTTPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 184
 DB 121 SVWKDLLEDTTPTIOTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVKMALYDVVS 180
 QY 185 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
 DB 181 TLPQAVMGSSYGFQYSPQRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTESDIRVESIY 240
 QY 245 QCCDLAPPEARQAIRSLTERLYVGGPMWNSKQNCYRRCRASGLVTTSCGNTLTCYLKAA 304
 CC

Db 241 QCCLAPARQAISLTERLYIGGPILTNSKQNGCYRRCRASGVLTTSCGNTLTCTVLKAS 300
 QY 305 AACRAAKLDCTMLVNGDDLVIKESAGTQEDAAASLRVFTTEAMTRYSAAPPQPEYDL 364
 Db 301 AACRAAKLDCTMLVNGDDLVIKESAGTQEDAAANLRVFTTEAMTRYSAAPPQPEYDL 360
 QY 365 ELITSCSSNVVAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 424
 Db 361 ELITSCSSNVVAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTILW 420
 QY 425 ARWMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGISAFSLHSYSPG 484
 Db 421 ARWMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGISAFSLHSYSPG 480
 QY 485 EINRVASCLKLGVPPLRVWRHARSVRAKLSQGGRAAICGKYLEFNWAVRTKLKLTIP 544
 Db 481 EINRVASCLKLGVPPLRVWRHARSVRAKLSQGGRAATCGKYLEFNWAVRTKL 534
 QY 545 AASRLDLSGFWAGYSGGDIYHSLSRARPRHHHHH 580
 Db 535 -AAALE-----HHHHH 545

RESULT 12

AARS58592

ID AARS58592 standard; protein; 462 AA.

AC AARS58592;

XX

DT 09-MAY-1995 (first entry)

XX

DE Hepatitis C virus 8003-9388 fragment antigen.

XX

KW Non-A non-B hepatitis virus antigens; NANBH; hepatitis C virus.

XX

OS Hepatitis C virus.

XX

PN JP06225770-A.

XX

PD 16-AUG-1994.

XX

PF 08-JUL-1993; 93JP-00193104.

XX

PR 10-JUL-1992; 92JP-00207391.

XX

PA (TOKR-) ZH TOKYOTO RINSHO IGAKU SOGO KENKYUSHO.

XX

PA (SANW) SANWA KAGAKU KENKYUSHO CO.

XX

PA (TOFU) TONEN CORP.

XX

PA (KOKU-) KOKUSAI SHIYAKU KK.

XX

XX WPI; 1994-298800/37.

DR N-PSDB; AAQ70542.

XX

XX A nucleic acid fragment coding Non-A Non-B Hepatitis virus antigens - for

PT diagnosis of NANBH and detection of HCV.

XX

PS Claim 1; Page 16; 22pp; Japanese.

XX

CC AAQ70542 is a fragment of hepatitis C virus (HCV) or non-A non-B hepatitis

CC virus (NANBH) non-structural coding region five, encompassing base pairs

CC 8003-9388. It codes for AARS58592 an antigen to a non-structural region of

CC the HCV virus, which can be used in the diagnosis of NANBH patients and

CC the detection of HCV carriers

XX

XX Sequence 462 AA;

SQ

Query Match 74.6%; Score 2279; DB 2; Length 462;

Best Local Similarity 93.0%; Pred. No. 3.2e-210;

Matches 426; Conservative 18; Mismatches 14; Indels 0; Gaps 0;

QY 117 SRVNHIRSVKMDLLEDDTTPIQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEK 176

Db 1 SKAVNHIRSVKMDLLEDDNVTPTVTTMAKSEVFCVQPEKGRKPARLIVFPDLGVRVCEK 60

QY 177 MALYDVVSTLPOAVNGSSYGFQYSPKQVRFVLTNTWKAKCPMGFSYDTRCFDSTVTEND 236
 Db 61 MALYDVVSTLPOAVNGSSYGLQYSPQVRFVLTNTWKAKCPMGFSYDTRCFDSTVTESD 120
 QY 237 IRVESIYQCCDLAPARQAISLTERLYIGGPILTNSKQNGCYRRCRASGVLTTSCGNT 296
 Db 121 IRVESIYQCCDLAPARQAISLTERLYIGGPILTNSKQNGCYRRCRASGVLTTSCGNT 180
 QY 297 LTCYLKAAAACRAAKLDCTMLVNGDDLVIKESAGTQEDAAASLRVFTTEAMTRYSAAPPD 356
 Db 181 LTCYLKAAAACRAAKLDCTMLVNGDDLVIKESAGTQEDAAASLRVFTTEAMTRYSAAPPD 240
 QY 357 PPOPEYDLLELTITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNI 416
 Db 241 PPRPEYDLLELTITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNI 300
 QY 417 IMYAPTILWARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAF 476
 Db 301 IMYAPTILWARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAF 360
 QY 477 SLHSYSPGEINRVASCLKLGVPPLRVWRHARSVRAKLSQGGRAAICGKYLEFNWAVRT 536
 Db 361 SLHSYSPGEINRVASCLKLGVPPLRVWRHARSVRAKLSQGGRAATCGKYLEFNWAVRT 420
 QY 537 KLKLTPIPAASRLDLSGFWAGYSGGDIYHSLSRARPR 574
 Db 421 KLKLTPIPAASRLDLSGFWAGYSGGDIYHSLSRARPR 458

RESULT 13

ADL17783

ID ADL17783 standard; protein; 462 AA.

XX

AC ADL17783;

XX

DT 06-MAY-2004 (first entry)

XX

DE Hepatitis C virus protein (clone C6-82).

XX

KW non-A non-B type hepatitis virus antigen;

KW hepatitis C virus antibody detection; clone C260-1.

XX

OS Hepatitis C virus.

XX

PN JP2004000150-A.

XX

PD 08-JAN-2004.

XX

PF 24-FEB-2003; 2003JP-00046379.

XX

PR 10-JUL-1992; 92JP-00207391.

XX

PR 08-JUL-1993; 93JP-00193104.

XX

PA (KOKU-) KOKUSAI SHIYAKU KK.

XX

XX WPI; 2004-085213/09.

DR N-PSDB; ADL17778.

XX

XX Novel non-A non-B type hepatitis virus nucleic acid fragment useful for

PT diagnosing non-A non-B-hepatitis patient and non-A non-B type hepatitis

PT virus carrier.

XX

XX Disclosure; Page 32-33; 35pp; Japanese.

XX

XX This invention relates to a novel isolated nucleic acid fragment encoding

CC a non-A non-B type hepatitis virus antigen protein sequence.

CC Specifically, it refers to a method for diagnosing non-A non-B type

CC hepatitis patients, as well as for detecting those people who are

CC carriers. The present invention describes a diagnosis method that uses a

CC hepatitis C virus antibody detection reagent and subsequent PCR

CC amplification to identify a clone C260-1 that encodes the non-A non-B

CC type hepatitis virus antigen sequence. This polypeptide sequence is the

CC non-A-non-B type hepatitis virus protein fragment of the invention. NOTE:
 CC This sequence is given in the sequence listing as an embedded protien and
 CC is not further referred to in the specification.

XX SQ Sequence 462 AA;
 Query Match 74.6%; Score 2279; DB 8; Length 462;
 Best Local Similarity 93.0%; Pred. No. 3.2e-210;
 Matches 426; Conservative 18; Mismatches 14; Indels 0; Gaps 0;
 QY 117 SRVNHRSVWKKLLEDDTDTPIQTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCVK 176
 Db 1 SKAVNHRSVWKKLLEDDNVTVDVTIMAKSEVFCVQPEKGRKPARLIVFPDLGVRCVK 60
 QY 177 MALYDVVSTLPQAVMGSSYGQYSPKORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTEND 236
 Db 61 MALYDVVSTLPQAVMGSSYGQYSPQORVEFLVNTWKAKKCPMGFSYDTRCFDSTVTESD 120
 QY 237 IRVESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQYRCRASGLVLTSCGNT 296
 Db 121 IRVESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQYRCRASGLVLTSCGNT 180
 QY 297 LTCYLKASAAKRAKLDCTMLVNGDDLVVICESAGTQEDAAASLVFTEATRYSAAPGD 356
 Db 181 LTCYLKASAAKRAKLDCTMLVNGDDLVVICESAGTQEDAAASLVFTEATRYSAAPGD 240
 QY 357 PQPEYDLELITSCSSNVSVAHDSAGKRVYVLTTRDPTVPLARAATWETARHTFPVNSWLGNI 416
 Db 241 PQPEYDLELITSCSSNVSVAHDSAGKRVYVLTTRDPTVPLARAATWETARHTFPVNSWLGNI 300
 QY 417 IMYAPTLWARMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAP 476
 Db 301 IMYAPTLWARMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAP 360
 QY 477 SLHYSYSGEINRVASCLKGLGVPLVRVWRHARSVRAKLLSQGGRAATCGKYLFWNAVRT 536
 Db 361 SLHYSYSGEINRVASCLKGLGVPLVRVWRHARSVRAKLLSQGGRAATCGKYLFWNAVRT 420
 QY 537 KLKLTPIPAASRLDLSGFWFVAGYSGGDIYHLSRARPR 574
 Db 421 KLKLTPIPAASRLDLSGFWFVAGYSGGDIYHLSRARPR 458

RESULT 14
 AAR67630
 ID AAR67630 standard; protein; 547 AA.
 XX AC AAR67630;
 XX DT 27-AUG-2003 (revised)
 DT 25-MAR-2003 (revised)
 DT 18-AUG-1995 (first entry)
 XX DE Non-A Non-B hepatitis virus non-structural protein.
 XX KW Non-A Non-B hepatitis virus; structural region; cDNA to genomic RNA;
 KW detection; reagent; anti-Non-A Non-B hepatitis virus antibody; vaccine;
 XX antigen; epitope; diagnosis.
 OS non-A.
 OS non-B hepatitis virus.

XX Key Location/Qualifiers
 FT Peptide 52.72
 FT /note="putative epitope site (see AAR67641)"
 XX EP628572-A2.
 XX 14-DEC-1994.
 XX 27-MAY-1994; 94EP-00108256.
 XX 28-MAY-1993; 93JP-00126709.

PR 02-MAR-1994; 94JP-00032201.
 XX (EISA) EISAI CO LTD.
 XX Aoyama M, Obara T, Tohmatsu J, Sawada T, Hosoda T, Iwasaki Y;
 FI Arima T;
 XX WPI; 1995-015655/03.
 DR N-PSDB; RAQ75819.
 XX New non-A non-B hepatitis virus sub-type - used to develop prods. for
 PT detection, diagnosis, prevention and treatment of non-A non-B hepatitis.
 PT
 XX Claim 1; Page 33-37; 59pp; English.
 XX AAR67630 is the structural protein of the Non-A Non-B (NANB) hepatitis
 CC virus encoded by a partial cDNA to genomic RNA sequence. Regions of the
 CC polypeptide were studied for suitability as an epitope. The novel
 CC epitopes are effective in the diagnosis of NANB hepatitis. The nucleotide
 CC sequences (see AAQ75817-19) were isolated from the plasma of donors in
 CC Japan with high s-GTP levels, and were found to be different from
 CC previously reported NANB hepatitis viruses. The DNA can be used as a
 CC reagent for detecting the NANB hepatitis viral gene. The polypeptides can
 CC be used as reagents for detecting anti-NANB hepatitis antibodies or as a
 CC NANB hepatitis viral vaccine. (Updated on 25-MAR-2003 to correct PN
 CC field.) (Updated on 27-AUG-2003 to correct OS field.)
 XX SQ Sequence 547 AA;

Query Match 70.2%; Score 2144; DB 2; Length 547;
 Best Local Similarity 75.5%; Pred. No. 4.4e-197;
 Matches 397; Conservative 55; Mismatches 74; Indels 0; Gaps 0;
 QY 49 ASLRQKQVTRDRLQVLDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYG 108
 Db 1 ASLRQKQVTRDRLQVLDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSGFYG 60
 QY 109 AKOVRSLSSRAVNHRSVWKKLLEDDTDTPIQTIMAKNEVFCVQPEKGRKPARLIVFPD 168
 Db 61 AKOVRSLSSRAVNHRSVWKKLLEDDTDTPIQTIMAKNEVFCVQPEKGRKPARLIVFPD 120
 QY 169 LGVRVCEKMALYDVVSTLPQAVMGSSYGQYSPKORVEFLVNTWKAKKCPMGFSYDTRCF 228
 Db 121 LGVRVCEKMALYDVVSTLPQAVMGSSYGQYSPKORVEFLVNTWKAKKCPMGFSYDTRCF 180
 QY 229 DSTVTENDIRVESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQYRCRASGV 288
 Db 181 DSTVTENDIRVESIYQCCDLAPPEARQAIRSLTERLYVGGPMTNSKGQYRCRASGV 240
 QY 289 LTTSCGNTLTCYLKASAAKRAKLDCTMLVNGDDLVVICESAGTQEDAAASLVFTEAMT 348
 Db 241 LTTSCGNTLTCYLKASAAKRAKLDCTMLVNGDDLVVICESAGTQEDAAASLVFTEAMT 300
 QY 349 RYSAPPGDPPQPEYDLELITSCSSNVSVAHDSAGKRVYVLTTRDPTVPLARAATWETARHTP 408
 Db 301 RYSAPPGDPPQPEYDLELITSCSSNVSVAHDSAGKRVYVLTTRDPTVPLARAATWETARHTP 360
 QY 409 VNSWLGNIIMYAPTLWARMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIE 468
 Db 361 VNSWLGNIIMYAPTLWARMLMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIE 420
 QY 469 RLHGLSAPSLHYSYSGEINRVASCLKGLGVPLVRVWRHARSVRAKLLSQGGRAATCGKY 528
 Db 421 RLHGLSAPSLHYSYSGEINRVASCLKGLGVPLVRVWRHARSVRAKLLSQGGRAATCGKY 480
 QY 529 LFNWAVTKLKLTPIPAASRLDLSGFWFVAGYSGGDIYHLSRARPR 574
 Db 481 LFNWAVTKLKLTPIPAASRLDLSGFWFVAGYSGGDIYHLSRARPR 526

RESULT 15
 AAR29906
 ID AAR29906 standard; protein; 389 AA.

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:47:55 ; Search time 43 Seconds
(without alignments)
1297.808 Million cell updates/sec

Title: US-10-712-479-4

Perfect score: 3055

Sequence: 1 MASMSYTWGALITPCAA.....GGDIYHLSLRARPRHHHH 580

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 248019

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_79.*

1: pir1.*

2: pir2.*

3: pir3.*

4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1777	58.2	365	2 JQ0879	NS5 protein - hepa
2	1655	54.2	365	2 JQ0880	NS5 protein - hepa
3	951	31.1	189	2 S60587	non-structural pro
4	774	25.3	284	2 P50104	genome polyprotein
5	744	24.4	259	2 P50102	genome polyprotein
6	667	21.8	135	2 S44214	genome polyprotein
7	630	20.6	156	2 D39109	genome polyprotein
8	569	18.6	113	2 PCL278	NS5 protein - hepa
9	563	18.4	113	2 PCL277	NS5 protein - hepa
10	562	18.4	113	2 PCL274	NS5 protein - hepa
11	562	18.4	113	2 PCL275	NS5 protein - hepa
12	560	18.3	113	2 PCL276	NS5 protein - hepa
13	513	16.8	113	2 PCL279	NS5 protein - hepa
14	426	13.9	113	2 PCL282	NS5 protein - hepa
15	426	13.9	113	2 PCL275	polyprotein - hepa
16	425	13.9	113	2 PCL276	polyprotein - hepa
17	424	13.9	113	2 PCL281	NS5 protein - hepa
18	422	13.8	113	2 PCL283	NS5 protein - hepa
19	409	13.4	113	2 PCL280	NS5 protein - hepa
20	408	13.4	113	2 PCL273	polyprotein - hepa
21	406	13.3	113	2 PCL274	polyprotein - hepa
22	402	13.2	78	2 PS0085	hypothetical prote
23	336	11.0	266	2 P00393	genome polyprotein
24	300	9.8	132	2 P00396	genome polyprotein
25	298	9.8	132	2 P00394	genome polyprotein
26	296	9.7	60	2 S44215	genome polyprotein
27	264	8.6	71	2 PCL300	genome polyprotein
28	261	8.5	71	2 PCL302	genome polyprotein
29	260	8.5	71	2 PCL301	genome polyprotein

30	225	7.4	52	2 P00555	nonstructural prot
31	224	7.3	52	2 P00558	nonstructural prot
32	223	7.3	52	2 P00556	nonstructural prot
33	221	7.2	52	2 P00554	nonstructural prot
34	215	7.0	52	2 P00557	nonstructural prot
35	131	4.3	535	2 B49600	probable polymeras
36	128.5	4.2	532	1 RRVQC2	RNA-directed RNA p
37	123.5	4.0	581	2 JQ1879	hypothetical 65.4k
38	106	3.5	317	2 AC3410	peptidylprolyl iso
39	105.5	3.5	356	2 G96806	thauartin-like pro
40	103	3.4	315	2 T16359	hypothetical prote
41	96.5	3.2	546	2 B40407	sterol carrier pro
42	94	3.1	535	2 AE3202	hypothetical prote
43	92.5	3.0	565	2 T47423	hypothetical prote
44	91	3.0	523	2 JC7556	linoleoyl-CoA desa
45	90	2.9	476	2 AE2126	pyruvate kinase [i

ALIGNMENTS

RESULT 1

JQ0879

NS5 protein - hepatitis C virus (strain J4) (fragment)

C:Species: hepatitis C virus

C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004

C:Accession: JQ0879

R:Okamoto, H.

submitted to JIPID, January 1991

A:Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis

A:Reference number: JQ0879

A:Accession: JQ0879

A:Molecule type: genomic RNA

A:Residues: 1-365 <OKA>

A:Cross-references: UNIPROT:Q81717

A:Experimental source: strain J4

C:Superfamily: hepatitis C virus genome polyprotein

Query Match 58.2%; Score 1777; DB 2; Length 365;

Best Local Similarity 96.8%; Pred. No. 7e-129;

Matches 333; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

Qy	231	TVTENDIRVESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVLT	290
Db	1	TVTESDIRVESIYQCCDLAPEARQAIRSLTERLYVGGPLTNSKGQNGCYRRCRASGVLT	60
Qy	291	TSCGNLTTCYLKAAACRAAKLQDCTMLVNGDDLWVICESAGTOEDASLAVFTTEAMTRY	350
Db	61	TSCGNLTTCYLKATAACRAAKLQDCTMLVNGDDLWVICESAGTOEDAAALRVFTTEAMTRY	120
Qy	351	SAPPDPPQPPYDLELITSCSSNVSAHDAGKRVYVLTTRDPTVPLARAANETARHTPN	410
Db	121	SAPPDPPQPPYDLELITSCSSNVSAHDAGKRVYVLTTRDPTVPLARAANETARHTPN	180
Qy	411	SWLGNIIWYAPTLWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIERL	470
Db	181	SWLGNIIWYAPALWARMLTMTHFFSILLAQBLEKALDCQIYGACYSIEPLDLPOIERL	240
Qy	471	HGLSAPLSHSYSPGEINRVASCLKGLVPPPLRVWRHARSVRAKLLSQGGRAAICGKYL	530
Db	241	HGLSAPLSHSYSPGEINRVASCLKGLVPPPLRVWRHARSVRAKLLSQGGRAATCGRYL	300
Qy	531	NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDIYHLSLRARPR	574
Db	301	NWAVRTKLKLTPIPAASRLDLSGMFVAGYSGGDIYHLSLRARPR	344

RESULT 2

JQ0880

NS5 protein - hepatitis C virus (strain J1) (fragment)

C:Species: hepatitis C virus

C:Date: 12-Feb-1993 #sequence_revision 12-Feb-1993 #text_change 09-Jul-2004

C:Accession: JQ0880

R;Okamoto, H.
submitted to JIPID, January 1991
A:Description: The 5'-terminal and 3'-terminal sequences of the genomic RNA of hepatitis
A:Reference number: JQ0879
A:Accession: JQ0880
A:Molecule type: genomic RNA
A:Residues: 1-365 <OKA>
A:Cross-references: UNIPROT:Q81716
A:Experimental source: strain J1
C:Superfamily: hepatitis C virus genome polyprotein

Query Match 54.2%; Score 1655; DB 2; Length 365;
Best Local Similarity 88.7%; Pred. No. 1.7e-119;
Matches 305; Conservative 22; Mismatches 17; Indels 0; Gaps 0;

Qy 231 TVTENDIRVESIYQCCDLAPAPARQAIRSLTERLYVGGPMTNKSGONGYRRCRASGVLT 290
Db 1 TVTSDIRTEBAIYQCCDLDPQARVAIKSLTERLYVGGPLNLSRGNGCYRRCRASGVLT 60
Qy 291 TSCGNTLTCTYLKAAACRAAKLODCTMLVNGDDLVVICESAGTOEDAAASLVFTTEMTRY 350
Db 61 TSCGNTLTCTYIKAAACRAAGLRDCTMLVCGDDLVVICESQGVQEDAAASLVFTTEMTRY 120
Qy 351 SAPGDDPPQPEYDLELITSCSNVSVAHDAGKRVYVLTTRDPTVPLARAAWETARHTPVN 410
Db 121 SAPGDDPPQPEYDLELITSCSNVSVAHDGTGKRVYVLTTRDPTVPLARAAWETARHTPVN 180
Qy 411 SWLGNIIIMYAPTLWARMILMTHFFSILIAOBFKALDCQIYGACYSIEPLDLPQIIRL 470
Db 181 SWLGNIIIMFAPTLWARMILMTHFFSILVLIARDQEQALDCIYGACYSIEPLDLPQIIRL 240
Qy 471 HGLSAFSLHSYSPGEINRVASCIKLGVPPLRVWRHRARSVRAKLLSQGGRAAICGKYL 530
Db 241 HGLSAFSLHSYSPGEINRVAACTKRLGVPPLRVWRHRARSVRALLSRGGRAAICGKYL 300
Qy 531 NWAVRTKLKLTPIPAASRLDLSGWFVAGYSGDDIYHLSRARPR 574
Db 301 NWAVRTKLKLTPIAAGRLDLSGWFAGYSGDDIYHVSVARPR 344

RESULT 3
S60587
non-structural protein NS5 - hepatitis C virus (fragment)
C:Species: hepatitis C virus
C:Date: 19-Mar-1997 #sequence_revision 09-May-1997 #text_change 09-Jul-2004
C:Accession: S60587
R;Xu, L.Z.; Martinot-Peignoux, M.; Marcellin, P.; Benhamou, J.P.; Larzul, D.
J. Hepatol. 20, 598-602, 1994
A:Title: Comparison of the sensitivity of nested PCR in the 5' non-coding and the NS5 re
A:Reference number: S60587; MUID:94351175; PMID:8071535
A:Accession: S60587
A:Status: preliminary; translation not shown
A:Molecule type: genomic RNA
A:Residues: 1-189 <XUL>
A:Cross-references: UNIPROT:Q68959; EMBL:X59934; NID:g556891; PIDN:CAA42557.1; PID:g4388
C:Superfamily: hepatitis C virus genome polyprotein

Query Match 31.1%; Score 951; DB 2; Length 189;
Best Local Similarity 93.7%; Pred. No. 9.4e-66;
Matches 177; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

Qy 153 PEKGGKPARLIVPDILGVRCEKALYDVVSTLPQAVMGSSYGFQYSPKQVFEFLVNTW 212
Db 1 PEKGGKPARLIVPDILGVRCEKALYDVVSTLPQAVMGSSYGFQYSPQQRVFEFLVNAW 60
Qy 213 KAKCKPMGFSDYTRCFDSTVTVENDIRVEESIQCCDLAPAPARQAIRSLTERLYVGGPMTN 272
Db 61 KSKCKPMGFADYTRCFDSTVTVESDIRVEESIQCCDLAPAPARQVIRSLTERLYIGGPLTN 120
Qy 273 SKGQNGYRRCRASGVLTSTCGNTLTCTYLKAAACRAAKLODCTMLVNGDDLVVICESAG 332
Db 121 SKGQNGYRRCRASGVLTSTCGNTLTCTYLKASACRAAKLODCTMLVCGDDLVVICESGG 180

Qy 333 TOEDAASLR 341
Db 181 TOEDAASLR 189

RESULT 4
PS0104
genome polyprotein - hepatitis C virus (isolate pt) (fragments)
N:Contains: NS5 protein; structural protein
C:Species: hepatitis C virus
A:Note: host Pan troglodytes (chimpanzee)
C:Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C:Accession: PS0104
R;Takeuchi, K.; Boonmar, S.; Kubo, Y.; Katayama, T.; Harada, H.; Ohbayashi, A.; Choo, Q.I.
Gene 91, 287-291, 1990
A:Title: Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated i
A:Reference number: PS0102; MUID:91007289; PMID:2170237
A:Accession: PS0104
A:Molecule type: genomic RNA
A:Residues: 1-284 <TAK>
A:Cross-references: UNIPROT:Q81633; GB:D90078; GB:D90079
A:Note: the authors translated the codon TGT for residue 274 as Lys
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: polyprotein
F:1-129/Product: structural protein (fragment) #status predicted <XPR>
F:130-284/Product: NS5 protein (fragment) #status predicted <NS5>

Query Match 25.3%; Score 774; DB 2; Length 284;
Best Local Similarity 88.6%; Pred. No. 6.6e-52;
Matches 140; Conservative 13; Mismatches 5; Indels 0; Gaps 0;

Qy 378 HDASGKRVYVLTTRDPTVPLARAAWETARHTPVNSWLGNIIMYAPTLWARMILMTHFFSIL 437
Db 127 HKFAGKRVYVLTTRDPTVPLARAAWETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVL 186
Qy 438 LAOBFKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSPGEINRVASCLRLKLG 497
Db 187 IARDQEQALDCIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSPGEINRVAACTRLKLG 246
Qy 498 VPPLRVWRHRARSVRAKLLSQGGRAAICGKYLFWAVR 535
Db 247 VPPLRVWRHRARSVRALLSRGGRAAICGKYLFWAVR 284

RESULT 5
PS0102
genome polyprotein - hepatitis C virus (isolate J1) (fragments)
N:Contains: NS5 protein; structural protein
C:Species: hepatitis C virus
A:Note: host Homo sapiens (man)
C:Date: 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change 09-Jul-2004
C:Accession: PS0102
R;Takeuchi, K.; Boonmar, S.; Kubo, Y.; Katayama, T.; Harada, H.; Ohbayashi, A.; Choo, Q.I.
Gene 91, 287-291, 1990
A:Title: Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated i
A:Reference number: PS0102; MUID:91007289; PMID:2170237
A:Contents: J1
A:Accession: PS0102
A:Molecule type: genomic RNA
A:Residues: 1-259 <TAK>
A:Cross-references: UNIPROT:Q81617; GB:D90077; GB:D90080
A:Note: the authors translated the codon TGT for residue 255 as Lys
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: polyprotein
F:1-117/Product: structural protein (fragment) #status predicted <SPR>
F:118-259/Product: NS5 protein (fragment) #status predicted <NS5>

Query Match 24.4%; Score 744; DB 2; Length 259;
Best Local Similarity 99.3%; Pred. No. 1.2e-49;
Matches 141; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 388 LTRDPTVPLARAAWETARHTPVNSWLGNIIMYAPTLWARMILMTHFFSILIAOBFKAL 447

Db 118 LTRDPTVPLARAWEHTARHTPNVSNLGNITMAYPTLHARMILMTHTFFSILLAQEOLEKAL 177
QY 448 DCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEINRVASCLRLKLGVPPLRVWRHR 507
Db 178 DCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEINRVASCLRLKLGVPPLRVWRHR 237
QY 508 ARSVRAKLLSQGGRAAICGKYL 529
Db 238 ARSVRAKLLSQGGRAATCGKYL 259

RESULT 6
S44214
genome polyprotein - hepatitis C virus (fragment)
N:Contains: NS5a protein
C:Species: hepatitis C virus
C>Date: 13-Jan-1995 #sequence_revision 26-Jul-1996 #text_change 09-Jul-2004
C:Accession: S44214
R:Feucht, H.H.
submitted to the EMBL Data Library, April 1994
A:Reference number: S44213
A:Accession: S44214
A:Molecule type: mRNA
A:Residues: 1-135 <F&U>
A:Cross-references: UNIPROT:Q68962; EMBL:X78954; NID:9475176; PIDN:CAA55551.1; PID:G9398
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: polyprotein
F,1-135/Product: NS5a protein #status predicted <MAT>

Query Match 21.8%; Score 667; DB 2; Length 135;
Best Local Similarity 91.9%; Pred. No. 4.1e-44;
Matches 124; Conservative 6; Mismatches 5; Indels 0; Gaps 0;

QY 147 EVFCVQPEKGRKPARLIVFPDLGVRCVKALYDVSTLPOAVNGSSYGFQYSPQQRVE 206
Db 1 EVFCVQPEKGRKPARLIVFPDLGVRCVKALYDVSTLPOAVNGSSYGFQYSPQQRVE 60

QY 207 FLVNTWKAACPMGFSYDTRCFDSTVTENDIRVEESIYQCCDLAPAPARQAIRSLTERLYV 266
Db 61 FLVNAWKSQKPMGFAYTRCFDSTVTESDIRVEESIYQCCDLAPAPARQAIRSLTERLYV 120

QY 267 GGPMTNSKGQNGYR 281
Db 121 GGPLTNSKGQNGYR 135

RESULT 7
D39109
genome polyprotein - hepatitis C virus (fragments)
C:Species: hepatitis C virus
C>Date: 18-Oct-1991 #sequence_revision 18-Oct-1991 #text_change 17-Nov-2000
C:Accession: D39109
R:Han, J.H.; Shyamala, V.; Richman, K.H.; Brauer, M.J.; Irvine, B.; Urdea, M.S.; Tekamp-
Proc. Natl. Acad. Sci. U.S.A. 88, 1711-1715, 1991
A:Title: Characterization of the terminal regions of hepatitis C viral RNA: identifica-
A:Reference number: A39109; MUID:91156678; PMID:1705704
A:Accession: D39109
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-156 <HAN>
A:Cross-references: GB:M58406; GB:M58407
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: polyprotein

Query Match 20.6%; Score 630; DB 2; Length 156;
Best Local Similarity 89.2%; Pred. No. 3.5e-41;
Matches 116; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

QY 445 KALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEINRVASCLRLKLGVPPLRVW 504
Db 6 KALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHSYSGEINRVASCLRLKLGVPPLRVW 65

QY 505 RHRARSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIPAASRLDLSGWFVAGSGDI 564

Db 66 RHRARSVRARLLARGGRAAICGKYLFWNAVRTKLTPTIPAAGOLDLSGWFAGYSGDI 125
QY 565 YHLSRARPR 574
Db 126 YHSVSHARPR 135

RESULT 8
PC1278
NS5 protein - hepatitis C virus (strain KI-4) (fragment)
C:Species: hepatitis C virus
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: PC1278
R:Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A:Title: There are two major types of hepatitis C virus in Japan.
A:Reference number: PC1274; MUID:90358793; PMID:2117923
A:Accession: PC1278
A:Molecule type: mRNA
A:Residues: 1-113 <ENO>
A:Cross-references: UNIPROT:Q01187; GB:D10645; GB:D90554; NID:9221668; PIDN:BA001492.1; I
C:Genetics:
A:Gene: NS5
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: capsid protein

Query Match 18.6%; Score 569; DB 2; Length 113;
Best Local Similarity 95.6%; Pred. No. 1.1e-36;
Matches 108; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 230 STVTENDIRVEESIYQCCDLAPAPARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVL 289
Db 1 STVTENDIRVEESIYQCCDLAPAPARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVL 60

QY 290 TTSCGNTLTCTYKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 342
Db 61 TTSCGNTLTCTYKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 113

RESULT 9
PC1277
NS5 protein - hepatitis C virus (strain KI-3) (fragment)
C:Species: hepatitis C virus
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C:Accession: PC1277
R:Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A:Title: There are two major types of hepatitis C virus in Japan.
A:Reference number: PC1274; MUID:90358793; PMID:2117923
A:Accession: PC1277
A:Molecule type: mRNA
A:Residues: 1-113 <ENO>
A:Cross-references: UNIPROT:Q070640; GB:D10644; GB:D90553; NID:9221666; PIDN:BA001491.1; I
C:Genetics:
A:Gene: NS5
C:Superfamily: hepatitis C virus genome polyprotein
C:Keywords: capsid protein

Query Match 18.4%; Score 563; DB 2; Length 113;
Best Local Similarity 94.7%; Pred. No. 3.2e-36;
Matches 107; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 230 STVTENDIRVEESIYQCCDLAPAPARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVL 289
Db 1 STVTENDIRVEESIYQCCDLAPAPARQAIRSLTERLYVGGPMTNSKGQNGYRRCRASGVL 60

QY 290 TTSCGNTLTCTYKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 342
Db 61 TTSCGNTLTCTYKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 113

RESULT 10

PC1274
NS5 protein - hepatitis C virus (strain KI) (fragment)
C/Species: hepatitis C virus
C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C/Accession: PC1274
R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A;Title: There are two major types of hepatitis C virus in Japan.
A;Reference number: PC1274; MUID:90358793; PMID:2117923
A;Accession: PC1274
A;Molecule type: mRNA
A;Residues: 1-113 <ENO>
A;Cross-references: UNIPROT:Q01192; GB:D10641; GB:D90550; NID:g221658; PIDN:BAA01488.1;
C;Genetics:
A;Gene: NS5
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: capsid protein

Query Match 18.4%; Score 562; DB 2; Length 113;
Best Local Similarity 95.6%; Pred. No. 3.8e-36;
Matches 108; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVLVICSAGTQEDAASLRV 342
Db 61 TTSCGNTLTCYLKATAACRAAKLQDCTMLVCGDDLVLVICSAGTQEDAASLRV 113

RESULT 11
PC1275
NS5 protein - hepatitis C virus (strain KI-1) (fragment)
C/Species: hepatitis C virus
C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C/Accession: PC1275
R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A;Title: There are two major types of hepatitis C virus in Japan.
A;Reference number: PC1274; MUID:90358793; PMID:2117923
A;Accession: PC1275
A;Molecule type: mRNA
A;Residues: 1-113 <ENO>
A;Cross-references: UNIPROT:Q01184; GB:D10642; GB:D90551; NID:g221662; PIDN:BAA01489.1;
C;Genetics:
A;Gene: NS5
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: capsid protein

Query Match 18.4%; Score 562; DB 2; Length 113;
Best Local Similarity 94.7%; Pred. No. 3.8e-36;
Matches 107; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVLVICSAGTQEDAASLRV 342
Db 61 TTSCGNTLTCYLKASACRAAKLQDCTMLVCGDDLVLVICSAGTQEDAANLRV 113

RESULT 12
PC1276
NS5 protein - hepatitis C virus (strain KI-2) (fragment)
C/Species: hepatitis C virus
C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C/Accession: PC1276
R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A;Title: There are two major types of hepatitis C virus in Japan.
A;Reference number: PC1274; MUID:90358793; PMID:2117923

A;Accession: PC1276
A;Molecule type: mRNA
A;Residues: 1-113 <ENO>
A;Cross-references: UNIPROT:Q01185; GB:D10643; GB:D90552; NID:g221664; PIDN:BAA01490.1; I
C;Genetics:
A;Gene: NS5
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: capsid protein

Query Match 18.3%; Score 560; DB 2; Length 113;
Best Local Similarity 93.8%; Pred. No. 5.4e-36;
Matches 106; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTESDIRVEESIQCCDLAPEARQIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVLVICSAGTQEDAASLRV 342
Db 61 TTSCGNTLTCYLKASACRAAKLQDCTMLVCGDDLVLVICSAGTQEDAASLRV 113

RESULT 13
PC1279
NS5 protein - hepatitis C virus (strain PT-1) (fragment)
C/Species: hepatitis C virus
C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C/Accession: PC1279
R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A;Title: There are two major types of hepatitis C virus in Japan.
A;Reference number: PC1274; MUID:90358793; PMID:2117923
A;Accession: PC1279
A;Molecule type: mRNA
A;Residues: 1-113 <ENO>
A;Cross-references: UNIPROT:Q01193; GB:D10646; GB:D90555; NID:g221670; PIDN:BAA01493.1; I
C;Genetics:
A;Gene: NS5
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: capsid protein

Query Match 16.8%; Score 513; DB 2; Length 113;
Best Local Similarity 85.7%; Pred. No. 2.2e-32;
Matches 96; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPEARQAIRSLTERLYYGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTESDIRTEAIIYQCCDLDPQARVAIKSLTERLYYGGPLTNSRGNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLVLVICSAGTQEDAASLR 341
Db 61 TTSCGNTLTCYIKARAAACRAAGLRDCTMLVCGDDLVLVICSAGVQEDAASLR 112

RESULT 14
PC1282
NS5 protein - hepatitis C virus (strain K2b) (fragment)
C/Species: hepatitis C virus
C/Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 09-Jul-2004
C/Accession: PC1282
R;Enomoto, N.; Tanaka, A.; Nakao, T.; Date, T.
Biochem. Biophys. Res. Commun. 170, 1021-1025, 1990
A;Title: There are two major types of hepatitis C virus in Japan.
A;Reference number: PC1274; MUID:90358793; PMID:2117923
A;Accession: PC1282
A;Molecule type: mRNA
A;Residues: 1-113 <ENO>
A;Cross-references: UNIPROT:Q01189; GB:D10649; GB:D90558; NID:g221676; PIDN:BAA01496.1; I
C;Genetics:
A;Gene: NS5
C;Superfamily: hepatitis C virus genome polyprotein
C;Keywords: capsid protein

Search completed: September 22, 2005, 14:54:47
Job time : 44 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:47:32 ; Search time 175 Seconds
(without alignments)
1697.177 Million cell updates/sec

Title: US-10-712-479-4
Perfect score: 3055
Sequence: 1 MASMSYWTGALITPCAA.....GGDIYHSLSRPRHHHH 580

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1438883

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt_03.*

1: uniprot_sprot.*

2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2873	94.0	571	2 Q6B4Q1	Q6B4q1 hepatitis c
2	2870	93.9	571	2 Q66NA8	Q66na8 hepatitis c
3	2857	93.5	571	2 Q66N95	Q66n95 hepatitis c
4	2857	93.5	571	2 Q66NA6	Q66na6 hepatitis c
5	2856	93.5	571	2 Q66N84	Q66n84 hepatitis c
6	2853	93.4	571	2 Q6B4Q2	Q6B4q2 hepatitis c
7	2851	93.3	571	2 Q66N79	Q66n79 hepatitis c
8	2846	93.2	571	2 Q66N83	Q66n83 hepatitis c
9	2839	92.9	571	2 Q66NA2	Q66na2 hepatitis c
10	2837	92.9	571	2 Q66N78	Q66n78 hepatitis c
11	2837	92.9	571	2 Q66NA0	Q66na0 hepatitis c
12	2836	92.8	571	2 Q66N74	Q66n74 hepatitis c
13	2820	92.3	571	2 Q66N89	Q66n89 hepatitis c
14	2803	91.8	571	2 Q66NB0	Q66nb0 hepatitis c
15	2679	87.7	571	2 Q66N7	Q66na7 hepatitis c
16	2673	87.5	571	2 Q66N75	Q66n75 hepatitis c
17	2673	87.5	571	2 Q66N5	Q66na5 hepatitis c
18	2672	87.5	571	2 Q66N86	Q66n86 hepatitis c
19	2672	87.5	571	2 Q66N93	Q66n93 hepatitis c
20	2672	87.5	571	2 Q66NA4	Q66na4 hepatitis c
21	2671	87.4	571	2 Q66N99	Q66n99 hepatitis c
22	2669	87.4	571	2 Q66N91	Q66n91 hepatitis c
23	2668	87.3	571	2 Q66N93	Q66nb3 hepatitis c
24	2665	87.2	571	2 Q66N94	Q66n94 hepatitis c
25	2664	87.2	571	2 Q66N98	Q66n98 hepatitis c
26	2663	87.2	571	2 Q66N83	Q66na3 hepatitis c
27	2661	87.1	571	2 Q66N82	Q66n82 hepatitis c
28	2661	87.1	571	2 Q66NA1	Q66na1 hepatitis c
29	2661	87.1	571	2 Q66N95	Q66nb5 hepatitis c
30	2660	87.1	571	2 Q66N85	Q66n85 hepatitis c
31	2660	87.1	571	2 Q66N90	Q66n90 hepatitis c

32	2660	87.1	571	2 Q66N96	Q66n96 hepatitis c
33	2660	87.1	571	2 Q66NA9	Q66na9 hepatitis c
34	2659	87.0	571	2 Q66N81	Q66n81 hepatitis c
35	2658	87.0	571	2 Q66N80	Q66n80 hepatitis c
36	2657	87.0	571	2 Q66N82	Q66nb2 hepatitis c
37	2656	86.9	571	2 Q66N88	Q66n88 hepatitis c
38	2655	86.9	571	2 Q66N76	Q66n76 hepatitis c
39	2655	86.9	571	2 Q66N87	Q66n87 hepatitis c
40	2650	86.7	571	2 Q66N77	Q66n77 hepatitis c
41	2646	86.6	571	2 Q66N73	Q66n73 hepatitis c
42	2646	86.6	571	2 Q66N92	Q66n92 hepatitis c
43	2644	86.5	571	2 Q66NB1	Q66nb1 hepatitis c
44	2644	86.5	571	2 Q66NB4	Q66nb4 hepatitis c
45	2636	86.3	571	2 Q66N97	Q66n97 hepatitis c

ALIGNMENTS

RESULT 1
Q6B4Q1 PRELIMINARY; PRT; 571 AA.
AC Q6B4Q1;
DT 25-OCT-2004 (Tremblrel. 28, Created)
DT 25-OCT-2004 (Tremblrel. 28, Last sequence update)
DT 25-OCT-2004 (Tremblrel. 28, Last annotation update)
DE NS5b (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682462; AAT84167.1; -;
DR GO: GO:0005524; F:ATP binding; IEA.
DR GO: GO:0003723; F:RNA binding; IEA.
DR GO: GO:0003688; F:RNA-directed RNA polymerase activity; IEA.
DR GO: GO:0006350; P:transcription; IEA.
DR GO: GO:0019079; P:viral genome replication; IEA.
DR InterPro: IPR002166; HCV_RDRP.
DR InterPro: IPR007095; RNA_pol_DS_PS.
DR InterPro: IPR007094; RNA_pol_PSVir.
DR Pfam: PF00998; Viral_RDRP; 1.
FT NON TER 1
FT NON TER 571
SQ SEQUENCE 571 AA; 63223 MW; 975788F1925D0DBC CRC64;

Query Match 94.0%; Score 2873; DB 2; Length 571;
Best Local Similarity 95.8%; Pred. No. 6.9e-218;
Matches 543; Conservative 13; Mismatches 11; Indels 0; Gaps 0;

Qy	5	SMSYWTGALITPCAAEESKLPI	NALSRLHNLVYVSTSRASLR	OKKVTDFRLOVL	64
Db	5	SMSYWTGALITPCAAEESKLPI	NALSRLHNLVYVSTSRASLR	OKKVTDFRLOVL	64
Qy	65	DDHYRDVLKEMKAKASTVKA	LLSVEEACKLTPHSAKSKFGY	CAKDVRSLSRAVNHIR	124
Db	65	DDHYRDVLKEMKAKASTVKA	LLSVEEACKLTPHSAKSKFGY	CAKDVRSLSRAVNHIR	124
Qy	125	SVNKKLLLEDDTPTQTTIM	AKNEVFCVQPEKGGKRP	ARLIVFPDLGVRCVKMAL	YDVVS 184
Db	125	SVNKKLLLEDDTPTQTTIM	AKNEVFCVQPEKGGKRP	ARLIVFPDLGVRCVKMAL	YDVVS 184
Qy	185	TLPOAVNGSSYGFQYSPQR	VEFLVNTWKAKKCPMGFSY	TRCFDSTVTENDIRVEESI	Y 244
Db	185	TLPOAVNGSSYGFQYSPQR	VEFLVNTWKAKKCPMGFSY	TRCFDSTVTENDIRVEESI	Y 244
Qy	245	QCCLDAPEARQAIRSLTER	LYVGGPMTNSKQNCGYRRC	ASGVLTTTSCGNLTLCY	LKAA 304

```
Db 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRRCRASGVLTTCGNTLTCTYLKAT 304
Qy 305 AACRAAKLQDCMTLVNGDDLVVICESAGTQDEASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 305 AACRAAKLQDCMTLVNGDDLVVICESAGTQDEASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Qy 425 ARMLTMTFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 425 ARMLTMTFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGAACICGKYLFWNAVTKLKLTPIP 544
Db 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGAACICGKYLFWNAVTKLKLTPIP 544
Qy 545 AASRLDLGWFVAGYSGGDIYHLSRA 571
Db 545 AASRLDLGWFVAGYSGGDIYHLSRA 571
```

RESULT 2

```
Q66NA8 PRELIMINARY; PRT; 571 AA.
AC Q66NA8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polyprotein (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682754; AAU08311.1; -
DR InterPro: IPR002166; HCV_RdRP.
DR InterPro: IPR007095; RNA_pol_DS_PS.
DR InterPro: IPR007094; RNA_pol_PSVir.
DR Pfam: PF00998; Viral_RdRP; 1.
KW Polyprotein.
FT NON_TER 1 1
FT NON_TER 571 571
SQ SEQUENCE 571 AA; 63201 MW; 5590C9F59B69B2A0 CRC64;
```

Query Match 93.9%; Score 2870; DB 2; Length 571;
Best Local Similarity 95.8%; Pred. No. 1.2e-217;
Matches 543; Conservative 14; Mismatches 10; Indels 0; Gaps 0;

```
Qy 5 SMSYTWTCALITPCAABESKLPINALNSLLRHNLVYTTSSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWTCALITPCAABETKLPINALNSLLRHNLVYTTSSASLRQKKVTFDRLOVL 64
Qy 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR 124
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAICKPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAICKPMGFSYDTRCFDSTVTENDIRVESIY 244
```

```
Qy 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRRCRASGVLTTCGNTLTCTYLKAA 304
Db 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKQNGYRRCRASGVLTTCGNTLTCTYLKAT 304
Qy 305 AACRAAKLQDCMTLVNGDDLVVICESAGTQDEASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 305 AACRAAKLQDCMTLVNGDDLVVICESAGTQDEASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Qy 425 ARMLTMTFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 425 ARMLTMTFFSILLAQEQLEKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGAACICGKYLFWNAVTKLKLTPIP 544
Db 485 EINRVASCLRLKGLVPPPLRVWRHARSVRAKLLSQGGAACICGKYLFWNAVTKLKLTPIP 544
Qy 545 AASRLDLGWFVAGYSGGDIYHLSRA 571
Db 545 AASRLDLGWFVAGYSGGDIYHLSRA 571
```

RESULT 3

```
Q66N95 PRELIMINARY; PRT; 571 AA.
AC Q66N95;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polyprotein (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682754; AAU08324.1; -
DR InterPro: IPR002166; HCV_RdRP.
DR InterPro: IPR007095; RNA_pol_DS_PS.
DR InterPro: IPR007094; RNA_pol_PSVir.
DR Pfam: PF00998; Viral_RdRP; 1.
KW Polyprotein.
FT NON_TER 1 1
FT NON_TER 571 571
SQ SEQUENCE 571 AA; 63249 MW; F76482BE94526FDA CRC64;
```

Query Match 93.5%; Score 2857; DB 2; Length 571;
Best Local Similarity 94.9%; Pred. No. 1.3e-216;
Matches 536; Conservative 17; Mismatches 12; Indels 0; Gaps 0;

```
Qy 5 SMSYTWTCALITPCAABESKLPINALNSLLRHNLVYTTSSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWTCALITPCAABESKLPINALNSLLRHNLVYTTSSASLRQKKVTFDRLOVL 64
Qy 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYCAKDVRSLSRAVNHIR 124
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAICKPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 185 TLPOAVMGSSYGFQYSPQKRVFELVNTWKAICKPMGFSYDTRCFDSTVTENDIRVESIY 244
```



```

Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTCTYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTCTYLKAA 304
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYSPAPGPPQPEYDL 364
Db 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYSPAPGPPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW 424
Db 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW 424
Qy 425 ARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 425 ARMVLTTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGVPPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
Db 485 EINRVASCLRLKGVPPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
Qy 545 AASRLDLSGWFVAGYSGGDIYHSLSRA 571
Db 545 AASRLDLSGWFVAGYSGGDIYHSLSRA 571

```

RESULT 4

```

ID Q66NA6 PRELIMINARY; PRT; 571 AA.
AC Q66NA6;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polyprotein (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682756; AAU08313.1; -
DR InterPro; IPR002166; HCV_RDRP.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RDRP; 1.
KW Polyprotein.
FT NON TER 1 1
FT NON TER 571 571
SQ SEQUENCE 571 AA; 63183 MW; 445C9E3B09394146 CRC64;

```

```

Query Match 93.5%; Score 2857; DB 2; Length 571;
Best Local Similarity 95.2%; Pred. No. 1.3e-216;
Matches 540; Conservative 15; Mismatches 12; Indels 0; Gaps 0;

```

```

Qy 5 SMSYTWGALITPCAABESKLPINALSNLRLHNHLYVSTTSRSASLRQKKVTFDLQVL 64
Db 5 SMSYTWGALITPCAABESKLPINALSNLRLHNHLYVSTTSRSASLRQKKVTFDLQVL 64
Qy 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDFRCFDSTVTENDIRVEESIY 244

```

```

Db 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDFRCFDSTVTENDIRVEESIY 244
Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTCTYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNCYRRCRASGVLTTCGNTLTCTYLKAA 304
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYSPAPGPPQPEYDL 364
Db 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRVFTAMTRYSPAPGPPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW 424
Db 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIMYAPTLW 424
Qy 425 ARMILMTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 425 ARMVLTTHFFSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGVPPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
Db 485 EINRVASCLRLKGVPPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIP 544
Qy 545 AASRLDLSGWFVAGYSGGDIYHSLSRA 571
Db 545 AASRLDLSGWFVAGYSGGDIYHSLSRA 571

```

RESULT 5

```

ID Q66N84 PRELIMINARY; PRT; 571 AA.
AC Q66N84;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polyprotein (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682779; AAU08335.1; -
DR InterPro; IPR002166; HCV_RDRP.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RDRP; 1.
KW Polyprotein.
FT NON TER 1 1
FT NON TER 571 571
SQ SEQUENCE 571 AA; 63393 MW; CD0FE085358BEE67 CRC64;

```

```

Query Match 93.5%; Score 2856; DB 2; Length 571;
Best Local Similarity 95.1%; Pred. No. 1.5e-216;
Matches 539; Conservative 17; Mismatches 11; Indels 0; Gaps 0;

```

```

Qy 5 SMSYTWGALITPCAABESKLPINALSNLRLHNHLYVSTTSRSASLRQKKVTFDLQVL 64
Db 5 SMSYTWGALITPCAABESKLPINALSNLRLHNHLYVSTTSRSASLRQKKVTFDLQVL 64
Qy 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSSRAVNHIR 124
Qy 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTDTPITQTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWKAKCPMGFSYDFRCFDSTVTENDIRVEESIY 244

```

Db 185 TLPOAVMGSSYGFQYSPQQRVEFLVNAWKKCPMGFPAYDTRCFDSTVTESDIRVESIY 244
Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAT 304
Qy 305 AACRAAKLODCTMLVNGDDLVVICESAGTQDAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Db 305 AACRAAKLODCTMLVNGDDLVVICESAGTQDAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Qy 365 ELITSCSNVSAHDASGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Db 365 ELITSCSNVSAHDATGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Qy 425 ARMILMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIIRLHGLSFAFSLHSYSPG 484
Db 425 ARMILMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIIRLHGLSFAFSLHSYSPG 484
Qy 485 EINRVASCLRLKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 544
Db 485 EINRVASCLRLKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 544
Qy 545 AASRLDLSGMFVAGYSGGDIYHLSLSRA 571
Db 545 AASRLDLSGMFVAGYSGGDIYHLSLSRA 571

RESULT 6

Q6B4Q2 ID Q6B4Q2 PRELIMINARY; PRT; 571 AA.
AC Q6B4Q2
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE NS5b (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects."
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY682461; AAT94166.1; -
DR GO; GO:0005524; P:ATP binding; IEA.
DR GO; GO:0003723; P:RNA binding; IEA.
DR GO; GO:0003968; P:RNA-directed RNA polymerase activity; IEA.
DR GO; GO:0006350; P:transcription; IEA.
DR GO; GO:0019079; P:Viral genome replication; IEA.
DR InterPro; IPR002166; HCV RdRP.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RdRP; 1.
FT NON TER 1
FT NON TER 571
SQ SEQUENCE 571 AA; 63123 MW; 931743E7C7819F36 CRC64;

Query Match 93.4%; Score 2853; DB 2; Length 571;
Best Local Similarity 95.2%; Pred. No. 2.6e-216;
Matches 540; Conservative 15; Mismatches 12; Indels 0; Gaps 0;

Qy 5 SMSYTWITGALITPCAAEESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWITGALITPCAAEESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Qy 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAQVRSLSRAVNHIR 124

Qy 125 SVMKDLLEDTDTRITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVMKDLLEDTATPIDDTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPQQRVEFLVNAWKKCPMGFPAYDTRCFDSTVTESDIRVESIY 244
Db 185 TLPOAVMGSSYGFQYSPQQRVEFLVNAWKKCPMGFPAYDTRCFDSTVTESDIRVESIY 244
Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCGNTLTCYLKAS 304
Qy 305 AACRAAKLODCTMLVNGDDLVVICESAGTQDAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Db 305 AACRAAKLODCTMLVNGDDLVVICESAGTQDAASLRVFTAMTRYSAAPPDPPQPEYDL 364
Qy 365 ELITSCSNVSAHDASGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Db 365 ELITSCSNVSAHDATGKRVYILTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
Qy 425 ARMILMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIIRLHGLSFAFSLHSYSPG 484
Db 425 ARMILMTHFFSILLAQEOLEKALDCQIYGACYSIEPLDLPQIIIRLHGLSFAFSLHSYSPG 484
Qy 485 EINRVASCLRLKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 544
Db 485 EINRVASCLRLKLGVPPLRVWHRARSVRAKLLSOGGAAICGKYLFWNAVTKLTPIP 544
Qy 545 AASRLDLSGMFVAGYSGGDIYHLSLSRA 571
Db 545 AASRLDLSGMFVAGYSGGDIYHLSLSRA 571

RESULT 7

Q66N79 ID Q66N79 PRELIMINARY; PRT; 571 AA.
AC Q66N79
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Polyprotein (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects."
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY682784; AAU08340.1; -
DR InterPro; IPR002166; HCV RdRP.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RdRP; 1.
FT NON TER 1
FT NON TER 571
SQ SEQUENCE 571 AA; 63317 MW; 4BC8AC1E98153857 CRC64;

Query Match 93.3%; Score 2851; DB 2; Length 571;
Best Local Similarity 95.2%; Pred. No. 3.7e-216;
Matches 540; Conservative 13; Mismatches 14; Indels 0; Gaps 0;

Qy 5 SMSYTWITGALITPCAAEESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWITGALITPCAAEESKLPINALSNLSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Qy 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 65 DDHYRDVLKEMKAKASTVAKLLSVEEACKLTTPPHSAKSKFGYGAQVRSLSRAVNHIR 124

QY 125 SVWKOLLEDTTPITTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
 DB 125 SVWKOLLEDTTPITTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
 QY 185 TLPOAVMGSSYGFQSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 DB 185 TLPOAVMGSSYGFQSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 QY 245 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 304
 DB 245 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAT 304
 QY 305 AACRAAKLQDCTMLVNGDDLVIICISAGTQEDAAASLRVFTTEAMTRYSPAPPDPPPEYDL 364
 DB 305 AACRAAKLQDCTMLVNGDDLVIICISAGTQEDAAASLRVFTTEAMTRYSPAPPDPPPEYDL 364
 QY 365 ELITSCSNVSAVHADSGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 DB 365 ELITSCSNVSAVHADSGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 QY 425 ARMILMTHFFSILLAOEALDQCIYGCYSIEPLDLPOLIERLHGLSFAFSLHSYSPG 484
 DB 425 ARMILMTHFFSILLAOEALDQCIYGCYSIEPLDLPOLIERLHGLSFAFSLHSYSPG 484
 QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
 DB 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAATCGKYLFWNAVRTKLTPIIP 544
 QY 545 AASRLDLSGWFVAGYSGGDIYHLSRA 571
 DB 545 DASRLDLSGWFVAGYSGGHIYHVSVA 571

RESULT 8

Q66N83 ID Q66N83 PRELIMINARY; PRT; 571 AA.
 AC Q66N83; DT 25-OCT-2004 (TReMBLrel. 28, Created)
 DT 25-OCT-2004 (TReMBLrel. 28, Last sequence update)
 DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)
 DE Polyprotein (Fragment).
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
 OC Hepacivirus.
 OC NCBI_TaxID=11103;
 EN [1]
 RP SEQUENCE FROM N.A.
 RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
 RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
 RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
 RT HCV/HIV Coinfected Subjects."
 RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY682780; AAU08336.1; -;
 DR InterPro; IPR002166; HCV RdRP.
 DR InterPro; IPR007095; RNA pol DS PS.
 DR InterPro; IPR007094; RNA pol_PSVir.
 DR Pfam; PF00998; Viral_RDRP; 1.
 KW Polyprotein.
 FT NON TER 1 571
 FT NON TER 571 571
 SQ SEQUENCE 571 AA; 63177 MW; 8649F9B5ED28DEED CRC64;

Query Match 93.2%; Score 2846; DB 2; Length 571;
 Best Local Similarity 94.9%; Pred. No. 9.3e-216;
 Matches 538; Conservative 17; Mismatches 12; Indels 0; Gaps 0;
 QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTFRDLQVL 64
 DB 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTFRDLQVL 64
 QY 65 DDHYRDVLKEMKAKASTVKAALLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVNHIR 124

DB 65 DDHYRDVLKEMKAKASTVKAALLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVNHIR 124
 QY 125 SVWKOLLEDTTPITTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
 DB 125 SVWKOLLEDTTPITTTIMAKNEVFCVQPEKGRKPARLIVFPDGLGVRVCEKALYDVVS 184
 QY 185 TLPOAVMGSSYGFQSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 DB 185 TLPOAVMGSSYGFQSPQORVEFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
 QY 245 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAA 304
 DB 245 OCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCLYKAT 304
 QY 305 AACRAAKLQDCTMLVNGDDLVIICISAGTQEDAAASLRVFTTEAMTRYSPAPPDPPPEYDL 364
 DB 305 AACRAAKLQDCTMLVNGDDLVIICISAGTQEDAAASLRVFTTEAMTRYSPAPPDPPPEYDL 364
 QY 365 ELITSCSNVSAVHADSGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 DB 365 ELITSCSNVSAVHADSGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMVAPTLW 424
 QY 425 ARMILMTHFFSILLAOEALDQCIYGCYSIEPLDLPOLIERLHGLSFAFSLHSYSPG 484
 DB 425 ARMILMTHFFSILLAOEALDQCIYGCYSIEPLDLPOLIERLHGLSFAFSLHSYSPG 484
 QY 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAAICGKYLFWNAVRTKLTPIIP 544
 DB 485 EINRVASCLRLKGLVPPPLRVWRHRSVRKALLSQGGRAATCGKYLFWNAVRTKLTPIIP 544
 QY 545 AASRLDLSGWFVAGYSGGDIYHLSRA 571
 DB 545 AASRLDLSGWFVAGYSGGDIYHSGSHA 571

RESULT 9

Q66N83 ID Q66N83 PRELIMINARY; PRT; 571 AA.
 AC Q66N83; DT 25-OCT-2004 (TReMBLrel. 28, Created)
 DT 25-OCT-2004 (TReMBLrel. 28, Last sequence update)
 DT 25-OCT-2004 (TReMBLrel. 28, Last annotation update)
 DE Polyprotein (Fragment).
 OS Hepatitis C virus.
 OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
 OC Hepacivirus.
 OC NCBI_TaxID=11103;
 EN [1]
 RP SEQUENCE FROM N.A.
 RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
 RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
 RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
 RT HCV/HIV Coinfected Subjects."
 RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AY682760; AAU08317.1; -;
 DR InterPro; IPR002166; HCV RdRP.
 DR InterPro; IPR007095; RNA pol DS PS.
 DR InterPro; IPR007094; RNA pol_PSVir.
 DR Pfam; PF00998; Viral_RDRP; 1.
 KW Polyprotein.
 FT NON TER 1 571
 FT NON TER 571 571
 SQ SEQUENCE 571 AA; 63227 MW; F54BDE550ACDEEBC CRC64;

Query Match 92.9%; Score 2839; DB 2; Length 571;
 Best Local Similarity 94.5%; Pred. No. 3.3e-215;
 Matches 536; Conservative 19; Mismatches 12; Indels 0; Gaps 0;
 QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTFRDLQVL 64
 DB 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKVTFRDLQVL 64
 QY 65 DDHYRDVLKEMKAKASTVKAALLSVEEACKLTPPHSAKSKFGYGAOVRSLSRAVNHIR 124

```
Db 65 DDHYRDVLEKEIKAKASTVKAKLLSVEACKLTPPHSARSKFGYGAQVRSLSRAVNHIR 124
Qy 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLILFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPQGRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 185 TLPOAVMGSSYGFQYSPQGRVEFLVNAWKSKNPMGFSYDTRCFDSTVTENDIRVESIY 244
Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCSCGNTLTCYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCSCGNTLTCYLKAS 304
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAGDPDPQPEYDL 364
Db 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAGDPDPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Qy 425 ARMLTMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Db 425 ARMLTMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGLVPPPLVRWHRARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPIIP 544
Db 485 EINRVASCLRLKGLVPPPLVRWHRARNVRAKLLSOGGAAATCGKYLFWNAVRTKLTPIIP 544
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSRA 571
Db 545 AASQLDLSGWFVAGYSGGDIYHVSVA 571
```

RESULT 10

```
Q66N78 ID Q66N78 PRELIMINARY; PRT; 571 AA.
AC Q66N78;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polypeptide (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682785; AAU08341.1;
DR InterPro: IPR002166; HCV_RdRP.
DR InterPro: IPR007095; RNA_pol_DS_PS.
DR InterPro: IPR007094; RNA_pol_PSVir.
DR Pfam: PF00998; Viral_RdRP; 1.
KW Polyprotein.
FT NON_TER 1 571
FT NON_TER 571 571
SQ SEQUENCE 571 AA; 63360 MW; 4521656175D8334A CRC64;
```

```
Query Match 92.9%; Score 2837; DB 2; Length 571;
Best Local Similarity 94.7%; Pred. No. 4.8e-215;
Matches 537; Conservative 17; Mismatches 13; Indels 0; Gaps 0;
Qy 5 SMSYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
```

```
Qy 65 DDHYRDVLEKEMKAKASTVKAKLLSVEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
Db 65 DDHYRDVLEKEMKAKASTVKAKLLSVEACKLTPPHSARSKFGYGAQVRSLSRAVNHIR 124
Qy 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Db 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
Qy 185 TLPOAVMGSSYGFQYSPQGRVEFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 185 TLPOAVMGSSYGFQYSPQGRVEFLVNAWKSKNPMGFSYDTRCFDSTVTENDIRVESIY 244
Qy 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCSCGNTLTCYLKAA 304
Db 245 QCCDLAPARQAIRSLTERLYVGGPMTNSKQNGCYRRCRASGVLTTCSCGNTLTCYLKAS 304
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAGDPDPQPEYDL 364
Db 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAGDPDPQPEYDL 364
Qy 365 ELITSCSSNVSAHDASGRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 365 ELITSCSSNVSAHDATGKRVYVLTTRDPTVPLARAAMETARHTPVNSWLGNIIMYAPTLW 424
Qy 425 ARMLTMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Db 425 ARMLTMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPOIIRLHGLSAFSLHSYSPG 484
Qy 485 EINRVASCLRLKGLVPPPLVRWHRARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPIIP 544
Db 485 EINRVASCLRLKGLVPPPLVRWHRARSVRAKLLSOGGAAATCGKYLFWNAVRTKLTPIIP 544
Qy 545 AASRLDLSGWFVAGYSGGDIYHLSRA 571
Db 545 AASQLDLSGWFVAGYSGRHHYHVSVA 571
```

RESULT 11

```
Q66N80 ID Q66N80 PRELIMINARY; PRT; 571 AA.
AC Q66N80;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Polypeptide (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682782; AAU08319.1;
DR InterPro: IPR002166; HCV_RdRP.
DR InterPro: IPR007095; RNA_pol_DS_PS.
DR InterPro: IPR007094; RNA_pol_PSVir.
DR Pfam: PF00998; Viral_RdRP; 1.
KW Polyprotein.
FT NON_TER 1 571
FT NON_TER 571 571
SQ SEQUENCE 571 AA; 63254 MW; 475D83341A64631B CRC64;
```

```
Query Match 92.9%; Score 2837; DB 2; Length 571;
Best Local Similarity 94.5%; Pred. No. 4.8e-215;
Matches 536; Conservative 18; Mismatches 13; Indels 0; Gaps 0;
Qy 5 SMSYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 5 SMSYTWGALITPCAABESKLPINALNSLRHNLVYSTTSRSASLRQKKVTFDRLOVL 64
```

Qy	65	DDHYRDLVKEMKAKASTVWAKLLSVEEBA CKLTPPHSAKSKEGYGAKOVRSLSRAVNHR	124
Dd	65	DKHYQDVLKEMKAKASTVWAKLLSVEEA CKLTPPHSARSKEGYGAKOVRLNLSKRAVRHN	124
Qy	125	SVWKDILLEDTPITOTTIMAXNEVFVCUPEKGGRKPARIIVFPDLGVRCCKMAYLDVVVS	184
Dd	125	SVWKDILLEDNETPDTTIMAXNEVFVCUPEKGGRKPARIIVFPDLGVRCCKMAYLDVVVS	184
Qy	185	TLPQAVNGSSYGFQYSPQRQFVFLVNTWKAKCPCMGFSYTRCFDSTVTENDIRVEESIY	244
Dd	185	TLPQAVNGSSYGFQYSPGORVEFLVNAWKSRNPMGFAYDRCFDSTVTENDIRVEESIY	244
Qy	245	OCCDLAPEARQAIFSLTERLVVGGPMTNSKGCNGYRCRASGLVTTSCGNLTLCYLKAA	304
Dd	245	OCCDLAPEARQAIKSLTERLYIGPLTNSKGCNGYRCRASGLVTTSCGNLTLCYLKAS	304
Qy	305	AACRAAKLQDCTMLVNGDDLVIICESAGTQBDAAASLRVFTBAMTRYSA PGPDPPOPEYDL	364
Dd	305	AACRAAKLQDCTMLVCGDDLVIICESAGTQEDAASLRVFTBAMTRYSA PGPDPPOPEYDL	364
Qy	365	ELITS CSSNVSAVDASGRVYYLTRDPTVPLARAAMETARHTP VNSWIGNIIMVAPTLW	424
Dd	365	ELITS CSSNVSAVDATGKRYYLTRDPTTPLARAAMETARHTP VNSWLGINIIMVAPTLW	424
Qy	425	ARMILMTHTFSSILIAQOELEKALDCOIIYGACYSTIEPLDLPOLIERLHGISAFSLHSYSPG	484
Dd	425	ARMILMTHTFSSILIAQOELEKALDCOIIYGACYSTIEPLDPLIIQRKHGLSA FSLHSYSPG	484
Qy	485	EINRVASCLRKLGVPPLRVWRHRRARSVRAKLLSQGGRAAI C K Y L F N W A V R T K L X L T I P	544
Dd	485	EINRVASCLRKLGVPPLRVWRHRRARSVRAKLLSQGGRAAI C K Y L F N W A V R T K L X L T I P	544
Qy	545	AASRLDLSGWFVAGYSGGDIYHYSLSRA	571
Dd	545	AASRLDLSGWFVAGYSGGDIYHYSVSHA	571

```

RESULT 12
Q66N74
ID Q66N74 PRELIMINARY; PRT; 571 AA.
AC Q66N74;
DT 25-OCT-2004 (T-EMBLrel. 28, Created)
DT 25-OCT-2004 (T-EMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (T-EMBLrel. 28, Last annotation update)
DE Polypeptide (Fragment).
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RA Parker M., Lamson D., Wroblewski D., Reilly A., Philippott S.,
RA Kleiner D., Holman S., Augenbraun M., Taylor J.;
RT "Sequence Analysis of Hepatitis C Virus Replication Functions in
RT HCV/HIV Coinfected Subjects.";
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY682789; AAU08345.1; -
DR InterPro; IPR002166; HCV_RdRP.
DR InterPro; IPR007095; RNA_pol_DS_PS.
DR InterPro; IPR007094; RNA_pol_PSVir.
DR Pfam; PF00998; Viral_RdRP; 1.
DR Polypeptide.
FT NON_TER 1 1
FT NON_TER 571 571
SQ SEQUENCE 571 AA; 63220 MW; 7461A702D6S805AD CRC64;

Query Match 92.8%; Score 2836; DB 2; Length 571;
Best Local Similarity 94.0%; Pred. No. 5,7e-215;
Matches 533; Conservative 23; Mismatches 11; Indels 0; Gaps 0

QY 5 SMSYVTGALITPCAAESKLPINALNSLLRHNLVYVTSRSASLRQKVTDFRLQVL 64

```

Db 5 SMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNMVYATTSRSASQRCKVTFDRQLVL 64

Qy 65 DDHYRDVLKEMKAKASTVAKALLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124

Db 65 DDHYQDVLKEMKAKASTVAKALLSIEEACKLTPPHSAKSKFGYGAKDVRNLSSKAINHIR 124

Qy 125 SVMKDILLEDTDPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184

Db 125 SVWEDLLEDTDPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184

Qy 185 TLPQAVNGSSYGFQYSPKQVPELVNVTWAKKCPMGFSYDTRCFDSTVTENDIRVBEESY 244

Db 185 TLPQAVNGSAYGFQYSPGQVPELVNWKSKRTPMGFAYDTRCFDSTVTESDIRVBEESY 244

Qy 245 QCDDLAPEARQAIRSUTERLYVGGPMWNSKGQNCGYRRCRASGLVTTSCGNTLTCYLKA 304

Db 245 QCDDLAPEARQAIRSUTERLYIGPPTNSKGQNCGYRRCRASGLVTTSCGNTLTCYLKAS 304

Qy 305 AACRAAKLODCTMLVNGDDLWVICSAGTQEDAAISLRVTEAMTRYASAPGPPQPEYDL 364

Db 305 AACRAAKLODCTMLVCGDDLWVICSAGTQEDAAANLRVTEAMTRYASAPGPPQPEYDL 364

Qy 365 ELITSCSSNSVVAHDASGRVYVLTDRPTVPLARAANAETARHTPVNSWLGNIIMYAPTILW 424

Db 365 ELITSCSSNSVVAHDATGRVYVLTDRPTTPLARAANAETARHTPVNSWLGNIIMYAPTILW 424

Qy 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHYSYSPG 484

Db 425 ARMILMTHFFSILLAEQLEKALDCQIYGACYSIEPLDLPQIIRLHGLSAFSLHYSYSPG 484

Qy 485 EINRVASCLRKLGVPLRVWRHRARSVRAKLISQGGRAALCGKYLEFNWAVRTKLTPTIP 544

Db 485 EINRVASCLRKLGVPLRVWRHRARSVRAKLISQGGRAATCGRYLEFNWAVRTKLTPTIS 544

Qy 545 AASRLDLSGWFVAGYSGGDIYHLSLRA 571

Db 545 AASQLDLSGWFVAGYSGGQIYHVSUSA 571

RESULT 13

Q66N89 PRELIMINARY; PRT; 571 AA.

ID Q66N89 PRELIMINARY; PRT; 571 AA.

AC Q66N89; PRELIMINARY; PRT; 571 AA.

DT 25-OCT-2004 (TrEMBLrel. 28, Created)

DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)

DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)

DE Polypeptide (Fragment).

OS Hepatitis C virus.

OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;

OC Hepacivirus.

OX NCBI TaxID=11103;

RP [1]

RN SEQUENCE FROM N.A.

RA Parker M., Lamson D., Wroblewski D., Reilly A., Philpott S.,

RA Kleiner D., Holman S., Augenbraun M., Taylor J.;

RT "Sequence Analysis of Hepatitis C Virus Replication Functions in

RT HCV/HIV Coinfected Subjects."

RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.

DR EMBL: AY682774; AAU08330.1; -

DR InterPro: IPR002166; HCV_RdRP.

DR InterPro: IPR007095; RNA_pol_DS_PS.

DR InterPro: IPR007094; RNA_pol_PSVir.

DR Pfam: PF00998; Viral_RdRP; 1.

KW Polyprotein.

FT NON_TER 1 1

FT NON_TER 571 571

SQ SEQUENCE 571 AA; 63492 MW; 111E17000D53EB8C CRC64;

Query Match 92.3%; Score 2820; DB 2; Length 571;

Best Local Similarity 94.0%; Pred. No. 1e-213;

Matches 533; Conservative 20; Mismatches 14; Indels 0; Gaps 0;

Qy 5 SMSYTTWTGALITPCAAEESKLPINALSNSLLRHHNMVYATTSRSASLRCKVTFDRQLVL 64

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:48:15 ; Search time 43 Seconds
(without alignments)
1006.894 Million cell updates/sec

Title: US-10-712-479-4

Perfect score: 3055

Sequence: 1 MASMSYTTGALITPCAA.....GGDIYHLSRARPRHHHHH 580

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 489056

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents_AA.*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep.*

2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep.*

3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep.*

4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep.*

5: /cgn2_6/ptodata/1/iaa/PTCUS_COMB.pep.*

6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2879	94.2	576	4	US-09-541-990A-1
2	1124	36.8	496	3	US-08-867-611-10
3	1124	36.8	496	4	US-09-690-359-10
4	1124	36.8	496	5	PCT-US92-06965A-15
5	908	29.7	504	1	US-07-853-985A-6
6	908	29.7	504	1	US-07-681-703B-6
7	908	29.7	504	1	US-08-184-236-6
8	908	29.7	504	2	US-08-407-410B-6
9	908	29.7	504	2	US-08-485-500-6
10	908	29.7	504	5	PCT-US91-02370-6
11	908	29.7	504	5	PCT-US94-04174-6
12	884	28.9	187	1	US-07-853-985A-2
13	884	28.9	187	1	US-07-681-703B-2
14	884	28.9	187	1	US-08-184-236-2
15	884	28.9	187	2	US-08-407-410B-2
16	884	28.9	187	2	US-08-485-500-2
17	884	28.9	187	5	PCT-US91-02370-2
18	884	28.9	187	5	PCT-US94-04174-2
19	759	24.8	152	3	US-08-444-818-62
20	748	24.5	171	3	US-08-444-818-58
21	686	22.5	387	3	US-08-867-611-12
22	686	22.5	387	4	US-09-690-359-12
23	686	22.5	387	5	PCT-US92-06965A-17
24	678	22.2	156	5	PCT-US94-04174-19
25	621	20.3	133	3	US-08-444-818-60
26	613.5	20.1	393	3	US-08-867-611-14
27	613.5	20.1	393	4	US-09-690-359-14

ALIGNMENTS

RESULT 1

US-09-541-990A-1

; Sequence 1, Application US/09541990A

; Patent No. 6434489

; GENERAL INFORMATION:

; APPLICANT: Lesburg, Charles A.

; APPLICANT: Cable, Michael

; APPLICANT: Hong, Zhi

; APPLICANT: Mannarino, Anthony

; APPLICANT: Weber, Patricia

; TITLE OF INVENTION: Compositions of Hepatitis C Virus NS5B Polymerase and

; TITLE OF INVENTION: Methods for Crystallizing Same

; FILE REFERENCE: IN0988 US

; CURRENT APPLICATION NUMBER: US/09/541,990A

; CURRENT FILING DATE: 2000-04-03

; NUMBER OF SEQ ID NOS: 1

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 1

; LENGTH: 576

; TYPE: PRT

; ORGANISM: Hepatitis C virus

; FEATURE:

; NAME/KEY: VARIANT

; LOCATION: (335)

; OTHER INFORMATION: amino acids at 335, 344 and 550 may be threonine

; OTHER INFORMATION: or valine at 335, valine or alanine at 344 and

; OTHER INFORMATION: arginine or glutamine at 550

US-09-541-990A-1

Query Match 94.2%; Score 2879; DB 4; Length 576;

Best local Similarity 96.0%; Pred. No. 1.2e-286;

Matches 545; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

Qy	7	SYTTGALITPCAAEESKLPINALNSLLRHNLVYTTSSASILROKKVTFDRLOVLDD	66
Db	9	SYTTGALITPCAAEESKLPINALNSLLRHNLVYTTSSASILROKKVTFDRLOVLDD	68
Qy	67	HYRDLVKEMKAKASTVKAKLLSVEACKLTTPPHSAKSKFGYGAKDVRSLSSRVNHI	126
Db	69	HYRDLVKEMKAKASTVKAKLLSVEACKLTTPPHSAKSKFGYGAKDVRNLSKAVNHI	128
Qy	127	WKDLLEDTDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKALYDVVSTL	186
Db	129	WKDLLEDTDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKALYDVVSTL	188
Qy	187	PQAVMGSSYGFQYSPKORVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESI	246
Db	189	PQVVMGSSYGFQYSPKORVFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESI	248
Qy	247	CDLAPEARQAIRSLTERLYVGPGMTNSKGQCGYRRRCRASGLVTTSCGNTLTCLV	306

Db 249 CDLAPEARQAISLTERLYIGPLTNSKGQYRCRASCGLTSCGNTLTCLYKASAA 308
Qy 307 CRAAKLODCTMLVNGDDLWVICSAGTOEDDAASLRVFTTEAMTRYSAAPPDPPQPEYDLEL 366
Db 309 CRAAKLODCTMLVNGDDLWVICSAGQOEDAASLRXFTTEAMTRYSAAPPDPPQPEYDLEL 368
Qy 367 ITSCSSNVSAHDASGKRVYVLTDRPTVPLARAAWETARHTPVNSWLGNIIMYAPTLPWAR 426
Db 369 ITSCSSNVSAHDASGKRVYVLTDRPTVPLARAAWETARHTPVNSWLGNIIMYAPTLPWAR 428
Qy 427 MILMTHFFSILLAQOEKALDCQIYGACYSIEPLDLFQIIRLHGLSAFSLHSYSGEI 486
Db 429 MILMTHFFSILLAQOEKALDCQIYGACYSIEPLDLFQIIRLHGLSAFSLHSYSGEI 488
Qy 487 NRVASCLRKLGVPPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPTIPAA 546
Db 489 NRVASCLRKLGVPPLRVWRHRSVRKLLSQGGRAATCGKYLEFNWAVTKLTPTIPAA 548
Qy 547 SRLDLSGWFVAGYSGGDIYHLSLRARPR 574
Db 549 SXLDLSGWFVAGYSGGDIYHLSLRARPR 576

RESULT 2
US-08-67-611-10
; Sequence 10, Application US/08867611
; Patent No. 6172189
; GENERAL INFORMATION:
; APPLICANT: DEVARE, SUSHIL G
; APPLICANT: DESAI, SURESH M
; APPLICANT: CASEY, JAMES M
; APPLICANT: DAILEY, STEPHEN H
; APPLICANT: DAWSON, GEORGE J
; APPLICANT: GUTIERREZ, ROBIN A
; APPLICANT: LESNIEWSKI, RICHARD R
; APPLICANT: STEWART, JAMES L
; APPLICANT: RUPPRECHT, KEVIN R
; TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: ONE ABBOTT PARK ROAD, CHAD377/AP6D2
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/867,611
; FILING DATE: 02-JUN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/646,757
; FILING DATE:
; APPLICATION NUMBER: US/08/179,896
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/572,822
; FILING DATE: 24-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/614,069
; FILING DATE: 07-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/748,561
; FILING DATE: 21-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/748,565

; FILING DATE: 21-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/748,566
; FILING DATE: 21-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 4834. US.P6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-937-9556
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 496 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-67-611-10
Query Match 36.8%; Score 1124; DB 3; Length 496;
Best Local Similarity 84.8%; Pred. No. 2.4e-106;
Matches 212; Conservative 14; Mismatches 24; Indels 0; Gaps 0;
Qy 64 LDDHYRDVLKEMKAKASTVAKLISVEEACKLTTPPHSAKSKFGYGAQDVRSLSRAVNNHI 123
Db 247 LDSHYQDVLKVKAAASKVKANLLSVEEACSLTTPPHSAKSKFGYGAQDVRSLSRAVNNHI 306
Qy 124 RSVWKOLLEDDTPIQTTIMAKNEVFCVQPEKGGKRPARLIVFPDPLGVRVCEKALYDVV 183
Db 307 NSVWKOLLEDDTPIQTTIMAKNEVFCVQPEKGGKRPARLIVFPDPLGVRVCEKALYDVV 366
Qy 184 STLPAQVWSSYSGFYSPKORVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVRESI 243
Db 367 TKLPLAVWSSYSGFYSPKORVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVRESI 426
Qy 244 YQCCDLAPARQAIRSLTERLYVGGPMTNSKGQYRCRASCGLTSCGNTLTCLYKAA 303
Db 427 YQCCDLAPARQAIRSLTERLYVGGPMTNSKGQYRCRASCGLTSCGNTLTCLYKAA 486
Qy 304 AACRAAKLQ 313
Db 487 RAACRAAGLQ 496
RESULT 3
US-09-690-359-10
; Sequence 10, Application US/09690359
; Patent No. 6593083
; GENERAL INFORMATION:
; APPLICANT: DEVARE, SUSHIL G
; APPLICANT: DESAI, SURESH M
; APPLICANT: CASEY, JAMES M
; APPLICANT: DAILEY, STEPHEN H
; APPLICANT: DAWSON, GEORGE J
; APPLICANT: GUTIERREZ, ROBIN A
; APPLICANT: LESNIEWSKI, RICHARD R
; APPLICANT: STEWART, JAMES L
; APPLICANT: RUPPRECHT, KEVIN R
; TITLE OF INVENTION: HEPATITIS C ASSAY UTILIZING RECOMBINANT
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES
; STREET: ONE ABBOTT PARK ROAD, CHAD377/AP6D2
; CITY: ABBOTT PARK
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/690,359
; FILING DATE: 17-Oct-2000
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/867,611
; FILING DATE: 02-JUN-1997
; APPLICATION NUMBER: US/08/646,757
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US/08/179,896
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US/07/572,822
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: US/07/614,069
; FILING DATE: 07-NOV-1990
; APPLICATION NUMBER: US/07/748,561
; FILING DATE: 21-AUG-1991
; APPLICATION NUMBER: US/07/748,565
; FILING DATE: 21-AUG-1991
; APPLICATION NUMBER: US/07/748,566
; FILING DATE: 21-AUG-1991
;
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 4834.US.P6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-937-9556
;
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 496 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-690-359-10

```

```

Query Match 36.8%; Score 1124; DB 4; Length 496;
Best Local Similarity 84.8%; Pred. No. 2.4e-106;
Matches 212; Conservative 14; Mismatches 24; Indels 0; Gaps 0;

Qy 64 LDDHYRDLKEMKAKASTVTKAKLLSVEEACKLTTPHSAKSKFGYGAQDVRLSSRAVNH 123
Db 247 LDSHYQDVLKEVKAASVKVAKNLLSVEEACSLTTPHSAKSKFGYGAQDVRLSSRAVNH 306

Qy 124 RSVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRVCEKMAIDV 183
Db 307 NSVWKDLLEDNVTPTIOTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRVCEKMAIDV 366

Qy 184 STLPAQVMGSSYGFQYSPQKQVFLVNTWKAQKCPMGFSYDTRCFDSTVTTENDIRVESI 243
Db 367 TKPLAVMGSSYGFQYSPQKQVFLVNTWKAQKCPMGFSYDTRCFDSTVTTENDIRTESAI 426

Qy 244 YQCCLDAPARQATRLSLRLYVGGPMTNSKGQNGYRRCRASGVLTTSCGNLTTCYLKA 303
Db 427 YQCCLDAPARQATRLSLRLYVGGPMTNSKGQNGYRRCRASGVLTTSCGNLTTCYLKA 486

Qy 304 AAACRAAKLQ 313
Db 487 RAACRAAGLQ 496

```

```

RESULT 4
PCT-US92-06965A-15
; Sequence 15, Application PC/TUS9206965A
; GENERAL INFORMATION:
; APPLICANT: DEVARE, S.
; APPLICANT: DESAI, S.
; APPLICANT: DAILEY, S.
; TITLE OF INVENTION: HCV SYNTHETIC PEPTIDE FROM NS1 REGION
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ABBOTT LABORATORIES

```

```

; STREET: ONE ABBOTT PARK ROAD
; CITY: ABBOTT PARK
; STATE: ILLINOIS
; COUNTRY: U.S.
; ZIP: 60065-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/06965A
; FILING DATE: 19920821
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: FOREMSKI, PRISCILLA E.
; REGISTRATION NUMBER: 33,207
; REFERENCE/DOCKET NUMBER: 4834PC.02
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 708-937-6365
; TELEFAX: 708-937-9556
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 496 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US92-06965A-15

Query Match 36.8%; Score 1124; DB 5; Length 496;
Best Local Similarity 84.8%; Pred. No. 2.4e-106;
Matches 212; Conservative 14; Mismatches 24; Indels 0; Gaps 0;

Qy 64 LDDHYRDLKEMKAKASTVTKAKLLSVEEACKLTTPHSAKSKFGYGAQDVRLSSRAVNH 123
Db 247 LDSHYQDVLKEVKAASVKVAKNLLSVEEACSLTTPHSAKSKFGYGAQDVRLSSRAVNH 306

Qy 124 RSVWKDLLEDTDPTIOTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRVCEKMAIDV 183
Db 307 NSVWKDLLEDNVTPTIOTTIMAKNEVFCVQPEKGGKPARLIVFPDLGVRVCEKMAIDV 366

Qy 184 STLPAQVMGSSYGFQYSPQKQVFLVNTWKAQKCPMGFSYDTRCFDSTVTTENDIRVESI 243
Db 367 TKPLAVMGSSYGFQYSPQKQVFLVNTWKAQKCPMGFSYDTRCFDSTVTTENDIRTESAI 426

Qy 244 YQCCLDAPARQATRLSLRLYVGGPMTNSKGQNGYRRCRASGVLTTSCGNLTTCYLKA 303
Db 427 YQCCLDAPARQATRLSLRLYVGGPMTNSKGQNGYRRCRASGVLTTSCGNLTTCYLKA 486

Qy 304 AAACRAAKLQ 313
Db 487 RAACRAAGLQ 496

RESULT 5
US-07-853-985A-6
; Sequence 6, Application US/07853985A
; Patent No. 5436318
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Moeckli, Randolph
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Peter J. Dehlinger
; STREET: P.O. BOX 60850
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

```
;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/07/853,985A
;   FILING DATE: 19920320
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US 07/505,611
;   FILING DATE: 06-APR-1990
;   APPLICATION NUMBER: US 07/594,854
;   FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
;   NAME: Dehlinger, Peter J.
;   REGISTRATION NUMBER: 28,006
;   REFERENCE/DOCKET NUMBER: 4600-0076.22
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 415-324-0880
;   TELEFAX: 415-324-0960
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 504 amino acids
;   TYPE: AMINO ACID
;   TOPOLOGY: linear
;   MOLECULE TYPE: protein
; US-07-853-985A-6

Query Match      29.7%; Score 908; DB 1; Length 504;
Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAARESKLPINALSNLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 302 SMSYSWGALVTPCAAEQKLPINALSNLLRHHNLVYSTTSRSACQKKVTFDRLOVL 361
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHIN 421
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 422 SVWKDLLEDNVTPIDITTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVT 481
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 482 KLPLAVMGSSYGFQYSPGQVVEF 504
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 6
US-07-681-703B-6
; Sequence 6, Application US/07681703B
; Patent No. 5443965
; GENERAL INFORMATION:
;   APPLICANT: Reyes, Gregory
;   APPLICANT: Kim, Jungshuh P.
;   APPLICANT: Moeckli, Randolph
;   TITLE OF INVENTION: Hepatitis C Virus Epitopes
;   NUMBER OF SEQUENCES: 55
;   CORRESPONDENCE ADDRESS:
;     STREET: 350 Cambridge Ave., Suite 250
;     CITY: Palo Alto
;     STATE: CA
;     COUNTRY: USA
;     ZIP: 94306
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/07/681,703B
;     FILING DATE: 05-APR-1991

;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/07/853,985A
;   FILING DATE: 19920320
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US 07/505,611
;   FILING DATE: 06-APR-1990
;   APPLICATION NUMBER: US 07/594,854
;   FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
;   NAME: Dehlinger, Peter J.
;   REGISTRATION NUMBER: 28,006
;   REFERENCE/DOCKET NUMBER: 4600-0076.22
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 415-324-0880
;   TELEFAX: 415-324-0960
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 504 amino acids
;   TYPE: AMINO ACID
;   TOPOLOGY: linear
;   MOLECULE TYPE: protein
; US-07-853-985A-6

Query Match      29.7%; Score 908; DB 1; Length 504;
Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWGALITPCAARESKLPINALSNLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 302 SMSYSWGALVTPCAAEQKLPINALSNLLRHHNLVYSTTSRSACQKKVTFDRLOVL 361
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHIN 421
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 125 SVWKDLLEDTPITQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVS 184
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 422 SVWKDLLEDNVTPIDITTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMALYDVVT 481
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 482 KLPLAVMGSSYGFQYSPGQVVEF 504
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 7
US-08-184-236-6
; Sequence 6, Application US/08184236
; Patent No. 5538865
; GENERAL INFORMATION:
;   APPLICANT: Reyes, Gregory
;   APPLICANT: Kim, Jungshuh P.
;   APPLICANT: Moeckli, Randolph
;   TITLE OF INVENTION: Hepatitis C Virus Epitopes
;   NUMBER OF SEQUENCES: 10
;   CORRESPONDENCE ADDRESS:
;     STREET: P.O. BOX 60850
;     CITY: Palo Alto
;     STATE: CA
;     COUNTRY: US
;     ZIP: 94306
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: PatentIn Release #1.24
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/184,236
;     FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US 07/505,611
;   FILING DATE: 06-APR-1990
;   APPLICATION NUMBER: US 07/594,854
;   FILING DATE: 09-OCT-1990
```

APPLICATION NUMBER: US 07/853,985
FILING DATE: 20-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0113
TELEPHONE: 415-324-0880
TELEFAX: 415-324-0960
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 504 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-184-236-6

Query Match 29.7%; Score 908; DB 1; Length 504;

Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
DB 302 SMSYTWTCALITPCAABESKLPINALNSLLRHHNLVYSTTSRSACQKKVTFDRLOVL 361
QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAQVRCARKAVTHIN 421
QY 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCERKALYDVVS 184
DB 422 SVWKDLLEDNVTPIIDTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCERKALYDVVT 481
QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
DB 482 KLPLAVMGSSYGFQYSPQQRVEF 504

RESULT 8

US-08-407-410B-6
Sequence 6, Application US/08407410B
Patent No. 5843636
GENERAL INFORMATION:
APPLICANT: Reyes, Gregory
APPLICANT: Kim, Jungshuh P.
APPLICANT: Moeckli, Randolph
APPLICANT: Simonsen, Christian C.
TITLE OF INVENTION: Hepatitis C Virus Epitopes
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Peter J. Dehlinger
STREET: 350 Cambridge Ave., Suite 100
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/407,410B
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 505,611
FILING DATE: 06-APR-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 594,854
FILING DATE: 09-OCT-1990
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.

REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-076.21
TELEPHONE: (415) 323-8302
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 504 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-407-410B-6

Query Match 29.7%; Score 908; DB 2; Length 504;

Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
DB 302 SMSYTWTCALITPCAABESKLPINALNSLLRHHNLVYSTTSRSACQKKVTFDRLOVL 361
QY 65 DDHYRDVLKEMKAKASTVKALLSVEEACKLTPPHSAKSKFGYGAQVRSLSRAVNHIR 124
DB 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAQVRCARKAVTHIN 421
QY 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCERKALYDVVS 184
DB 422 SVWKDLLEDNVTPIIDTTIMAKNEVFCVQPEKGRKPARLIIVPDLGVRVCERKALYDVVT 481
QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
DB 482 KLPLAVMGSSYGFQYSPQQRVEF 504

RESULT 9

US-08-485-500-6
Sequence 6, Application US/08485500
Patent No. 5843639
GENERAL INFORMATION:
APPLICANT: Reyes, Gregory
APPLICANT: Kim, Jungshuh P.
APPLICANT: Moeckli, Randolph
APPLICANT: Simonsen, Christian C.
TITLE OF INVENTION: Hepatitis C Virus Epitopes
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Peter J. Dehlinger
STREET: 350 Cambridge Ave., Suite 100
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,500
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/407,410
FILING DATE:
APPLICATION NUMBER: US 505,611
FILING DATE: 06-APR-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 594,854
FILING DATE: 09-OCT-1990
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-076.21
TELECOMMUNICATION INFORMATION:

```
; TELEPHONE: (415) 323-8302
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 504 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-485-500-6

Query Match 29.7%; Score 908; DB 2; Length 504;
Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALSNLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 302 SMSYSWTGALVTPCAABEQKLPINALSNLLRHHNLVYSTTSRSACQKQKVTFRLOVL 361
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
Db 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAQDVRCARKAVTHIN 421
QY 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 422 SVWKDLLEDNVTPIIDTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVT 481
QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
Db 482 KLPLAVMGSSYGFQYSPGQVVEF 504

RESULT 10
PCT-US91-02370-6
; Sequence 6, Application PC/TUS9102370
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsu P.
; APPLICANT: Moeckli, Randolph
; APPLICANT: Simonsen, Christian C.
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Peter J. Dehlinger
; STREET: P.O. BOX 60850
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02370
; FILING DATE: 19910405
; CLASSIFICATION: 435.5
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,611
; FILING DATE: 06-APR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 594,854
; FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-076.41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 323-8302
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 504 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear

; MOLECULE TYPE: protein
PCT-US94-04174-6

Query Match 29.7%; Score 908; DB 5; Length 504;
Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALSNLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
Db 302 SMSYSWTGALVTPCAABEQKLPINALSNLLRHHNLVYSTTSRSACQKQKVTFRLOVL 361
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
Db 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAQDVRCARKAVTHIN 421
QY 125 SVWKDLLEDTPITOTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVS 184
Db 422 SVWKDLLEDNVTPIIDTTIMAKNEVFCVQPEKGRKPARLIIVFPDLGVRVCEKMALYDVVT 481
QY 185 TLPOAVMGSSYGFQYSPKQVVEF 207
Db 482 KLPLAVMGSSYGFQYSPGQVVEF 504

RESULT 11
PCT-US94-04174-6
; Sequence 6, Application PC/TUS9404174
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsu P.
; APPLICANT: Moeckli, Randolph
; APPLICANT: HCV Immunodiagnostic Antigens and Antibodies
; TITLE OF INVENTION: HCV Immunodiagnostic Antigens and Antibodies
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Peter J. Dehlinger
; STREET: 350 Cambridge Avenue, Suite 300
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04174
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,611
; FILING DATE: 06-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-324-0880
; TELEFAX: 415-324-0960
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 504 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
PCT-US94-04174-6

Query Match 29.7%; Score 908; DB 5; Length 504;
Best Local Similarity 87.2%; Pred. No. 3.9e-84;
Matches 177; Conservative 7; Mismatches 19; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALSNLLRHHNLVYSTTSRSASLRQKKVTFDRLOVL 64
```

Db 302 SMSYWTGALVTPCAAEBOQLPINALNSLLRHHNLVYVTSRSACORQKKVTFRLQVL 361
QY 65 DPHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAKDVRSLSSRAVNHIR 124
Db 362 DSHYQDVLKEVKAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVTHIN 421
QY 125 SVWKDLLEDTPDTPIOTTIMAKNEVFCVQPEKGRGPABRLIVFPDGLGVRVCEKMAIYDVVS 184
Db 422 SVWKDLLEDNVPIDTTIMAKNEVFCVQPEKGRGPABRLIVFPDGLGVRVCEKMAIYDVVT 481
QY 185 TLPOAVMGSSYGFQYSPKORVEF 207
Db 482 KLPLAVMGSSYGFQYSPCORVEF 504

RESULT 12
US-07-853-985A-2
; Sequence 2, Application US/07853985A
; Patent No. 5436318
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsuh P.
; APPLICANT: Moeckli, Randolph
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Peter J. Dehlinger
; STREET: P.O. BOX 60850
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/853.985A
; FILING DATE: 19920320
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/505,611
; FILING DATE: 06-APR-1990
; APPLICATION NUMBER: US 07/594,854
; FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Dehlinger, Peter J.
; REGISTRATION NUMBER: 28,006
; REFERENCE/DOCKET NUMBER: 4600-0076.22
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-324-0880
; TELEFAX: 415-324-0960

; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 187 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-853-985A-2

Query Match 28.9%; Score 884; DB 1; Length 187;
Best Local Similarity 87.6%; Pred. No. 2.2e-82;
Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

QY 206 EFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIYQCCDLAPARQAIRSLTERLY 265
Db 1 EFLVQWKSXKTPMGFSYDTRCFDSTVTESDIRTEAIIYQCCDLDPQARVAIKSLTERLY 60
QY 266 VGGPMTNSKGCNCGYRRCRASGLVLTSCGNTLTCTYLKAAACRAAKLODCTMLVNGDDL 325
Db 61 VGGPLTNSRGENCGYRRCRASGLVLTSCGNTLTCTYIKARAAACRAAGLODCTMLVCGDDL 120

QY 326 VICRSAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLELITSCSSNNVSAHDAGSKRV 385
Db 121 VICRSAGVQEDAAASLRFAFTTEAMTRYSAAPPDPPQPEYDLELITSCSSNNVSAHDAGSKRV 180
QY 386 YYLTRD 391
Db 181 YYLTR 186

RESULT 13
US-07-681-703B-2
; Sequence 2, Application US/07681703B
; Patent No. 5443965
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsuh P.
; APPLICANT: Moeckli, Randolph
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 55
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/681,703B
; FILING DATE: 05-APR-1991
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,611
; FILING DATE: 06-APR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 594,854
; FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-076.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880

; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 187 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-07-681-703B-2

Query Match 28.9%; Score 884; DB 1; Length 187;
Best Local Similarity 87.6%; Pred. No. 2.2e-82;
Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

QY 206 EFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVEESIYQCCDLAPARQAIRSLTERLY 265
Db 1 EFLVQWKSXKTPMGFSYDTRCFDSTVTESDIRTEAIIYQCCDLDPQARVAIKSLTERLY 60
QY 266 VGGPMTNSKGCNCGYRRCRASGLVLTSCGNTLTCTYLKAAACRAAKLODCTMLVNGDDL 325
Db 61 VGGPLTNSRGENCGYRRCRASGLVLTSCGNTLTCTYIKARAAACRAAGLODCTMLVCGDDL 120
QY 326 VICRSAGTQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLELITSCSSNNVSAHDAGSKRV 385
Db 121 VICRSAGVQEDAAASLRFAFTTEAMTRYSAAPPDPPQPEYDLELITSCSSNNVSAHDAGSKRV 180
QY 386 YYLTRD 391
Db 181 YYLTR 186

Db 181 YYLTR 186

RESULT 14

US-08-184-236-2
; Sequence 2, Application US/08184236
; Patent No. 5538865
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsuh P.
; APPLICANT: Moeckli, Randolph
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: P.O. BOX 60850
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/184,236
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/505,611
; FILING DATE: 06-APR-1990
; APPLICATION NUMBER: US 07/594,854
; FILING DATE: 09-OCT-1990
; APPLICATION NUMBER: US 07/853,985
; FILING DATE: 20-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0113
; TELEPHONE: 415-324-0880
; TELEFAX: 415-324-0960
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 187 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-08-184-236-2

Query Match 28.9%; Score 884; DB 1; Length 187;

Best Local Similarity 87.6%; Pred. No. 2.2e-82;
Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

Qy	206	EFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIYQCCDLAPEARQAIRSLTERLY	265
Db	1	EFLVQWKSXKTPMGFSYDTRCFDSTVTESDIRTEAIYQCCDLDPQARVAIKSLTERLY	60
Qy	266	VGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCTYLKAAACRAAKLQDCTMLVNGDDL	325
Db	61	VGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCTYIKARACRAAGLQDCTMLVCGDDL	120
Qy	326	VICESAGTQEDASLRVFTTEAMTRYSPAPGPPQPEYDLELITSCSSNVSAHDAGKRV	385
Db	121	VICESAGVQEDASLRFTTEAMTRYSPAPGPPQPEYDLELITSCSSNVSAHDAGKRV	180
Qy	386	YYLTRD 391	
Db	181	YYLTR 186	

Search completed: September 22, 2005, 14:55:37

Job time : 44 secs

RESULT 15

US-08-407-410B-2

; Sequence 2, Application US/08407410B
; Patent No. 5843636
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory
; APPLICANT: Kim, Jungsuh P.
; APPLICANT: Moeckli, Randolph
; APPLICANT: Simonsen, Christian C.
; TITLE OF INVENTION: Hepatitis C Virus Epitopes
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Peter J. Dehlinger
; STREET: 350 Cambridge Ave., Suite 100
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/407,410B
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,611
; FILING DATE: 06-APR-1990
; APPLICATION NUMBER: US 594,854
; FILING DATE: 09-OCT-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-076.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 323-8302
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 187 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-08-407-410B-2

Query Match 28.9%; Score 884; DB 2; Length 187;

Best Local Similarity 87.6%; Pred. No. 2.2e-82;
Matches 163; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

Qy	206	EFLVNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIYQCCDLAPEARQAIRSLTERLY	265
Db	1	EFLVQWKSXKTPMGFSYDTRCFDSTVTESDIRTEAIYQCCDLDPQARVAIKSLTERLY	60
Qy	266	VGGPMTNSKQNGCYRRCRASGVLTTSCGNTLTCTYLKAAACRAAKLQDCTMLVNGDDL	325
Db	61	VGGPLTNSRGENCGYRRCRASGVLTTSCGNTLTCTYIKARACRAAGLQDCTMLVCGDDL	120
Qy	326	VICESAGTQEDASLRVFTTEAMTRYSPAPGPPQPEYDLELITSCSSNVSAHDAGKRV	385
Db	121	VICESAGVQEDASLRFTTEAMTRYSPAPGPPQPEYDLELITSCSSNVSAHDAGKRV	180
Qy	386	YYLTRD 391	
Db	181	YYLTR 186	

Search completed: September 22, 2005, 14:55:37

Job time : 44 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 22, 2005, 14:49:36 ; Search time 173 Seconds
(without alignments)
1364.549 Million cell updates/sec

Title: US-10-712-479-4

Perfect score: 3055

Sequence: 1 MASMSYTWGALITPCAA.....GGDIYHSLSRAPRHHHH 580

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1826521 seqs, 407012169 residues

Total number of hits satisfying chosen parameters: 1677200

Minimum DB seq length: 0

Maximum DB seq length: 585

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
- 2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
- 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
- 4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
- 5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
- 7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
- 8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
- 9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
- 10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
- 11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
- 12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
- 13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
- 14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
- 15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
- 16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep.*
- 17: /cgn2_6/ptodata/2/pubpaa/US10E_PUBCOMB.pep.*
- 18: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
- 19: /cgn2_6/ptodata/2/pubpaa/US11A_PUBCOMB.pep.*
- 20: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
- 21: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
- 22: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	ID	Description
1	3055	100.0	580	16	US-10-712-479-4	Sequence 4, Appli
2	2958	96.8	576	17	US-10-842-046-1	Sequence 1, Appli
3	2936	96.1	578	14	US-10-211-455-1	Sequence 1, Appli
4	2936	96.1	578	16	US-10-471-164-3	Sequence 3, Appli
5	2879	94.2	576	14	US-10-170-131-1	Sequence 1, Appli
6	2734.5	89.5	545	16	US-10-471-164-4	Sequence 4, Appli
7	1391	45.5	300	9	US-09-921-397-107	Sequence 107, App
8	1283	42.0	352	17	US-10-927-520-17	Sequence 17, Appl
9	1232	40.3	260	9	US-09-921-397-109	Sequence 109, App
10	975.5	31.9	576	14	US-10-211-455-3	Sequence 3, Appli
11	915	30.0	199	9	US-09-921-397-108	Sequence 108, App

12	623	20.4	127	9	US-09-921-397-110	Sequence 110, App
13	585	19.1	137	9	US-09-921-397-106	Sequence 106, App
14	570	18.7	113	9	US-09-294-121A-82	Sequence 82, Appl
15	570	18.7	113	9	US-09-899-082A-82	Sequence 82, Appl
16	570	18.7	113	9	US-09-899-302-82	Sequence 82, Appl
17	570	18.7	113	10	US-09-899-046-214	Sequence 214, App
18	570	18.7	113	10	US-09-878-281-214	Sequence 214, App
19	570	18.7	113	10	US-09-899-044-82	Sequence 82, Appl
20	570	18.7	113	10	US-09-873-224-214	Sequence 214, App
21	570	18.7	113	16	US-10-822-711-82	Sequence 82, Appl
22	549	18.0	113	9	US-09-851-138-58	Sequence 58, Appl
23	548	17.9	120	14	US-10-292-129-17	Sequence 17, Appl
24	536	17.5	113	9	US-09-851-138-54	Sequence 54, Appl
25	535	17.5	113	9	US-09-851-138-56	Sequence 56, Appl
26	531	17.4	113	9	US-09-851-138-62	Sequence 62, Appl
27	521	17.1	113	9	US-09-851-138-68	Sequence 68, Appl
28	499	16.3	113	9	US-09-851-138-64	Sequence 64, Appl
29	492	16.1	102	9	US-09-921-397-31	Sequence 31, Appl
30	467	15.3	100	8	US-08-424-550B-396	Sequence 396, App
31	464	15.2	113	9	US-09-294-121A-92	Sequence 92, Appl
32	464	15.2	113	9	US-09-899-082A-92	Sequence 92, Appl
33	464	15.2	113	9	US-09-899-302-92	Sequence 92, Appl
34	464	15.2	113	10	US-09-899-046-160	Sequence 160, App
35	464	15.2	113	10	US-09-878-281-160	Sequence 160, App
36	464	15.2	113	10	US-09-899-044-92	Sequence 92, Appl
37	464	15.2	113	10	US-09-873-224-160	Sequence 160, App
38	464	15.2	113	16	US-10-822-711-92	Sequence 92, Appl
39	445	14.6	113	9	US-09-294-121A-89	Sequence 89, Appl
40	445	14.6	113	9	US-09-899-082A-89	Sequence 89, Appl
41	445	14.6	113	9	US-09-899-302-89	Sequence 89, Appl
42	445	14.6	113	10	US-09-899-046-113	Sequence 113, App
43	445	14.6	113	10	US-09-878-281-113	Sequence 113, App
44	445	14.6	113	10	US-09-899-044-89	Sequence 89, Appl
45	445	14.6	113	10	US-09-873-224-113	Sequence 113, App

ALIGNMENTS

RESULT 1

US-10-712-479-4
; Sequence 4, Application US/10712479
; Publication No. US20040209283A1
; GENERAL INFORMATION:
; APPLICANT: Yagi, Yoshihiko
; APPLICANT: Sheets, Michael P.
; APPLICANT: Wells, Peter A.
; APPLICANT: Shelly, John A.
; APPLICANT: Poorman, Roger A.
; APPLICANT: Epps, Dennis E.
; TITLE OF INVENTION: A Continuous-Read Assay for the Detection of De Novo HCV RNA Polyn
; FILE OF INVENTION: Activity
; FILE REFERENCE: 02-333-A
; CURRENT APPLICATION NUMBER: US/10712,479
; CURRENT FILING DATE: 2003-11-13
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 580
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: C-terminally truncated HCV NS5B polymerase (C delta 21 NS5B)

Query Match 100.0%; Score 3055; DB 16; Length 580;
Best Local Similarity 100.0%; Pred. No. 4.1e-269;
Matches 580; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MASMSYTWGALITPCAAESKLPINALSNSLRHNLVYSTRSASLRQKVTDR 60

DB 1 MASMSYTWGALITPCAAESKLPINALSNSLRHNLVYSTRSASLRQKVTDR 60

```
QY 61 LQVLDHVRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAV 120
DB 61 LQVLDHVRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAV 120
QY 121 NHRSVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIY 180
DB 121 NHRSVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIY 180
QY 181 DWSTLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
DB 181 DWSTLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
QY 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTY 300
DB 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTY 300
QY 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQP 360
DB 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQP 360
QY 361 EYDLELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYA 420
DB 361 EYDLELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYA 420
QY 421 PTLWARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHS 480
DB 421 PTLWARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHS 480
QY 481 YSPGEINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 540
DB 481 YSPGEINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 540
QY 541 TPIPAASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 580
DB 541 TPIPAASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 580

RESULT 2
US-10-842-046-1
; Sequence 1, Application US/10842046
; Publication No. US2005000348A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim International GmbH
; TITLE OF INVENTION: Hepatitis C Virus NS5B Polymerase Inhibitor Binding Pocket
; FILE REFERENCE: 13/123
; CURRENT APPLICATION NUMBER: US/10/842,046
; CURRENT FILING DATE: 2004-05-07
; PRIOR APPLICATION NUMBER: US 60/469,604
; PRIOR FILING DATE: 2003-05-09
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 1
; LENGTH: 576
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-10-842-046-1

Query Match 96.8%; Score 2958; DB 17; Length 576;
Best Local Similarity 96.0%; Pred. No. 2.8e-260;
Matches 553; Conservative 16; Mismatches 7; Indels 0; Gaps 0;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYVTSRSASLRQKKVTFDRLOVL 64
DB 1 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYVTSRSASLRQKKVTFDRLOVL 60
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
DB 61 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 120
QY 125 SVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIYDVVS 184
DB 121 SVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIYDVVS 180

QY 61 LQVLDHVRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAV 120
DB 61 LQVLDHVRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAV 120
QY 121 NHRSVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIY 180
DB 121 NHRSVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIY 180
QY 181 DWSTLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
DB 181 DWSTLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVE 240
QY 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTY 300
DB 241 ESIYQCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTY 300
QY 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQP 360
DB 301 LKAAACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQP 360
QY 361 EYDLELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYA 420
DB 361 EYDLELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYA 420
QY 421 PTLWARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHS 480
DB 421 PTLWARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHS 480
QY 481 YSPGEINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 540
DB 481 YSPGEINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 540
QY 541 TPIPAASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 580
DB 541 TPIPAASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 580
```

```
QY 185 TLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 181 TLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 240
QY 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTYLKAA 304
DB 241 QCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTYLKAT 300
QY 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQPEYDL 364
DB 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQEDAAASLRFVTEAMTRYSAAPPDPPQPEYDL 360
QY 365 ELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYAPTLW 424
DB 361 ELITSCSSNSVVAHDASGKRVYLTDRPTVPLARAANETARHTPVNSWLGNIIMYAPTLW 420
QY 425 ARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG 484
DB 421 ARMILMTHFFSILLAQOLEKALDCQIYGACYSIEPLDLPOIERLHGLSAFSLHSYSPG 480
QY 485 EINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 544
DB 481 EINRVASCLRKLGVPPLRVHRARSVRAKLLSQGGRAAICGKYLFWNAVRTKLTIP 540
QY 545 AASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 580
DB 541 AASRLDLSGFWFVAGYSGGDIYHLSLRARPRHHHHH 576

RESULT 3
US-10-211-455-1
; Sequence 1, Application US/10211455
; Publication No. US20030108862A1
; GENERAL INFORMATION:
; APPLICANT: Boehringer Ingelheim (Canada) Ltd.
; TITLE OF INVENTION: DIRECT BINDING ASSAY FOR IDENTIFYING
; TITLE OF INVENTION: INHIBITORS OF HCV POLYMERASE
; FILE REFERENCE: 13/088
; CURRENT APPLICATION NUMBER: US/10/211,455
; CURRENT FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: 60/310,272
; PRIOR FILING DATE: 2001-08-07
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 578
; TYPE: PRT
; ORGANISM: HCV
US-10-211-455-1

Query Match 96.1%; Score 2936; DB 14; Length 578;
Best Local Similarity 95.5%; Pred. No. 2.9e-258;
Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;

QY 5 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYVTSRSASLRQKKVTFDRLOVL 64
DB 1 SMSYTWTCALITPCAABESKLPINALNSLRHNLVYVTSRSASLRQKKVTFDRLOVL 60
QY 65 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 124
DB 61 DDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHSAKSKFGYGAQDVRSLSRAVNHIR 120
QY 125 SVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIYDVVS 184
DB 121 SVWKDLEDLTDPTQTTIMAKNEVFCVQPEKGGKPKARLIVFPDLGVVRVCEKMAIYDVVS 180
QY 185 TLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 244
DB 181 TLPOAVNGSSYGFQSPKQRFVFLVNTWKAKKCPMGFSYDTRCFDSTVTENDIRVEESIY 240
QY 245 QCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTYLKAA 304
DB 241 QCCDLAPEARQAIRSLTERLYVGGPMTNSKGONCYRRCRASGVLTTCGNTLTCTYLKAS 300
```

```
Qy 305 AACRAAKLQDCTMLVNGDDLVI CESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 301 AACRAAKLQDCTMLVNGDDLVI CESAGTQBDAAANLRVFTTEAMTRYSAAPPDLPQPEYDL 360
Qy 365 ELITSCSSNVSAHDASGKRYVYLTRDPTVPLAARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 361 ELITSCSSNVSAHDASGKRYVYLTRDPTVPLAARAAMETARHTPVNSWLGNIIMYAPTLW 420
Qy 425 ARMTLMTHTFSSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSFAFSLHSYSPG 484
Db 421 ARMTLMTHTFSSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSFAFSLHSYSPG 480
Qy 485 EINRVASCLRKGLVPPPLRVWRHARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPI 544
Db 481 EINRVASCLRKGLVPPPLRVWRHARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPI 540
Qy 545 AASRLDLSGWFVAGYSGGDIYHSLSRAPR--HHHHH 580
Db 541 AASRLDLSGWFVAGYSGGDIYHSLSRAPRLEHHHHH 578

RESULT 4
US-10-471-164-3
; Sequence 3, Application US/10471164
; Publication No. US20040110126A1
; GENERAL INFORMATION:
; APPLICANT: GEORGE KUKOLJ and Ginette MCKERCHER
; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
; FILE REFERENCE: 13/094
; CURRENT APPLICATION NUMBER: US/10/471.164
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 578
; TYPE: PRP
; ORGANISM: HCV
US-10-471-164-3

Query Match 96.1%; Score 2936; DB 16; Length 578;
Best Local Similarity 95.5%; Pred. No. 2.9e-258;
Matches 552; Conservative 18; Mismatches 6; Indels 2; Gaps 1;

Qy 5 SMSYTWGALITPCAABESKLPINALNSLLRHNLVYTSRSASLRQKVTDFRLQVL 64
Db 1 SMSYTWGALITPCAABESKLPINALNSLRHNMVYTSRSAAALRQKVTDFRLQVL 60
Qy 65 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYGAADVRSLSRAVNHR 124
Db 61 DDHYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYGAADVRSLSRAVDHR 120
Qy 125 SVWKDLLEDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVS 184
Db 121 SVWKDLLEDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVS 180
Qy 185 TLPOAVNGSSYGFQYSPKQRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 181 TLPOAVNGSSYGFQYSPKQRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIY 240
Qy 245 QCCDLAPEARQAIKSLTERLYIGGPMNTNSKQNGCYRRCRASGLVTTSCGNTLTCYLKAA 304
Db 241 QCCDLAPEARQAIKSLTERLYIGGPMNTNSKQNGCYRRCRASGLVTTSCGNTLTCYLKAS 300
Qy 305 AACRAAKLQDCTMLVNGDDLVI CESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 301 AACRAAKLQDCTMLVNGDDLVI CESAGTQBDAAANLRVFTTEAMTRYSAAPPDLPQPEYDL 360
Qy 365 ELITSCSSNVSAHDASGKRYVYLTRDPTVPLAARAAMETARHTPVNSWLGNIIMYAPTLW 424
Db 361 ELITSCSSNVSAHDASGKRYVYLTRDPTVPLAARAAMETARHTPVNSWLGNIIMYAPTLW 420
```

```
Qy 425 ARMTLMTHTFSSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSFAFSLHSYSPG 484
Db 421 ARMTLMTHTFSSILLAQEOLKALDCQIYGACYSIEPLDLPQIIERLHGLSFAFSLHSYSPG 480
Qy 485 EINRVASCLRKGLVPPPLRVWRHARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPI 544
Db 481 EINRVASCLRKGLVPPPLRVWRHARSVRAKLLSOGGAAICGKYLFWNAVRTKLTPI 540
Qy 545 AASRLDLSGWFVAGYSGGDIYHSLSRAPR--HHHHH 580
Db 541 AASRLDLSGWFVAGYSGGDIYHSLSRAPRLEHHHHH 578

RESULT 5
US-10-170-131-1
; Sequence 1, Application US/10170131
; Publication No. US20030171874A1
; GENERAL INFORMATION:
; APPLICANT: Lesburg, Charles A.
; APPLICANT: Cable, Michael
; APPLICANT: Hong, Zhi
; APPLICANT: Mannarino, Anthony
; APPLICANT: Weber, Patricia
; TITLE OF INVENTION: Compositions of Hepatitis C Virus NS5B Polymerase and
; FILE REFERENCE: IN0988 US
; CURRENT APPLICATION NUMBER: US/10/170.131
; CURRENT FILING DATE: 2002-06-12
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 576
; TYPE: PRP
; ORGANISM: Hepatitis C virus
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (335)
; OTHER INFORMATION: amino acids at 335, 344 and 550 may be threonine
; OTHER INFORMATION: or valine at 335, valine or alanine at 344 and
; OTHER INFORMATION: arginine or glutamine at 550
US-10-170-131-1

Query Match 94.2%; Score 2879; DB 14; Length 576;
Best Local Similarity 96.0%; Pred. No. 4.5e-253;
Matches 545; Conservative 11; Mismatches 12; Indels 0; Gaps 0;

Qy 7 SYTWGALITPCAABESKLPINALNSLLRHNLVYTSRSASLRQKVTDFRLQVLDD 66
Db 9 SYTWGALITPCAABESKLPINALNSLLRHNMVYATTSRAGLRQKVTDFRLQVLDD 68
Qy 67 HYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYGAADVRSLSRAVNHRSV 126
Db 69 HYRDVLKEMKAKASTVAKLLSVEACKLTPPHSAKSKFGYGAADVRSLSRAVNHISV 128
Qy 127 WKOLLEDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVSTL 186
Db 129 WKOLLEDTPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRCCKMALYDVVSTL 188
Qy 187 POAVNGSSYGFQYSPKQRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQC 246
Db 189 POAVNGSSYGFQYSPKQRFVLTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQC 248
Qy 247 CDLAPEARQAIKSLTERLYIGGPMNTNSKQNGCYRRCRASGLVTTSCGNTLTCYLKAAA 306
Db 249 CDLAPEARQAIKSLTERLYIGGPMNTNSKQNGCYRRCRASGLVTTSCGNTLTCYLKASAA 308
Qy 307 CRAAKLQDCTMLVNGDDLVI CESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 366
Db 309 CRAAKLQDCTMLVNGDDLVI CESAGTQBDAAASLRVFTTEAMTRYSAAPPDPPQPEYDL 368
Qy 367 ITS CSSNVSAHDASGKRYVYLTRDPTVPLAARAAMETARHTPVNSWLGNIIMYAPTLW 426
```

Db 369 ITSCSSNVSAHDASGRKVVYLTTRDPTTTLARAAWETARHTTPVNSWLGNIIMYPTLWAR 428
Qy 427 MILMTHFFSILLAQEALDKCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSGEI 486
Db 429 MILMTHFFSILLAQEALDKCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSGEI 488
Qy 487 NRVASCLRLKGLVPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPIPA 546
Db 489 NRVASCLRLKGLVPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPIPA 548
Qy 547 SRLDLGWFVAGYSGGDIYHLSLRARPR 574
Db 549 SXLDLSGWFVAGYSGGDIYHLSLRARPR 576

RESULT 6
US-10-471-164-4
; Sequence 4, Application US/10471164
; Patent No. US20040110126A1
; GENERAL INFORMATION:
; APPLICANT: GEORGE KUKOLJ and Ginette MCKERCHER
; TITLE OF INVENTION: HCV POLYMERASE INHIBITOR ASSAY
; FILE REFERENCE: 13/094
; CURRENT APPLICATION NUMBER: US/10/471.164
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: 60/274,374
; PRIOR FILING DATE: 2001-03-08
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 545
; TYPE: PRP
; ORGANISM: HCV
US-10-471-164-4

Query Match 89.5%; Score 2734.5; DB 16; Length 545;
Best Local Similarity 90.1%; Pred. No. 6.2e-240;
Matches 519; Conservative 19; Mismatches 7; Indels 31; Gaps 2;

Qy 5 SMSYTWGALITPCAAEESKLPINALSNLSLRHNLVYITTSRSASLRQKVTDFRLQVL 64
Db 1 SMSYTWGALITPCAAEESKLPINALSNLSLRHNLVYITTSRSASLRQKVTDFRLQVL 60
Qy 65 DDHYRDVLKEMKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSRAVNHIR 124
Db 61 DDHYRDVLKEMKASTVKALLSVEACKLTPPHSAKSKFGYKADVRSLSRAVNHIR 120
Qy 125 SVWKDLLEDTDPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVS 184
Db 121 SVWKDLLEDTDPIQTTIMAKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVS 180
Qy 185 TLPOAVMGSSYGFQYSPKQRFVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVESIY 244
Db 181 TLPOAVMGSSYGFQYSPKQRFVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVESIY 240
Qy 245 QCCDLAPARQAIRSLTERLVGGPMNNSKQNGYRCRCRAGVLTTCGNTLTCYLYKAA 304
Db 241 QCCDLAPARQAIRSLTERLVGGPMNNSKQNGYRCRCRAGVLTTCGNTLTCYLYKAS 300
Qy 305 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 364
Db 301 AACRAAKLQDCTMLVNGDDLVIICESAGTQDAASLRVFTTEAMTRYSAAPPDPPQPEYDL 360
Qy 365 ELITSCSSNVSAHDASGRKVVYLTTRDPTTTLARAAWETARHTTPVNSWLGNIIMYPTLW 424
Db 361 ELITSCSSNVSAHDASGRKVVYLTTRDPTTTLARAAWETARHTTPVNSWLGNIIMYPTLW 420
Qy 425 ARMLTMTHFFSILLAQEALDKCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 484
Db 421 ARMLTMTHFFSILLAQEALDKCOIYGACYSIEPLDLPQIIERLHGLSAFSLHSYSPG 480
Qy 485 EINRVASCLRLKGLVPLRVWRHRSVRKLLSQGGRAAICGKYLFWNAVRTKLTPI 544

Db 481 EINRVASCLRLKGLVPLRVWRHRSVRKLLSQGGRAATCGKYLFWNAVRTKL----- 534
Qy 545 AASRLDLGWFVAGYSGGDIYHLSLRARPRHHHHH 580
Db 535 -AAALG-----HHHHHH 545

RESULT 7
US-09-921-397-107
; Sequence 107, Application US/09921397
; Patent No. US20020151484A1
; GENERAL INFORMATION:
; APPLICANT: HYBRIGENICS
; TITLE OF INVENTION: SID nucleic acids and polypeptides selected from a
; TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
; TITLE OF INVENTION: applications thereof
; FILE REFERENCE: B4809A - JAZ
; CURRENT APPLICATION NUMBER: US/09/921.397
; CURRENT FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: EP 00402225.7
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 107
; LENGTH: 300
; TYPE: PRP
; ORGANISM: Hepatitis C virus
US-09-921-397-107

Query Match 45.5%; Score 1391; DB 9; Length 300;
Best Local Similarity 87.7%; Pred. No. 7.4e-118;
Matches 263; Conservative 13; Mismatches 24; Indels 0; Gaps 0;

Qy 84 AKLLSVEEACKLTPPHSAKSKFGYKADVRSLSRAVNHRSVWKLLDSTDPIQTTIM 143
Db 1 ANLLSVEEACSLTPPHSAKSKFGYKADVRSLSRAVNHRSVWKLLDSTDPIQTTIM 60
Qy 144 AKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVSITLPOAVMGSSYGFQYSPKQ 203
Db 61 AKNEVFCVQPEKGRKPARLIVFPDLGVRVCEKMAKYDVSITLPOAVMGSSYGFQYSPKQ 120
Qy 204 RVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQCCDLAPARQAIRSLTER 263
Db 121 RVFLVNTWAKKCPMGFSYDTRCFDSTVTENDIRVESIYQCCDLAPARQAIRSLTER 180
Qy 264 LYVGGPMNNSKQNGYRCRCRAGVLTTCGNTLTCYLYKAAACRAAKLQDCTMLVNGDD 323
Db 181 LYVGGPMNNSKQNGYRCRCRAGVLTTCGNTLTCYLYKAAACRAAKLQDCTMLVNGDD 240
Qy 324 LVVICSAGVQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLITSCSSNVSAHDASGK 383
Db 241 LVVICSAGVQEDAAASLRVFTTEAMTRYSAAPPDPPQPEYDLITSCSSNVSAHDASGK 300

RESULT 8
US-10-927-520-17
; Sequence 17, Application US/10927520
; Patent No. US20050069870A1
; GENERAL INFORMATION:
; APPLICANT: Innogenetics N.V.
; TITLE OF INVENTION: New HCV clade and prototype sequences thereof
; FILE REFERENCE: 157
; CURRENT APPLICATION NUMBER: US/10/927.520
; CURRENT FILING DATE: 2004-08-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 352
; TYPE: PRP
; ORGANISM: hepatitis C virus
US-10-927-520-17

Query Match 42.0%; Score 1283; DB 17; Length 352;

Query Match	40.3%;	Score 1232;	DB 9;	Length 260;
Best Local Similarity	89.2%;	Pred. No. 1.9e-103;		
Matches 232;	Conservative 11;	Mismatches 17;	Indels 0;	Gaps 0;
QY	130	LLEDTPITOTTIMAKNEVFCVQPEKGRKPARIIVFPDLGVRCEKMALVDVVSTLPQA	189	
DB		: : : : : : : : : :		
	1	LLEDSVTPIDTTIMAKNEVFCVQPEKGRKPARIIVFPDLGVRCEKMALVDVVSKLPLA	60	
QY	190	VMGSSYGFQYSRKORVEFLNTWKAKCPMGFSYDTRCFDSTVTENDIRVEESIYQCDDL	249	
DB		: : : : : : : : : :		
	61	VMGSSYGFQYSPGORVEFLVQAMKSCTPMGFSYDTRCFDSTVTESDIRTEEAIYQCDDL	120	
QY	250	APEAROAIRSLTERLYVGGPMTNSKGONCGYRRCRASGLVTTSCGNLTTCYLKAAAACRA	309	
DB		: : : : : : : : : :		
	121	DPOARVAIKSLTERLYVGGPLTNSRGECGYRRCRASGLVTTSCGNLTTCVIKARAACRA	180	
QY	310	AKLQDCTMLVNGDDLWVICESAGTQEDAASLRVFTEAMTRYSAFPPQPPEYDLEITS	369	
DB		: : : : : : : : : :		
	181	AGI-QDCMTLCVGDDLVVICESAGVQEDAASLRAFTEAMTRYSAFPPQPPEYDLEITS	240	
QY	370	CSSNVSVAHNDASKRVYYLT	389	
DB		: : : : : : : : : :		
	241	CSSNVSVAHNDGAGRYYLT	260	

RESULT 11
US-09-921-397-108
; Sequence 108, Application US/09921397
; Patent No. US2002015148A1
; GENERAL INFORMATION:

```
; APPLICANT: HYBRIGENICS
; TITLE OF INVENTION: SID nucleic acids and polypeptides selected from a
; TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
; TITLE OF INVENTION: applications thereof
; FILE REFERENCE: B4809A - JAZ
; CURRENT APPLICATION NUMBER: US/09/921.397
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: EP 00402225.7
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 108
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-09-921-397-108

Query Match          30.0%; Score 915; DB 9; Length 199;
Best Local Similarity 85.9%; Pred. No. 9.9e-75;
Matches 171; Conservative 11; Mismatches 17; Indels 0; Gaps 0;

Qy 90 BEACKLTPPHSAKSGYGAQKDVSLSSRAVNHRSVWKKLLEDTDTPIQTTIMAKNEVF 149
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 BEACSLTPPHSAKSGYGAQKDVSRCHARKAVAHINSVWKKLLEDSVTPIDTTIMAKNEVF 60

Qy 150 CVQPEKGGKPARLIVPDLGVRVCEKALYDVVSTLPQAVNGSSYGFQYSPKORVFLV 209
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 CVQPEKGGKPARLIVPDLGVRVCEKALYDVVSKUPLAVNGSSYGFQYSPGQVRFVLV 120

Qy 210 NTWAKKCPMGFSYDTRCFDSTVTENDIRVBESYQCCDLAPEARQAIRSLTERLYVGGP 269
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 121 QAWSKKTPMGFSYDTRCFDSTVTESDIRTEAIYQCCDLDPQARVAIKSLTERLYVGGP 180

Qy 270 MTNSKGQNGCYRRCRASGV 288
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 181 LTNSRGNGCYRRCRASGV 199

RESULT 12
US-09-921-397-110
; Sequence 110, Application US/09921397
; Patent No. US20020151484A1
; GENERAL INFORMATION:
; APPLICANT: HYBRIGENICS
; TITLE OF INVENTION: SID nucleic acids and polypeptides selected from a
; TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
; TITLE OF INVENTION: applications thereof
; FILE REFERENCE: B4809A - JAZ
; CURRENT APPLICATION NUMBER: US/09/921.397
; CURRENT FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: EP 00402225.7
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 110
; LENGTH: 127
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-09-921-397-110

Query Match          20.4%; Score 623; DB 9; Length 127;
Best Local Similarity 89.8%; Pred. No. 2.1e-48;
Matches 114; Conservative 9; Mismatches 4; Indels 0; Gaps 0;

Qy 326 VICESAGTQEDAAALRVFTTEAMTRYSPGDPPOPEYDLELITSCSNVSVVAHDASGRV 385
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 VICESAGVQEDAAALRVFTTEAMTRYSPGDPPOPEYDLELITSCSNVSVVAHDAGKRV 60

Qy 386 YLTLRDTPTPLARAWEATARTPTVNSLGNIMTAPTLWARMILMTWFFSILLAOBLEK 445
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 YLTLRDTPTPLARAWEATARTPTVNSLGNIMTAPTLWARMILMTWFFSVLIARDOLEQ 120

Qy 446 ALDCQIV 452
```

```
|||:||||
Db 121 ALNCEIY 127

RESULT 13
US-09-921-397-106
; Sequence 106, Application US/09921397
; Patent No. US20020151484A1
; GENERAL INFORMATION:
; APPLICANT: HYBRIGENICS
; TITLE OF INVENTION: SID nucleic acids and polypeptides selected from a
; TITLE OF INVENTION: pathogenic strain of the hepatitis C virus and
; TITLE OF INVENTION: applications thereof
; FILE REFERENCE: B4809A - JAZ
; CURRENT APPLICATION NUMBER: US/09/921.397
; CURRENT FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: EP 00402225.7
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 106
; LENGTH: 137
; TYPE: PRT
; ORGANISM: Hepatitis C virus
US-09-921-397-106

Query Match          19.1%; Score 585; DB 9; Length 137;
Best Local Similarity 83.9%; Pred. No. 6.9e-45;
Matches 115; Conservative 7; Mismatches 15; Indels 0; Gaps 0;

Qy 9 TWTGALITPCAABESKLPINALNSLLRHHNLVYSTTSRSASLRQKVTFFORLQVLDHY 68
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 1 SWTGALITPCAABESKLPINALNSLLRHHNLVYSTTSRSACQKQKVTFFORLQVLDHY 60

Qy 69 RDVLKEMKAKASTYKAKLLSVEEACKLTPPHSAKSGYGAQKDVRSLSRAVNHRSVWK 128
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 61 QDVLKEVKAASVKYKANLLSVEEACSLTPPHSAKSGYGAQKDVSRCHARKAVAHINSVWK 120

Qy 129 DLLEDTDTPITQTTIMAK 145
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db 121 DLLEDSTVPTIDTTIMAK 137

RESULT 14
US-09-294-121A-82
; Sequence 82, Application US/09294121A
; Patent No. US20020069422A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/294.121A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
```

```

; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 82:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 113 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; IMMEDIATE SOURCE:
; CLONE: be90
; POSITION IN GENOME: ns5
; MAP POSITION: ns5
US-09-294-121A-82

```

```

Query Match 18.7%; Score 570; DB 9; Length 113;
Best Local Similarity 95.6%; Pred. No. 1.2e-43;
Matches 108; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTENDIRVEESIQCCDLAPARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 342
Db 61 TTSCGNTLTCYLKASAAACRAAKLQDCTMLVCGDDLWVICSAGTQEDAAASLRV 113

```

RESULT 15

```

US-09-899-082A-82
; Sequence 82, Application US/09899082A
; Patent No. US20020106638A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,082A
; FILING DATE: 06-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993

```

```

; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 82:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 113 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; IMMEDIATE SOURCE:
; CLONE: be90
; POSITION IN GENOME: ns5
; MAP POSITION: ns5
; SEQUENCE DESCRIPTION: SEQ ID NO: 82:
US-09-899-082A-82

```

```

Query Match 18.7%; Score 570; DB 9; Length 113;
Best Local Similarity 95.6%; Pred. No. 1.2e-43;
Matches 108; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 230 STVTENDIRVEESIQCCDLAPARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVL 289
Db 1 STVTENDIRVEESIQCCDLAPARQAIRSLTERLYVGGPMTNSKGQNGCYRRCRASGVL 60

Qy 290 TTSCGNTLTCYLKAAACRAAKLQDCTMLVNGDDLWVICSAGTQEDAAASLRV 342
Db 61 TTSCGNTLTCYLKASAAACRAAKLQDCTMLVCGDDLWVICSAGTQEDAAASLRV 113

```

Search completed: September 22, 2005, 14:58:37
Job time : 175 secs

This Page Blank (uspto)